0001326732-24-00004310-Q Xencor Inc 20240805202408051612391612401612400 0001326732-24-000043 10-Q 70 20240630 20240805 20240805 Xencor Inc 0001326732 2834 201622502 DE 1231 10-Q 34 001-36182 241174886 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107 626-305-5900 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107 10-Q 1 xncr-20240630.htm 10-Q xncr-20240630000132673212-
312024Q2false2442433643673643643583643xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purexncr:installmentxncr:phasexncr:programxncr:target00013267322024-01-012024-06-30000132673220024-07-30000132673220024-06-30000132673220023-12-31000132673220024-04-012024-06-30000132673220023-04-012023-06-30000132673220023-01-012023-06-30000132673us-gaap:CommonStockMember2023-12-310001326732us-gaap:AdditionalPaidInCapitalMember2023-12-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001326732us-gaap:RetainedEarningsMember2023-12-310001326732us-gaap:NoncontrollingInterestMember2023-12-310001326732us-gaap:CommonStockMember2024-01-012024-03-310001326732us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001326732202401-012024-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001326732us-gaap:RetainedEarningsMember2024-01-012024-03-310001326732us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001326732us-gaap:CommonStockMember2024-03-310001326732us-gaap:AdditionalPaidInCapitalMember2024-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001326732us-gaap:RetainedEarningsMember2024-03-310001326732us-gaap:NoncontrollingInterestMember2024-03-310001326732us-gaap:CommonStockMember2024-04-012024-06-300001326732us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001326732us-gaap:RetainedEarningsMember2024-04-012024-06-300001326732us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001326732us-gaap:CommonStockMember2024-06-300001326732us-gaap:AdditionalPaidInCapitalMember2024-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001326732us-gaap:RetainedEarningsMember2024-06-300001326732us-gaap:NoncontrollingInterestMember2024-06-300001326732us-gaap:CommonStockMember2022-12-310001326732us-gaap:AdditionalPaidInCapitalMember2022-12-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001326732us-gaap:RetainedEarningsMember2022-12-310001326732us-gaap:NoncontrollingInterestMember2022-12-310001326732202212-310001326732us-gaap:CommonStockMember2023-01-012023-03-310001326732us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001326732202301-012023-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001326732us-gaap:RetainedEarningsMember2023-01-012023-03-310001326732us-gaap:CommonStockMember2023-03-310001326732us-gaap:AdditionalPaidInCapitalMember2023-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001326732us-gaap:RetainedEarningsMember2023-03-310001326732us-gaap:NoncontrollingInterestMember2023-03-310001326732202303-310001326732us-gaap:CommonStockMember2023-04-012023-06-300001326732us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001326732us-gaap:RetainedEarningsMember2023-04-012023-06-300001326732us-gaap:CommonStockMember2023-06-300001326732us-gaap:AdditionalPaidInCapitalMember2023-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001326732us-gaap:RetainedEarningsMember2023-06-300001326732us-gaap:NoncontrollingInterestMember2023-06-300001326732023-06-300001326732xncr:InProcessIntangibleAssetsMember2024-04-012024-06-300001326732xncr:InProcessIntangibleAssetsMember2024-01-012024-06-300001326732xncr:InProcessIntangibleAssetsMember2023-04-012023-06-300001326732xncr:InProcessIntangibleAssetsMember2023-01-012023-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001326732us-gaap:FairValueMeasurementsRecurringMember2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300001326732us-gaap:CorporateDebtSecuritiesMember2024-06-300001326732us-gaap:USTreasuryAndGovernmentMember2024-06-300001326732us-gaap:CashAndCashEquivalentsMember2024-06-300001326732xncr:MarketableSecuritiesMember2024-06-300001326732us-gaap:MoneyMarketFundsMember2023-12-310001326732us-gaap:CorporateDebtSecuritiesMember2023-12-310001326732us-gaap:USTreasuryAndGovernmentMember2023-12-310001326732us-gaap:CashAndCashEquivalentsMember2023-12-310001326732xncr:MarketableSecuritiesMember2023-12-310001326732us-gaap:CorporateDebtSecuritiesMember2024-06-300001326732us-gaap:USTreasuryAndGovernmentMember2024-06-300001326732us-gaap:CorporateDebtSecuritiesMember2023-12-310001326732us-gaap:USTreasuryAndGovernmentMember2023-12-310001326732us-gaap:CommonStockMemberxncr:AstriaMember2024-06-300001326732us-gaap:CommonStockMemberxncr:AstriaMember2023-12-310001326732us-gaap:CommonStockMemberxncr:InmuneBioIncMember2024-06-300001326732us-gaap:CommonStockMemberxncr:InmuneBioIncMember2023-12-310001326732us-gaap:CommonStockMemberxncr:ViridianMember2024-06-300001326732us-gaap:CommonStockMemberxncr:ViridianMember2023-12-310001326732us-gaap:CommonStockMember2024-06-300001326732us-gaap:CommonStockMember2023-12-310001326732us-gaap:CommonStockMemberxncr:AstriaMemberxncr:LicenseAgreementMember2024-01-012024-06-300001326732us-gaap:CommonStockMemberxncr:AstriaMemberxncr:LicenseAgreementMember2024-04-012024-06-300001326732us-gaap:CommonStockMemberxncr:AstriaMemberxncr:LicenseAgreementMember2024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:CatabasisPharmaceuticalsIncMember2024-04-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:CatabasisPharmaceuticalsIncMember2024-01-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:CatabasisPharmaceuticalsIncMember2023-04-012023-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:CatabasisPharmaceuticalsIncMember2023-01-012023-06-300001326732us-gaap:CommonStockMemberxncr:LicenseAgreementMemberxncr:InmuneBioIncMember2024-06-300001326732xncr:LicenseAgreementMemberxncr:InmuneBioIncMember2024-04-012024-06-300001326732xncr:LicenseAgreementMemberxncr:InmuneBioIncMember2024-01-012024-06-300001326732xncr:LicenseAgreementMemberxncr:InmuneBioIncMember2023-04-012023-06-300001326732xncr:LicenseAgreementMemberxncr:InmuneBioIncMember2023-01-012023-06-300001326732us-gaap:CommonStockMemberxncr:TechnologyLicenseAgreementMemberxncr:ViridianMember2024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ViridianMember2024-04-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ViridianMember2024-01-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ViridianMember2023-04-012023-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ViridianMember2023-01-012023-06-300001326732us-gaap:PreferredStockMemberxncr:ZenasBioPharmaLimitedMember2024-06-300001326732us-gaap:PreferredStockMemberxncr:ZenasBioPharmaLimitedMember2023-12-310001326732xncr:ZenasBioPharmaLimitedMember2024-01-012024-06-300001326732xncr:The2023PlanMember2023-06-140001326732xncr:The2023PlanMember2024-06-300001326732xncr:The2013And2023PlansMember2024-01-012024-06-300001326732us-gaap:EmployeeStockMember2024-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2024-01-012024-06-300001326732us-gaap:EmployeeStockMember2024-01-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMemberxncr:The2023PlanMember2024-01-012024-06-300001326732xncr:ExtendedExpirationDatesMember2024-01-012024-06-300001326732xncr:ExtendedVestingPeriodsMember2024-01-012024-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001326732us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001326732us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001326732us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001326732us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001326732us-gaap:EmployeeStockMember2024-04-012024-06-300001326732us-gaap:EmployeeStockMember2023-04-012023-06-300001326732us-gaap:EmployeeStockMember2023-01-012023-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001326732us-gaap:EmployeeStockOptionMember2023-12-310001326732us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001326732us-gaap:EmployeeStockOptionMember2024-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2024-04-012024-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2024-04-012024-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2023-04-012023-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2023-04-012023-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2024-01-012024-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2023-01-012023-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2023-01-012023-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2023-12-310001326732us-gaap:RestrictedStockUnitsRSUMember2024-06-300001326732xncr:MonroviaCAOfficeAndLaboratorySpaceMember2024-06-300001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMember2021-06-012021-06-300001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMember2022-08-010001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMembersrt:ScenarioForecastMember2026-09-300001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMember2022-08-310001326732322024-01-012024-01-310001326732us-gaap:LetterOfCreditMember2024-06-300001326732xncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2013-01-012013-01-310001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2024-01-012024-06-300001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2024-04-012024-06-300001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2023-04-012023-06-300001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2023-01-012023-06-300001326732xncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2024-06-300001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2019-02-012019-02-280001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2019-02-280001326732xncr:DevelopmentBasedMilestonesMemberxncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2019-02-280001326732xncr:CollaborationAndLicenseAgreementMemberxncr:RegulatoryBasedMilestonesMemberxncr:GenentechMember2019-02-280001326732xncr:SalesBasedMilestonesMemberxncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2019-02-280001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2024-04-012024-06-300001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2024-01-012024-06-300001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2023-04-012023-06-300001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2023-01-012023-06-300001326732xncr:Xmab24306ProductMemberxncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMember2024-06-300001326732xncr:CollaborationAndLicenseAgreementMemberxncr:GenentechMemberxncr:ResearchActivityMember2024-06-300001326732xncr:JanssenBiotechIncMemberxncr:CollaborationAndLicenseAgreementMember2024-01-012024-06-300001326732xncr:JanssenBiotechIncMemberxncr:CollaborationAndLicenseAgreementMember2023-04-012023-06-300001326732xncr:JanssenBiotechIncMemberxncr:CollaborationAndLicenseAgreementMember2024-04-012024-06-300001326732xncr:JanssenBiotechIncMemberxncr:CollaborationAndLicenseAgreementMember2023-01-012023-06-300001326732xncr:JanssenBiotechIncMemberxncr:CollaborationAndLicenseAgreementMember2024-06-300001326732xncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2021-10-012021-10-010001326732xncr:JanssenBiotechIncMembersrt:MinimumMemberxncr:SecondCollaborationAndLicenseAgreementMember2021-10-012021-10-010001326732srt:MaximumMemberxncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2021-10-012021-10-010001326732xncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2024-06-300001326732xncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2024-01-012024-06-300001326732xncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2024-04-012024-06-300001326732xncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2023-04-012023-06-

300001326732xncr:JanssenBiotechIncMemberxncr:SecondCollaborationAndLicenseAgreementMember2023-01-012023-06-300001326732xncr:MorphoSysMemberus-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMember2024-04-012024-06-300001326732xncr:MorphoSysMemberus-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMember2024-01-012024-06-300001326732xncr:MorphoSysMemberus-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMember2023-04-012023-06-300001326732xncr:MorphoSysMemberus-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMember2023-01-012023-06-300001326732xncr:MorphoSysMemberus-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMember2024-06-300001326732xncr:MorphoSysMemberxncr:CollaborationAndLicenseAgreementMember2024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-01-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-04-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:VegaTherapeuticsInc.Member2021-10-012021-10-310001326732xncr:TechnologyLicenseAgreementMemberxncr:VegaTherapeuticsInc.Member2024-01-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:VegaTherapeuticsInc.Member2023-04-012023-06-300001326732xncr:PatentLicenseAgreementMemberxncr:VirMember2019-10-012019-12-310001326732xncr:PatentLicenseAgreementMemberus-gaap:RoyaltyMemberxncr:VirMember2024-01-012024-06-300001326732xncr:PatentLicenseAgreementMemberus-gaap:RoyaltyMemberxncr:VirMember2023-04-012023-06-300001326732xncr:PatentLicenseAgreementMemberus-gaap:RoyaltyMemberxncr:VirMember2023-01-012023-06-300001326732xncr:PatentLicenseAgreementMemberxncr:VirMember2024-06-300001326732xncr:LicenseAgreementMemberus-gaap:PreferredStockMemberxncr:ZenasBioPharmaLimitedMemberxncr:MilestoneMember2023-12-310001326732xncr:ZenasBioPharmaLimitedMember2024-01-012024-06-300001326732xncr:ZenasBioPharmaLimitedMember2023-04-012023-06-300001326732xncr:ZenasBioPharmaLimitedMember2023-01-012023-06-300001326732xncr:LicenseAgreementMemberxncr:ZenasBioPharmaLimitedMember2024-01-012024-06-300001326732xncr:LicenseAgreementMemberxncr:ZenasBioPharmaLimitedMember2024-04-012024-06-300001326732xncr:LicenseAgreementMemberxncr:ZenasBioPharmaLimitedMember2023-01-012023-06-300001326732xncr:LicenseAgreementMemberxncr:ZenasBioPharmaLimitedMember2023-04-012023-06-300001326732xncr:LicenseAgreementMemberxncr:ZenasBioPharmaLimitedMember2024-06-300001326732xncr:PatentLicenseAgreementMemberxncr:ThirdPartyLicenseAgreementMember2024-01-012024-06-300001326732xncr:PatentLicenseAgreementMemberxncr:ThirdPartyLicenseAgreementMember2024-04-012024-06-300001326732xncr:PatentLicenseAgreementMemberxncr:ThirdPartyLicenseAgreementMember2024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:GaleMember2024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:GaleMember2024-04-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:GaleMember2024-01-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:GaleMemberus-gaap:SubsequentEventMember2024-07-012024-07-310001326732xncr:AlexionPharmaceuticalsIncMember2024-04-012024-06-300001326732xncr:AlexionPharmaceuticalsIncMember2023-04-012023-06-300001326732xncr:AlexionPharmaceuticalsIncMember2024-01-012024-06-300001326732xncr:AlexionPharmaceuticalsIncMember2023-01-012023-06-300001326732xncr:JanssenMember2024-04-012024-06-300001326732xncr:JanssenMember2023-04-012023-06-300001326732xncr:JanssenMember2024-01-012024-06-300001326732xncr:JanssenMember2023-01-012023-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-04-012024-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2023-04-012023-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-01-012024-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2023-01-012023-06-300001326732xncr:MorphoSysMember2024-04-012024-06-300001326732xncr:MorphoSysMember2023-04-012023-06-300001326732xncr:MorphoSysMember2024-01-012024-06-300001326732xncr:MorphoSysMember2023-01-012023-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:VegaTherapeuticsInc.Member2024-04-012024-06-300001326732xncr:TechnologyLicenseAgreementMemberxncr:VegaTherapeuticsInc.Member2023-01-012023-06-300001326732xncr:VirMember2024-04-012024-06-300001326732xncr:VirMember2023-04-012023-06-300001326732xncr:VirMember2024-01-012024-06-300001326732xncr:VirMember2023-01-012023-06-300001326732xncr:ZenasBioPharmaLimitedMember2024-04-012024-06-300001326732xncr:ThirdPartyLicenseAgreementMember2024-04-012024-06-300001326732xncr:ThirdPartyLicenseAgreementMember2023-04-012023-06-300001326732xncr:ThirdPartyLicenseAgreementMember2024-01-012024-06-300001326732xncr:ThirdPartyLicenseAgreementMember2023-01-012023-06-300001326732xncr:ResearchCollaborationMember2024-04-012024-06-300001326732xncr:ResearchCollaborationMember2023-04-012023-06-300001326732xncr:ResearchCollaborationMember2024-01-012024-06-300001326732xncr:ResearchCollaborationMember2023-01-012023-06-300001326732xncr:LicenseAgreementMember2024-04-012024-06-300001326732xncr:LicenseAgreementMember2023-04-012023-06-300001326732xncr:LicenseAgreementMember2024-01-012024-06-300001326732xncr:LicenseAgreementMember2023-01-012023-06-300001326732xncr:MilestoneMember2024-04-012024-06-300001326732xncr:MilestoneMember2023-04-012023-06-300001326732xncr:MilestoneMember2024-01-012024-06-300001326732xncr:MilestoneMember2023-01-012023-06-300001326732us-gaap:RoyaltyMember2024-04-012024-06-300001326732us-gaap:RoyaltyMember2023-04-012023-06-300001326732us-gaap:RoyaltyMember2024-01-012024-06-300001326732us-gaap:RoyaltyMember2023-01-012023-06-300001326732xncr:NonCashRoyaltyMember2024-04-012024-06-300001326732xncr:NonCashRoyaltyMember2023-04-012023-06-300001326732xncr:NonCashRoyaltyMember2024-01-012024-06-300001326732xncr:NonCashRoyaltyMember2023-01-012023-06-300001326732xncr:BassilDahiyatMember2024-01-012024-06-300001326732xncr:BassilDahiyatMember2024-04-012024-06-300001326732xncr:BassilDahiyatMember2024-06-300001326732xncr:JohnDesjarlaisMember2024-01-012024-06-300001326732xncr:JohnDesjarlaisMember2024-04-012024-06-300001326732xncr:JohnDesjarlaisMember2024-06-300001326732xncr:EllenFeigalMember2024-01-012024-06-300001326732xncr:EllenFeigalMember2024-04-012024-06-300001326732xncr:EllenFeigalMember2024-06-300001326732xncr:KevinGormanMember2024-01-012024-06-300001326732xncr:KevinGormanMember2024-04-012024-06-300001326732xncr:KevinGormanMember2024-06-300001326732xncr:KurtGustafsonMember2024-01-012024-06-300001326732xncr:KurtGustafsonMember2024-04-012024-06-300001326732xncr:KurtGustafsonMember2024-06-300001326732xncr:DagmarRosaBjorkesenMember2024-01-012024-06-300001326732xncr:DagmarRosaBjorkesenMember2024-04-012024-06-300001326732xncr:DagmarRosaBjorkesenMember2024-06-300001326732xncr:RichardRanieriMember2024-01-012024-06-300001326732xncr:RichardRanieriMay2024PlanMemberxncr:RichardRanieriMember2024-04-012024-06-300001326732xncr:RichardRanieriMember2024-04-012024-06-300001326732xncr:RichardRanieriMay2024PlanMemberxncr:RichardRanieriMember2024-06-300001326732xncr:RichardRanieriJune2024PlanMemberxncr:RichardRanieriMember2024-04-012024-06-300001326732xncr:RichardRanieriJune2024PlanMemberxncr:RichardRanieriMember2024-06-300001326732xncr:ABruceMontgomeryMember2024-01-012024-06-300001326732xncr:ABruceMontgomeryMember2024-04-012024-06-300001326732xncr:ABruceMontgomeryMember2024-06-30Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549_____FORM 10-Q(Mark One)xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended JuneÂ 30, 2024oroTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____Commission file number: 001-36182Xencor, Inc.(Exact name of registrant as specified in its charter)Delaware20-1622502(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)465 North Halstead Street, Suite 200, Pasadena, CA91107(Address of principal executive offices)(Zip Code)(626) 305-5900(Registrantâ€™s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.01 per shareXNCRThe Nasdaq Global MarketIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of â€œlarge accelerated filerâ€, â€œaccelerated filerâ€, â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company oIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No xIndicate the number of shares outstanding of each of the issuerâ€™s classes of common stock, as of the latest practicable date:ClassOutstanding at JulyÂ 30, 2024Common stock, par value $0.01 per share61,833,530Table of ContentsXencor, Inc.Quarterly Report on Form 10-Q for the Quarter Ended JuneÂ 30, 2024Table of ContentsPageSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS3PART I.FINANCIAL INFORMATION5Item 1.Financial Statements5Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 20235Consolidated Statements of Loss for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)6Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited) 7Consolidated Statements of Stockholdersâ€™ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)8Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (unaudited)9Notes to Consolidated Financial Statements (unaudited)11Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations26Item 3.Quantitative and Qualitative Disclosures About Market Risk37Item 4.Controls and Procedures37PART II.OTHER INFORMATION39Item 1.Legal Proceedings39Item 1A.Risk Factors39Item 5.Other Information39Item 6.Exhibits40Signatures41In this report, unless otherwise stated or the context otherwise indicates, references to â€œXencor,â€ â€œthe Company,â€ â€œwe,â€ â€œus,â€ â€œourâ€ and similar references refer to Xencor, Inc. The Xencor logo is a registered trademark of Xencor, Inc. This report also contains registered marks, trademarks, and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.2Table of ContentsSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). You should not place undue reliance on these statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or managementâ€™s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, â€œRisk Factorsâ€ in this Quarterly Report. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as â€œmay,â€ â€œwill,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œplan,â€ â€œbelieve,â€ â€œestimate,â€ the negative of such terms or other words indicating future results.These forward-looking statements should, therefore, be considered in light of various important factors, including but not limited to, the following:â€¢the effects of inflation on our financial condition, results of operations, cash flows and performance;â€¢our ability to execute on our plans to research, develop and commercialize our product candidates; â€¢the success of our ongoing and planned clinical trials; â€¢the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; â€¢our ability to identify additional products or product candidates with significant commercial potential that are consistent with our business objectives; â€¢our ability to receive research funding and achieve anticipated milestones under our collaborations; â€¢our partners' abilities to advance drug candidates into, and successfully complete, clinical trials;â€¢our ability to attract collaborators with development, regulatory, and commercialization expertise;â€¢the ability of our publicly announced preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments;â€¢our ability to protect our intellectual property position; â€¢the rate and degree of market acceptance and clinical utility of our products; â€¢costs of compliance and our failure to comply with new and existing governmental regulations; â€¢the capabilities and strategy of our suppliers and vendors including key manufacturers of our clinical drug supplies; â€¢significant competition in our industry; â€¢costs of litigation and the failure to successfully defend lawsuits and other claims against us; â€¢the potential loss or retirement of key members of management; â€¢our failure to successfully execute our growth strategy including any delays in our planned future growth;â€¢our failure to maintain effective internal controls; and3Table of Contentsâ€¢our ability to accurately estimate expenses, future revenues, capital requirements and needs for additional financing.The factors, risks and uncertainties referred to above and others are more fully described under the heading â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 and this Quarterly Report on Form 10-Q. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. We cannot guarantee future results, events, levels of activity, performance, or achievements. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.4Table of ContentsPART I â€” FINANCIAL INFORMATIONItem 1. Financial StatementsXencor, Inc.Consolidated Balance Sheets(in thousands, except share and per share data)June 30,2024December 31,2023(unaudited)AssetsCurrent assetsCash and cash equivalents$30,768Â $53,790Â Marketable debt securities449,372Â 497,725Â Marketable equity securities28,271Â 42,210Â Accounts receivable 22,073Â 11,290Â Prepaid expenses and other current assets23,986Â 18,145Â Total current assets 554,470Â 623,160Â Property and equipment, net 63,868Â 66,124Â Patents, licenses, and other intangible assets, net 18,778Â 18,663Â Restricted cash384Â 380Â Marketable debt securities - long term104,862Â 145,512Â Marketable equity securities - long term43,780Â 64,210Â Right of use (ROU) asset39,527Â 33,995Â Other assets 498Â 648Â Total assets $826,167Â $952,692Â Liabilities and stockholdersâ€™ equity Current liabilitiesAccounts payable $15,838Â $13,914Â Accrued expenses 19,557Â 23,564Â Income tax payableâ€”Â 5,782Â Lease liabilities1,262Â 3,435Â Deferred income36,472Â 31,682Â Debt6,947Â 6,332Â Total current liabilities 80,076Â 84,709Â Lease liabilities, net of current portion67,156Â 59,025Â Deferred income, net of current portion104,081Â 125,183Â Debt, net of current portion12,313Â 14,642Â Total liabilities 263,626Â 283,559Â Commitments and contingencies Stockholdersâ€™ equityPreferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at JuneÂ 30, 2024 and DecemberÂ 31, 2023â€”Â â€”Â Common stock, $0.01 par value: 200,000,000 authorized shares at JuneÂ 30, 2024 and DecemberÂ 31, 2023; 61,766,054 issued and outstanding at JuneÂ 30, 2024 and 60,998,191 issued and outstanding at DecemberÂ 31, 2023619Â 611Â Additional paid-in capital 1,162,726Â 1,131,266Â Accumulated other comprehensive (loss) income(652)1,291Â Accumulated deficit (598,368)(464,372)Total stockholdersâ€™ equity attributable to Xencor, Inc.564,325Â 668,796Â Non-controlling interest(1,784)337Â Total stockholdersâ€™ equity 562,541Â 669,133Â Total liabilities and stockholdersâ€™ equity $826,167Â $952,692Â See accompanying notes.5Table of ContentsXencor, Inc.Consolidated Statements of Loss(unaudited)(in thousands, except share and per share data)Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023RevenueCollaborations, milestones, and royalties$16,960Â $45,523Â $29,765Â $64,485Â Operating expensesResearch and development 61,531Â 60,060Â 118,404Â 125,612Â General and administrative 17,746Â 11,460Â 31,533Â 25,613Â Total operating expenses79,277Â 71,520Â 149,937Â 151,225Â Loss from operations(62,317)(25,997)(120,172)(86,740)Other income (expense)Interest income7,681Â 3,771Â 16,229Â 6,670Â Interest expense(844)(7)(1,921)(14)Other expense, net(4)(9)(4)(23)Impairment on equity securities220Â â€”Â (20,430)â€”Â Gain (loss) on equity securities, net(12,027)288Â (9,702)(2,610)Total other income (expense), net(4,974)4,043Â (15,828)4,023Â Loss

before income tax expense(67,291)(21,954)(136,000)(82,717)Income tax expense117Â â€”Â 117Â â€”Â Net loss(67,408)(21,954)(136,117)(82,717)Net loss attributable to non-controlling interest(1,445)â€”Â (2,121)â€”Â Net loss attributable to Xencor, Inc.$(65,963)$(21,954)$(133,996)$(82,717)Basic and diluted net loss per common share attributable to Xencor, Inc.(1.07)(0.37)(2.18)(1.38)Basic and diluted weighted average common shares outstanding61,676,44459,807,55861,444,38459,922,784See accompanying notes.6Table of ContentsXencor, Inc.Consolidated Statements of Comprehensive Loss(unaudited)(in thousands, except share and per share data)Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Net loss(67,408)(21,954)(136,117)(82,717)Other comprehensive income (loss)Net unrealized gain (loss) on marketable debt securities (498)1,765Â (1,942)5,093Â Comprehensive loss(67,906)(20,189)(138,059)(77,624)Comprehensive loss attributable to non-controlling interest(1,445)â€”Â (2,121)â€”Â Comprehensive loss attributable to Xencor, Inc.$(66,461)$(20,189)$(135,938)$(77,624)See accompanying notes.7Table of ContentsXencor, Inc.Consolidated Statements of Stockholdersâ€™ Equity(unaudited) (in thousands, except share data)Common StockAdditionalPaid-inCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitNon-Controlling InterestTotalStockholdersâ€™EquityStockholdersâ€™ EquitySharesAmountBalance, December 31, 202360,998,191$611Â $1,131,266Â $1,291Â $(464,372)$337Â $669,133Â Issuance of common stock upon exercise of stock awards152,6821Â 1,786Â â€”Â â€”Â â€”Â 1,787Â Issuance of restricted stock units483,8125Â (5)â€”Â â€”Â â€”Â â€”Â Comprehensive lossâ€”Â â€”Â (1,445)(68,033)(676)(70,154)Stock-based compensationâ€”â€”Â 11,421Â â€”Â â€”Â â€”Â 11,421Â Balance, March 31, 202461,634,685$617Â $1,144,468Â (154)(532,405)(339)612,187Â Issuance of common stock upon exercise of stock awards10,213â€”Â 140Â â€”Â â€”Â â€”Â 140Â Issuance of restricted stock units67,1601Â (1)â€”Â â€”Â â€”Â â€”Â Issuance of common stock under the Employee Stock Purchase Plan53,9961Â 929Â â€”Â â€”Â â€”Â 930Â Comprehensive lossâ€”â€”Â â€”Â (498)(65,963)(1,445)(67,906)Stock-based compensationâ€”â€”Â 17,190Â â€”Â â€”Â â€”Â 17,190Â Balance, June 30, 2024 (unaudited)61,766,054$619Â $1,162,726Â (652)(598,368)$(1,784)$562,541Â Common StockAdditionalPaid-inCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitNon-Controlling InterestTotalStockholdersâ€™EquityStockholdersâ€™ EquitySharesAmountBalance, December 31, 202259,997,713$601Â $1,072,132Â $(6,952)$(338,285)$â€”Â $727,496Â Issuance of common stock upon exercise of stock awards34,388â€”Â 924Â â€”Â â€”Â â€”Â 924Â Issuance of restricted stock units349,4994Â (4)â€”Â â€”Â â€”Â â€”Â Comprehensive income (loss)â€”â€”Â â€”Â 3,327Â (60,763)â€”Â (57,436)Stock-based compensationâ€”â€”Â 12,599Â â€”Â â€”Â â€”Â 12,599Â Balance, March 31, 202360,381,600$605Â $1,085,651Â $(3,625)$(399,048)$â€”Â $683,583Â Issuance of common stock upon exercise of stock awards145,0031Â 676Â â€”Â â€”Â â€”Â 677Â Issuance of restricted stock units18,148â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock under the Employee Stock Purchase Plan55,3091Â 1,241Â â€”Â â€”Â â€”Â 1,242Â Comprehensive income (loss)â€”â€”Â â€”Â 1,765Â (21,954)â€”Â (20,189)Stock-based compensationâ€”â€”Â 13,563Â â€”Â â€”Â â€”Â 13,563Â Balance, June 30, 2023 (unaudited)60,600,060$607Â $1,101,131Â $(1,860)$(421,002)$â€”Â $678,876Â See accompanying notes.8Table of ContentsXencor, Inc.Consolidated Statements of Cash Flows(unaudited)(in thousands)Six Months EndedJune 30,20242023Cash flows from operating activitiesNet loss$(136,117)$(82,717)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization 6,059Â 5,130Â Accretion of discount on marketable debt securities(10,037)(4,345)Stock-based compensation 28,611Â 26,162Â Equity received in connection with license agreementsâ€”Â (10,000)Abandonment of capitalized intangible assets 784Â 594Â Gain on sale of marketable debt securities(3)â€”Â Change in fair value of equity securities9,702Â 2,610Â Impairment on equity securities20,430Â â€”Â Non-cash interest expense1,900Â â€”Â Loss on disposal of assets6Â 1,379Â Changes in operating assets and liabilities:Accounts receivable(10,783)8,978Â Interest receivable from marketable debt securities(1,705)420Â Prepaid expenses and other assets(5,691)1,127Â Accounts payable 1,924Â 4,009Â Accrued expenses (4,007)(288)Income taxes(5,782)â€”Â Lease liabilities and ROU assets426Â 582Â Deferred revenueâ€”Â (22,455)Deferred income(16,312)â€”Â Net cash used in operating activities (120,595)(68,814)Cash flows from investing activitiesPurchase of marketable securities (259,130)(276,715)Sale of equity securities4,236Â â€”Â Purchase of patents, licenses, and other intangible assets(1,549)(1,490)Purchase of property and equipment (3,158)(14,636)Proceeds from maturities of marketable securities 347,966Â 339,580Â Proceeds from sale of marketable securities9,969Â â€”Â Net cash provided by investing activities 98,334Â 46,739Â Cash flows from financing activitiesProceeds from issuance of common stock upon exercise of stock awards1,927Â 1,601Â Proceeds from issuance of common stock under the Employee Stock Purchase Plan930Â 1,242Â Reduction of liability for sale of future royalties(3,614)â€”Â Net cash (used in) provided by financing activities (757)2,843Â Net decrease in cash, cash equivalents, and restricted cash(23,018)(19,232)Cash, cash equivalents, and restricted cash, beginning of period 54,170Â 53,942Â Cash, cash equivalents, and restricted cash, end of period $31,152Â $34,710Â 9Table of ContentsSix Months EndedJune 30,20242023Supplemental disclosure of cash flow informationCash paid during the period for:Interest$21Â $14Â Income taxes$6,100Â $â€”Â Supplemental disclosures of non-cash activitiesUnrealized (loss) gain on marketable securities$(1,942)$5,093Â ROU assets obtained$7,166Â $â€”Â Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheetsCash and cash equivalents$30,768Â $34,710Â Restricted cash384Â â€”Â Total cash, cash equivalents, and restricted cash shown in the statement of cash flows$31,152Â $34,710Â See accompanying notes. 10Table of ContentsXencor, Inc.Notes to Financial Statements(unaudited)JuneÂ 30, 20241. Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited consolidated interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of consolidated interim financial statements requires the use of managementâ€™s estimates and assumptions that affect reported amounts of assets and liabilities at the date of the consolidated interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period.The accompanying unaudited consolidated interim financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2024.Principles of ConsolidationThe accompanying consolidated financial statements include the accounts of Xencor, Inc. and Gale Therapeutics Inc. (Gale), a variable interest entity (VIE) in which we are the primary beneficiary. Since we own less than 100% of Gale, the Company records net loss attributable to non-controlling interests in its consolidated statements of loss equal to the percentage of the economic or ownership interests retained in Gale by the non-controlling party.In determining whether we are the primary beneficiary of a VIE, we apply a qualitative approach that determines whether we have (1) the power to direct the activities of the VIE that most significantly impact the entity's economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to the VIE. We continuously assess whether we are the primary beneficiary of Gale as changes to existing relationships or future transactions may result in us consolidating or deconsolidating Gale.Use of EstimatesThe preparation of consolidated interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive income (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these consolidated interim financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets.ReclassificationsCertain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. During the six months ended JuneÂ 30, 2024, we adopted a change in 11Table of Contentspresentation on our consolidated statements of loss to include loss from disposal of fixed assets in operating expenses. The prior period has been revised to reflect this change in the presentation.Intangible AssetsThe Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There was no impairment charge recorded for the three and six months ended JuneÂ 30, 2024 and 2023.The Company capitalizes certain in-process intangible assets that are then abandoned when they are no longer pursued or used in current research activities. We abandoned $0.4 million and $0.8 million of in-process intangible assets for the three and six months ended JuneÂ 30, 2024. We abandoned $0.3 million and $0.6 million of in-process intangible assets during the three and six months ended JuneÂ 30, 2023. Marketable Debt and Equity SecuritiesThe Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The investment policy limits the maturity of any individual security to a maximum of 36 months. The average maturity of securities in the portfolio as of JuneÂ 30, 2024 is less than 12 months. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale because it is not more likely than not that the Company will be required to sell the securities before recovery of the amortized cost. These assets are carried at fair value and any impairment losses and recoveries related to the underlying issuerâ€™s credit standing are recognized within other income (expense), while non-credit related impairment losses and recoveries are recognized within accumulated other comprehensive income (loss). There were no impairment losses or recoveries recorded for the three and six months ended JuneÂ 30, 2024 and 2023. Accrued interest on marketable debt securities is included in the marketable securitiesâ€™ carrying value. Each reporting period, the Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if each securityâ€™s fair value has declined below its amortized cost basis. During the three and six months ended JuneÂ 30, 2024, the Company recorded an unrealized loss of $0.5 million and $1.9 million in its portfolio of marketable debt securities. During the three and six months ended JuneÂ 30, 2023, the Company recorded an unrealized gain of $1.8 million and $5.1 million. The unrealized loss is due to the changing interest rate environment and is not due to changes in the credit quality of the underlying securities. The unrealized gain (loss) is recorded in other comprehensive income (loss) for the three and six months ended JuneÂ 30, 2024 and 2023.The Company receives equity securities in connection with certain licensing transactions with its partners. These investments in equity securities are carried at fair value with changes in fair value recognized each period and reported within other income (expense). For equity securities with a readily determinable fair value, the Company remeasures these equity investments at each reporting period until such time that the investment is sold or disposed. If the Company sells an investment, any realized gain or loss on the sale of the securities will be recognized within other income (expense) in the consolidated statements of loss in the period of sale.The Company also has investments in equity securities without a readily determinable fair value, where the Company elects the measurement alternative to record the investment at its initial cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There was an impairment charge of $20.4 million recorded for the six months ended JuneÂ 30, 2024 in connection with equity securities without a readily determinable fair value. There was no impairment charge recorded for the three and six months ended JuneÂ 30, 2023.12Table of ContentsLiability Related to the Sale of Future RevenuesWe treat the sale of future Monjuvi royalties as debt, amortized under the effective interest rate method over the estimated life of the Monjuvi Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future Monjuvi royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Non-cash Interest Expense on the Liability Related to the Sale of Future RoyaltiesThe total expected royalty payments less the net proceeds received are recorded as non-cash interest expense over the life of the liability. Interest is imputed on the unamortized portion using the effective interest method and is recorded based on the timing of the payments received over the term of the Monjuvi Royalty Sale Agreement. The actual interest rate will be affected by the timing of the royalty payments and changes in the forecasted revenue.Deferred Income Related to the Sale of Future RevenuesWe treat the sale of future Ultomiris royalties as deferred income, amortized under the units-of-revenue method by computing a ratio of the proceeds received to the total expected payments over the term of the Ultomiris Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid.Recent Accounting PronouncementsThere have been no material changes in recently issued or adopted accounting standards from those disclosed in the Company's 2023 Annual Report on Form 10-K. The Company has reviewed all recently issued accounting pronouncements and does not believe they will have a material impact on our results of operations, financial condition or cash flows.There have been no other material changes to the significant accounting policies previously disclosed in the Companyâ€™s 2023 Annual Report on Form 10-K.2. Fair Value of Financial InstrumentsFinancial instruments included in the financial statements include cash and cash equivalents, marketable debt and equity securities, accounts receivable, accounts payable, and accrued expenses. Marketable debt securities, equity securities, and cash equivalents are carried at fair value. The fair value of the other financial instruments closely approximates their fair value due to their short-term maturities.The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosure about fair value measurements. The ASC 820 hierarchy ranks the quality of reliable inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:Level 1â€”Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets or liabilities.Level 2â€”Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in markets that are not active. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. Level 3â€”Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by the reporting entity â€“ e.g., determining an appropriate discount factor for illiquidity associated with a given security. 13Table of ContentsThe Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands):June 30, 2024(unaudited)December 31, 2023TotalFair ValueLevel 1Level 2TotalFair ValueLevel 1Level 2Money Market Funds $11,624Â $11,624Â $â€”Â $25,520Â $25,520Â $â€”Â Corporate Securities211,657Â â€”Â 211,657Â 228,723Â â€”Â 228,723Â Government Securities342,577Â â€”Â 342,577Â 414,514Â â€”Â 414,514Â $565,858Â $11,624Â $554,234Â $668,757Â $25,520Â $643,237Â Our policy is to record transfers of assets between Level 1 and Level 2 at their fair values as of the end of each reporting period, consistent with the date of the determination of fair value. During the three and six months ended JuneÂ 30, 2024 and 2023, there were no transfers between Level 1 and Level 2. 3. Net Loss Per Common ShareBasic net loss per common share is computed by dividing the net loss attributable to Xencor by the weighted-average number of common shares outstanding during the period without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to Xencor by the weighted-average number of common stock equivalents outstanding for the period. Potentially dilutive securities consisting of stock issuable pursuant to outstanding options and restricted stock units (RSUs), and stock issuable pursuant to the 2013 Employee Stock Purchase Plan (ESPP) are not included in the per common share calculation in periods when the inclusion of such shares would have an anti-dilutive effect.Basic and diluted net loss per common share is computed as follows:Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023(in thousands, except share and per share data)(in thousands, except share and per share data)Numerator:Net loss attributable to Xencor, Inc.$(65,963)$(21,954)$(133,996)$(82,717)Denominator:Weighted-average common shares outstanding used in computing basic and diluted net loss61,676,44459,807,55861,444,38459,922,784Basic and diluted net loss per common share attributable to Xencor, Inc.(1.07)(0.37)(2.18)(1.38)For the three and six months ended JuneÂ 30, 2024 and 2023, all outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share as the effect of including such securities would have been anti-dilutive. 4. Comprehensive LossComprehensive loss is comprised of net loss and other comprehensive income (loss). For each of the three and six-month periods ended

JuneÂ 30, 2024 and 2023, the only component of other comprehensive income (loss) is net unrealized gain (loss) on marketable debt securities. There were no material reclassifications out of accumulated other comprehensive loss during each of the three and six-month periods ended JuneÂ 30, 2024 and 2023.14Table of Contents5. Marketable Debt and Equity SecuritiesThe Companyâ€™s marketable debt securities held as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are summarized below:June 30, 2024AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(in thousands)Money Market Funds $11,624Â $â€”Â $â€”Â $11,624Â Corporate Securities211,930Â 6Â (279)211,657Â Government Securities342,945Â 6Â (374)342,577Â $566,499Â $12Â (653)565,858Â Reported asCash and cash equivalents$11,624Â Marketable securities554,234Â Total investments$565,858Â December 31, 2023AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(in thousands)Money Market Funds $25,520Â $â€”Â $â€”Â $25,520Â Corporate Securities228,382Â 342Â (1)228,723Â Government Securities413,553Â 1,037Â (76)414,514Â $667,455Â $1,379Â (77)668,757Â Reported asCash and cash equivalents$25,520Â Marketable securities643,237Â Total investments$668,757Â The maturities of the Companyâ€™s marketable debt securities as of JuneÂ 30, 2024 are as follows:June 30, 2024AmortizedCostEstimatedFair Value(in thousands)Mature in one year or less$449,715Â $449,372Â Mature within two years105,160Â 104,862Â $554,875Â $554,234Â 15Table of ContentsThe unrealized losses on available-for-sale investments and their related fair values as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Less than 12 months12 months or greaterJune 30, 2024Fair valueUnrealizedlossesFair valueUnrealizedlosses(in thousands)Corporate Securities$119,044Â (217)11,895Â $(62)Government Securities246,154Â (132)79,478Â (242)$365,198Â (349)91,373Â $(304)Less than 12 months12 months or greaterDecember 31, 2023Fair valueUnrealizedlossesFair valueUnrealizedlosses(in thousands)Corporate Securities$8,073Â $(1)â€”Â $â€”Â Government Securities66,546Â (76)â€”Â â€”Â $74,619Â (77)â€”Â $â€”Â The unrealized losses from the available-for-sale securities are due to changes in the interest rate environment and not changes in the credit quality of the underlying securities in the portfolio.The Companyâ€™s equity securities include securities with a readily determinable fair value. These investments are carried at fair value with changes in fair value recognized each period and reported within other income (expense), net. For the three and six months ended JuneÂ 30, 2024, net losses of $12.0 million and $9.7 million were recorded under other income (expense) related to these securities. For the three and six months ended JuneÂ 30, 2023, a net gain of $0.3 million and a net loss of $2.6 million were recorded under other income (expense). Equity securities with a readily determinable fair value, which are categorized as Level 1 in the fair value hierarchy under ASC 820, and their fair values (in thousands) as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Fair ValueFair ValueJune 30, 2024December 31, 2023Astria Common Stock$2,311Â $5,360Â INmune Common Stock16,630Â 21,231Â Viridian Common Stock9,330Â 15,619Â $28,271Â $42,210Â The Company sold 443,909 shares of common stock of Astria Therapeutics, Inc. (Astria) and held 253,958 shares of common stock of Astria as of JuneÂ 30, 2024. In July 2024, the Company sold the remaining shares of the common stock of Astria. The common stock has a readily determinable fair value. For the remaining equity interest in Astria held at JuneÂ 30, 2024, the Company recorded an unrealized loss of $1.3 million and an unrealized gain of $0.4 million for the three and six months ended JuneÂ 30, 2024, respectively. The Company recorded unrealized losses of $3.5 million and $3.9 million related to its equity interest in Astria for the three and six months ended JuneÂ 30, 2023, respectively.The Company currently holds 1,885,533 shares of common stock of INmune Bio, Inc. (INmune). The 1,885,533 shares of INmune common stock are classified as equity securities with a readily determinable fair value. For the three and six months ended JuneÂ 30, 2024, the Company recorded unrealized losses of $5.5 million and $4.6 million, respectively, related to its investment in INmune. For the three and six months ended JuneÂ 30, 2023, the Company recorded unrealized gains of $4.9 million and $5.2 million, respectively.The Company currently holds 717,144 shares of common stock of Viridian Therapeutics, Inc. (Viridian). The shares of Viridian common stock are classified as equity securities with a readily determinable fair value. The Company 16Table of Contentsrecorded unrealized losses of $3.2 million and $6.3 million for the three and six months ended JuneÂ 30, 2024, respectively. The Company recorded unrealized losses of $1.2 million and $3.9 million for the three and six months ended JuneÂ 30, 2023, respectively, related to the shares of Viridian common stock. Below is a reconciliation of net gain (loss) recorded on equity securities during the three and six months ended JuneÂ 30, 2024 and 2023:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Net gain (loss) recorded on equity securities$(12,027)$288Â $(9,702)$(2,610)Less: Net gain (loss) recorded on sale of equity securities(2,012)â€”Â 827Â â€”Â Unrealized gain (loss) recorded on equity securities held at the reporting date$(10,015)$288Â $(10,529)$(2,610)The Company also has investments in equity securities without a readily determinable fair value. The Company elects the measurement alternative to record these investments at their initial cost and evaluates such investments at each reporting period for evidence of impairment, or observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Equity securities without a readily determinable fair value and their carrying values (in thousands) as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Carrying ValueCarrying ValueJune 30, 2024December 31, 2023Zenas Preferred Stock$43,780Â $64,210Â The Company currently holds an equity interest in Zenas BioPharma, Inc. (Zenas), a private biotechnology company. The Companyâ€™s equity interests include preferred stock in Zenas which were received as upfront payments and a milestone payment for licensing certain clinical and preclinical assets from the Company. The Company elected the measurement alternative to carry the Zenas equity at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. During the six months ended JuneÂ 30, 2024, we recorded $20.4Â million of impairment charge as a result of Zenas closing a Series C financing transaction on May 3, 2024.6. Stock Based CompensationIn June 2023, our Board of Directors (the Board) and stockholders approved the 2023 Equity Incentive Plan (the 2023 Plan), which became effective as of JuneÂ 14, 2023. The Board and the requisite stockholders previously approved the 2013 Equity Incentive Plan (the 2013 Plan). We suspended the 2013 Plan, and no additional award may be granted under the 2013 Plan. The 2023 Plan reserve consists of 3,000,000 shares and the remaining available shares from the 2013 Plan as of the effective date of the 2023 Plan. In addition, any shares of common stock covered by awards granted under the 2013 Plan that terminate on or after JuneÂ 14, 2023 by expiration, forfeiture, cancellation, or other means without the issuance of such shares will be added to the 2023 Plan reserve. The 2023 Plan does not include a provision for an automatic increase in shares, also known as an evergreen provision.As of JuneÂ 30, 2024, the total number of shares of common stock available for issuance under the 2023 Plan is 18,721,104, which includes shares of common stock that were available for issuance under the prior Plans as of the effective date of the 2023 Plan. As of JuneÂ 30, 2024, a total of 2,380,651 options have been granted under the 2023 Plan.In November 2013, the Board and our stockholders approved the ESPP, which became effective as of December 5, 2013. As of JuneÂ 30, 2024, the total number of shares of common stock available for issuance under the ESPP is 987,344. Unless otherwise determined by the Board, beginning on January 1, 2014, and continuing until January 1, 2023, the total number of shares of common stock available for issuance under the ESPP automatically increased annually on January 1 by the lesser of (i) 1% of the total number of issued and outstanding shares of common stock as of DecemberÂ 31 17Table of Contentsof the immediately preceding year, or (ii) 621,814 shares of common stock. The automatic increase has expired, and the number of shares of common stock available for issuance under the ESPP was not increased on JanuaryÂ 1, 2024. As of JuneÂ 30, 2024, we have issued a total of 787,474 shares of common stock under the ESPP.During the six months ended JuneÂ 30, 2024, the Company awarded 959,071 RSUs to certain employees. The standard vesting of these awards is generally in three equal annual installments and is contingent on an employeeâ€™s continued service to the Company. The fair value of these awards is determined based on the intrinsic value of the stock on the date of grant and will be recognized as stock-based compensation expense over the requisite service period. As of JuneÂ 30, 2024, a total of 1,045,738 RSUs have been granted under the 2023 Plan.The Company extended vesting periods and expiration dates of equity awards for employees who retired in April 2024. There is a $3.1 million incremental expense as a result of the extension of the expiration dates, and there is a $1.2 million expense as a result of the extension of the vesting periods.Total employee, director and non-employee stock-based compensation expense recognized for the three and six months ended JuneÂ 30, 2024 and 2023 are as follows (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023General and administrative $8,469Â $4,471Â $13,168Â $8,747Â Research and development 8,721Â 9,092Â 15,443Â 17,415Â $17,190Â $13,563Â $28,611Â $26,162Â Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Stock options$10,945Â $6,842Â $17,818Â $13,825Â ESPP211Â 341Â 417Â 663Â RSUs6,034Â 6,380Â 10,376Â 11,674Â $17,190Â $13,563Â $28,611Â $26,162Â The following table summarizes option activity under our stock plans and related information:Number ofShares Subjectto OutstandingOptionsWeightedAverageExercisePrice(PerShare)WeightedAverageRemainingContractualTerm(in years)AggregateIntrinsicValue(in thousands)Balance at December 31, 202311,142,986$29.60Â 6.03$9,977Â Options granted2,167,253$22.43Â Options forfeited(485,918)$32.84Â Options exercised(162,895)$11.83Â Balance at June 30, 202412,661,426$28.48Â 6.18$5,813Â Exercisable8,295,121$29.38Â 4.76$5,745Â We calculate the intrinsic value as the difference between the exercise price of the options and the closing price of common stock of $18.93 per share as of JuneÂ 30, 2024.The weighted-average fair value of options granted during the six-month periods ended JuneÂ 30, 2024 and 2023 were $22.43 and $30.65 per share, respectively. There were 1,941,412 options granted during the six-month period ended JuneÂ 30, 2023. We estimated the fair value of each equity award, including stock options and shares issued under our ESPP, using the Black-Scholes option-pricing model based on the date of grant of such stock option or ESPP share 18Table of Contentsissuance date, with the following weighted average assumptions for the three and six months ended JuneÂ 30, 2024 and 2023:OptionsOptions Three Months EndedJune 30,Six Months EndedJune 30,20242023202320242023Expected term (years)6.46.56.46.1Expected volatility50.4Â %51.2Â %50.1Â %50.5Â %Risk-free interest rate4.42Â %3.69Â %4.18Â %4.17Â %Expected dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â %ESPPESPP Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Expected term (years)0.5 - 2.00.5 - 2.00.5 - 2.00.5 -2.0Expected volatility43.0% - 44.6%38.2% - 55.7%43.0% - 44.6%38.2% - 55.7%Risk-free interest rate4.71% - 5.40%0.13% - 5.39%4.71% - 5.40%0.13% - 5.39%Expected dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â %As of JuneÂ 30, 2024, the unamortized compensation expense related to unvested stock options was $56.9 million. The remaining unamortized compensation expense will be recognized over the next 2.7 years. As of JuneÂ 30, 2024, the unamortized compensation expense under our ESPP was $1.3 million. The remaining unamortized expense will be recognized over the next 1.4 years.The following table summarizes the RSU activity for the six-month period ended JuneÂ 30, 2024:RestrictedStockUnitsWeighted Average Grant Date Fair Value(Per unit)Unvested RSUs at December 31, 20231,490,040$30.66Â Granted959,07122.58Â Vested(550,972)31.72Â Forfeited(119,483)29.80Â Unvested RSUs at June 30, 20241,778,656$26.02Â As of JuneÂ 30, 2024, the unamortized compensation expense related to unvested RSUs was $37.0Â million. The remaining unamortized expense will be recognized over the next 2.1 years.7. LeasesThe Company leases office and laboratory space in Monrovia, California under a lease that expires in December 2025 with an option to renew for an additional five years at then market rates. The Company has assessed that it is unlikely to exercise the option to extend the lease term. In June 2021, the Company entered into an Agreement of Lease (Lease Agreement) for laboratory and office space in Pasadena, California, which will expire in July 2035. The Lease Agreement provides for two separate phases of lease and occupancy. The first phase commenced on AugustÂ 1, 2022 and provides the Company with an improvement allowance up to $17.0 million. The second phase of the lease agreement will commence no later than SeptemberÂ 30, 2026 and includes an additional improvement allowance up to $3.3 million. In August 2022, the Company entered into an amendment, which the Company received an additional $5.0 million in tenant improvement allowance in exchange for an 19Table of Contentsincrease in the rental rate of the phase 1 space. The Company received delivery of the second phase premises on December 1, 2022. The Company placed the new facility into service in February 2023. In January 2024, the Company entered into an amendment, in which the Company will be paid for $0.7 million of tenant improvement allowance from the second phase for HVAC costs in the first phase. In August 2023, the Company entered into a Sublease Agreement for office space in San Diego, California. The term of the Sublease Agreement begins in September 2023 and ends in December 2027. In connection with the Sublease Agreement, the Company provided a $0.4 million Letter of Credit to the landlord. The Letter of Credit will decline over the term of the lease. The Company also entered into a Cash Collateral Agreement for $0.4 million, which is classified as restricted cash in the Consolidated Balance Sheets.The Companyâ€™s lease agreements do not contain any residual value guarantees or restrictive covenants.The following table reconciles the undiscounted cash flows for the operating leases at JuneÂ 30, 2024 to the operating lease liabilities recorded on the balance sheet (in thousands):Years ending December 31,For the remainder of 2024$2,792Â 20258,022Â 20269,238Â 20279,560Â 20289,076Â 20299,331Â Thereafter57,104Â Total undiscounted lease payments105,123Â Less: Tenant allowance(3,252)Less: Imputed interest(33,453)Present value of lease payments$68,418Â Lease liabilities - short-term$1,262Â Lease liabilities - long-term67,156Â Total lease liabilities$68,418Â The following table summarizes lease costs and cash payments for the three and six months ended JuneÂ 30, 2024 and 2023 (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Operating lease cost$1,881Â $2,020Â $3,762Â $4,200Â Variable lease cost310Â 219Â 1,140Â 453Â Total lease costs$2,191Â $2,239Â $4,902Â $4,653Â Cash paid for amounts included in the measurement of lease liabilities$807Â $721Â $1,877Â $1,445Â As of JuneÂ 30, 2024, the weighted-average remaining lease term for operating leases is 10.7 years, and the weighted-average discount rate for operating leases is 7.0%. As of JuneÂ 30, 2023, the weighted-average remaining lease term for operating leases was 11.7 years, and the weighted-average discount rate for operating leases was 8.9%.20Table of Contents8. Commitments and ContingenciesFrom time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred. The Company is obligated to make future payments to third parties pursuant to certain license agreements, including sublicense fees, royalties, and payments that become due and payable on the achievement of certain development and commercialization milestones. As the amount and timing of sublicense fees and the achievement and timing of these milestones are not probable and estimable, such commitments have not been included on the Companyâ€™s balance sheets for the periods ended JuneÂ 30, 2024 and DecemberÂ 31, 2023. The Company has also entered into agreements with third-party vendors that will require us to make future payments upon the delivery of goods and services in future periods.9. Collaboration and Licensing AgreementsThe following is a summary description of the material collaboration arrangements in the three and six months ended JuneÂ 30, 2024 and 2023.Alexion Pharmaceuticals, Inc.In January 2013, the Company entered into an Option and License Agreement (the Alexion Agreement) with Alexion Pharmaceuticals, Inc. (Alexion). Under the terms of the Alexion Agreement, the Company granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use the Companyâ€™s Xtend technology to evaluate and advance compounds. Alexion exercised its rights to one target program, ALXN1210, which is now marketed as UltomirisÂ®.The Company is entitled to receive royalties based on a percentage of net sales of Ultomiris sold by Alexion, its affiliates or its sublicensees, which percentage is in the low single digits. Alexionâ€™s royalty obligations continue on a product-by-product and country-by-country basis until the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country.On November 3, 2023, the Company entered into the Ultomiris Royalty Sale Agreement with OMERS, in which OMERS acquired the rights to certain royalties associated with the existing license relating to Ultomiris in exchange for cash consideration. For the six months ended JuneÂ 30, 2024, Company earned and recognized $16.3 million in non-cash royalty revenue under the Ultomiris Royalty Sale Agreement. The Company recognized $6.9 million and $16.3 million of non-cash royalty revenue during the three and six months ended JuneÂ 30, 2024, respectively, and $11.2 million and $21.6 million of royalty revenue under this arrangement for the three and six months ended JuneÂ 30, 2023, respectively. As of JuneÂ 30, 2024, there is no receivable and no deferred revenue related to this agreement.Genentech, Inc., and F. Hoffmann-La Roche LtdIn February 2019, the Company entered into a collaboration and license agreement (the Genentech Agreement) with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively, Genentech) for the development and commercialization of novel IL-15 collaboration products (Collaboration Products), including efbalropendekin alfa (also named XmAb306 and RG6323), the Companyâ€™s IL-15/IL15RÎ±-Fc candidate.Under the terms of the Genentech Agreement, Genentech received an exclusive worldwide license to XmAb306, and we shared in 45% of development and commercialization costs of Collaboration Products, and we were eligible to share in 45% of net profits and losses from the sale of approved products. However, in the fourth quarter of 2023, we agreed with Genentech to convert our current development cost and profit-sharing arrangement into a royalty and milestone payment-based arrangement. Pursuant to the terms of the amended agreement with Genentech, effective June 1, 2024, Genentech assumed sole responsibility over all clinical, regulatory and commercial activities. We are eligible to receive up to $600.0Â million in milestones, including $115.0Â million in development milestones, $185.0Â million in regulatory milestones and $300.0Â million in sales-based milestones and tiered royalties ranging from low double-digit to mid-teens percentages.21Table of ContentsThe Company did not recognize revenue related to the Genentech Agreement for the three and six months ended JuneÂ 30, 2024 or 2023. As of JuneÂ 30, 2024, there is a $7.6 million payable related to cost-sharing development activities during the first half of 2024 for development studies being conducted under the Genentech Agreement. There is no deferred revenue as of JuneÂ 30, 2024, as obligations to perform research activities have expired.Janssen Biotech, Inc., a Johnson & Johnson companyJ&J AgreementIn November 2020, the Company entered into a Collaboration and License Agreement (the J&J Agreement) with Janssen Biotech, Inc., a Johnson & Johnson company, pursuant to which the Company and J&J conducted research and

development activities to discover novel CD28 bispecific antibodies for the treatment of prostate cancer. Xencor together with J&J conducted joint research activities to discover XmAb bispecific antibodies against CD28 and against an undisclosed prostate tumor-target with J&J maintaining exclusive worldwide rights to develop and commercialize licensed products identified from the research activities.Under the J&J Agreement, the Company conducted research activities and applied its bispecific Fc technology to antibodies targeting prostate cancer provided by J&J. Upon completion of the research activities J&J had a candidate selection option to advance an identified candidate for development and commercialization. In November 2021, the Company completed its performance obligations under the research activities and delivered CD28 bispecific antibodies to J&J. In December 2021, J&J selected a bispecific CD28 candidate for further development. J&J will assume full responsibility for development and commercialization of the CD28 bispecific antibody candidate. The Company did not recognize revenue for the three and six months ended JuneÂ 30, 2024 and 2023 under the J&J Agreement. As of JuneÂ 30, 2024, there is no deferred revenue related to this Agreement. Second J&J AgreementOn OctoberÂ 1, 2021, the Company entered into a second Collaboration and License Agreement (the Second J&J Agreement) with J&J pursuant to which the Company granted J&J an exclusive worldwide license to develop, manufacture, and commercialize plamotamab, the Companyâ€™s CD20 x CD3 development candidate, and pursuant to which Xencor and J&J conducted research and development activities to discover novel CD28 bispecific antibodies. The parties conducted joint research activities for a two-year period to discover XmAb bispecific antibodies against CD28 and undisclosed B cell tumor-targets with J&J receiving exclusive worldwide rights, subject to certain Xencor opt-in rights, to develop, manufacture and commercialize pharmaceutical products that contain one or more of such discovered antibodies (CD28 Licensed Antibodies). The Agreement became effective on November 5, 2021.The Company collaborated with J&J on clinical development of plamotamab with J&J and shared development costs with J&J paying 80% and the Company paying 20% of certain development costs. In June 2024, the Company was notified that J&J will terminate its rights to plamotamab.The Company is generally responsible for conducting research activities under the Second J&J Agreement, and J&J is generally responsible for all development, manufacturing, and commercialization activities for CD28 Licensed Antibodies that are advanced. Revenue from the research activities was recognized over a period of time through the end of the research term that services were rendered as we determined that the input method was the appropriate approach to recognize income for such services. There is a receivable of $5.2 million as of JuneÂ 30, 2024, related to cost-sharing activities for development of plamotamab under the Second J&J Agreement. No revenue was recognized for the three and six months ended JuneÂ 30, 2024, and the Company recognized $22.2 million and $27.5 million of revenue for the three and six months ended JuneÂ 30, 2023, respectively. There is no deferred revenue as of JuneÂ 30, 2024 related to the Second J&J Agreement as obligations to perform research activities have expired.MorphoSys AG/Incyte CorporationIn June 2010, the Company entered into a Collaboration and License Agreement with MorphoSys AG (MorphoSys), which was subsequently amended. Under the agreement, we granted MorphoSys an exclusive worldwide license to the Companyâ€™s patents and know-how to research, develop and commercialize the XmAb5574 product candidate 22Table of Contents(subsequently renamed MOR208 and tafasitamab) with the right to sublicense under certain conditions. In February 2024, Incyte Corporation acquired exclusive global development and commercialization rights to tafasitamab. If certain developmental, regulatory and sales milestones are achieved, the Company is eligible to receive future milestone payments and royalties. On November 3, 2023, the Company entered into the Monjuvi Royalty Sale Agreement with OMERS, pursuant to which OMERS acquired the rights to certain royalties earned after July 1, 2023 associated with the existing license relating to Monjuvi. The Company recognized $1.6 million and $4.4 million of non-cash royalty revenue during the three and six months ended JuneÂ 30, 2024, respectively. The Company recognized $2.0 million and $3.9 million of royalty revenue during the three and six months ended JuneÂ 30, 2023, respectively. As of JuneÂ 30, 2024, there is a receivable of $2.1 million related to estimated royalties due under the arrangement. As of JuneÂ 30, 2024, there is no deferred revenue related to this agreement.Shanghai Mabgeek Biotech Co., Ltd.On December 22, 2023, the Company entered into a Technology License Agreement with Shanghai Mabgeek Biotech Co., Ltd. (Mabgeek), and the Company and Mabgeek entered into Amendment No. 1 on June 21, 2024 (collectively, Mabgeek Agreement). Under the Mabgeek Agreement, the Company received an upfront payment of $1.5 million and up to $11.9 million of milestones. In addition, the Company is eligible to receive royalties on the net sales of approved products in the low single digits.The Company evaluated the Mabgeek Agreement and determined that the single performance obligation was access to a non-exclusive license to certain patents of the Company which were transferred to Mabgeek in June 2024.The Company recognized $1.5 million of license revenue related to the agreement for the three and six months ended JuneÂ 30, 2024. There is no deferred revenue as of JuneÂ 30, 2024 related to this agreement.Vega Therapeutics, Inc.In October 2021, the Company entered into a Technology License Agreement (the Vega Agreement) with Vega Therapeutics, Inc. (Vega), in which the Company provided Vega a non-exclusive license to its Xtend Fc technology. In March 2024, Vega notified the Company that it initiated a Phase 1 study, and the Company recorded milestone revenue of $0.5 million.The Company recognized $0.5 million of revenue for the six months ended JuneÂ 30, 2024. No revenue was recognized for the three months ended JuneÂ 30, 2024 or the three and six months ended JuneÂ 30, 2023.Vir Biotechnology, Inc.In 2019, the Company entered into a Patent License Agreement (the Vir Agreement) with Vir Biotechnology, Inc. (Vir) pursuant to which the Company provided a non-exclusive license to its Xtend technology for up to two targets.In March 2020, the Company entered into a second Patent License Agreement (the Second Vir Agreement) with Vir pursuant to which the Company provided a non-exclusive license to its Xtend technology to extend the half-life of novel antibodies Vir developed as potential treatments for patients with COVID-19, including sotrovimab. Under the terms of the Second Vir Agreement, Vir is responsible for all research, development, regulatory and commercial activities for the antibodies, and the Company is eligible to receive royalties on the net sales of approved products in the mid-single digit percentage range. Vir and its marketing partner, GSK, began recording sales for sotrovimab beginning in June 2021.The Company recognized $0.1 million of revenue for the six months ended JuneÂ 30, 2024, and the Company recognized $0.1 million and $1.5 million of royalty revenue for the three and six months ended JuneÂ 30, 2023, respectively. As of JuneÂ 30, 2024, there is no receivable related to estimated royalty due under this agreement, and there is no deferred revenue related to this agreement. 23Table of ContentsZenas BioPharma, Inc.In November 2020, the Company entered into a License Agreement (the Zenas Agreement) with Zenas, pursuant to which the Company received an equity interest in Zenas in exchange for the exclusive, worldwide rights to develop and commercialize drug candidates from the Company. The equity in Zenas is recorded at the fair value as of the date of the Zenas Agreement and is reviewed each reporting period for impairment or other evidence of change in value. In November 2021, the Company entered into a second License Agreement (Second Zenas Agreement) with Zenas, pursuant to which the Company received additional equity in Zenas in exchange for the exclusive worldwide rights to develop and commercialize the Companyâ€™s obexelimab (XmAb5871) drug candidate. Under the license, the Company is eligible to receive development, regulatory and sales milestones in connection with the development of obexelimab and royalties on net sales of approved products. The original equity received for the second license was a warrant to acquire additional shares of Zenas. The warrant was exchanged for additional preferred stock in Zenas in November 2022. The warrant in Zenas was recorded at its fair value as of the date of the Second Zenas Agreement and was reviewed each reporting period for impairment or other evidence of change in value. The preferred shares received in exchange for the warrant were recorded at their fair value at the date of the exchange and is reviewed each reporting period for impairment or other evidence of change in value.In 2023, Zenas initiated a Phase 3 clinical study with obexelimab and also dosed a second patient in the study. The Company received a development milestone in the form of additional preferred stock in Zenas with a fair value of $10.0 million.The Company recognized an impairment charge of $20.4 million in the six months ended JuneÂ 30, 2024 due to an impairment analysis resulting from the Zenas Series C financing transaction. The Company did not record an impairment charge or change in the value of the Zenas equity in the three and six months ended JuneÂ 30, 2023. The Company did not recognize any revenue for the three and six months ended JuneÂ 30, 2024. The Company recognized $10.0 million of milestone revenue for the three and six months ended JuneÂ 30, 2023, and there is no deferred revenue related to this agreement.Third-Party LicenseeIn May 2024, the Company entered into a Patent License Agreement (Third-Party Licensee Agreement) with a third-party licensee. The Company completed delivery of the performance obligation under the agreement, and the Company will receive a payment of $7.0 million.The Company recognized $7.0 million of license revenue for the three and six months ended JuneÂ 30, 2024, and there is a receivable of $7.0 million. There is no deferred revenue related to this agreement.Gale Therapeutics Inc.In the fourth quarter of 2023, the Company formed a subsidiary, Gale Therapeutics Inc. (Gale), to develop novel drug candidates with its Fc technologies. In December 2023, the Company entered into a Technology License Agreement (Gale License Agreement) with Gale in which Gale received an exclusive worldwide, royalty-bearing, non-transferable license to preclinical assets in exchange for royalties on future sales and an option for future drug candidates that Gale will develop. Concurrently, the Company entered into a Service Agreement (Gale Services Agreement) to provide research and development services and administrative support for Gale. In exchange for $7.5 million of funding, the Company acquired a majority stake in Gale. Total charges of $4.6 million and $8.0 million under the Gale Services Agreement for the three and six months ended JuneÂ 30, 2024, respectively, were eliminated in consolidation. In July 2024, the Company entered into a preferred stock purchase agreement to purchase additional shares in Gale for $3.0 million. 24Table of ContentsRevenues earned The revenues recorded for the three and six months ended JuneÂ 30, 2024 and 2023 were earned principally from the following licensees (in millions):Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Alexion$6.9Â $11.2Â $16.3Â $21.6Â Janssenâ€”Â 22.2Â â€”Â 27.5Â Mabgeek$1.5Â $â€”Â $1.5Â $â€”Â MorphoSys1.6Â 2.0Â 4.4Â 3.9Â Vegaâ€”Â â€”Â 0.5Â â€”Â Virâ€”Â 0 Party Licensee$7.0Â $â€”Â $7.0Â $â€”Â Total$17.0Â $45.5Â $29.8Â $64.5Â The table below summarizes the disaggregation of revenue recorded for the three and six months ended JuneÂ 30, 2024 and 2023 (in millions):Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Research collaboration$â€”Â $22.2Â $â€”Â $22.5Â License8.5Â â€”Â 8.5Â â€”Â Milestoneâ€”Â 10.0Â 0.5Â 15.0Â Royaltiesâ€”Â 13.3Â 0.1Â 27.0Â Non-cash royalties8.5Â â€”Â 20.7Â â€”Â Total$17.0Â $45.5Â $29.8Â $64.5Â Remaining Performance Obligations and Deferred RevenueThe Company does not have any remaining performance obligation as of JuneÂ 30, 2024. As of JuneÂ 30, 2023, the Company had deferred revenue of $7.9 million for conducting research activities pursuant to the Second J&J Agreement. All deferred revenue as of JuneÂ 30, 2023 was classified as current liabilities as the Companyâ€™s obligations to perform services are due on demand when requested by J&J under the Second J&J Agreement. 10. Income taxesThe Company recorded $0.1 million of income tax expense for the three and six months ended JuneÂ 30, 2024. There is no provision for income tax for the three and six months ended JuneÂ 30, 2023. As of JuneÂ 30, 2024, the Companyâ€™s deferred income tax assets, consisting primarily of net operating loss and tax credit carryforwards, have been fully offset by a valuation allowance.25Table of Contents11. Sale of Future RoyaltiesUltomiris Royalty Sale AgreementThe Company evaluated the arrangement and determined that the proceeds from the sale of future royalties should be recorded as deferred income on the balance sheets as none of the criteria for classification as debt were met in accordance with ASC 470 Debt. The Company records the non-cash royalty revenue under the â€œunits-of-revenueâ€ method in the consolidated statements of loss. For the three and six months ended JuneÂ 30, 2024, the Company recognized $6.9 million and $16.3 million of non-cash royalty revenue, respectively. There is $140.6 million in deferred income as of JuneÂ 30, 2024.Monjuvi Royalty Sale AgreementThe Company evaluated the arrangement and determined that the proceeds from the sale of future royalties should be classified as debt pursuant to ASC 470 Debt. At JuneÂ 30, 2024, the Company reassessed the estimate of total future royalty payments and updated the estimated effective interest rate to 17.5%. The Company will continue to reassess the estimate of total future royalty payment and prospectively adjust the imputed interest rate and related amortization if the estimate is materially different. For the three and six months ended JuneÂ 30, 2024, the Company recognized $1.6 million and $4.4 million of non-cash royalty revenue, respectively, and $0.8 million and $1.9 million of non-cash interest expense, respectively.The following table shows the activity within debt for the six months ended JuneÂ 30, 2024 (in thousands):June 30, 2024Beginning balance of debt related to sale of future royalties$20,974Â Royalties owed to OMERS834Â Royalties paid to OMERS(4,448)Non-cash interest expense recognized1,900Â Ending balance of debt related to sale of future royalties$19,260Â Debt - short-term6,947Â Debt - long-term12,313Â Total debt$19,260Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto for the fiscal year ended DecemberÂ 31, 2023 and the related Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. See also â€œSpecial Note Regarding Forward-Looking Statementsâ€ included in this Quarterly Report on Form 10-Q.Company OverviewWe are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and other serious diseases, who have unmet medical needs. We are advancing a broad portfolio of clinical-stage XmAbÂ® drug candidates from our proprietary Fc technology platforms. We also use our protein engineering capabilities to increase our understanding of protein structure and interactions and to design new Fc technologies and XmAb development candidates with improved properties. In addition to engineering protein-target interactions, our approach to protein design includes engineering Fc domains, the parts of antibodies that interact with multiple segments of the immune system and control antibody structure. The Fc domain is constant and interchangeable among antibodies, and our engineered Fc domains can be readily substituted for natural Fc domains. 26Table of ContentsOur protein engineering capabilities and Fc technologies enable us and our partners to develop XmAb antibodies and other types of biotherapeutic drug candidates with improved properties and functionality, which can provide innovative approaches to treating disease and potential clinical advantage over other treatment options. For example, we developed an antibody scaffold to rapidly create novel multi-specific antibodies that bind two or more different targets simultaneously, creating entirely new biological mechanisms. Other applications of our protein engineering technologies enhance antibody performance by increasing immune inhibitory activity, improving cytotoxicity, extending circulating half-life and stabilizing novel protein structures. Three marketed XmAb medicines have been developed with our protein engineering technologies.Refer to Part I, Item 1, "XmAb Bispecific Fc Domain and New Multi-Specific Antibody Formats" and "Other XmAb Fc Domains" in the description of our business included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 for a discussion of our core Fc technology platforms.Clinical-Stage XmAb Drug CandidatesOur modular XmAb bispecific technology and protein engineering capabilities enable us to rapidly advance multiple drug candidates into clinical development. We are currently enrolling Phase 1 or Phase 2 studies for four wholly-owned candidates to treat patients with many different types of serious diseases.Vudalimab (PD-1 x CTLA-4): Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4, two immune checkpoint receptors, to selectively activate the tumor microenvironment, and it is being developed for patients with metastatic castration-resistant prostate cancer (mCRPC) and patients with locally advanced or metastatic non-small cell lung cancer. Data from a Phase 1 study that enrolled heavily pretreated patients with multiple solid tumor types indicated that vudalimab was generally well-tolerated with encouraging clinical activity. We are conducting a Phase 2 study of vudalimab in patients with mCRPC, as a monotherapy or in combination with chemotherapy for patients with aggressive variant prostate cancer, as these patients represent a high unmet medical need. We are also conducting a second Phase 2 study in patients with clinically-defined high-risk mCRPC, in which initial data indicates that vudalimab monotherapy has been generally well tolerated and associated with response to treatment in multiple patients who have visceral or lymph node metastases. In March 2024, we disclosed additional clinical data showing characteristics of patients with clinical response (n=5/12) and per label rates of immune-mediated hepatitis for ipilimumab (anti-CTLA-4; 1 mg/kg) + nivolumab (anti-PD-1; 3 mg/kg) combination treatment, as generally comparable to the rate of all hepatobiliary disorder adverse events including immune-mediated hepatitis for vudalimab among all patients treated at doses greater than or equal to 10 mg/kg.We are also conducting a Phase 1b/2 study evaluating vudalimab as a first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer.XmAb819 (ENPP3 x CD3): XmAb819 is a bispecific T-cell engager that targets ENPP3, a tumor-associated antigen in renal cell carcinoma (RCC), and CD3, an activating receptor on T cells. The XmAb 2+1 multivalent format used in XmAb819 enables greater selectivity for ENPP3 expressing tumor cells compared to normal cells, which also express ENPP3 at lower levels. We are currently enrolling a Phase 1 study to evaluate XmAb819 in patients with advanced clear cell RCC.XmAb808 (B7-H3 x CD28): XmAb808 is a tumor-selective, co-stimulatory XmAb 2+1 bispecific T-cell engager designed to bind to the broadly expressed tumor antigen B7-H3 and selectively to the CD28 T-cell co-receptor only when bound to tumor cells. We are conducting a Phase 1 study to evaluate XmAb808 in combination with pembrolizumab in patients with advanced solid tumors.XmAb541 (CLDN6 x CD3): XmAb541 is a bispecific T-cell engager that targets Claudin-6 (CLDN6), a tumor-associated antigen in ovarian cancer and other solid tumors, and CD3. The XmAb 2+1 multivalent format used in XmAb541 enables greater selectivity for CLDN6 over similar Claudin family members, such as CLDN9, CLDN3 and CLDN4. We are currently enrolling a Phase 1 study to evaluate XmAb541 in patients with ovarian cancer and other CLDN6 expressing tumor types. The first patient was dosed in April 2024.XmAb564 (IL2-Fc Cytokine): XmAb564 is a monovalent interleukin-2 Fc (IL-2-Fc) fusion protein engineered to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of patients with autoimmune diseases. 27Table of ContentsIn the first half of 2024, we concluded a Phase 1b study that was evaluating the safety and tolerability of multiple ascending doses of XmAb564, administered subcutaneously in patients, and we have paused further

development.XmAb662 (IL12-Fc Cytokine): XmAb662 is a potency-reduced interleukin-12 Fc (IL12-Fc) fusion protein engineered to increase anti-tumor activity and immunogenicity in the tumor microenvironment by promoting high levels of interferon gamma secretion from T cells and NK cells. In the first half of 2024, we concluded a Phase 1 study that was evaluating XmAb662 in patients with advanced solid tumors, and we have paused further development.Candidates Previously Co-Developed with PartnersPlamotamab (CD20 x CD3): Plamotamab is a bispecific T-cell engager that targets CD20, a target receptor on B cells, and CD3. Results from the expansion portion of a Phase 1 study indicate that intravenous plamotamab monotherapy was well tolerated and demonstrated encouraging clinical activity in heavily pretreated patients with an advanced form of lymphoma at the recommended Phase 2 intravenous dose. In 2023, we completed patient enrollment in subcutaneous dose escalation cohorts of the Phase 1 study. We had been co-developing plamotamab with Johnson & Johnson (J&J), and in June 2024, we regained exclusive worldwide rights to develop and commercialize the candidate. We are reviewing plamotamab's potential for addressing the unmet medical needs of patients.Efbalropendekin alfa (IL15/IL15RÎ±-Fc Cytokine): Efbalropendekin alfa (XmAb306/RG6323) is a reduced-potency IL15/IL15RÎ±-Fc fusion protein that incorporates our Xtend extended half-life technology, and we previously co-developed this program in collaboration with Genentech, a member of the Roche Group. Genentech is conducting a Phase 1 study of efbalropendekin as a single agent and in combination with atezolizumab in patients with advanced solid tumors and is also conducting a Phase 1 study evaluating efbalropendekin in patients with relapsed/refractory multiple myeloma in combination with cevostamab (FcRH5 x CD3 bispecific antibody). In the fourth quarter of 2023, we agreed with Genentech to convert our current development cost and profit-sharing arrangement into a royalty and milestone payment-based arrangement. Pursuant to the terms of the amended agreement with Genentech, effective June 1, 2024, Genentech assumed sole responsibility over all clinical, regulatory and commercial activities. We are eligible for up to $600.0 million in milestones and tiered royalties on approved sales from low double-digit to mid-teen percentages range.Advancements Expanding XmAb Bispecific PlatformsWe conduct further research into the function and application of antibody components in order to expand the scope of our XmAb technology platforms and identify additional XmAb drug candidates. We use the modularity of our XmAb bispecific Fc technology to build antibody-based therapeutics in a variety of formats, such as T cell engaging bispecific antibodies of a mixed valency format, the XmAb 2+1 bispecific antibody. XmAb 2+1 bispecific antibodies may preferentially kill tumor cells with high target expression, which may be especially beneficial in designing antibodies that target solid tumors. This selectivity potentially empowers T cell engaging bispecifics (e.g., CD3, CD28) to address an expanded set of tumor antigens. Five clinical-stage programs utilize our XmAb 2+1 format: XmAb819, XmAb808, XmAb541, xaluritamig and ASP2138.Additionally, we have engineered CD28 bispecific antibodies to provide conditional CD28 co-stimulation of T cells, activating them when bound to tumor cells. Targeted CD28 bispecific antibodies may provide conditional co-stimulation of T cells, for example, to T cells recognizing neoantigens or in concert with CD3 T-cell engaging bispecific antibodies. In addition to our first clinical-stage CD28 program, XmAb808, our CD28 platform is the subject of two collaborations with J&J. JNJ-9401 and JNJ-1493 are clinical-stage XmAb bispecific antibodies that J&J is developing in prostate cancer and B-cell malignancies, respectively, and both entered clinical development during the fourth quarter of 2023.In the first quarter of 2024, we amended the MorphoSys Agreement, which included releasing us from certain exclusivity obligations relating to CD19.Progress Across PartnershipsA key part of our business strategy is to leverage our protein engineering capabilities, XmAb Fc domains and drug candidates with partnerships, collaborations and licenses. Through these arrangements we generate revenues in the form of upfront payments, milestone payments and royalties. For partnerships for our drug candidates, we aim to retain a major economic interest in the form of keeping major geographic commercial rights; profit-sharing; co-development options; and 28Table of Contentsthe right to conduct studies with drug candidates developed in the collaboration. The types of arrangements that we have entered into with partners include product licenses, novel bispecific antibody collaborations, technology licensing agreements and strategic collaborations.Product LicensesProduct licenses are arrangements in which we have internally developed drug candidates and, based on a strategic review, licensed partial or full rights to third parties to continue development and potential commercialization. We seek partners that can provide infrastructure and resources to successfully develop our drug candidates, have a track record of successfully developing and commercializing medicines, or have a portfolio of development-stage candidates and commercialized medicines that could potentially be developed in rational combinations with our drug candidates.The FDA approved MonjuviÂ® (tafasitamab-cxix) under accelerated approval in July 2020. Monjuvi is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In August 2021, the European Commission granted conditional marketing authorization for MinjuviÂ® (tafasitamab) in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). Tafasitamab was created and initially developed by us. Tafasitamab is marketed by Incyte Corporation under the brand name Monjuvi in the U.S. and under the brand name Minjuvi in Europe and Canada. Incyte has exclusive commercialization rights to tafasitamab outside the U.S. MonjuviÂ® and MinjuviÂ® are registered trademarks of Incyte. In February 2024, Incyte acquired exclusive global development and commercialization rights to tafasitamab from MorphoSys AG. We earned $1.6 million in estimated non-cash royalties from MorphoSys for the three months ended JuneÂ 30, 2024.Technology License AgreementsWe enter into technology licensing agreements in which we license access to one or more of our XmAb Fc domains on a restricted basis, typically to an XmAb Cytotoxic Fc Domain and/or the Xtend Fc Domain. Our partners are responsible for all research, development, and commercialization activities of the drug candidates. The plug-and-play nature of XmAb technologies allows us to license access to our platforms with limited or no internal research and development activities.Alexionâ€™s UltomirisÂ® uses Xtend Fc technology for longer half-life. Ultomiris has received marketing authorizations in global markets for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), for certain patients with atypical hemolytic uremic syndrome (aHUS), for certain patients with generalized myasthenia gravis (gMG) and for certain patients with neuromyelitis optica spectrum disorder (NMOSD). Ultomiris was approved in the U.S. for the treatment of adult patients with anti-aquaporin-4 antibody-positive NMOSD in March 2024. Alexion is also evaluating Ultomiris in a broad development program across additional hematology and neurology indications. We earned a total of $6.9 million in estimated non-cash royalties from Alexion for the three months ended JuneÂ 30, 2024. Refer to Part I, Item 1, Note 9, Collaboration and Licensing Agreements of the Notes to Financial Statements included in this Quarterly Report on Form 10-Q for a description of the key terms of our arrangements.We have over 1,500 issued and pending patents worldwide to protect our XmAb technology platform and XmAb drug candidates.Since we commenced active operations in 1998, we have devoted substantially all our resources to staffing our Company, business planning, raising capital, developing our technology platforms, identifying potential product candidates, undertaking preclinical and IND-enabling studies, and conducting clinical trials. We have no internally developed products approved for commercial sale and have not generated any revenues from our own product sales, and we continue to incur significant research and development expenses and other expenses related to our ongoing operations. To date, we have funded our operations primarily through the sale of stock and from payments generated from our product development partnerships and licensing arrangements.29Table of ContentsAs of JuneÂ 30, 2024, we had an accumulated deficit of $598.4 million. Substantially all of the operating losses that we have incurred resulted from expenses incurred in connection with our product candidate development programs, our research activities and general and administrative costs associated with our operations.Results of OperationsComparison of the Three Months Ended JuneÂ 30, 2024 and 2023The following table summarizes our results of operations for the three months ended JuneÂ 30, 2024 and 2023 (in millions):Three Months EndedJune 30,20242023ChangeRevenues:Research collaboration$â€”Â $22.2Â $(22.2)License8.5Â â€”Â 8.5Â Â Â Milestoneâ€”Â 10.0Â (10.0)Royalties8.5Â 13.3Â (4.8)Total revenues17.0Â 45.5Â (28.5)Operating expenses:Â Research and development61.5Â 60.0Â 1.5Â Â General and administrative17.7Â 11.5Â 6.2Â Total operating expenses79.2Â 71.5Â 7.7Â Other income (expense), net(5.0)4.0Â (9.0)Loss before income tax expense(67.2)(22.0)(45.2)Income tax expense0.1Â â€”Â 0.1Â Net loss(67.3)(22.0)(45.3)Net loss attributable to non-controlling interest(1.4)â€”Â (1.4)Net loss attributable to Xencor, Inc.(65.9)(22.0)$(43.9)RevenuesRevenues for the three months ended JuneÂ 30, 2024 are primarily from licensing revenue from Mabgeek and a third-party licensee as well as non-cash royalty revenue from Alexion and MorphoSys/Incyte. Revenues for the three months ended JuneÂ 30, 2023 are primarily from research revenue from our second collaboration with Janssen, royalty revenue from Alexion, and milestone revenue from Zenas.30Table of ContentsResearch and Development ExpensesThe following tables summarize our research and development expenses for the three months ended JuneÂ 30, 2024 and 2023 (in millions):Three Months EndedJune 30,20242023ChangeProduct programs:Bispecific programs:CD3 programs:Plamotamab*$2.8Â $4.1Â $(1.3)XmAb819 (ENPP3 x CD3)6.8Â 4.8Â 2.0Â XmAb541 (CLDN6 X CD3)4.5Â 6.3Â (1.8)Total CD3 programs14.1Â 15.2Â (1.1)XmAb808 (B7-H3 x CD28)5.2Â 4.3Â 0.9Â Tumor micro environment (TME) activator programs:Vudalimab12.2Â 9.6Â 2.6Â XmAb1040.7Â 5.8Â (5.1)Total TME activators programs12.9Â 15.4Â (2.5)Subtotal bispecific programs32.2Â 34.9Â (2.7)Cytokine programs:XmAb306/RG6323 programs*4.9Â (0.5)5.4Â XmAb5642.3Â 5.9Â (3.6)XmAb662 (IL-12-Fc)2.0Â 3.8Â (1.8)Total cytokine programs9.2Â 9.2Â â€”Â Other, research and early stage programs 19.9Â 14.7Â 5.2Â Wind down costs of terminated programs (1)0.2Â 1.2Â (1.0)Total research and development expenses$61.5Â $60.0Â $1.5Â *Includes net reimbursements to and from our partners pursuant to agreements that include cost-sharing arrangements.(1)Research and development expenses include wind down costs of programs that terminated in prior periods including the vibecotamab, tidutamab, and XmAb841 programs.31Table of ContentsThree Months EndedJune 30,20242023ChangeExternal research and development expenses$29.6Â $25.0Â $4.6Â Internal research and development expenses23.2Â 25.9Â (2.7)Stock based compensation8.7Â 9.1Â (0.4)Total research and development expenses$61.5Â $60.0Â $1.5Â Research and development expenses increased by $1.5 million for the three months ended JuneÂ 30, 2024 over the same period in 2023 primarily due to increased spending on other research and early stage programs, partially offset by decreased spending on our XmAb104 program.General and Administrative ExpensesThe following table summarizes our general and administrative expenses for the three months ended JuneÂ 30, 2024 and 2023 (in millions):Three Months EndedJune 30,20242023ChangeGeneral and administrative$17.7Â $11.5Â $6.2Â General and administrative expenses increased by $6.2 million for the three months ended JuneÂ 30, 2024 over the same period in 2023 primarily due to increased spending on corporate activities, including stock-based compensation costs related to the extension of vesting periods and expiration dates of equity awards for employees who retired in April 2024.Other Income (Expense), NetOther (expense), net was $(5.0) million for the three months ended JuneÂ 30, 2024, which consists of unrealized and realized losses recognized from the change in fair value and the sale of our equity investments, partially offset by interest income earned on investments. Other income, net was $4.0 million for the three months ended JuneÂ 30, 2023, which consists primarily of interest income earned on investments.32Table of ContentsComparison of the Six Months Ended JuneÂ 30, 2024 and 2023The following table summarizes our results of operations for the six months ended JuneÂ 30, 2024 and 2023 (in millions):Six Months EndedJune 30,20242023ChangeRevenues:Research collaboration$â€”Â $22.5Â $(22.5)License8.5Â â€”Â 8.5Â Â Â Milestone0.5Â 15.0Â (14.5)Royalties20.8Â 27.0Â (6.2)Total revenues29.8Â 64.5Â (34.7)Operating expenses:Â Research and development118.4Â 125.6Â (7.2)Â General and administrative31.5Â 25.6Â 5.9Â Total operating expenses149.9Â 151.2Â (1.3)Other income (expense), net(15.8)4.0Â (19.8)Loss before income tax expense(135.9)(82.7)(53.2)Income tax expense0.1Â â€”Â 0.1Â Net loss(136.0)(82.7)$(53.3)Net loss attributable to non-controlling interest(2.1)â€”Â (2.1)Net loss attributable to Xencor, Inc.(133.9)(82.7)$(51.2)RevenuesRevenues for the six months ended JuneÂ 30, 2024 are primarily licensing revenue from Mabgeek and a third-party licensee as well as non-cash royalty revenue from Alexion and MorphoSys. Revenues for the six months ended JuneÂ 30, 2023 are primarily from research revenue from our second collaboration with Janssen, royalty revenue from Alexion, and milestone revenue from Janssen and Zenas.33Table of ContentsResearch and Development ExpensesThe following tables summarize our research and development expenses for the six months ended JuneÂ 30, 2024 and 2023 (in millions):Six Months EndedJune 30,20242023ChangeProduct programs:Bispecific programs:CD3 programs:Plamotamab*$5.0Â $9.8Â $(4.8)XmAb819 (ENPP3 x CD3)13.1Â 9.3Â 3.8Â XmAb541 (CLDN6 X CD3)7.0Â 10.9Â (3.9)Total CD3 programs25.1Â 30.0Â (4.9)XmAb808 (B7-H3 x CD28)10.5Â 8.1Â 2.4Â Tumor micro environment (TME) activator programs:Vudalimab23.7Â 17.3Â 6.4Â XmAb1043.2Â 13.0Â (9.8)Total TME activators programs26.9Â 30.3Â (3.4)Subtotal bispecific programs62.5Â 68.4Â (5.9)Cytokine programs:XmAb306/RG6323 programs*10.4Â 4.5Â 5.9Â XmAb5646.8Â 12.5Â (5.7)XmAb662 (IL-12-Fc)4.8Â 7.0Â (2.2)Total cytokine programs22.0Â 24.0Â (2.0)Other, research and early stage programs 33.2Â 28.9Â 4.3Â Wind down costs of terminated programs (1)0.7Â 4.3Â (3.6)Total research and development expenses$118.4Â $125.6Â $(7.2)*Includes net reimbursements to and from our partners pursuant to agreements that include cost-sharing arrangements.(1)Research and development expenses include wind down costs of programs that terminated in prior periods including the vibecotamab, tidutamab, and XmAb841 programs.34Table of ContentsSix Months EndedJune 30,20242023ChangeExternal research and development expenses$55.3Â $54.0Â $1.3Â Internal research and development expenses47.7Â 54.2Â (6.5)Stock based compensation15.4Â 17.4Â (2.0)Total research and development expenses$118.4Â $125.6Â $(7.2)Research and development expenses decreased by $7.2 million for the six months ended JuneÂ 30, 2024 over the same period in 2023 primarily due to decreased spending on our XmAb104 program, partially offset by increased spending on other research and early stage programs.General and Administrative ExpensesThe following table summarizes our general and administrative expenses for the six months ended JuneÂ 30, 2024 and 2023 (in millions):Six Months EndedJune 30,20242023ChangeGeneral and administrative$31.5Â $25.6Â $5.9Â General and administrative expenses increased by $5.9 million for the six months ended JuneÂ 30, 2024 over the same period in 2023 primarily due to increased corporate activities including stock-based compensation costs related to the extension of vesting periods and expiration dates of equity awards for employees who retired in April 2024.Other Income (Expense), NetOther income (expense), net was $(15.8) million and $4.0 million for the six months ended JuneÂ 30, 2024 and 2023, respectively. Other expense, net for the six months ended JuneÂ 30, 2024 consists of an impairment charge on Zenas, our equity investment without a readily determinable fair value, and unrealized and realized losses recognized from the change in fair value and the sale of our other equity investments with readily determinable fair values, partially offset by interest income earned on investments. Other income, net for the same period in 2023 consists primarily of interest income earned on investments, partially offset by unrealized loss recognized from the change in fair value of our equity investments.Cash FlowsThe following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands):Six Months EndedJune 30,20242023ChangeNet cash provided by (used in):Operating activities$(120,595)$(68,814)$(51,781)Investing activities$98,334Â $46,739Â $51,595Â Financing activities(757)2,843Â $(3,600)Net decrease in cash$(23,018)$(19,232)$(3,786)35Table of ContentsOperating ActivitiesCash used in operating activities for the six months ended JuneÂ 30, 2024 and 2023 was $120.6 million and $68.8 million, respectively. The increase in cash used in operating activities is due to the decrease in royalty revenue received as a result of the sale of future royalties in 2023 and higher spending in the six months ended JuneÂ 30, 2024.Investing ActivitiesInvesting activities consist primarily of investments in marketable debt securities available-for-sale, purchases of intangible assets, capitalization of patent and licensing costs and purchases of property and equipment.Financing ActivitiesNet cash used in financing activities for the six months ended JuneÂ 30, 2024 is due to the reduction in our liability under the OMERS agreement for Monjuvi, partially offset by net proceeds from the exercise of stock options and purchase of ESPP. Net cash provided by financing activities for the six months ended JuneÂ 30, 2023 represents net proceeds from the exercise of stock options and purchase of ESPP. Liquidity and Capital ResourcesWe have financed our operations primarily through private placements of our equity securities, the issuance of convertible notes, public offerings of our common stock, and payments received under our product development partnerships and licensing arrangements. As of JuneÂ 30, 2024, we had $585.4Â million of cash, cash equivalents, restricted cash, and marketable debt securities compared to $697.4Â million as of DecemberÂ 31, 2023. The investments in marketable debt securities are further described above in Note 5, Marketable Debt and Equity Securities, of Notes to Financial Statements included in this Quarterly Report on Form 10-Q. We expect to continue to receive additional payments from our collaborators for research and development services rendered, additional milestone, opt-in and contingent payments, and royalties. Our ability to receive additional milestone payments and contingent payments from our partners is dependent upon either our ability or our partnersâ€™ abilities to achieve certain levels of research and development activities and is therefore uncertain at this time.Funding RequirementsWe have not generated any revenue from the sale of products developed by us to date and do not expect to do so until we obtain regulatory approval of and commercialize one or more of our internal product development candidates. As we are currently in the clinical stage of development, it will be some time before we expect to achieve this, and it is uncertain that we ever will commercialize one or more of our internal product development candidates. We expect that we will continue to increase our operating expenses in connection with ongoing, and additional clinical and preclinical development of product candidates in our pipeline and also development candidates that we are co-developing with our partners.Although it is difficult to predict our funding requirements, based upon our

current operating plan, we expect that our existing cash, cash equivalents, marketable securities, and certain potential milestone payments will fund our operating expenses and capital expenditure requirements into 2027. We have based these estimates on assumptions that may prove to be wrong which would cause us to use our capital resources sooner than we currently expect. Off-Balance Sheet ArrangementsWe did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements.Contractual Obligations and CommitmentsThere were no material changes outside of the ordinary course of business to our specific contractual obligations during the three months ended JuneÂ 30, 2024.36Table of ContentsCritical Accounting PoliciesFor a discussion of our material changes in critical accounting policies, see â€œRecent Accounting Pronouncementsâ€ in Note 1, Summary of Significant Accounting Policies, of the Notes to Financial Statements included in this Quarterly Report on Form 10-Q.Item 3. Quantitative and Qualitative Disclosures about Market RiskThere have been no material changes in the quantitative or qualitative aspects of our market risk profile. For additional information regarding the Companyâ€™s exposure to certain market risks, see â€œItem 7A. Quantitative and Qualitative Disclosures About Market Riskâ€ included in the Form 10-K for the fiscal year ended DecemberÂ 31, 2023.Item 4. Controls and Procedures Disclosure Controls and ProceduresAs required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, with the supervision of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(b) and 15d-15(e)) as of JuneÂ 30, 2024. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Quarterly Report on Form 10-Q has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure. Notwithstanding the material weakness described in "Item 4. Controls and Procedures" of our Form 10-Q for the quarter ended March 31, 2024 and completion of additional procedures, our management, including our chief executive officer and chief financial officer, has concluded that our financial statements represent fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America. The material weakness did not result in any restatements of consolidated financial statements previously reported by us, nor were there any changes to previously released financial results.Material Weakness Remediation EffortsWe continue to make further progress in implementing changes to our internal control over financial reporting to remediate the material weakness described in "Item 4. Controls and Procedures" of our Form 10-Q for the quarter ended March 31, 2024. Our plan to address the material weakness includes (1) expand managementâ€™s oversight of the impairment analysis of its equity investments in securities without readily determinable fair value, (2) continue to implement improved processes and controls for documenting the impairment valuation process of securities without a readily determinable fair value, (3) engage external resources when required to assist with the assessment of valuation methodologies for securities without a readily determinable fair value and (4) continue to formalize and communicate policies related to the evaluation of early indicators of impairment of securities without a readily determinable fair value. We have made necessary improvements in the design of our internal controls and implemented additional controls around the impairment analysis. We have engaged an external resource to assist with the valuation of securities without a readily determinable fair value and we have formalized our policies related to the evaluation of early indicators of impairment by documenting our impairment analysis and having a formal communications framework regarding the Company's knowledge of any indicators of impairment.Management is committed to maintaining an effective internal control environment and remediating the identified material weakness in a timely manner, with appropriate oversight from our Audit Committee. The elements of our remediation plan can only be accomplished over time. This material weakness will not be considered remediated until the applicable remediated controls operate for a sufficient period of time and management has concluded, through testing, that 37Table of Contentsthese controls are operating effectively. Management will monitor the effectiveness of its remediation plan and will refine it appropriately. Changes in Internal ControlOther than the remediation actions described above, there were no changes in our internal control over financial reporting that occurred during the six months ended JuneÂ 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.38Table of ContentsPART II â€” OTHER INFORMATIONItem 1. Legal ProceedingsThe disclosure in Note 8, Commitments and Contingencies, of the Notes to Financial Statements included in this Quarterly Report on Form 10-Q includes a discussion of our legal proceedings and is incorporated herein by reference.Item 1A. Risk Factors You should carefully consider the factors discussed in Part I, â€œItem 1A. Risk Factorsâ€ in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, which could materially affect our business, financial position, or future results of operations. See also â€œSpecial Note Regarding Forward-Looking Statementsâ€ included in this Quarterly Report on Form 10-Q. In addition to the risks set forth in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business.Item 5. Other Information (c) Rule 10b5-1 PlansOn June 14, 2024, Bassil Dahiyat, our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 66,192 shares of the Company's common stock until February 13, 2025.On June 14, 2024, John Desjarlais, our Executive Vice President and Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 81,458 shares of the Company's common stock until February 12, 2025.On June 28, 2024, Ellen Feigal, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025.On June 28, 2024, Kevin Gorman, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,827 shares of the Company's common stock until June 30, 2025.On June 28, 2024, Kurt Gustafson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025.On June 28, 2024, Dagmar Rosa-Bjorkeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025.On May 23, 2024, Richard Ranieri, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 15,000 shares of the Company's common stock until May 16, 2025, and it was terminated on June 27, 2024. On June 28, 2024, he adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,496 shares of the Company's common stock until June 27, 2025.On June 27, 2024, A Bruce Montgomery, a member of our Board of Directors, terminated a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) entered on August 7, 2023. On June 28, 2024, he adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 26,568 shares of the Company's common stock until June 27, 2025.39Table of ContentsItem 6. ExhibitsExhibitNumberDescription of Document3.1Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on December 11, 2013).3.2Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on February 27, 2023).4.1Form of Common Stock Certificate of the Company (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 25, 2013).4.2Third Amended and Restated Investor Rights Agreement, dated June 26, 2013, among the Company and certain of its stockholders incorporated by reference to Exhibit 4.2 to the Companyâ€™s Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11, 2013).10.1Consulting Agreement by and between the Company and John J. Kuch, dated April 19, 2024.10.2Executive Employment Agreement Addendum No. 2 dated June 1, 2024 by and between the Company and Nancy Valente31.1Rule 13a-14(a) Certification of Principal Executive Officer.31.2Rule 13a-14(a) Certification of Principal Financial Officer.32.1Section 1350 Certification of Principal Executive Officer and Principal Financial Officer.101.INSInline XBRL Instance Document â€“ The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.101.SCHInline XBRL Schema Document101.CALInline XBRL Calculation Linkbase Document101.DEFInline XBRL Definition Linkbase Document101.LABInline XBRL Labels Linkbase Document101.PREInline XBRL Presentation Linkbase Document104104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)40Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. XENCOR, INC.BY:/s/ BASSIL I. DAHIYATBassil I. Dahiyat, Ph.D.President and Chief Executive Officer(Principal Executive Officer)BY:/s/ BART JAN CORNELISSENBart Jan CornelissenChief Financial Officer(Principal Financial Officer)Dated: AugustÂ 5, 202441 EX-10.1 2 xncr-20240630xexx101.htm EX-10.1 DocumentExhibit 10.1XENCOR, INC.CONSULTING AGREEMENTEffective Date: April 19, 2024This Consulting Agreement (the â€œAgreementâ€) is made as of the Effective Date set forth above by and between Xencor, Inc. (â€œClientâ€) and the consultant named on the signature page hereto (â€œConsultantâ€).WHEREAS, Client and Consultant entered into and agreed to a consulting arrangement on April [x], 2024 for Consultant to provide business and corporate development services to Client in exchange for Clientâ€™s agreement to continue certain option vesting and option exercise periods during the term of the arrangement;WHEREAS, Client and Consultant wish to document the arrangement in writing in a formal Consulting Agreement;THEREFORE, for good and valuable consideration the sufficiency of which is acknowledged, the parties agree as follows:1.Engagement of Services. Client may issue Project Assignments to Consultant in the form attached to this Agreement as Exhibit A (each, a â€œProject Assignmentâ€). Subject to the terms of this Agreement, Consultant will render the services set forth in Project Assignment(s) accepted by Consultant (the â€œServicesâ€) by the completion dates set forth therein. Except as otherwise provided in the applicable Project Assignment, Consultant will be free of control and direction from the Client (other than general oversight and control over the results of the Services), and will have exclusive control over the manner and means of performing the Services, including the choice of place and time. Consultant will provide, at Consultantâ€™s own expense, a place of work and all equipment, tools and other materials necessary to complete the Services; however, to the extent necessary to facilitate performance of the Services, Client may, in its discretion, make certain of its equipment or facilities available to Consultant at Consultantâ€™s request. While on the Clientâ€™s premises, Consultant agrees to comply with Clientâ€™s then-current access rules and procedures, including those related to safety, security and confidentiality. Consultant agrees and acknowledges that Consultant has no expectation of privacy with respect to Clientâ€™s telecommunications, networking or information processing systems (including stored computer files, email messages and voice messages) and that Consultantâ€™s activities, including the sending or receiving of any files or messages, on or using those systems may be monitored, and the contents of such files and messages may be reviewed and disclosed, at any time, without notice.2.Compensation. Client will provide the compensation, if any, set forth in each Project Assignment for Services rendered pursuant to this Agreement as Consultantâ€™s sole compensation for such Services; it being expressly understood that except for the consideration set forth in Exhibit A, Client is not offering and Consultant is not relying on any additional compensation. Consultant will be reimbursed only for expenses that are expressly provided for in a Project Assignment or that have been approved in advance in writing by Client, provided Consultant has furnished such documentation for authorized expenses as Client may reasonably request. 3.Ownership of Work Product. Consultant hereby irrevocably assigns to Client all right, title and interest worldwide in and to any deliverables specified in a Project Assignment and to any ideas, concepts, processes, discoveries, developments, formulae, information, materials, improvements, designs, artwork, content, software programs, other copyrightable works, and any other work product created, conceived or developed by Consultant (whether alone or jointly with others) for Client during or before the term of this Agreement, including all copyrights, patents, trademarks, trade secrets, and other intellectual property rights therein (collectively, the â€œWork Productâ€). Consultant retains no rights to use the Work Product and agrees not to challenge the validity of Clientâ€™s ownership of the Work Product. Consultant agrees to execute, at Clientâ€™s request and expense, all documents and other instruments necessary or desirable to confirm such assignment, including without limitation, any copyright assignment or patent assignment provided by the Client. Consultant hereby irrevocably appoints Client as Consultantâ€™s attorney-in-fact for the purpose of executing such documents on Consultantâ€™s behalf, which appointment is coupled with an interest. At Clientâ€™s request, Consultant will promptly record any such patent assignment with the United States Patent and Trademark Office. Client will reimburse Consultant for any reasonable out-of-pocket expenses actually incurred by Consultant in fulfilling its obligations under this section. Consultant will deliver each item of Work Product specified in each Project Assignment and disclose promptly in writing to Client all other Work Product. 4.Other Rights. If Consultant has any rights, including without limitation â€œartistâ€™s rightsâ€ or â€œmoral rights,â€ in the Work Product that cannot be assigned, Consultant hereby unconditionally and irrevocably grants to Client an exclusive (even as to Consultant), worldwide, fully paid and royalty-free, irrevocable, perpetual license, with rights to sublicense through multiple tiers of sublicensees, to use, reproduce, distribute, create derivative works of, publicly perform and publicly display the Work Product in any medium or format, whether now known or later developed. In the event that Consultant has any rights in the Work Product that cannot be assigned or licensed, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind against Client or Clientâ€™s customers.5.License to Preexisting IP. Consultant agrees not to use or incorporate into Work Product any intellectual property developed by any third party or by Consultant other than in the course of performing services for Client (â€œPreexisting IPâ€) unless the Preexisting IP has been specifically identified and described in the applicable Project Assignment. In the event Consultant uses or incorporates Preexisting IP into Work Product, Consultant hereby grants to Client a non-exclusive, worldwide, fully-paid and royalty-free, irrevocable, perpetual license, with the right to sublicense through multiple tiers of sublicensees, to use, reproduce, distribute, create derivative works of, publicly perform and publicly display in any medium or format, whether now known or later developed, such Preexisting IP incorporated or used in Work Product. 6.Representations and Warranties. Consultant represents and warrants that: (a) the Services will be performed in a professional manner and in accordance with the industry standards and the Work Product will comply with the requirements set forth in the applicable Project Assignment, (b) the Work Product will be an original work of Consultant, (c) Consultant has the right and unrestricted ability to assign the ownership of Work Product to Client as set forth in Section 3 (including without limitation the right to assign the ownership of any Work Product created by Consultantâ€™s employees or contractors), (d) neither the Work Product nor any element thereof will infringe upon or misappropriate any copyright, patent, trademark, trade secret, right of publicity or privacy, or any other proprietary right of any person, whether contractual, statutory or common law, (e) Consultant has an unqualified right to grant to Client the license to Preexisting IP set forth in Section 5, (f) none of the Work Product incorporates any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Client, except as expressly agreed by the Client in writing, and (g) Consultant will comply with all applicable federal, state, local and foreign laws governing self-employed individuals, including laws requiring the payment of taxes, such as income and employment taxes, and social security, disability, and other contributions. Consultant further represents and warrants that Consultant is self-employed in an independently established trade, occupation, or business; maintains and operates a business that is separate and independent from Clientâ€™s business; holds himself or herself out to the public as independently competent and available to provide applicable services similar to the Services; has obtained and/or expects to obtain clients or customers other than Client for whom Consultant performs services; and will perform work for Client that Consultant understands is outside the usual course of Clientâ€™s business. Consultant agrees to indemnify and hold Client harmless from any and all damages, costs, claims, expenses or other liability (including reasonable attorneysâ€™ fees) arising from or relating to the breach or alleged breach by Consultant of the representations and warranties set forth in this Section 6.7.Independent Contractor Relationship. Consultantâ€™s relationship with Client is that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship between Client and any of Consultantâ€™s employees or agents. Consultant is not authorized to make any representation, contract or commitment on behalf of Client. Consultant (if Consultant is an individual) and Consultantâ€™s employees will not be entitled to any of the benefits that Client may make available to its employees, including, but not limited to, group health or life insurance, profit-sharing or retirement benefits. Because Consultant is an independent contractor, Client will not withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain workersâ€™ compensation insurance on behalf of Consultant. Consultant is solely responsible for, and will file, on a timely basis, all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of Services and receipt of fees under this Agreement. Consultant is solely responsible for, and must maintain adequate records of, expenses incurred in the course of performing Services under this Agreement. No part of Consultantâ€™s compensation will be subject to withholding by Client for the payment of any social security, federal, state or any other employee payroll taxes. Client will regularly report amounts paid to Consultant by filing Form 1099-MISC with the Internal Revenue

Service as required by law. If, notwithstanding the foregoing, Consultant is reclassified as an employee of Client, or any affiliate of Client, by the U.S. Internal Revenue Service, the U.S. Department of Labor, or any other federal or state or foreign agency as the result of any administrative or judicial proceeding, Consultant agrees that Consultant will not, as the result of such reclassification, be entitled to or eligible for, on either a prospective or retrospective basis, any employee benefits under any plans or programs established or maintained by Client.8.Confidential Information. During the term of this Agreement and thereafter Consultant (i) will not use or permit the use of Clientâ€™s Confidential Information in any manner or for any purpose not expressly set forth in this Agreement, (ii) will hold such Confidential Information in confidence and protect it from unauthorized use and disclosure, and (iii) will not disclose such Confidential Information to any third parties except as set forth in this section and in Section 9 below. Consultant will protect Clientâ€™s Confidential Information from unauthorized use, access or disclosure in the same manner as Consultant protects its own confidential information of a similar nature, but in no event will it exercise less than reasonable care. Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Client and Consultant, nothing in this Agreement shall limit Consultantâ€™s right to report possible violations of law or regulation with any federal, state, or local government agency or to discuss the terms and conditions of Consultantâ€™s engagement by Client to the extent that such disclosure is protected under applicable provisions of law or regulation, including but not limited to â€œwhistleblowerâ€ statutes or other similar provisions that protect such disclosure. â€œConfidential Informationâ€ as used in this Agreement means all information disclosed by Client to Consultant, whether during or before the term of this Agreement, that is not generally known in the Clientâ€™s trade or industry and will include, without limitation: (a) concepts and ideas relating to the development and distribution of content in any medium or to the current, future and proposed products or services of Client or its subsidiaries or affiliates; (b) trade secrets, drawings, inventions, know-how, software programs, and software source documents; (c) information regarding plans for research, development, new service offerings or products, marketing and selling, business plans, business forecasts, budgets and unpublished financial statements, licenses and distribution arrangements, prices and costs, suppliers and customers; (d) existence of any business discussions, negotiations or agreements between the parties; and (e) any information regarding the skills and compensation of employees, contractors or other agents of Client or its subsidiaries or affiliates. Confidential Information also includes proprietary or confidential information of any third party who may disclose such information to Client or Consultant in the course of Clientâ€™s business. Confidential Information does not include information that (x) is or becomes a part of the public domain through no act or omission of Consultant, (y) is disclosed to Consultant by a third party without restrictions on disclosure, or (z) was in Consultantâ€™s lawful possession without obligation of confidentiality prior to the disclosure and was not obtained by Consultant either directly or indirectly from Client. In addition, this section will not be construed to prohibit disclosure of Confidential Information to the extent that such disclosure is required by law or valid order of a court or other governmental authority; provided, however, that Consultant will first have given notice to Client and will have made a reasonable effort to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued. All Confidential Information furnished to Consultant by Client is the sole and exclusive property of Client or its suppliers or customers. Upon request by Client, Consultant agrees to promptly deliver to Client the original and any copies of the Confidential Information. Notwithstanding the foregoing nondisclosure obligations, pursuant to 18 U.S.C. Section 1833(b), Consultant will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.8.1.Personal Information. With respect to any Confidential Information that constitutes personal data, personal information, personally identifiable information or similar information under applicable privacy or data security laws (collectively, â€œPersonal Informationâ€), Consultant shall not (i) sell Personal Information or (ii) retain, use or disclose Personal Information for any purpose other than the specific purpose of providing the Services. For the avoidance of doubt, the foregoing prohibits Consultant from â€œsellingâ€ Personal Information, as defined in the California Consumer Privacy Act of 2018 (as amended, the â€œCCPAâ€), and from retaining, using, or disclosing Personal Information outside of the direct business relationship between Consultant and Client or for a â€œcommercial purposeâ€ (as defined in the CCPA). Consultant hereby certifies that it understands the obligations under this Section 8.1 and will comply with them.8.1.1.Consultant shall use reasonable security measures appropriate to the nature of any Personal Information in its possession or control to protect the Personal Information from unauthorized access, destruction, use, modification, or disclosure. 8.1.2.The parties acknowledge and agree that Consultantâ€™s access to Personal Information is not part of the consideration exchanged by the parties in respect of the Agreement.8.1.3.If any individual contacts Consultant to make a request pertaining to their Personal Information, Consultant shall promptly forward the request to the Client and shall not respond to the individual except as instructed by Client. Consultant shall promptly take such actions and provide such information as Client may request to help Client fulfill requests of individuals to exercise their rights under the applicable privacy or data security laws, including, without limitation, requests to access, delete, opt-out of the sale of, or receive information about the processing of, Personal Information pertaining to them. Consultant agrees to cooperate with Client to further amend the Agreement as may be necessary to address compliance with applicable privacy or data security laws.9.Consultantâ€™s Employees, Consultants and Agents. Consultant shall have the right to disclose Confidential Information only to those of its employees, consultants, and agents who have a need to know such information for the purpose of performing Services and who have entered into a binding written agreement that is expressly for the benefit of Client and protects Clientâ€™s rights and interests in and to the Confidential Information to at least the same degree as this Agreement. Client reserves the right to refuse or limit Consultantâ€™s use of any employee, consultant or agent or to require Consultant to remove any employee, consultant or agent already engaged in the performance of the Services. Clientâ€™s exercise of such right will in no way limit Consultantâ€™s obligations under this Agreement.10.No Conflict of Interest. During the term of this Agreement, Consultant will not accept work, enter into a contract, or accept an obligation from any third party, inconsistent or incompatible with Consultantâ€™s obligations under this Agreement, or the scope of Services. Consultant warrants that there is no other contract or duty on its part inconsistent with this Agreement. Consultant agrees to indemnify Client from any and all loss or liability incurred by reason of the alleged breach by Consultant of any services agreement with any third party.11.Term and Termination. 11.1.Term. The term of this Agreement shall begin on the Effective Date set forth above and end on March 2, 2033 (the â€œTermâ€), unless earlier terminated as provided in this Agreement.11.2.Termination. Either party may terminate this Agreement with or without cause, at any time upon written notice to the other party. 11.3.Survival. The rights and obligations contained in Sections 3 (â€œOwnership of Work Productâ€), 4 (â€œOther Rightsâ€), 5 (â€œLicense to Preexisting IPâ€), 6 (â€œRepresentations and Warrantiesâ€), 8 (â€œConfidential Informationâ€), 13 (â€œNonsolicitationâ€), 14 (â€œAgreement to Arbitrate All Disputesâ€), and 15Â (â€œOther Provisionsâ€) will survive any termination or expiration of this Agreement.12.Noninterference with Business. Consultant agrees that during the Term of this Agreement, Consultant will not, without Clientâ€™s express written consent, either directly or indirectly engage in any employment or business activity that is competitive with, or would otherwise conflict with the Services rendered to, or that would otherwise interfere with the business of, the Client. 13.Nonsolicitation. Consultant agrees that during the Term of this Agreement, and for one year thereafter, Consultant will not either directly or indirectly, solicit or attempt to solicit any employee, independent contractor, or consultant of Client to terminate his, her or its relationship with Client in order to become an employee, consultant, or independent contractor to or for any other person or entity.14.Return of Client Property. Consultant agrees that, upon termination, Consultant will perform a good faith search for, and return to Client, all Client documents (and all copies thereof) and other Client property in Consultantâ€™s possession or control, including, but not limited to, Consultantâ€™s files, correspondence, memoranda, notes, notebooks, drawings, books and records, plans, forecasts, reports, proposals, studies, agreements, financial information, personnel information, sales and marketing information, research and development information, systems information, specifications, computer-recorded information, tangible property and equipment, credit cards, entry cards, identification badges and keys, and any materials of any kind that contain or embody any proprietary or confidential information of Client (and all reproductions thereof in whole or in part). 15.Agreement to Arbitrate All Disputes.Â To ensure the timely and economical resolution of disputes that may arise between Consultant and Client, both Consultant and Client mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. Â§1-16, and to the fullest extent permitted by applicable law, Consultant and Client will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to:Â (i)Â the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or (ii) Consultantâ€™s relationship with Client (including but not limited to all statutory claims); or (iii) the termination of Consultantâ€™s relationship with Client (including but not limited to all statutory claims).Â BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH CONSULTANT AND CLIENT WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING.Â 15.1.Arbitrator Authority.Â Â The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.Â 15.2.Individual Capacity Only.Â All claims, disputes, or causes of action under this Section, whether by Consultant or Client, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.Â Â The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.Â To the extent that the preceding sentences in this paragraph are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.Â Â 15.3.Arbitration Process.Â Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by JAMS, Inc. (â€œJAMSâ€) or its successor, under the then applicable JAMS Comprehensive Arbitration Rules & Procedures available upon request and also currently available atÂ https://www.jamsadr.com/rules-comprehensive-arbitration/).Â Â Consultant and Client both have the right to be represented by legal counsel at any arbitration proceeding, at each partyâ€™s own expense.Â Â The location of the arbitration proceeding shall take place San Diego, California. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute; (ii) issue a written arbitration decision, to include the arbitratorâ€™s essential findings and conclusions and a statement of the award; and (iii) be authorized to award any or all remedies that Consultant or Client would be entitled to seek in a court of law. Client shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Consultant if the dispute were decided in a court of law.Â Â 15.4.Excluded Claims.Â This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law (including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended), to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the â€œExcluded Claimsâ€).Â In the event Consultant intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration.15.5.Injunctive Relief and Final Orders.Â Nothing in this Section is intended to prevent either Consultant or Client from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.16.Other Provisions. 16.1.Successors and Assigns. Consultant may not subcontract or otherwise delegate or assign this Agreement or any of its obligations under this Agreement without Clientâ€™s prior written consent. Any attempted assignment in violation of the foregoing will be null and void. Subject to the foregoing, this Agreement will be for the benefit of Clientâ€™s successors and assigns, and will be binding on Consultantâ€™s assignees.16.2.Notices. Any notice required or permitted by this Agreement will be in writing and will be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice will be sent to the addresses set forth below or such other address as either party may specify in writing.16.3.Governing Law. This Agreement will be governed in all respects by the laws of the United States of America and by the laws of the State of California, without giving effect to any conflicts of laws principles that require the application of the law of a different jurisdiction. 16.4.Severability. Should any provisions of this Agreement be held by a court of law to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement will not be affected or impaired thereby.16.5.Waiver. The waiver by Client of a breach of any provision of this Agreement by Consultant will not operate or be construed as a waiver of any other or subsequent breach by Consultant.16.6.Injunctive Relief for Breach. Consultantâ€™s obligations under this Agreement are of a unique character that gives them particular value; breach of any of such obligations will result in irreparable and continuing damage to Client for which there will be no adequate remedy at law; and, in the event of such breach, Client will be entitled to injunctive relief and/or a decree for specific performance, and such other and further relief as may be proper (including monetary damages if appropriate).16.7.Entire Agreement. This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all services undertaken by Consultant for Client; provided, however, that in the event of any conflict between the terms of this Agreement and any Project Assignment, the terms of the applicable Project Assignment will control, provided that the Project Assignment specifically calls out the applicable Section number of this Agreement to be superseded and has been signed by an authorized officer of Client. This Agreement may only be changed or amended by mutual agreement of authorized representatives of the parties in writing. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.[Remainder of page intentionally left blank]The parties have executed this Agreement as of the Effective Date.CLIENT:Xencor, Inc.By:/s/ Bassil DahiyatName:Bassil DahiyatTitle:President & CEOEmail:baz@xencor.comAddress: 465 N. Halstead, Suite 200Pasadena, California 91107CONSULTANT:/s/ John KuchJohn KuchEmail:jkuch@xencor.comAddress:555 Huntington Dr.San Marino, CA 91108EXHIBIT AProject Assignment Under Consulting AgreementDated: April 19, 2024Services:Consultant will provide advice regarding the Companyâ€™s finance and accounting operations (the â€œServicesâ€).Schedule Of Work: Consultant will be available during business hours as necessary and agreed upon by Consultant and Client to complete the Services.Fees And Reimbursement:As consideration for the Services, Client will consider the period during which Consultant provides Services to Client under this Consulting Agreement to be â€œContinuous Serviceâ€ for purposes of Clientâ€™s 2013 Equity Incentive Plan (the â€œEquity Planâ€), and therefore Consultantâ€™s outstanding equity awards will continue to vest and, as applicable, remain exercisableÂ in accordance with their terms during the Term of the Consulting Agreement; Vesting of the equity awards will cease at the end of the Term and Consultantâ€™s rights to exercise or otherwise acquire any vested shares shall be governed and controlled by the Equity Plan and the applicable grant documents (the â€œEquity Documentsâ€).Â All terms, conditions and limitations applicable to the equity awards will continue to be subject to the applicable Equity Documents. Consultant will be reimbursed for expenses (at cost) if approved in writing in advance by Client. Consultant will provide such reasonable receipts or other documentation of expenses as Client might request.The parties have executed this Project Assignment as of the date first written above.CLIENT:Xencor, Inc.By:/s/ Bassil DahiyatName:Bassil DahiyatTitle:President and CEOCONSULTANT:/s/ John KuchJohn Kuch EX-10.2 3 xncr-20240630xexx102.htm EX-10.2 DocumentExecutive Employment Letter Addendum #2Whereas, Nancy Valente (â€œExecutiveâ€) is employed by Xencor, Inc. (â€œCompanyâ€) as its Executive Vice President & Chief Development Officer and Executive is subject to an Employment Letter, dated April 7, 2023, and an addendum thereto, dated November 7, 2023 (together, the â€œEmployment Letterâ€);Whereas, pursuant to the Employment Letter, Executive was entitled to receive reimbursement for temporary housing costs for up to nine (9) months from the commencement of employment with the Company, subject to applicable tax withholding and gross up thereon; Whereas, the temporary housing costs Executive was eligible to receive pursuant to the Employment Letter have ended and the Company desires to provide Executive with additional temporary living costs, subject to Executiveâ€™s continued employment with the Company.Now, therefore, Executive and the Company agree as follows: Executive will be eligible to be reimbursed for temporary living expenses near Pasadena, CA for a duration of twelve (12) months from the effective date of this agreement, subject to Executiveâ€™s continued employment with the Company. The maximum reimbursement Executive is eligible to receive will be $6,000 per month, subject to applicable tax withholding to the extent the Company determines the reimbursement will constitute taxable income to Executive pursuant to applicable law.In Witness Whereof, each of the parties has executed this agreement, in the case of the Company, by its duly authorized officer. Executive:/s/ Nancy ValenteÂ Â Â Â

DahiyatÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Name Bassil DahiyatÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Title President and Chief Executive OfficerÂ Â Â Â Â Â Â Â EX-31.1 4 xncr-20240630xexx311.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Bassil I. Dahiyat, Ph.D., certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Xencor, Inc., (the â€œCompanyâ€);2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;4.The Companyâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the Companyâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the Companyâ€™s internal control over financial reporting that occurred during the Companyâ€™s most recent fiscal quarter (the Companyâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting; and5.The Companyâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Companyâ€™s auditors and the audit committee of the Companyâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Companyâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Companyâ€™s internal control over financial reporting./s/ BASSIL I. DAHIYATBassil I. Dahiyat, Ph.D.President & Chief Executive Officer(Principal Executive Officer)Date: AugustÂ 5, 2024 EX-31.2 5 xncr-20240630xexx312.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Bart Jan Cornelissen, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Xencor, Inc., (the â€œCompanyâ€);2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;4.The Companyâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the Companyâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the Companyâ€™s internal control over financial reporting that occurred during the Companyâ€™s most recent fiscal quarter (the Companyâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting; and5.The Companyâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Companyâ€™s auditors and the audit committee of the Companyâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Companyâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Companyâ€™s internal control over financial reporting./s/ BART JAN CORNELISSENBart Jan CornelissenChief Financial Officer(Principal Financial Officer)Date: AugustÂ 5, 2024 EX-32.1 6 xncr-20240630xexx321.htm EX-32.1 DocumentExhibit 32.1CERTIFICATIONPursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Bassil I. Dahiyat, President & Chief Executive Officer of Xencor, Inc. (the â€œCompanyâ€), and Bart Cornelissen, Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:1.The Companyâ€™s Quarterly Report on Form 10-Q for the period ended JuneÂ 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Dated: AugustÂ 5, 2024IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 5th day of August 2024./s/ BASSIL I. DAHIYAT/s/ BART JAN CORNELISSENBassil I. DahiyatBart Jan CornelissenPresident & Chief Executive OfficerChief Financial Officer(Principal Executive Officer)(Principal Financial Officer)This certification accompanies the Periodic Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xencor, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-101.SCH 7 xncr-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Statements of Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Marketable Debt and Equity Securities link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Collaboration and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Sales of Future Royalties link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Polices) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Marketable Debt and Equity Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Collaboration and Licensing Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Sales of Future Royalties (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Marketable Debt and Equity Securities - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Marketable Debt and Equity Securities - Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Marketable Debt and Equity Securities - Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Marketable Debt and Equity Securities - Equity Securities with Readily Determinable Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Marketable Debt and Equity Securities - Equity Securities Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Marketable Debt and Equity Securities - Net Gains and Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Marketable Debt and Equity Securities - Equity Securities without Readily Determinable Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Stock Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Stock-Based Compensation - Employee Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Stock-Based Compensation - Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Stock-Based Compensation - FV of Employee Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stock Based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Leases - Undiscounted Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Leases - Undiscounted Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Leases - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Collaboration and Licensing Agreements - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Sales of Future Royalties - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Sales of Future Royalties - Debt of Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 xncr-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 xncr-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 xncr-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Equity Securities Debt and Equity Securities, FV-NI [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Summary of Lease Costs and Cash Disclosures Lease, Cost [Table Text Block] Vega Vega Therapeutics, Inc. [Member] Vega Therapeutics, Inc. Cover [Abstract] Cover [Abstract] Richard Ranieri [Member] Richard Ranieri Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Operating Lease Liabilities Maturities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Trading Symbol Trading Symbol Less: Net gain (loss) recorded on sale of equity securities Equity Securities, FV-NI, Realized Gain (Loss) Comprehensive loss Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Net Loss per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income taxes Income Taxes Paid, Net Deferred income Deferred Income, Current Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Gain (loss) on equity securities, net Change in fair value of equity securities Net gain (loss) recorded on equity securities Net gain (loss) recorded on equity securities Equity Securities, FV-NI, Gain (Loss) Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Patent License Agreement Patent License Agreement Information relating to a Patent License Agreement. Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Deferred income Increase (Decrease) in Loans, Deferred Income Lease liabilities, net of current portion Lease liabilities - long-term Operating Lease, Liability, Noncurrent Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Collaboration research and licensing agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Collaboration and License Agreement Collaboration and License Agreement Represents information pertaining to the Collaboration and License agreement. Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Money Market Funds Money Market Funds [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Deferred income, net of current portion Deferred Income, Noncurrent Non-cash interest expense recognized Royalty Liability, Non-Cash Interest Expense Royalty Liability, Non-Cash Interest Expense Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Marketable securities Estimated Fair Value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Sales of Future Royalties [Table] Sales of Future Royalties [Table] Sales of Future Royalties [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate intrinsic value, balance outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Investments [Domain] Investments [Domain] Compensation Amount Outstanding Recovery Compensation Amount Richard Ranieri May 2024 Plan [Member] Richard Ranieri May 2024 Plan Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Janssen Janssen Biotech, Inc [Member] Represents information pertaining to Janssen Biotech, Inc. Tabular List, Table Tabular List [Table Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Summary of Stock Option Activity Schedule of Stock Options Roll Forward [Table Text Block] Extended Vesting Periods Extended Vesting Periods [Member] Extended Vesting Periods Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Schedule of Available-for-sale Securities Debt Securities, Available-for-Sale [Line Items] Issuance of common stock under the Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued expenses Accrued Liabilities, Current Equity securities without

readily determinable fair value Equity Securities without Readily Determinable Fair Value [Line Items] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents, and restricted cash, beginning of period Cash, cash equivalents, and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Janssen Janssen [Member] Represents information pertaining to Janseen Accretion of discount on marketable debt securities Accretion (Amortization) of Discounts and Premiums, Investments Marketable equity securities Equity securities with readily determinable fair value Equity Securities, FV-NI, Current Current assets Assets, Current [Abstract] Development-based Development-based Represents information pertaining to development-based potential milestones. Debt - short-term Royalty Liabilities, Short-Term Debt Royalty Liabilities, Short-Term Debt Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table] Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table] Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Stock options Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Weighted average grant date fair value, vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Comprehensive loss attributable to Xencor, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income tax payable Accrued Income Taxes, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Cash paid during the period for: Supplemental Cash Flow Information Cash Paid [Abstract] Supplemental Cash Flow Information Cash Paid [Abstract] Security Exchange Name Security Exchange Name Debt of Future Royalties Debt of Future Royalties [Table Text Block] Debt of Future Royalties Schedule of Maturities of Marketable Securities Investments Classified by Contractual Maturity Date [Table Text Block] Non-cash interest expense Paid-in-Kind Interest Award Type [Axis] Award Type [Axis] Schedule of Equity Securities with Readily Determinable Fair Value Equity Securities, FV-NI [Table Text Block] Tabular disclosure of equity securities with readily determinable fair value. Corporate Securities Corporate Debt Securities [Member] Annual percentage increase in shares of common stock available for issuance Share Based Compensation Arrangement by Share Based Payment Award Annual Percentage Increase in Shares Authorized Represents the annual percentage increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based compensation plan. Gale Gale [Member] Gale Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Milestone Milestone [Member] Payment for achievement or success. Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Non-controlling interest Equity, Attributable to Noncontrolling Interest Percentage of responsibility for development costs Collaborative Agreement, Percentage of Responsibility Assumed for Development Costs Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development. Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Deferred revenue Collaboration Agreement, Deferred Revenue Collaboration Agreement, Deferred Revenue Research and development Research and Development Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Unrealized Losses on Available-for-Sale Investments Unrealized Gain (Loss) on Investments [Table Text Block] Expiration Date Trading Arrangement Expiration Date Number of shares owned (in shares) Investment Owned, Balance, Shares Second Collaboration And License Agreement Second Collaboration And License Agreement [Member] Represents information relating to second collaboration and license agreement. Lease liabilities Lease liabilities - short-term Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Summary of Restricted Stock Unit Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Income taxes Increase (Decrease) in Income Taxes Payable Sale of Future Royalties Future Royalties Sale Disclosure [Text Block] Future Royalties Sale Disclosure Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Letter of credit amount Line of Credit Facility, Maximum Borrowing Capacity Impairment loss or recoveries Marketable Securities Impairment Losses And Recoveries Amount of impairment loss or recovery related to marketable securities. Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price (Per Share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Net unrealized gain (loss) on marketable debt securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Diluted weighted average common shares outstanding (in shares) Weighted-average common shares outstanding used in computing diluted net loss (in shares) Weighted Average Number of Shares Outstanding, Diluted Royalties owed to OMERS Royalty Liability, Owed Royalty Liability, Owed MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Total stockholdersâ€™ equity attributable to Xencor, Inc. Equity, Attributable to Parent Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Mature in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Renewal term Lessee, Operating Lease, Renewal Term Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Interest expense Interest Expense, Nonoperating Third Party Licensee Third Party License Agreement [Member] Third Party License Agreement Amortized Cost Cash and Cash Equivalents and Marketable Securities Amortized Cost This item represents the total cost of cash and cash equivalents and marketable securities. Gain on sale of marketable debt securities Debt Securities, Available-for-Sale, Gain (Loss) Bassil Dahiyat [Member] Bassil Dahiyat Debt Debt, Current Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable Receivable Accounts Receivable, after Allowance for Credit Loss, Current Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Fair value, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Total number of shares of common stock available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Schedule of Assets Recorded at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Royalties paid to OMERS Royalty Liability, Payments Royalty Liability, Payments Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted-average remaining contractual term, balance outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate The 2013 and 2023 Plans The 2013 and 2023 Plans [Member] The 2013 and 2023 Plans Total debt Royalty Liability, Debt, Long-Term and Short-Term, Combined Amount Royalty Liability, Debt, Long-Term and Short-Term, Combined Amount Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] In-process intangible assets In-process intangible assets In Process Intangible Assets [Member] Purchase of marketable securities Payments to Acquire Marketable Securities Weighted-average remaining contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Deferred revenue Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accounts payable Accounts Payable, Current Investment Type [Axis] Investment Type [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Revenue Revenues [Abstract] Schedule of Equity Securities Without Readily Determinable Fair Value Equity Securities without Readily Determinable Fair Value [Table Text Block] Schedule of Weighted Average Assumptions Used for Estimation of Fair Value of Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease costs Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-cash revenue recognized Collaboration Agreement, Non-Cash Revenue Recognized Collaboration Agreement, Non-Cash Revenue Recognized Potential Milestones Type [Axis] Potential Milestones Type [Axis] Potential Milestones Type Awards issued under the plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Issuance of common stock upon exercise of stock awards (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Variable lease cost Variable Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Kevin Gorman [Member] Kevin Gorman Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Investment, Name [Axis] Investment, Name [Axis] Restricted cash Cash collateral for letters of credit Restricted Cash, Noncurrent Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Forecast Forecast [Member] Class of Stock [Axis] Class of Stock [Axis] Diluted net loss per common share attributable to Xencor, Inc. (in dollars per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Non-cash royalties Non-cash Royalty [Member] Non-cash Royalty Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accounts receivable Increase (Decrease) in Accounts and Other Receivables and Contract with Customer Assets Increase (Decrease) in Accounts Receivable and Contract with Customer Assets Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation Total employee, director and non-employee stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Other income (expense) Nonoperating Income (Expense) [Abstract] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Period to recognize unamortized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Collaborations, milestones, and royalties Revenue recorded Revenue from Contract with Customer, Excluding Assessed Tax Purchase of patents, licenses, and other intangible assets Payments to Acquire Intangible Assets Total other income (expense), net Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Total liabilities and stockholdersâ€™ equity Liabilities and Equity Annual installment vesting periods Number Of Annual Installment Vesting Period Represents the number of annual installment vesting periods. All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Regulatory-based Regulatory-based Represents information pertaining to regulatory-based potential milestones. Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] ROU assets obtained Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Issuance of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Options forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Restricted cash Restricted Cash Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Product and Service [Axis] Product and Service [Axis] Weighted average assumptions for estimated fair value of employee stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Weighted average grant date fair value, beginning balance (in dollars per share) Weighted average grant date fair value, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholdersâ€™ equity Liabilities and Equity [Abstract] Less: Tenant allowance Lessee, Operating Lease, Liability, Tenant Allowance Amount of monetary allowance granted by the landlord to a tenant for operating lease. Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Alexion Alexion Pharmaceuticals, Inc. [Member] Represents information pertaining to Alexion Pharmaceuticals, Inc., with which the entity has entered into a option and license agreement. Royalties Royalty [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date Phases of lease term Phases of Lease Term Represents the number of phases associated with a lease term. Collaboration and Licensing Agreements Collaboration and Licensing Agreements Collaboration and Licensing Agreements Balance at the beginning of the period (in dollars per share) Balance at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right of use (ROU) asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Balance at the beginning of the period (in shares) Balance at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Zenas Zenas Bio Pharma Limited [Member] Represents information pertaining to Zenas bio pharma. Exercise Price Award Exercise Price Non-cash interest expense recognized Royalty Liability, Interest Expense Including Amortization Of Closing Costs Royalty Liability, Interest Expense Including Amortization Of Closing Costs Net Loss Per Common Share Earnings Per Share [Text Block] Service agreement charges Collaboration Agreement, Service Agreement Charges Collaboration Agreement, Service Agreement Charges Genentech Genentech [Member] Represent information pertaining to Genetech. Arrangement Duration Trading Arrangement Duration Issuance of common stock under the Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Subsequent Event Subsequent Event [Member] Technology License Agreement Technology License Agreement Information relating to a Technology License Agreement. Schedule of Weighted Average Assumptions Used for Estimation of Fair Value of ESPP Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Extended Expiration Dates Extended Expiration Dates [Member] Extended Expiration Dates Stockholdersâ€™ equity Equity, Attributable to Parent [Abstract] Weighted average grant date fair value, granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Sales of Future Royalties

[Line Items] Sales of Future Royalties [Line Items] Sales of Future Royalties [Line Items] Total investments Investments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Annual increase in shares of common stock available for issuance (in shares) Share Based Compensation Arrangement by Share Based Payment Award Annual Increase in Shares Authorized Represents the annual increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based compensation plan. Improvement allowance Leasehold Improvements, Gross Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Share development percentage Collaborative Agreement Share Percentage Of Development Cost, By Counterparty Represents the percentage of share assumed by the counter-party for development costs. Potential Milestones Type [Domain] Potential Milestones Type [Domain] Potential Milestones Type [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Patents, licenses, and other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Receivables [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Astria Astria [Member] Astria Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Proceeds from issuance of common stock upon exercise of stock awards Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Unamortized compensation expense related to unvested restricted stock units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Number of different target programs Collaborative Arrangement Number of Target Programs Represents the number of different target programs under the collaborative agreement. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Patents, licenses, and other intangible assets Finite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items] Finite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Interest rate Royalty Liability, Interest Rate Royalty Liability, Interest Rate Research license term Collaborative Arrangement Research License Term Represents the research license term under the collaborative agreement. Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Beginning balance of debt related to sale of future royalties Ending balance of debt related to sale of future royalties Royalty Liability, Noncurrent Royalty Liability, Noncurrent Local Phone Number Local Phone Number John Desjarlais [Member] John Desjarlais Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Risk-free interest rate, high end of range (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Marketable debt securities Debt Securities, Current PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Dagmar Rosa-Bjorkesen [Member] Dagmar Rosa-Bjorkesen Proceeds from maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Astria/Catabasis Astria/Catabasis Represents the information pertaining to Catabasis Pharmaceuticals, Inc. Interest receivable from marketable debt securities Increase (Decrease) in Accrued Investment Income Receivable Issuance of common stock upon exercise of stock awards Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Closing price of common stock (in dollars per share) Share Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Sale of common stock (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] General and administrative General and Administrative Expense [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] The 2023 Plan The 2023 Plan [Member] The 2023 Plan Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Richard Ranieri June 2024 Plan [Member] Richard Ranieri June 2024 Plan Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Expected volatility, low end of range (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Collaborative arrangement receivable (payable) related to cost sharing development activities Collaborative Arrangement Receivable (Payable) Related To Cost Sharing Development Activities Amount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities. Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Sales-based Sales-based Represents information pertaining to sales-based potential milestones. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title XmAb24306 XmAb24306 Represents information pertaining to product XmAb24306. Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Comprehensive loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest City Area Code City Area Code Debt - long-term Royalty Liabilities, Long-Term Debt Royalty Liabilities, Long-Term Debt Current liabilities Liabilities, Current [Abstract] A. Bruce Montgomery [Member] A. Bruce Montgomery Research collaboration Research collaboration [Member] Right to collaboration or assist on a project or agreement. Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Kurt Gustafson [Member] Kurt Gustafson Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Loss on disposal of assets Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Supplemental disclosures of non-cash activities Noncash Investing and Financing Items [Abstract] Preferred Stock Preferred Stock [Member] Accrued expenses Increase (Decrease) in Accrued Liabilities Exercisable options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Liability Related to the Sale of Future Revenues and Non-Cash Interest Expense on the Liability Related to the Sale of Future Royalties and Deferred Income Related to the Sale of Future Revenues Future Royalties, Policy [Policy Text Block] Future Royalties, Policy Debt, net of current portion Long-Term Debt, Excluding Current Maturities Weighted Average Grant Date Fair Value (Per unit) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity shares estimated fair value Equity Securities without Readily Determinable Fair Value, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net income (loss) per share attributable to common stockholders: Earnings Per Share [Abstract] Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Royalty milestones Revenue Recognition Milestone Method Pending Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. Marketable debt securities - long term Debt Securities, Noncurrent Class of Stock [Domain] Class of Stock [Domain] Lease liabilities and ROU assets Increase Decrease In Lease Liabilities and Right Of Use Assets The increase (decrease) during the reporting period relating to lease liabilities and right of use (ROU) assets. General and administrative General and Administrative Expense Unrealized gain (loss) on equity securities Unrealized gain (loss) recorded on equity securities held at the reporting date Equity Securities, FV-NI, Unrealized Gain (Loss) Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Discount rate Operating Lease, Weighted Average Discount Rate, Percent Present value of lease payments Operating Lease, Liability Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Marketable Debt and Equity Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Initial cost-sharing percentage Initial Cost-sharing Percentage The initial cost-sharing percentage. Entity Registrant Name Entity Registrant Name Net unrealized gain (loss) on marketable securities Marketable Security, Unrealized Gain (Loss) Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Fair Value as of Grant Date Award Grant Date Fair Value Sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Mature in one year or less Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Total Employee, Director and Non-Employee Stock-Based Compensation Expense Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock, $0.01 par value: 200,000,000 authorized shares at JuneÂ 30, 2024 and DecemberÂ 31, 2023; 61,766,054 issued and outstanding at JuneÂ 30, 2024 and 60,998,191 issued and outstanding at DecemberÂ 31, 2023 Common Stock, Value, Issued Reduction of liability for sale of future royalties Advance Future Royalty And Milestone Payments Advance Future Royalty And Milestone Payments Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Money Market Funds Cash and Cash Equivalents, at Carrying Value Payments for (proceeds from) tenant allowance Payments for (Proceeds from) Tenant Allowance Marketable equity securities - long term Equity Securities, FV-NI, Noncurrent Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Weighted average grant date fair value, forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Viridian Viridian [Member] Represents information pertaining to MiRagen/Viridian. Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at JuneÂ 30, 2024 and DecemberÂ 31, 2023 Preferred Stock, Value, Issued Number of Shares Subject to Outstanding Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] ESPP Employee Stock [Member] Basic net loss per common share attributable to Xencor, Inc. (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Research service Research service Represent information pertaining to research activity. Proceeds from issuance of common stock under the Employee Stock Purchase Plan Proceeds from Stock Plans Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Cash and cash equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Pasadena, CA - office and laboratory space Pasadena, CA - office and laboratory space [Member] Represents information pertaining to the laboratory and office space in Pasadena, California. Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Net loss attributable to Xencor, Inc. Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average shares used to compute net income (loss) per share attributable to common stockholders: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Unamortized compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Share-based payment arrangement, plan modification, incremental cost Share-Based Payment Arrangement, Plan Modification, Incremental Cost Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Government Securities US Treasury and Government [Member] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Equity Securities without Readily Determinable Fair Value [Table] Equity Securities without Readily Determinable Fair Value [Table] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies Commitments and Contingencies MorphoSys MorphoSys [Member] Represents information pertaining to MorphoSys. Risk-free interest rate, low end of range (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Termination Date Trading Arrangement Termination Date Expected volatility, high end of range (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum INmune INmune Represents information pertaining to the counterparty, INmune Bio, Inc. (INmune). License License Agreement [Member] Represents information pertaining to the License Agreement. Fair Value of Financial Instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Marketable Securities [Abstract] Marketable Securities [Abstract] Entity Address, City or Town Entity Address, City or Town Mature within two years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Marketable securities Marketable securities Primary financial statement caption encompassing marketable securities. Net loss attributable to Xencor, Inc. Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Ellen Feigal [Member] Ellen Feigal Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Abandonment of capitalized intangible assets Noncash Project Abandonment Costs Document Fiscal Year Focus Document Fiscal Year Focus Non-Controlling Interest Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Mabgeek Shanghai Mabgeek Biotech Co., Ltd. [Member] Shanghai Mabgeek Biotech Co., Ltd. Entity Address, Address Line Two Entity Address, Address Line Two Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Schedule of Revenue by Licensees Schedule of Revenue by Major Licensees [Table Text Block] Tabular disclosure of revenue by major licensees. Total Fair Value Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Sale of Future Royalty [Roll Forward] Sale of Future Royalty [Roll Forward] Sale of Future Royalty For the remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Aggregate intrinsic value, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Remaining lease term Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Marketable Debt and Equity Securities Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Impairment on equity securities Impairment on equity securities Equity Securities without Readily Determinable Fair

Value, Impairment Loss, Annual Amount Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Option and License agreement Option and license agreement [Member] Represents information pertaining to the option and license agreement. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Schedule of Marketable Securities Marketable Securities [Table Text Block] Revenue recognized Contract with Customer, Liability, Revenue Recognized Vir Vir [Member] Information pertaining to VIR Biotechnology (VirBio). Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Mature within two years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Schedule of Net Gains and Losses Gain (Loss) on Securities [Table Text Block] Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic weighted average common shares outstanding (in shares) Weighted-average common shares outstanding used in computing basic net loss (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Unrealized losses, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity received in connection with license agreements Noncash Consideration Received From Revenue Contracts Noncash Consideration Received From Revenue Contracts Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest RSUs Restricted Stock Units (RSUs) [Member] Unrealized (loss) gain on marketable securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Monrovia, CA - office and laboratory space Monrovia, CA - office and laboratory space [Member] Represents information pertaining to lease office and laboratory space in Monrovia, CA. Options forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Payments for repurchase of preferred stock and preference stock Payments for Repurchase of Preferred Stock and Preference Stock Unrealized losses, Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Transaction price Collaborative Arrangement, Transaction Price Collaborative Arrangement, Transaction Price Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 11 xncr-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Jul. 30, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-36182 Â Entity Registrant Name Xencor, Inc Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-1622502 Â Entity Address, Address Line One 465 North Halstead Street Â Entity Address, Address Line Two Suite 200 Â Entity Address, City or Town Pasadena Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 91107 Â City Area Code 626 Â Local Phone Number 305-5900 Â Title of 12(b) Security Common Stock, par value $0.01 per share Â Trading Symbol XNCR Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 61,833,530 Entity Central Index Key 0001326732 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 30,768 $ 53,790 Marketable debt securities 449,372 497,725 Marketable equity securities 28,271 42,210 Accounts receivable 22,073 11,290 Prepaid expenses and other current assets 23,986 18,145 Total current assets 554,470 623,160 Property and equipment, net 63,868 66,124 Patents, licenses, and other intangible assets, net 18,778 18,663 Restricted cash 384 380 Marketable debt securities - long term 104,862 145,512 Marketable equity securities - long term 43,780 64,210 Right of use (ROU) asset 39,527 33,995 Other assets 498 648 Total assets 826,167 952,692 Current liabilities Â Â Accounts payable 15,838 13,914 Accrued expenses 19,557 23,564 Income tax payable 0 5,782 Lease liabilities 1,262 3,435 Deferred income 36,472 31,682 Debt 6,947 6,332 Total current liabilities 80,076 84,709 Lease liabilities, net of current portion 67,156 59,025 Deferred income, net of current portion 104,081 125,183 Debt, net of current portion 12,313 14,642 Total liabilities 263,626 283,559 Commitments and contingencies Stockholdersâ€™ equity Â Â Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at JuneÂ 30, 2024 and DecemberÂ 31, 2023 0 0 Common stock, $0.01 par value: 200,000,000 authorized shares at JuneÂ 30, 2024 and DecemberÂ 31, 2023; 61,766,054 issued and outstanding at JuneÂ 30, 2024 and 60,998,191 issued and outstanding at DecemberÂ 31, 2023 619 611 Additional paid-in capital 1,162,726 1,131,266 Accumulated other comprehensive (loss) income (652) 1,291 Accumulated deficit (598,368) (464,372) Total stockholdersâ€™ equity attributable to Xencor, Inc. 564,325 668,796 Non-controlling interest (1,784) 337 Total stockholdersâ€™ equity 562,541 669,133 Total liabilities and stockholdersâ€™ equity $ 826,167 $ 952,692 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-

1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of debt and lease obligation, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit

loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current. + ReferencesNo definition available. + Details Name: us-gaap_DebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent. + ReferencesNo definition available. + Details Name: us-gaap_DebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01 Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, shares authorized (in shares) 200,000,000 200,000,000 Common stock, shares issued (in shares) 61,766,054 60,998,191 Common stock, shares outstanding (in shares) 61,766,054 60,998,191 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Statements of Loss (unaudited) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue Â Â Â Â Collaborations, milestones, and royalties $ 16,960,000 $ 45,523,000 $ 29,765,000 $ 64,485,000 Operating expenses Â Â Â Â Research and development 61,531,000 60,060,000 118,404,000 125,612,000 General and administrative 17,746,000 11,460,000 31,533,000 25,613,000 Total operating expenses 79,277,000 71,520,000 149,937,000 151,225,000 Loss from operations (62,317,000) (25,997,000) (120,172,000) (86,740,000) Other income (expense) Â Â Â Â Interest income 7,681,000 3,771,000 16,229,000 6,670,000 Interest expense (844,000) (7,000) (1,921,000) (14,000) Other expense, net (4,000) (9,000) (4,000) (23,000) Impairment on equity securities 220,000 0 (20,430,000) 0 Gain (loss) on equity securities, net (12,027,000) 288,000 (9,702,000) (2,610,000) Total other income (expense), net (4,974,000) 4,043,000 (15,828,000) 4,023,000 Loss before income tax expense (67,291,000) (21,954,000) (136,000,000) (82,717,000) Income tax expense 117,000 0 117,000 0 Net loss (67,408,000) (21,954,000) (136,117,000) (82,717,000) Net loss attributable to non-controlling interest (1,445,000) 0 (2,121,000) 0 Net loss attributable to Xencor, Inc. $ (65,963,000) $ (21,954,000) $ (133,996,000) $ (82,717,000) Basic net loss per common share attributable to Xencor, Inc. (in dollars per share) $ (1.07) $ (0.37) $ (2.18) $ (1.38) Diluted net loss per common share attributable to Xencor, Inc. (in dollars per share) $ (1.07) $ (0.37) $ (2.18) $ (1.38) Weighted average shares used to compute net income (loss) per share attributable to common stockholders: Â Â Â Â Basic weighted average common shares outstanding (in shares) 61,676,444 59,807,558 61,444,384 59,922,784 Diluted weighted average common shares outstanding (in shares) 61,676,444 59,807,558 61,444,384 59,922,784 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -

Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff

of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (67,408) $ (21,954) $ (136,117) $ (82,717) Net unrealized gain (loss) on marketable debt securities (498) 1,765 (1,942) 5,093 Comprehensive loss (67,906) (20,189) (138,059) (77,624) Comprehensive loss attributable to non-controlling interest (1,445) 0 (2,121) 0 Comprehensive loss attributable to Xencor, Inc. $ (66,461) $ (20,189) $ (135,938) $ (77,624) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Non-Controlling Interest Beginning balance (in shares) at Dec. 31, 2022 Â 59,997,713 Â Â Â Â Beginning balance at Dec. 31, 2022 $ 727,496 $ 601 $ 1,072,132 $ (6,952) $ (338,285) $ 0 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock upon exercise of stock awards (in shares) Â 34,388 Â Â Â Â Issuance of common stock upon exercise of stock awards 924 Â 924 Â Â Â Issuance of restricted stock units (in shares) Â 349,499 Â Â Â Â Issuance of restricted stock units 0 $ 4 (4) Â Â Â Comprehensive income (loss) (57,436) Â Â 3,327 (60,763) Â Stock-based compensation 12,599 Â 12,599 Â Â Â Ending balance (in shares) at Mar. 31, 2023 Â 60,381,600 Â Â Â Â Ending balance at Mar. 31, 2023 683,583 $ 605 1,085,651 (3,625) (399,048) 0 Beginning balance (in shares) at Dec. 31, 2022 Â 59,997,713 Â Â Â Â Beginning balance at Dec. 31, 2022 727,496 $ 601 1,072,132 (6,952) (338,285) 0 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Comprehensive income (loss) (77,624) Â Â Â Â Â Ending balance (in shares) at Jun. 30, 2023 Â 60,600,060 Â Â Â Â Ending balance at Jun. 30, 2023 678,876 $ 607 1,101,131 (1,860) (421,002) 0 Beginning balance (in shares) at Mar. 31, 2023 Â 60,381,600 Â Â Â Â Beginning balance at Mar. 31, 2023 683,583 $ 605 1,085,651 (3,625) (399,048) 0 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock upon exercise of stock awards (in shares) Â 145,003 Â Â Â Â Issuance of common stock upon exercise of stock awards 677 $ 1 676 Â Â Â Issuance of restricted stock units (in shares) Â 18,148 Â Â Â Â Issuance of restricted stock units 0 Â Â Â Â Â Issuance of common stock under the Employee Stock Purchase Plan (in shares) Â 55,309 Â Â Â Â Issuance of common stock under the Employee Stock Purchase Plan 1,242 $ 1 1,241 Â Â Â Comprehensive income (loss) (20,189) Â Â 1,765 (21,954) Â Stock-based compensation 13,563 Â 13,563 Â Â Â Ending balance (in shares) at Jun. 30, 2023 Â 60,600,060 Â Â Â Â Ending balance at Jun. 30, 2023 678,876 $ 607 1,101,131 (1,860) (421,002) 0 Beginning balance (in shares) at Dec. 31, 2023 Â 60,998,191 Â Â Â Â Beginning balance at Dec. 31, 2023 669,133 $ 611 1,131,266 1,291 (464,372) 337 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock upon exercise of stock awards (in shares) Â 152,682 Â Â Â Â Issuance of common stock upon exercise of stock awards 1,787 $ 1 1,786 Â Â Â Issuance of restricted stock units (in shares) Â 483,812 Â Â Â Â Issuance of restricted stock units 0 $ 5 (5) Â Â Â Comprehensive income (loss) (70,154) Â Â (1,445) (68,033) (676) Stock-based compensation 11,421 Â 11,421 Â Â Â Ending balance (in shares) at Mar. 31, 2024 Â 61,634,685 Â Â Â Â Ending balance at Mar. 31, 2024 612,187 $ 617 1,144,468 (154) (532,405) (339) Beginning balance (in shares) at Dec. 31, 2023 Â 60,998,191 Â Â Â Â Beginning balance at Dec. 31, 2023 669,133 $ 611 1,131,266 1,291 (464,372) 337 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Comprehensive income (loss) (138,059) Â Â Â Â Â Ending balance (in shares) at Jun. 30, 2024 Â 61,766,054 Â Â Â Â Ending balance at Jun. 30, 2024 562,541 $ 619 1,162,726 (652) (598,368) (1,784) Beginning balance (in shares) at Mar. 31, 2024 Â 61,634,685 Â Â Â Â Beginning balance at Mar. 31, 2024 612,187 $ 617 1,144,468 (154) (532,405) (339) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock upon exercise of stock awards (in shares) Â 10,213 Â Â Â Â Issuance of common stock upon exercise of stock awards 140 Â 140 Â Â Â Issuance of restricted stock units (in shares) Â 67,160 Â Â Â Â Issuance of restricted stock units 0 $ 1 (1) Â Â Â Issuance of common stock under the Employee Stock Purchase Plan (in shares) Â 53,996 Â Â Â Â Issuance of common stock under the Employee Stock Purchase Plan 930 $ 1 929 Â Â Â Comprehensive income (loss) (67,906) Â Â (498) (65,963) (1,445) Stock-based compensation 17,190 Â 17,190 Â Â Â Ending balance (in shares) at Jun. 30, 2024 Â 61,766,054 Â Â Â Â Ending balance at Jun. 30, 2024 $ 562,541 $ 619 $ 1,162,726 $ (652) $ (598,368) $ (1,784) X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65

-Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities Â Â Net loss $ (136,117) $ (82,717) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 6,059 5,130 Accretion of discount on marketable debt securities (10,037) (4,345) Stock-based compensation 28,611 26,162 Equity received in connection with license agreements 0 (10,000) Abandonment of capitalized intangible assets 784 594 Gain on sale of marketable debt securities (3) 0 Change in fair value of equity securities 9,702 2,610 Impairment on equity securities 20,430 0 Non-cash interest expense 1,900 0 Loss on disposal of assets 6 1,379 Changes in operating assets and liabilities: Â Â Accounts receivable (10,783) 8,978 Interest receivable from marketable debt securities (1,705) 420 Prepaid expenses and other assets (5,691) 1,127 Accounts payable 1,924 4,009 Accrued expenses (4,007) (288) Income taxes (5,782) 0 Lease liabilities and ROU assets 426 582 Deferred revenue 0 (22,455) Deferred income (16,312) 0 Net cash used in operating activities (120,595) (68,814) Cash flows from investing activities Â Â Purchase of marketable securities (259,130) (276,715) Sale of equity securities 4,236 0 Purchase of patents, licenses, and other intangible assets (1,549) (1,490) Purchase of property and equipment (3,158) (14,636) Proceeds from maturities of marketable securities 347,966 339,580 Proceeds from sale of marketable securities 9,969 0 Net cash provided by investing activities 98,334 46,739 Cash flows from financing activities Â Â Proceeds from issuance of common stock upon exercise of stock awards 1,927 1,601 Proceeds from issuance of common stock under the Employee Stock Purchase Plan 930 1,242 Reduction of liability for sale of future royalties (3,614) 0 Net cash (used in) provided by financing activities (757) 2,843 Net decrease in cash, cash equivalents, and restricted cash (23,018) (19,232) Cash, cash equivalents, and restricted cash, beginning of period 54,170 53,942 Cash, cash equivalents, and restricted cash, end of period 31,152 34,710 Cash paid during the period for: Â Â Interest 21 14 Income taxes 6,100 0 Supplemental disclosures of non-cash activities Â Â Unrealized (loss) gain on marketable securities (1,942) 5,093 ROU assets obtained 7,166 0 Cash and cash equivalents 30,768 34,710 Restricted cash $ 384 $ 0 X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in net unamortized loan origination fees and other fees that are collected at origination but recorded as income over the life of the loan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInLoansDeferredIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe expense charged against earnings to eliminate the capitalized costs of projects that have been terminated during the reporting period, which is added back to net income when calculating cash provided by (used in) operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_NoncashProjectAbandonmentCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -

Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAdvance Future Royalty And Milestone Payments + ReferencesNo definition available. + Details Name: xncr_AdvanceFutureRoyaltyAndMilestonePayments Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (Decrease) in Accounts Receivable and Contract with Customer Assets + ReferencesNo definition available. + Details Name: xncr_IncreaseDecreaseInAccountsAndOtherReceivablesAndContractWithCustomerAssets Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period relating to lease liabilities and right of use (ROU) assets. + ReferencesNo definition available. + Details Name: xncr_IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Consideration Received From Revenue Contracts + ReferencesNo definition available. + Details Name: xncr_NoncashConsiderationReceivedFromRevenueContracts Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSupplemental Cash Flow Information Cash Paid [Abstract] + ReferencesNo definition available. + Details Name: xncr_SupplementalCashFlowInformationCashPaidAbstract Namespace Prefix: xncr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited consolidated interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of consolidated interim financial statements requires the use of managementâ€™s estimates and assumptions that affect reported amounts of assets and liabilities at the date of the consolidated interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period.The accompanying unaudited consolidated interim financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2024.Principles of ConsolidationThe accompanying consolidated financial statements include the accounts of Xencor, Inc. and Gale Therapeutics Inc. (Gale), a variable interest entity (VIE) in which we are the primary beneficiary. Since we own less than 100% of Gale, the Company records net loss attributable to non-controlling interests in its consolidated statements of loss equal to the percentage of the economic or ownership interests retained in Gale by the non-controlling party.In determining whether we are the primary beneficiary of a VIE, we apply a qualitative approach that determines whether we have (1) the power to direct the activities of the VIE that most significantly impact the entity's economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to the VIE. We continuously assess whether we are the primary beneficiary of Gale as changes to existing relationships or future transactions may result in us consolidating or deconsolidating Gale.Use of EstimatesThe preparation of consolidated interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive income (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these consolidated interim financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets.ReclassificationsCertain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. During the six months ended JuneÂ 30, 2024, we adopted a change in presentation on our consolidated statements of loss to include loss from disposal of fixed assets in operating expenses. The prior period has been revised to reflect this change in the presentation.Intangible AssetsThe Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There was no impairment charge recorded for the three and six months ended JuneÂ 30, 2024 and 2023.The Company capitalizes certain in-process intangible assets that are then abandoned when they are no longer pursued or used in current research activities. We abandoned $0.4 million and $0.8 million of in-process intangible assets for the three and six months ended JuneÂ 30, 2024. We abandoned $0.3 million and $0.6 million of in-process intangible assets during the three and six months ended JuneÂ 30, 2023. Marketable Debt and Equity SecuritiesThe Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The investment policy limits the maturity of any individual security to a maximum of 36 months. The average maturity of securities in the portfolio as of JuneÂ 30, 2024 is less than 12 months. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale because it is not more likely than not that the Company will be required to sell the securities before recovery of the amortized cost. These assets are carried at fair value and any impairment losses and recoveries related to the underlying issuerâ€™s credit standing are recognized within other income (expense), while non-credit related impairment losses and recoveries are recognized within accumulated other comprehensive income (loss). There were no impairment losses or recoveries recorded for the three and six months ended JuneÂ 30, 2024 and 2023. Accrued interest on marketable debt securities is included in the marketable securitiesâ€™ carrying value. Each reporting period, the Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if each securityâ€™s fair value has declined below its amortized cost basis. During the three and six months ended JuneÂ 30, 2024, the Company recorded an unrealized loss of $0.5 million and $1.9 million in its portfolio of marketable debt securities. During the three and six months ended JuneÂ 30, 2023, the Company recorded an unrealized gain of $1.8 million and $5.1 million. The unrealized loss is due to the changing interest rate environment and is not due to changes in the credit quality of the underlying securities. The unrealized gain (loss) is recorded in other comprehensive income (loss) for the three and six months ended JuneÂ 30, 2024 and 2023.The Company receives equity securities in connection with certain licensing transactions with its partners. These investments in equity securities are carried at fair value with changes in fair value recognized each period and reported within other income (expense). For equity securities with a readily determinable fair value, the Company remeasures these equity investments at each reporting period until such time that the investment is sold or disposed. If the Company sells an investment, any realized gain or loss on the sale of the securities will be recognized within other income (expense) in the consolidated statements of loss in the period of sale.The Company also has investments in equity securities without a readily determinable fair value, where the Company elects the measurement alternative to record the investment at its initial cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There was an impairment charge of $20.4 million recorded for the six months ended JuneÂ 30, 2024 in connection with equity securities without a readily determinable fair value. There was no impairment charge recorded for the three and six months ended JuneÂ 30, 2023.Liability Related to the Sale of Future RevenuesWe treat the sale of future Monjuvi royalties as debt, amortized under the effective interest rate method over the estimated life of the Monjuvi Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future Monjuvi royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Non-cash Interest Expense on the Liability Related to the Sale of Future RoyaltiesThe total expected royalty payments less the net proceeds received are recorded as non-cash interest expense over the life of the liability. Interest is imputed on the unamortized portion using the effective interest method and is recorded based on the timing of the payments received over the term of the Monjuvi Royalty Sale Agreement. The actual interest rate will be affected by the

timing of the royalty payments and changes in the forecasted revenue.Deferred Income Related to the Sale of Future RevenuesWe treat the sale of future Ultomiris royalties as deferred income, amortized under the units-of-revenue method by computing a ratio of the proceeds received to the total expected payments over the term of the Ultomiris Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid.Recent Accounting PronouncementsThere have been no material changes in recently issued or adopted accounting standards from those disclosed in the Company's 2023 Annual Report on Form 10-K. The Company has reviewed all recently issued accounting pronouncements and does not believe they will have a material impact on our results of operations, financial condition or cash flows.There have been no other material changes to the significant accounting policies previously disclosed in the Companyâ€™s 2023 Annual Report on Form 10-K. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value of Financial Instruments 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments Fair Value of Financial InstrumentsFinancial instruments included in the financial statements include cash and cash equivalents, marketable debt and equity securities, accounts receivable, accounts payable, and accrued expenses. Marketable debt securities, equity securities, and cash equivalents are carried at fair value. The fair value of the other financial instruments closely approximates their fair value due to their short-term maturities.The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosure about fair value measurements. The ASC 820 hierarchy ranks the quality of reliable inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:Level 1â€”Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets or liabilities.Level 2â€”Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in markets that are not active. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. Level 3â€”Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by the reporting entity â€“ e.g., determining an appropriate discount factor for illiquidity associated with a given security. The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands):June 30, 2024(unaudited)December 31, 2023TotalFair ValueLevel 1Level 2TotalFair ValueLevel 1Level 2Money Market Funds $11,624Â $11,624Â $â€”Â $25,520Â $25,520Â $â€”Â Corporate Securities211,657Â â€”Â 211,657Â 228,723Â â€”Â 228,723Â Government Securities342,577Â â€”Â 342,577Â 414,514Â â€”Â 414,514Â $565,858Â $11,624Â $554,234Â $668,757Â $25,520Â $643,237Â Our policy is to record transfers of assets between Level 1 and Level 2 at their fair values as of the end of each reporting period, consistent with the date of the determination of fair value. During the three and six months ended JuneÂ 30, 2024 and 2023, there were no transfers between Level 1 and Level 2. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Common Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Net Loss Per Common Share Net Loss Per Common ShareBasic net loss per common share is computed by dividing the net loss attributable to Xencor by the weighted-average number of common shares outstanding during the period without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to Xencor by the weighted-average number of common stock equivalents outstanding for the period. Potentially dilutive securities consisting of stock issuable pursuant to outstanding options and restricted stock units (RSUs), and stock issuable pursuant to the 2013 Employee Stock Purchase Plan (ESPP) are not included in the per common share calculation in periods when the inclusion of such shares would have an anti-dilutive effect.Basic and diluted net loss per common share is computed as follows:Three Months EndedJune 30,Six Months EndedJune 30,202420232024023(in thousands, except share and per share data)(in thousands, except share and per share data)Numerator:Net loss attributable to Xencor, Inc.$(65,963)$(21,954)$(133,996)$(82,717)Denominator:Weighted-average common shares outstanding used in computing basic and diluted net loss61,676,44459,807,55861,444,38459,922,784Basic and diluted net loss per common share attributable to Xencor, Inc.(1.07)(0.37)(2.18)(1.38)For the three and six months ended JuneÂ 30, 2024 and 2023, all outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share as the effect of including such securities would have been anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Comprehensive Loss 6 Months Ended Jun. 30, 2024 Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Â Comprehensive Loss Comprehensive LossComprehensive loss is comprised of net loss and other comprehensive income (loss). For each of the three and six-month periods ended JuneÂ 30, 2024 and 2023, the only component of other comprehensive income (loss) is net unrealized gain (loss) on marketable debt securities. There were no material reclassifications out of accumulated other comprehensive loss during each of the three and six-month periods ended JuneÂ 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities 6 Months Ended Jun. 30, 2024 Marketable Securities [Abstract] Â Marketable Debt and Equity Securities Marketable Debt and Equity SecuritiesThe Companyâ€™s marketable debt securities held as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are summarized below:June 30, 2024AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(in thousands)Money Market Funds $11,624Â $â€”Â $â€”Â $11,624Â Corporate Securities211,930Â 6Â (279)211,657Â Government Securities342,945Â 6Â (374)342,577Â $566,499Â $12Â (653)565,858Â Reported asCash and cash equivalents$11,624Â Marketable securities554,234Â Total investments$565,858Â December 31, 2023AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(in thousands)Money Market Funds $25,520Â $â€”Â $â€”Â $25,520Â Corporate Securities228,382Â 342Â (1)228,723Â Government Securities413,553Â 1,037Â (76)414,514Â $667,455Â $1,379Â (77)668,757Â Reported asCash and cash equivalents$25,520Â Marketable securities643,237Â Total investments$668,757Â The maturities of the Companyâ€™s marketable debt securities as of JuneÂ 30, 2024 are as follows:June 30, 2024AmortizedCostEstimatedFair Value(in thousands)Mature in one year or less$449,715Â $449,372Â Mature within two years105,160Â 104,862Â $554,875Â $554,234Â The unrealized losses on available-for-sale investments and their related fair values as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Less than 12 months12 months or greaterJune 30, 2024Fair valueUnrealizedlossesFair valueUnrealizedlosses(in thousands)Corporate Securities$119,044Â (217)11,895Â $(62)Government Securities246,154Â (132)79,478Â (242)$365,198Â (349)91,373Â $(304)Less than 12 months12 months or greaterDecember 31, 2023Fair valueUnrealizedlossesFair valueUnrealizedlosses(in thousands)Corporate Securities$8,073Â (1)â€”Â $â€”Â Government Securities66,546Â (76)â€”Â â€”Â $74,619Â (77)â€”Â $â€”Â The unrealized losses from the available-for-sale securities are due to changes in the interest rate environment and not changes in the credit quality of the underlying securities in the portfolio.The Companyâ€™s equity securities include securities with a readily determinable fair value. These investments are carried at fair value with changes in fair value recognized each period and reported within other income (expense), net. For the three and six months ended JuneÂ 30, 2024, net losses of $12.0 million and $9.7 million were recorded under other income (expense) related to these securities. For the three and six months ended JuneÂ 30, 2023, a net gain of $0.3 million and a net loss of $2.6 million were recorded under other income (expense). Equity securities with a readily determinable fair value, which are categorized as Level 1 in the fair value hierarchy under ASC 820, and their fair values (in thousands) as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Fair ValueFair ValueJune 30, 2024December 31, 2023Astria Common Stock$2,311Â $5,360Â INmune Common Stock16,630Â 21,231Â Viridian Common Stock9,330Â 15,619Â $28,271Â $42,210Â The Company sold 443,909 shares of common stock of Astria Therapeutics, Inc. (Astria) and held 253,958 shares of common stock of Astria as of JuneÂ 30, 2024. In July 2024, the Company sold the remaining shares of the common stock of Astria. The common stock has a readily determinable fair value. For the remaining equity interest in Astria held at JuneÂ 30, 2024, the Company recorded an unrealized loss of $1.3 million and an unrealized gain of $0.4 million for the three and six months ended JuneÂ 30, 2024, respectively. The Company recorded unrealized losses of $3.5 million and $3.9 million related to its equity interest in Astria for the three and six months ended JuneÂ 30, 2023, respectively.The Company currently holds 1,885,533 shares of common stock of INmune Bio, Inc. (INmune). The 1,885,533 shares of INmune common stock are classified as equity securities with a readily determinable fair value. For the three and six months ended JuneÂ 30, 2024, the Company recorded unrealized losses of $5.5 million and $4.6 million, respectively, related to its investment in INmune. For the three and six months ended JuneÂ 30, 2023, the Company recorded unrealized gains of $4.9 million and $5.2 million, respectively.The Company currently holds 717,144 shares of common stock of Viridian Therapeutics, Inc. (Viridian). The shares of Viridian common stock are classified as equity securities with a readily determinable fair value. The Company recorded unrealized losses of $3.2 million and $6.3 million for the three and six months ended JuneÂ 30, 2024, respectively. The Company recorded unrealized losses of $1.2 million and $3.9 million for the three and six months ended JuneÂ 30, 2023, respectively, related to the shares of Viridian common stock. Below is a reconciliation of net gain (loss) recorded on equity securities during the three and six months ended JuneÂ 30, 2024 and 2023:Three Months EndedJune 30,Six Months EndedJune 30,202420232024023Net gain (loss) recorded on equity securities$(12,027)$288Â $(9,702)$(2,610)Less: Net gain (loss) recorded on sale of equity securities(2,012)â€”Â 827Â â€”Â Unrealized gain (loss) recorded on equity securities held at the reporting date$(10,015)$288Â $(10,529)$(2,610)The Company also has investments in equity securities without a readily determinable fair

value. The Company elects the measurement alternative to record these investments at their initial cost and evaluates such investments at each reporting period for evidence of impairment, or observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Equity securities without a readily determinable fair value and their carrying values (in thousands) as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Carrying ValueCarrying ValueJune 30, 2024December 31, 2023Zenas Preferred Stock$43,780Â $64,210Â The Company currently holds an equity interest in Zenas BioPharma, Inc. (Zenas), a private biotechnology company. The Companyâ€™s equity interests include preferred stock in Zenas which were received as upfront payments and a milestone payment for licensing certain clinical and preclinical assets from the Company. The Company elected the measurement alternative to carry the Zenas equity at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. During the six months ended JuneÂ 30, 2024, we recorded $20.4Â million of impairment charge as a result of Zenas closing a Series C financing transaction on May 3, 2024. X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Stock Based CompensationIn June 2023, our Board of Directors (the Board) and stockholders approved the 2023 Equity Incentive Plan (the 2023 Plan), which became effective as of JuneÂ 14, 2023. The Board and the requisite stockholders previously approved the 2013 Equity Incentive Plan (the 2013 Plan). We suspended the 2013 Plan, and no additional award may be granted under the 2013 Plan. The 2023 Plan reserve consists of 3,000,000 shares and the remaining available shares from the 2013 Plan as of the effective date of the 2023 Plan. In addition, any shares of common stock covered by awards granted under the 2013 Plan that terminate on or after JuneÂ 14, 2023 by expiration, forfeiture, cancellation, or other means without the issuance of such shares will be added to the 2023 Plan reserve. The 2023 Plan does not include a provision for an automatic increase in shares, also known as an evergreen provision.As of JuneÂ 30, 2024, the total number of shares of common stock available for issuance under the 2023 Plan is 18,721,104, which includes shares of common stock that were available for issuance under the prior Plans as of the effective date of the 2023 Plan. As of JuneÂ 30, 2024, a total of 2,380,651 options have been granted under the 2023 Plan.In November 2013, the Board and our stockholders approved the ESPP, which became effective as of December 5, 2013. As of JuneÂ 30, 2024, the total number of shares of common stock available for issuance under the ESPP is 987,344. Unless otherwise determined by the Board, beginning on January 1, 2014, and continuing until January 1, 2023, the total number of shares of common stock available for issuance under the ESPP automatically increased annually on January 1 by the lesser of (i) 1% of the total number of issued and outstanding shares of common stock as of DecemberÂ 31 of the immediately preceding year, or (ii) 621,814 shares of common stock. The automatic increase has expired, and the number of shares of common stock available for issuance under the ESPP was not increased on JanuaryÂ 1, 2024. As of JuneÂ 30, 2024, we have issued a total of 787,474 shares of common stock under the ESPP.During the six months ended JuneÂ 30, 2024, the Company awarded 959,071 RSUs to certain employees. The standard vesting of these awards is generally in three equal annual installments and is contingent on an employeeâ€™s continued service to the Company. The fair value of these awards is determined based on the intrinsic value of the stock on the date of grant and will be recognized as stock-based compensation expense over the requisite service period. As of JuneÂ 30, 2024, a total of 1,045,738 RSUs have been granted under the 2023 Plan.The Company extended vesting periods and expiration dates of equity awards for employees who retired in April 2024. There is a $3.1 million incremental expense as a result of the extension of the expiration dates, and there is a $1.2 million expense as a result of the extension of the vesting periods.Total employee, director and non-employee stock-based compensation expense recognized for the three and six months ended JuneÂ 30, 2024 and 2023 are as follows (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023General and administrative $8,469Â $4,471Â $13,168Â $8,747Â Research and development 8,721Â 9,092Â 15,443Â 17,415Â $17,190Â $13,563Â $28,611Â $26,162Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Stock options$10,945Â $6,842Â $17,818Â $13,825Â ESPP211Â 341Â 417Â 663Â RSUs6,034Â 6,380Â 10,376Â 11,674Â $17,190Â $13,563Â $28,611Â $26,162Â The following table summarizes option activity under our stock plans and related information:Number ofShares Subjectto OutstandingOptionsWeightedAverageExercisePrice(PerShare)WeightedAverageRemainingContractualTerm(in years)AggregateIntrinsicValue(in thousands)Balance at December 31, 202311,142,986$29.60Â 6.03$9,977Â Options granted2,167,253$22.43Â Options forfeited(485,918)$32.84Â Options exercised(162,895)$11.83Â Balance at June 30, 202412,661,426$28.48Â 6.18$5,813Â Exercisable8,295,121$29.38Â 4.76$5,745Â We calculate the intrinsic value as the difference between the exercise price of the options and the closing price of common stock of $18.93 per share as of JuneÂ 30, 2024.The weighted-average fair value of options granted during the six-month periods ended JuneÂ 30, 2024 and 2023 were $22.43 and $30.65 per share, respectively. There were 1,941,412 options granted during the six-month period ended JuneÂ 30, 2023. We estimated the fair value of each equity award, including stock options and shares issued under our ESPP, using the Black-Scholes option-pricing model based on the date of grant of such stock option or ESPP share issuance date, with the following weighted average assumptions for the three and six months ended JuneÂ 30, 2024 and 2023:OptionsOptions Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Expected term (years)6.46.56.46.1Expected volatility50.4Â %51.2Â %50.1Â %50.5Â %Risk-free interest rate4.42Â %3.69Â %4.18Â %4.17Â %Expected dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â %ESPPESPP Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Expected term (years)0.5 - 2.00.5 - 2.00.5 - 2.00.5 -2.0Expected volatility43.0% - 44.6%38.2% - 55.7%43.0% - 44.6%38.2% - 55.7%Risk-free interest rate4.71% - 5.40%0.13% - 5.39%4.71% - 5.40%0.13% - 5.39%Expected dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â %As of JuneÂ 30, 2024, the unamortized compensation expense related to unvested stock options was $56.9 million. The remaining unamortized compensation expense will be recognized over the next 2.7 years. As of JuneÂ 30, 2024, the unamortized compensation expense under our ESPP was $1.3 million. The remaining unamortized expense will be recognized over the next 1.4 years.The following table summarizes the RSU activity for the six-month period ended JuneÂ 30, 2024:RestrictedStockUnitsWeighted Average Grant Date Fair Value(Per unit)Unvested RSUs at December 31, 20231,490,040$30.66Â Granted959,07122.58Â Vested(550,972)31.72Â Forfeited(119,483)29.80Â Unvested RSUs at June 30, 20241,778,656$26.02Â As of JuneÂ 30, 2024, the unamortized compensation expense related to unvested RSUs was $37.0Â million. The remaining unamortized expense will be recognized over the next 2.1 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Leases LeasesThe Company leases office and laboratory space in Monrovia, California under a lease that expires in December 2025 with an option to renew for an additional five years at then market rates. The Company has assessed that it is unlikely to exercise the option to extend the lease term. In June 2021, the Company entered into an Agreement of Lease (Lease Agreement) for laboratory and office space in Pasadena, California, which will expire in July 2035. The Lease Agreement provides for two separate phases of lease and occupancy. The first phase commenced on AugustÂ 1, 2022 and provides the Company with an improvement allowance up to $17.0 million. The second phase of the lease agreement will commence no later than SeptemberÂ 30, 2026 and includes an additional improvement allowance up to $3.3 million. In August 2022, the Company entered into an amendment, which the Company received an additional $5.0 million in tenant improvement allowance in exchange for an increase in the rental rate of the phase 1 space. The Company received delivery of the second phase premises on December 1, 2022. The Company placed the new facility into service in February 2023. In January 2024, the Company entered into an amendment, in which the Company will be paid for $0.7 million of tenant improvement allowance from the second phase for HVAC costs in the first phase. In August 2023, the Company entered into a Sublease Agreement for office space in San Diego, California. The term of the Sublease Agreement begins in September 2023 and ends in December 2027. In connection with the Sublease Agreement, the Company provided a $0.4 million Letter of Credit to the landlord. The Letter of Credit will decline over the term of the lease. The Company also entered into a Cash Collateral Agreement for $0.4 million, which is classified as restricted cash in the Consolidated Balance Sheets.The Companyâ€™s lease agreements do not contain any residual value guarantees or restrictive covenants.The following table reconciles the undiscounted cash flows for the operating leases at JuneÂ 30, 2024 to the operating lease liabilities recorded on the balance sheet (in thousands):Years ending December 31,For the remainder of 2024$2,792Â 20258,022Â 20269,238Â 20279,560Â 20289,076Â 20299,331Â Thereafter57,104Â Total undiscounted lease payments105,123Â Less: Tenant allowance(3,252)Less: Imputed interest(33,453)Present value of lease payments$68,418Â Lease liabilities - short-term$1,262Â Lease liabilities - long-term67,156Â Total lease liabilities$68,418Â The following table summarizes lease costs and cash payments for the three and six months ended JuneÂ 30, 2024 and 2023 (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Operating lease cost$1,881Â $2,020Â $3,762Â $4,200Â Variable lease cost310Â 219Â 1,140Â 453Â Total lease costs$2,191Â $2,239Â $4,902Â $4,653Â Cash paid for amounts included in the measurement of lease liabilities$807Â $721Â $1,877Â $1,445Â As of JuneÂ 30, 2024, the weighted-average remaining lease term for operating leases is 10.7 years, and the weighted-average discount rate for operating leases is 7.0%. As of JuneÂ 30, 2023, the weighted-average remaining lease term for operating leases was 11.7 years, and the weighted-average discount rate for operating leases was 8.9%. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Commitments and ContingenciesFrom time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred. The Company is obligated to make future payments to third parties pursuant to certain license agreements, including sublicense fees, royalties, and payments that become due and payable on the achievement of certain development and commercialization milestones. As the amount and timing of sublicense fees and the achievement and timing of these milestones are not probable and estimable, such commitments have not been included on the Companyâ€™s balance sheets for the periods ended JuneÂ 30, 2024 and DecemberÂ 31, 2023. The Company has also entered into agreements with third-party vendors that will require us to make future payments upon the delivery of goods and services in future periods. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and Licensing Agreements 6 Months Ended Jun. 30, 2024 Collaboration and Licensing Agreements Â Collaboration and Licensing Agreements Collaboration and Licensing AgreementsThe following is a summary description of the material collaboration arrangements in the three and six months ended JuneÂ 30, 2024 and 2023.Alexion Pharmaceuticals, Inc.In January 2013, the Company entered into an Option and License Agreement (the Alexion Agreement) with Alexion Pharmaceuticals, Inc. (Alexion). Under the terms of the Alexion Agreement, the Company granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use the Companyâ€™s Xtend technology to evaluate and advance compounds. Alexion exercised its rights to one target program, ALXN1210, which is now marketed as UltomirisÂ®.The Company is entitled to receive royalties based on a percentage of net sales of Ultomiris sold by Alexion, its affiliates or its sublicensees, which percentage is in the low single digits. Alexionâ€™s royalty obligations continue on a product-by-product and country-by-country basis until the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country.On November 3, 2023, the Company entered into the Ultomiris Royalty Sale Agreement with OMERS, in which OMERS acquired the rights to certain royalties associated with the existing license relating to Ultomiris in exchange for cash consideration. For the six months ended JuneÂ 30, 2024, Company earned and recognized $16.3 million in non-cash royalty revenue under the Ultomiris Royalty Sale Agreement. The Company recognized $6.9 million and $16.3 million of non-cash royalty revenue during the three and six months ended JuneÂ 30, 2024, respectively, and $11.2 million and $21.6 million of royalty revenue under this arrangement for the three and six months ended JuneÂ 30, 2023, respectively. As of JuneÂ 30, 2024, there is no receivable and no deferred revenue related to this agreement.Genentech, Inc., and F. Hoffmann-La Roche LtdIn February 2019, the Company entered into a collaboration and license agreement (the Genentech Agreement) with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively, Genentech) for the development and commercialization of novel IL-15 collaboration products (Collaboration Products), including efbalropendekin alfa (also named XmAb306 and RG6323), the Companyâ€™s IL-15/IL15RÎ±-Fc candidate.Under the terms of the Genentech Agreement, Genentech received an exclusive worldwide license to XmAb306, and we shared in 45% of development and commercialization costs of Collaboration Products, and we were eligible to share in 45% of net profits and losses from the sale of approved products. However, in the fourth quarter of 2023, we agreed with Genentech to convert our current development cost and profit-sharing

arrangement into a royalty and milestone payment-based arrangement. Pursuant to the terms of the amended agreement with Genentech, effective June 1, 2024, Genentech assumed sole responsibility over all clinical, regulatory and commercial activities. We are eligible to receive up to $600.0Â million in milestones, including $115.0Â million in development milestones, $185.0Â million in regulatory milestones and $300.0Â million in sales-based milestones and tiered royalties ranging from low double-digit to mid-teens percentages.The Company did not recognize revenue related to the Genentech Agreement for the three and six months ended JuneÂ 30, 2024 or 2023. As of JuneÂ 30, 2024, there is a $7.6 million payable related to cost-sharing development activities during the first half of 2024 for development studies being conducted under the Genentech Agreement. There is no deferred revenue as of JuneÂ 30, 2024, as obligations to perform research activities have expired.Janssen Biotech, Inc., a Johnson & Johnson companyJ&J AgreementIn November 2020, the Company entered into a Collaboration and License Agreement (the J&J Agreement) with Janssen Biotech, Inc., a Johnson & Johnson company, pursuant to which the Company and J&J conducted research and development activities to discover novel CD28 bispecific antibodies for the treatment of prostate cancer. Xencor together with J&J conducted joint research activities to discover XmAb bispecific antibodies against CD28 and against an undisclosed prostate tumor-target with J&J maintaining exclusive worldwide rights to develop and commercialize licensed products identified from the research activities.Under the J&J Agreement, the Company conducted research activities and applied its bispecific Fc technology to antibodies targeting prostate cancer provided by J&J. Upon completion of the research activities J&J had a candidate selection option to advance an identified candidate for development and commercialization. In November 2021, the Company completed its performance obligations under the research activities and delivered CD28 bispecific antibodies to J&J. In December 2021, J&J selected a bispecific CD28 candidate for further development. J&J will assume full responsibility for development and commercialization of the CD28 bispecific antibody candidate. The Company did not recognize revenue for the three and six months ended JuneÂ 30, 2024 and 2023 under the J&J Agreement. As of JuneÂ 30, 2024, there is no deferred revenue related to this Agreement. Second J&J AgreementOn OctoberÂ 1, 2021, the Company entered into a second Collaboration and License Agreement (the Second J&J Agreement) with J&J pursuant to which the Company granted J&J an exclusive worldwide license to develop, manufacture, and commercialize plamotamab, the Companyâ€™s CD20 x CD3 development candidate, and pursuant to which Xencor and J&J conducted research and development activities to discover novel CD28 bispecific antibodies. The parties conducted joint research activities for a two-year period to discover XmAb bispecific antibodies against CD28 and undisclosed B cell tumor-targets with J&J receiving exclusive worldwide rights, subject to certain Xencor opt-in rights, to develop, manufacture and commercialize pharmaceutical products that contain one or more of such discovered antibodies (CD28 Licensed Antibodies). The Agreement became effective on November 5, 2021.The Company collaborated with J&J on clinical development of plamotamab with J&J and shared development costs with J&J paying 80% and the Company paying 20% of certain development costs. In June 2024, the Company was notified that J&J will terminate its rights to plamotamab.The Company is generally responsible for conducting research activities under the Second J&J Agreement, and J&J is generally responsible for all development, manufacturing, and commercialization activities for CD28 Licensed Antibodies that are advanced. Revenue from the research activities was recognized over a period of time through the end of the research term that services were rendered as we determined that the input method was the appropriate approach to recognize income for such services. There is a receivable of $5.2 million as of JuneÂ 30, 2024, related to cost-sharing activities for development of plamotamab under the Second J&J Agreement. No revenue was recognized for the three and six months ended JuneÂ 30, 2024, and the Company recognized $22.2 million and $27.5 million of revenue for the three and six months ended JuneÂ 30, 2023, respectively. There is no deferred revenue as of JuneÂ 30, 2024 related to the Second J&J Agreement as obligations to perform research activities have expired.MorphoSys AG/Incyte CorporationIn June 2010, the Company entered into a Collaboration and License Agreement with MorphoSys AG (MorphoSys), which was subsequently amended. Under the agreement, we granted MorphoSys an exclusive worldwide license to the Companyâ€™s patents and know-how to research, develop and commercialize the XmAb5574 product candidate (subsequently renamed MOR208 and tafasitamab) with the right to sublicense under certain conditions. In February 2024, Incyte Corporation acquired exclusive global development and commercialization rights to tafasitamab. If certain developmental, regulatory and sales milestones are achieved, the Company is eligible to receive future milestone payments and royalties. On November 3, 2023, the Company entered into the Monjuvi Royalty Sale Agreement with OMERS, pursuant to which OMERS acquired the rights to certain royalties earned after July 1, 2023 associated with the existing license relating to Monjuvi. The Company recognized $1.6 million and $4.4 million of non-cash royalty revenue during the three and six months ended JuneÂ 30, 2024, respectively. The Company recognized $2.0 million and $3.9 million of royalty revenue during the three and six months ended JuneÂ 30, 2023, respectively. As of JuneÂ 30, 2024, there is a receivable of $2.1 million related to estimated royalties due under the arrangement. As of JuneÂ 30, 2024, there is no deferred revenue related to this agreement.Shanghai Mabgeek Biotech Co., Ltd.On December 22, 2023, the Company entered into a Technology License Agreement with Shanghai Mabgeek Biotech Co., Ltd. (Mabgeek), and the Company and Mabgeek entered into Amendment No. 1 on June 21, 2024 (collectively, Mabgeek Agreement). Under the Mabgeek Agreement, the Company received an upfront payment of $1.5 million and up to $11.9 million of milestones. In addition, the Company is eligible to receive royalties on the net sales of approved products in the low single digits.The Company evaluated the Mabgeek Agreement and determined that the single performance obligation was access to a non-exclusive license to certain patents of the Company which were transferred to Mabgeek in June 2024.The Company recognized $1.5 million of license revenue related to the agreement for the three and six months ended JuneÂ 30, 2024. There is no deferred revenue as of JuneÂ 30, 2024 related to this agreement.Vega Therapeutics, Inc.In October 2021, the Company entered into a Technology License Agreement (the Vega Agreement) with Vega Therapeutics, Inc. (Vega), in which the Company provided Vega a non-exclusive license to its Xtend Fc technology. In March 2024, Vega notified the Company that it initiated a Phase 1 study, and the Company recorded milestone revenue of $0.5 million.The Company recognized $0.5 million of revenue for the six months ended JuneÂ 30, 2024. No revenue was recognized for the three months ended JuneÂ 30, 2024 or the three and six months ended JuneÂ 30, 2023.Vir Biotechnology, Inc.In 2019, the Company entered into a Patent License Agreement (the Vir Agreement) with Vir Biotechnology, Inc. (Vir) pursuant to which the Company provided a non-exclusive license to its Xtend technology for up to two targets.In March 2020, the Company entered into a second Patent License Agreement (the Second Vir Agreement) with Vir pursuant to which the Company provided a non-exclusive license to its Xtend technology to extend the half-life of novel antibodies Vir developed as potential treatments for patients with COVID-19, including sotrovimab. Under the terms of the Second Vir Agreement, Vir is responsible for all research, development, regulatory and commercial activities for the antibodies, and the Company is eligible to receive royalties on the net sales of approved products in the mid-single digit percentage range. Vir and its marketing partner, GSK, began recording sales for sotrovimab beginning in June 2021.The Company recognized $0.1 million of revenue for the six months ended JuneÂ 30, 2024, and the Company recognized $0.1 million and $1.5 million of royalty revenue for the three and six months ended JuneÂ 30, 2023, respectively. As of JuneÂ 30, 2024, there is no receivable related to estimated royalty due under this agreement, and there is no deferred revenue related to this agreement. Zenas BioPharma, Inc.In November 2020, the Company entered into a License Agreement (the Zenas Agreement) with Zenas, pursuant to which the Company received an equity interest in Zenas in exchange for the exclusive, worldwide rights to develop and commercialize drug candidates from the Company. The equity in Zenas is recorded at the fair value as of the date of the Zenas Agreement and is reviewed each reporting period for impairment or other evidence of change in value. In November 2021, the Company entered into a second License Agreement (Second Zenas Agreement) with Zenas, pursuant to which the Company received additional equity in Zenas in exchange for the exclusive worldwide rights to develop and commercialize the Companyâ€™s obexelimab (XmAb5871) drug candidate. Under the license, the Company is eligible to receive development, regulatory and sales milestones in connection with the development of obexelimab and royalties on net sales of approved products. The original equity received for the second license was a warrant to acquire additional shares of Zenas. The warrant was exchanged for additional preferred stock in Zenas in November 2022. The warrant in Zenas was recorded at its fair value as of the date of the Second Zenas Agreement and was reviewed each reporting period for impairment or other evidence of change in value. The preferred shares received in exchange for the warrant were recorded at their fair value at the date of the exchange and is reviewed each reporting period for impairment or other evidence of change in value.In 2023, Zenas initiated a Phase 3 clinical study with obexelimab and also dosed a second patient in the study. The Company received a development milestone in the form of additional preferred stock in Zenas with a fair value of $10.0 million.The Company recognized an impairment charge of $20.4 million in the six months ended JuneÂ 30, 2024 due to an impairment analysis resulting from the Zenas Series C financing transaction. The Company did not record an impairment charge or change in the value of the Zenas equity in the three and six months ended JuneÂ 30, 2023. The Company did not recognize any revenue for the three and six months ended JuneÂ 30, 2024. The Company recognized $10.0 million of milestone revenue for the three and six months ended JuneÂ 30, 2023, and there is no deferred revenue related to this agreement.Third-Party LicenseeIn May 2024, the Company entered into a Patent License Agreement (Third-Party Licensee Agreement) with a third-party licensee. The Company completed delivery of the performance obligation under the agreement, and the Company will receive a payment of $7.0 million.The Company recognized $7.0 million of license revenue for the three and six months ended JuneÂ 30, 2024, and there is a receivable of $7.0 million. There is no deferred revenue related to this agreement.Gale Therapeutics Inc.In the fourth quarter of 2023, the Company formed a subsidiary, Gale Therapeutics Inc. (Gale), to develop novel drug candidates with its Fc technologies. In December 2023, the Company entered into a Technology License Agreement (Gale License Agreement) with Gale in which Gale received an exclusive worldwide, royalty-bearing, non-transferable license to preclinical assets in exchange for royalties on future sales and an option for future drug candidates that Gale will develop. Concurrently, the Company entered into a Service Agreement (Gale Services Agreement) to provide research and development services and administrative support for Gale. In exchange for $7.5 million of funding, the Company acquired a majority stake in Gale. Total charges of $4.6 million and $8.0 million under the Gale Services Agreement for the three and six months ended JuneÂ 30, 2024, respectively, were eliminated in consolidation. In July 2024, the Company entered into a preferred stock purchase agreement to purchase additional shares in Gale for $3.0 million. Revenues earned The revenues recorded for the three and six months ended JuneÂ 30, 2024 and 2023 were earned principally from the following licensees (in millions):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Alexion$6.9Â $11.2Â $16.3Â $21.6Â Janssenâ€”Â 22.2Â â€”Â 27.5Â Mabgeek$1.5Â $â€”Â $1.5Â $â€”Â MorphoSys1.6Â 2.0Â 4.4Â 3.9Â Vegaâ€”Â â€”Â 0.5Â â€”Â Virâ€”Â 0 Party Licensee$7.0Â $â€”Â $7.0Â $â€”Â Total$17.0Â $45.5Â $29.8Â $64.5Â The table below summarizes the disaggregation of revenue recorded for the three and six months ended JuneÂ 30, 2024 and 2023 (in millions):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Research collaboration$â€”Â $22.2Â $â€”Â $22.5Â License8.5Â â€”Â 8.5Â â€”Â Milestoneâ€”Â 10.0Â 0.5Â 15.0Â Royaltiesâ€”Â 13.3Â 0.1Â 27.0Â Non-cash royalties8.5Â â€”Â 20.7Â â€”Â Total$17.0Â $45.5Â $29.8Â $64.5Â Remaining Performance Obligations and Deferred RevenueThe Company does not have any remaining performance obligation as of JuneÂ 30, 2024. As of JuneÂ 30, 2023, the Company had deferred revenue of $7.9 million for conducting research activities pursuant to the Second J&J Agreement. All deferred revenue as of JuneÂ 30, 2023 was classified as current liabilities as the Companyâ€™s obligations to perform services are due on demand when requested by J&J under the Second J&J Agreement. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionCollaboration and Licensing Agreements + ReferencesNo definition available. + Details Name: xncr_CollaborationResearchAndLicensingAgreementsDisclosureAbstract Namespace Prefix: xncr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Income taxesThe Company recorded $0.1 million of income tax expense for the three and six months ended JuneÂ 30, 2024. There is no provision for income tax for the three and six months ended JuneÂ 30, 2023. As of JuneÂ 30, 2024, the Companyâ€™s deferred income tax assets, consisting primarily of net operating loss and tax credit carryforwards, have been fully offset by a valuation allowance. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Sales of Future Royalties 6 Months Ended Jun. 30, 2024 Receivables [Abstract] Â Sale of Future Royalties Sale of Future RoyaltiesUltomiris Royalty Sale AgreementThe Company evaluated the arrangement and determined that the proceeds from the sale of future royalties should be recorded as deferred income on the balance sheets as none of the criteria for classification as debt were met in accordance with ASC 470 Debt. The Company records the non-cash royalty revenue under the â€œunits-of-revenueâ€ method in the consolidated statements of loss. For the three and six months ended JuneÂ 30, 2024, the Company recognized $6.9 million and $16.3 million of non-cash royalty revenue, respectively. There is $140.6 million in deferred income as of JuneÂ 30, 2024.Monjuvi Royalty Sale AgreementThe Company evaluated the arrangement and determined that the proceeds from the sale of future royalties should be classified as debt pursuant to ASC 470 Debt. At JuneÂ 30, 2024, the Company reassessed the estimate of total future royalty payments and updated the estimated effective interest rate to 17.5%. The Company will continue to reassess the estimate of total future royalty payment and prospectively adjust the imputed interest rate and related amortization if the estimate is materially different. For the three and six months ended JuneÂ 30, 2024, the Company recognized $1.6 million and $4.4 million of non-cash royalty revenue, respectively, and $0.8 million and $1.9 million of non-cash interest expense, respectively.The following table shows the activity within debt for the six months ended JuneÂ 30, 2024 (in thousands):June 30, 2024Beginning balance of debt related to sale of future royalties$20,974Â Royalties owed to

OMERS834Â Royalties paid to OMERS(4,448)Non-cash interest expense recognized1,900Â Ending balance of debt related to sale of future royalties$19,260Â Debt - short-term6,947Â Debt - long-term12,313Â Total debt$19,260Â X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture Royalties Sale Disclosure + ReferencesNo definition available. + Details Name: xncr_FutureRoyaltiesSaleDisclosureTextBlock Namespace Prefix: xncr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Net Income (Loss) $ (65,963) $ (21,954) $ (133,996) $ (82,717) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended 6 Months Ended Jun. 30, 2024 shares Jun. 30, 2024 shares Trading Arrangements, by Individual Â Â Non-Rule 10b5-1 Arrangement Adopted false Â Non-Rule 10b5-1 Arrangement Terminated false Â Bassil Dahiyat [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 14, 2024, Bassil Dahiyat, our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 66,192 shares of the Company's common stock until February 13, 2025. Name Bassil Dahiyat Â Title Chief Executive Officer Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 14, 2024 Â Expiration Date February 13, 2025 Â Arrangement Duration 244 days Â Aggregate Available 66,192 66,192 John Desjarlais [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 14, 2024, John Desjarlais, our Executive Vice President and Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 81,458 shares of the Company's common stock until February 12, 2025. Name John Desjarlais Â Title Executive Vice President and Chief Scientific Officer Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 14, 2024 Â Expiration Date February 12, 2025 Â Arrangement Duration 243 days Â Aggregate Available 81,458 81,458 Ellen Feigal [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 28, 2024, Ellen Feigal, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025. Name Ellen Feigal Â Title Board of Directors Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 28, 2024 Â Expiration Date June 27, 2025 Â Arrangement Duration 364 days Â Aggregate Available 5,496 5,496 Kevin Gorman [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 28, 2024, Kevin Gorman, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,827 shares of the Company's common stock until June 30, 2025. Name Kevin Gorman Â Title Board of Directors Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 28, 2024 Â Expiration Date June 30, 2025 Â Arrangement Duration 367 days Â Aggregate Available 5,827 5,827 Kurt Gustafson [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 28, 2024, Kurt Gustafson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025. Name Kurt Gustafson Â Title Board of Directors Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 28, 2024 Â Expiration Date June 27, 2025 Â Arrangement Duration 364 days Â Aggregate Available 5,496 5,496 Dagmar Rosa-Bjorkesen [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 28, 2024, Dagmar Rosa-Bjorkeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025. Name Dagmar Rosa-Bjorkeson Â Title Board of Directors Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 28, 2024 Â Expiration Date June 27, 2025 Â Arrangement Duration 364 days Â Aggregate Available 5,496 5,496 Richard Ranieri [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On May 23, 2024, Richard Ranieri, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 15,000 shares of the Company's common stock until May 16, 2025, and it was terminated on June 27, 2024. On June 28, 2024, he adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,496 shares of the Company's common stock until June 27, 2025. Name Richard Ranieri Â Title Board of Directors Â Arrangement Duration 358 days Â A. Bruce Montgomery [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On June 27, 2024, A Bruce Montgomery, a member of our Board of Directors, terminated a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) entered on August 7, 2023. On June 28, 2024, he adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 26,568 shares of the Company's common stock until June 27, 2025. Name A Bruce Montgomery Â Title Board of Directors Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 28, 2024 Â Rule 10b5-1 Arrangement Terminated true Â Termination Date June 27, 2024 Â Expiration Date June 27, 2025 Â Arrangement Duration 364 days Â Aggregate Available 26,568 26,568 Richard Ranieri May 2024 Plan [Member] | Richard Ranieri [Member] Â Â Trading Arrangements, by Individual Â Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date May 23, 2024 Â Rule 10b5-1 Arrangement Terminated true Â Termination Date June 27, 2024 Â Expiration Date May 16, 2025 Â Aggregate Available 15,000 15,000 Richard Ranieri June 2024 Plan [Member] | Richard Ranieri [Member] Â Â Trading Arrangements, by Individual Â Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date June 28, 2024 Â Expiration Date June 27, 2025 Â Aggregate Available 20,496 20,496 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrDuration Namespace Prefix: ecd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrTerminationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: ecd_IndividualAxis=xncr_BassilDahiyatMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=xncr_JohnDesjarlaisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=xncr_EllenFeigalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=xncr_KevinGormanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=xncr_KurtGustafsonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=xncr_DagmarRosaBjorkesenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X -

Details Name: ecd_IndividualAxis=xncr_RichardRanieriMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=xncr_ABruceMontgomeryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_TradingArrAxis=xncr_RichardRanieriMay2024PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_TradingArrAxis=xncr_RichardRanieriJune2024PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Polices) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThe accompanying unaudited consolidated interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of consolidated interim financial statements requires the use of managementâ€™s estimates and assumptions that affect reported amounts of assets and liabilities at the date of the consolidated interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period.The accompanying unaudited consolidated interim financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2024. Principles of Consolidation Principles of ConsolidationThe accompanying consolidated financial statements include the accounts of Xencor, Inc. and Gale Therapeutics Inc. (Gale), a variable interest entity (VIE) in which we are the primary beneficiary. Since we own less than 100% of Gale, the Company records net loss attributable to non-controlling interests in its consolidated statements of loss equal to the percentage of the economic or ownership interests retained in Gale by the non-controlling party.In determining whether we are the primary beneficiary of a VIE, we apply a qualitative approach that determines whether we have (1) the power to direct the activities of the VIE that most significantly impact the entity's economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to the VIE. We continuously assess whether we are the primary beneficiary of Gale as changes to existing relationships or future transactions may result in us consolidating or deconsolidating Gale. Use of Estimates Use of EstimatesThe preparation of consolidated interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive income (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these consolidated interim financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets. Reclassifications ReclassificationsCertain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. During the six months ended JuneÂ 30, 2024, we adopted a change in presentation on our consolidated statements of loss to include loss from disposal of fixed assets in operating expenses. The prior period has been revised to reflect this change in the presentation. Intangible Assets Intangible AssetsThe Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There was no impairment charge recorded for the three and six months ended JuneÂ 30, 2024 and 2023.The Company capitalizes certain in-process intangible assets that are then abandoned when they are no longer pursued or used in current research activities. We abandoned $0.4 million and $0.8 million of in-process intangible assets for the three and six months ended JuneÂ 30, 2024. We abandoned $0.3 million and $0.6 million of in-process intangible assets during the three and six months ended JuneÂ 30, 2023. Marketable Debt and Equity Securities Marketable Debt and Equity SecuritiesThe Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The investment policy limits the maturity of any individual security to a maximum of 36 months. The average maturity of securities in the portfolio as of JuneÂ 30, 2024 is less than 12 months. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale because it is not more likely than not that the Company will be required to sell the securities before recovery of the amortized cost. These assets are carried at fair value and any impairment losses and recoveries related to the underlying issuerâ€™s credit standing are recognized within other income (expense), while non-credit related impairment losses and recoveries are recognized within accumulated other comprehensive income (loss). There were no impairment losses or recoveries recorded for the three and six months ended JuneÂ 30, 2024 and 2023. Accrued interest on marketable debt securities is included in the marketable securitiesâ€™ carrying value. Each reporting period, the Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if each securityâ€™s fair value has declined below its amortized cost basis. During the three and six months ended JuneÂ 30, 2024, the Company recorded an unrealized loss of $0.5 million and $1.9 million in its portfolio of marketable debt securities. During the three and six months ended JuneÂ 30, 2023, the Company recorded an unrealized gain of $1.8 million and $5.1 million. The unrealized loss is due to the changing interest rate environment and is not due to changes in the credit quality of the underlying securities. The unrealized gain (loss) is recorded in other comprehensive income (loss) for the three and six months ended JuneÂ 30, 2024 and 2023.The Company receives equity securities in connection with certain licensing transactions with its partners. These investments in equity securities are carried at fair value with changes in fair value recognized each period and reported within other income (expense). For equity securities with a readily determinable fair value, the Company remeasures these equity investments at each reporting period until such time that the investment is sold or disposed. If the Company sells an investment, any realized gain or loss on the sale of the securities will be recognized within other income (expense) in the consolidated statements of loss in the period of sale.The Company also has investments in equity securities without a readily determinable fair value, where the Company elects the measurement alternative to record the investment at its initial cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There was an impairment charge of $20.4 million recorded for the six months ended JuneÂ 30, 2024 in connection with equity securities without a readily determinable fair value. There was no impairment charge recorded for the three and six months ended JuneÂ 30, 2023. Liability Related to the Sale of Future Revenues and Non-Cash Interest Expense on the Liability Related to the Sale of Future Royalties and Deferred Income Related to the Sale of Future Revenues Liability Related to the Sale of Future RevenuesWe treat the sale of future Monjuvi royalties as debt, amortized under the effective interest rate method over the estimated life of the Monjuvi Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future Monjuvi royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Non-cash Interest Expense on the Liability Related to the Sale of Future RoyaltiesThe total expected royalty payments less the net proceeds received are recorded as non-cash interest expense over the life of the liability. Interest is imputed on the unamortized portion using the effective interest method and is recorded based on the timing of the payments received over the term of the Monjuvi Royalty Sale Agreement. The actual interest rate will be affected by the timing of the royalty payments and changes in the forecasted revenue.Deferred Income Related to the Sale of Future RevenuesWe treat the sale of future Ultomiris royalties as deferred income, amortized under the units-of-revenue method by computing a ratio of the proceeds received to the total expected payments over the term of the Ultomiris Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Recent Accounting Pronouncements Recent Accounting PronouncementsThere have been no material changes in recently issued or adopted accounting standards from those disclosed in the Company's 2023 Annual Report on Form 10-K. The Company has reviewed all recently issued accounting pronouncements and does not believe they will have a material impact on our results of operations, financial condition or cash flows.There have been no other material changes to the significant accounting policies previously disclosed in the Companyâ€™s 2023 Annual Report on Form 10-K. Fair Value Measurement Financial instruments included in the financial statements include cash and cash equivalents, marketable debt and equity securities, accounts receivable, accounts payable, and accrued expenses. Marketable debt securities, equity securities, and cash equivalents are carried at fair value. The fair value of the other financial instruments closely approximates their fair value due to their short-term maturities.The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosure about fair value measurements. The ASC 820 hierarchy ranks the quality of reliable inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:Level 1â€”Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets or liabilities.Level 2â€”Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in markets that are not active. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. Level 3â€”Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by the reporting entity â€“ e.g., determining an appropriate discount factor for illiquidity associated with a given security. The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date.Our policy is to record transfers of assets between Level 1 and Level 2 at their fair values as of the end of each reporting period, consistent with the date of the determination of fair value. During the three and six months ended JuneÂ 30, 2024 and 2023, there were no transfers between Level 1 and Level 2. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 + Details Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name

Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionFuture Royalties, Policy + ReferencesNo definition available. + Details Name: xncr_FutureRoyaltiesPolicyPolicyTextBlock Namespace Prefix: xncr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value of Financial Instruments (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Assets Recorded at Fair Value The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands):June 30, 2024(unaudited)December 31, 2023TotalFair ValueLevel 1Level 2TotalFair ValueLevel 1Level 2Money Market Funds $11,624Â $11,624Â $â€”Â $25,520Â $25,520Â $â€”Â Corporate Securities211,657Â â€”Â 211,657Â 228,723Â â€”Â 228,723Â Government Securities342,577Â â€”Â 342,577Â 414,514Â â€”Â 414,514Â $565,858Â $11,624Â $554,234Â $668,757Â $25,520Â $643,237Â X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Common Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Basic and Diluted Net Loss per Common Share Basic and diluted net loss per common share is computed as follows:Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230(in thousands, except share and per share data)(in thousands, except share and per share data)Numerator:Net loss attributable to Xencor, Inc.$(65,963)$(21,954)$(133,996)$(82,717)Denominator:Weighted-average common shares outstanding used in computing basic and diluted net loss61,676,44459,807,55861,444,38459,922,784Basic and diluted net loss per common share attributable to Xencor, Inc.(1.07)(0.37)(2.18)(1.38) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities (Tables) 6 Months Ended Jun. 30, 2024 Marketable Securities [Abstract] Â Schedule of Marketable Securities The Companyâ€™s marketable debt securities held as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are summarized below:June 30, 2024AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(in thousands)Money Market Funds $11,624Â $â€”Â $â€”Â $11,624Â Corporate Securities211,930Â 6Â (279)211,657Â Government Securities342,945Â 6Â (374)342,577Â $566,499Â $12Â (653)565,858Â Reported asCash and cash equivalents$11,624Â Marketable securities554,234Â Total investments$565,858Â December 31, 2023AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(in thousands)Money Market Funds $25,520Â $â€”Â $â€”Â $25,520Â Corporate Securities228,382Â 342Â (1)228,723Â Government Securities413,553Â 1,037Â (76)414,514Â $667,455Â $1,379Â (77)668,757Â Reported asCash and cash equivalents$25,520Â Marketable securities643,237Â Total investments$668,757Â Schedule of Maturities of Marketable Securities The maturities of the Companyâ€™s marketable debt securities as of JuneÂ 30, 2024 are as follows:June 30, 2024AmortizedCostEstimatedFair Value(in thousands)Mature in one year or less$449,715Â $449,372Â Mature within two years105,160Â 104,862Â $554,875Â $554,234Â Schedule of Unrealized Losses on Available-for-Sale Investments The unrealized losses on available-for-sale investments and their related fair values as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Less than 12 months12 months or greaterJune 30, 2024Fair valueUnrealizedlossesFair valueUnrealizedlosses(in thousands)Corporate Securities$119,044Â (217)11,895Â $(62)Government Securities246,154Â (132)79,478Â (242)$365,198Â (349)91,373Â $(304)Less than 12 months12 months or greaterDecember 31, 2023Fair valueUnrealizedlossesFair valueUnrealizedlosses(in thousands)Corporate Securities$8,073Â (1)â€”Â $â€”Â Government Securities66,546Â (76)â€”Â â€”Â $74,619Â (77)â€”Â $â€”Â Schedule of Equity Securities with Readily Determinable Fair Value Equity securities with a readily determinable fair value, which are categorized as Level 1 in the fair value hierarchy under ASC 820, and their fair values (in thousands) as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Fair ValueFair ValueJune 30, 2024December 31, 2023Astria Common Stock$2,311Â $5,360Â INmune Common Stock16,630Â 21,231Â Viridian Common Stock9,330Â 15,619Â $28,271Â $42,210Â Schedule of Net Gains and Losses Below is a reconciliation of net gain (loss) recorded on equity securities during the three and six months ended JuneÂ 30, 2024 and 2023:Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Net gain (loss) recorded on equity securities$(12,027)$288Â $(9,702)$(2,610)Less: Net gain (loss) recorded on sale of equity securities(2,012)â€”Â 827Â â€”Â Unrealized gain (loss) recorded on equity securities held at the reporting date$(10,015)$288Â $(10,529)$(2,610) Schedule of Equity Securities Without Readily Determinable Fair Value Equity securities without a readily determinable fair value and their carrying values (in thousands) as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:Carrying ValueCarrying ValueJune 30, 2024December 31, 2023Zenas Preferred Stock$43,780Â $64,210Â X - DefinitionTabular disclosure of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of realized and unrealized gain (loss) on investment in security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GainLossOnInvestmentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments. + ReferencesNo definition available. + Details Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of unrealized gains and losses on investments. + ReferencesNo definition available. + Details Name: us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of equity securities with readily determinable fair value. + ReferencesNo definition available. + Details Name: xncr_EquitySecuritiesFvNiTableTextBlock Namespace Prefix: xncr_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Total Employee, Director and Non-Employee Stock-Based Compensation Expense Recognized Total employee, director and non-employee stock-based compensation expense recognized for the three and six months ended JuneÂ 30, 2024 and 2023 are as follows (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230General and administrative $8,469Â $4,471Â $13,168Â $8,747Â Research and development 8,721Â 9,092Â 15,443Â 17,415Â $17,190Â $13,563Â $28,611Â $26,162Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Stock options$10,945Â $6,842Â $17,818Â $13,825Â ESPP211Â 341Â 417Â 663Â RSUs6,034Â 6,380Â 10,376Â 11,674Â $17,190Â $13,563Â $28,611Â $26,162Â Summary of Stock Option Activity The following table summarizes option activity under our stock plans and related information:Number ofShares SubjectTo OutstandingOptionsWeightedAverageExercisePrice(PerShare)WeightedAverageRemainingContractualTerm(in years)AggregateIntrinsicValue(in thousands)Balance at December 31, 202311,142,986$29.60Â 6.03$9,977Â Options granted2,167,253$22.43Â Options forfeited(485,918)$32.84Â Options exercised(162,895)$11.83Â Balance at June 30, 202412,661,426$28.48Â 6.18$5,813Â Exercisable8,295,121$29.38Â 4.76$5,745Â Schedule of Weighted Average Assumptions Used for Estimation of Fair Value of Stock Options We estimated the fair value of each equity award, including stock options and shares issued under our ESPP, using the Black-Scholes option-pricing model based on the date of grant of such stock option or ESPP share issuance date, with the following weighted average assumptions for the three and six months ended JuneÂ 30, 2024 and 2023:OptionsOptions Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Expected term (years)6.46.56.46.1Expected volatility50.4Â %51.2Â %50.1Â %50.5Â %Risk-free interest rate4.42Â %3.69Â %4.18Â %4.17Â %Expected dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â % Schedule of Weighted Average Assumptions Used for Estimation of Fair Value of ESPP ESPPESPP Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Expected term (years)0.5 - 2.00.5 - 2.00.5 - 2.00.5 -2.0Expected volatility43.0% - 44.6%38.2% - 55.7%43.0% - 44.6%38.2% - 55.7%Risk-free interest rate4.71% - 5.40%0.13% - 5.39%4.71% - 5.40%0.13% - 5.39%Expected dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â % Summary of Restricted Stock Unit Activity The following table summarizes the RSU activity for the six-month period ended JuneÂ 30, 2024:RestrictedStockUnitsWeighted Average Grant Date Fair Value(Per unit)Unvested RSUs at December 31, 20231,490,040$30.66Â Granted959,07122.58Â Vested(550,972)31.72Â Forfeited(119,483)29.80Â Unvested RSUs at June 30, 20241,778,656$26.02Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in stock options. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Schedule of Operating Lease Liabilities Maturities The following table reconciles the undiscounted cash flows for the operating leases at JuneÂ 30, 2024 to the operating lease liabilities recorded on the balance sheet (in thousands):Years ending December 31,For the remainder of 2024$2,792Â 20258,022Â 20269,238Â 20279,560Â 20289,076Â 20299,331Â Thereafter57,104Â Total undiscounted lease payments105,123Â Less: Tenant allowance(3,252)Less: Imputed interest(33,453)Present value of lease payments$68,418Â Lease liabilities - short-term$1,262Â Lease liabilities - long-term67,156Â Total lease liabilities$68,418Â Summary of Lease Costs and Cash Disclosures The following table summarizes lease costs and cash payments for the three and six months ended JuneÂ 30, 2024 and 2023 (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Operating lease cost$1,881Â $2,020Â $3,762Â $4,200Â Variable lease cost310Â 219Â 1,140Â 453Â Total lease costs$2,191Â $2,239Â $4,902Â $4,653Â Cash paid for amounts included in the measurement of lease liabilities$807Â $721Â $1,877Â $1,445Â X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and Licensing Agreements (Tables) 6 Months Ended Jun. 30, 2024 Collaboration and Licensing Agreements Â Schedule of Revenue by Licensees The revenues recorded for the three and six months ended JuneÂ 30, 2024 and 2023 were earned principally from the following licensees (in millions):Three Months EndedJune 30,Six

Months EndedJune 30,2024202320242023Alexion$6.9Â $11.2Â $16.3Â $21.6Â Janssenâ€”Â 22.2Â â€”Â 27.5Â Mabgeek$1.5Â $â€”Â $1.5Â $â€”Â MorphoSys1.6Â 2.0Â 4.4Â 3.9Â Vegaâ€”Â â€”Â 0.5Â â€”Â Virâ€”Â 0 Party Licensee$7.0Â $â€”Â $7.0Â $â€”Â Total$17.0Â $45.5Â $29.8Â $64.5Â Schedule of Disaggregation of Revenue The table below summarizes the disaggregation of revenue recorded for the three and six months ended JuneÂ 30, 2024 and 2023 (in millions):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Research collaboration$â€”Â $22.2Â $â€”Â $22.5Â License8.5Â â€”Â 8.5Â â€”Â Milestoneâ€”Â 10.0Â 0.5Â 15.0Â Royaltiesâ€”Â 13.3Â 0.1Â 27.0Â Non-cash royalties8.5Â â€”Â 20.7Â â€”Â Total$17.0Â $45.5Â $29.8Â $64.5Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionCollaboration and Licensing Agreements + ReferencesNo definition available. + Details Name: xncr_CollaborationResearchAndLicensingAgreementsDisclosureAbstract Namespace Prefix: xncr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of revenue by major licensees. + ReferencesNo definition available. + Details Name: xncr_ScheduleOfRevenueByMajorLicenseesTableTextBlock Namespace Prefix: xncr_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Sales of Future Royalties (Tables) 6 Months Ended Jun. 30, 2024 Receivables [Abstract] Â Debt of Future Royalties The following table shows the activity within debt for the six months ended JuneÂ 30, 2024 (in thousands):June 30, 2024Beginning balance of debt related to sale of future royalties$20,974Â Royalties owed to OMERS834Â Royalties paid to OMERS(4,448)Non-cash interest expense recognized1,900Â Ending balance of debt related to sale of future royalties$19,260Â Debt - short-term6,947Â Debt - long-term12,313Â Total debt$19,260Â X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDebt of Future Royalties + ReferencesNo definition available. + Details Name: xncr_DebtOfFutureRoyaltiesTableTextBlock Namespace Prefix: xncr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Patents, licenses, and other intangible assets Â Â Â Â Impairment of intangible assets $ 0 $ 0 $ 0 $ 0 Abandonment of capitalized intangible assets Â Â 784,000 594,000 Impairment loss or recoveries 0 0 0 0 Net unrealized gain (loss) on marketable securities (500,000) 1,800,000 (1,900,000) 5,100,000 Impairment on equity securities (220,000) 0 20,430,000 0 In-process intangible assets Â Â Â Â Patents, licenses, and other intangible assets Â Â Â Â Abandonment of capitalized intangible assets $ 400,000 $ 300,000 $ 800,000 $ 600,000 X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe expense charged against earnings to eliminate the capitalized costs of projects that have been terminated during the reporting period, which is added back to net income when calculating cash provided by (used in) operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_NoncashProjectAbandonmentCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFinite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items] + ReferencesNo definition available. + Details Name: xncr_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: xncr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of impairment loss or recovery related to marketable securities. + ReferencesNo definition available. + Details Name: xncr_MarketableSecuritiesImpairmentLossesAndRecoveries Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=xncr_InProcessIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Fair Value of Financial Instruments Â Â Â Money Market Funds $ 30,768 $ 53,790 $ 34,710 Marketable securities 554,234 Â Â Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Total Fair Value 565,858 668,757 Â Money Market Funds Â Â Â Fair Value of Financial Instruments Â Â Â Money Market Funds 11,624 25,520 Â Money Market Funds | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Money Market Funds 11,624 25,520 Â Corporate Securities Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 211,657 228,723 Â Corporate Securities | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 211,657 228,723 Â Government Securities Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 342,577 414,514 Â Government Securities | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 342,577 414,514 Â Level 1 | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Total Fair Value 11,624 25,520 Â Level 1 | Money Market Funds | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Money Market Funds 11,624 25,520 Â Level 1 | Corporate Securities | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 0 0 Â Level 1 | Government Securities | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 0 0 Â Level 2 | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Total Fair Value 554,234 643,237 Â Level 2 | Money Market Funds | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Money Market Funds 0 0 Â Level 2 | Corporate Securities | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities 211,657 228,723 Â Level 2 | Government Securities | Fair Value, Recurring Â Â Â Fair Value of Financial Instruments Â Â Â Marketable securities $ 342,577 $ 414,514 Â X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Numerator: Â Â Â Â Net loss attributable to Xencor, Inc. $ (65,963) $ (21,954) $ (133,996) $ (82,717) Denominator: Â Â Â Â Weighted-average common shares outstanding used in computing basic net loss (in shares) 61,676,444 59,807,558 61,444,384 59,922,784 Weighted-average common shares outstanding used in computing diluted net loss (in shares) 61,676,444 59,807,558 61,444,384 59,922,784 Basic net loss per common share attributable to Xencor, Inc. (in dollars per share) $ (1.07) $ (0.37) $ (2.18) $ (1.38) Diluted net loss per common share attributable to Xencor, Inc. (in dollars per share) $ (1.07) $ (0.37) $ (2.18) $ (1.38) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Summary (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Schedule of Available-for-sale Securities Â Â Â Money Market Funds $ 30,768 $ 53,790 $ 34,710 Amortized Cost 554,875 Â Â Amortized Cost 566,499 667,455 Â Gross Unrealized Gains 12 1,379 Â Gross Unrealized Losses (653) (77) Â Marketable securities 554,234 Â Â Total investments 565,858 668,757 Â Money Market Funds Â Â Â Schedule of Available-for-sale Securities Â Â Â Money Market Funds 11,624 25,520 Â Corporate Securities Â Â Â Schedule of Available-for-sale Securities Â Â Â Amortized Cost 211,930 228,382 Â Gross Unrealized Gains 6 342 Â Gross Unrealized Losses (279) (1) Â Marketable securities 211,657 228,723 Â Government Securities Â Â Â Schedule of Available-for-sale Securities Â Â Â Amortized Cost 342,945 413,553 Â Gross Unrealized Gains 6 1,037 Â Gross Unrealized Losses (374) (76) Â Marketable securities 342,577 414,514 Â Cash and cash equivalents Â Â Â Schedule of Available-for-sale Securities Â Â Â Money Market Funds 11,624 25,520 Â Marketable securities Â Â Â Schedule of Available-for-sale Securities Â Â Â Marketable securities $ 554,234 $ 643,237 Â X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThis item represents the total cost of cash and cash equivalents and marketable securities. + ReferencesNo definition available. + Details Name: xncr_CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=xncr_MarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Maturities (Details) $ in Thousands Jun. 30, 2024 USD ($) Amortized Cost Â Mature in one year or less $ 449,715 Mature within two years 105,160 Amortized Cost 554,875 Estimated Fair Value Â Mature in one year or less 449,372 Mature within two years 104,862 Estimated Fair Value $ 554,234 X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFiveYearsFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Unrealized Losses (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Available-for-sale Securities Â Â Fair value, less than 12 months $ 365,198 $ 74,619 Unrealized losses, Less than 12 months (349) (77) Fair value, 12 months or greater 91,373 0 Unrealized losses, 12 months or greater (304) 0 Corporate Securities Â Â Schedule of Available-for-sale Securities Â Â Fair value, less than 12 months 119,044 8,073 Unrealized losses, Less than 12 months (217) (1) Fair value, 12 months or greater 11,895 0 Unrealized losses, 12 months or greater (62) 0 Government Securities Â Â Schedule of Available-for-sale Securities Â Â Fair value, less than 12 months 246,154 66,546 Unrealized losses, Less than 12 months (132) (76) Fair value, 12 months or greater 79,478 0 Unrealized losses, 12 months or greater $ (242) $ 0 X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Equity Securities with Readily Determinable Fair Value (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Equity Securities Â Â Â Â Â Net gain (loss) recorded on equity securities $ (12,027) $ 288 $ (9,702) $ (2,610) Â Equity securities with readily determinable fair value 28,271 Â 28,271 Â $ 42,210 Common Stock Â Â Â Â Â Equity Securities Â Â Â Â Â Equity securities with readily determinable fair value 28,271 Â 28,271 Â 42,210 Astria | Common Stock Â Â Â Â Â Equity Securities Â Â Â Â Â Equity securities with readily determinable fair value 2,311 Â 2,311 Â 5,360 INmune | Common

Stock Â Â Â Â Â Equity Securities Â Â Â Â Â Equity securities with readily determinable fair value 16,630 Â 16,630 Â 21,231 Viridian | Common Stock Â Â Â Â Â Equity Securities Â Â Â Â Â Equity securities with readily determinable fair value $ 9,330 Â $ 9,330 Â $ 15,619 X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details Name: us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_AstriaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_InmuneBioIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ViridianMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Equity Securities Transactions (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Equity Securities Â Â Â Â Unrealized gain (loss) on equity securities $ (10,015) $ 288 $ (10,529) $ (2,610) License | Astria | Common Stock Â Â Â Â Equity Securities Â Â Â Â Sale of common stock (in shares) 443,909 Â 443,909 Â Number of shares owned (in shares) 253,958 Â 253,958 Â License | INmune Â Â Â Â Equity Securities Â Â Â Â Unrealized gain (loss) on equity securities $ (5,500) 4,900 $ (4,600) 5,200 License | INmune | Common Stock Â Â Â Â Equity Securities Â Â Â Â Number of shares owned (in shares) 1,885,533 Â 1,885,533 Â Technology License Agreement | Astria/Catabasis Â Â Â Â Equity Securities Â Â Â Â Unrealized gain (loss) on equity securities $ (1,300) (3,500) $ 400 (3,900) Technology License Agreement | Viridian Â Â Â Â Equity Securities Â Â Â Â Unrealized gain (loss) on equity securities $ (3,200) $ (1,200) $ (6,300) $ (3,900) Technology License Agreement | Viridian | Common Stock Â Â Â Â Equity Securities Â Â Â Â Number of shares owned (in shares) 717,144 Â 717,144 Â X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalanceShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details Name: us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_AstriaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_InmuneBioIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_CatabasisPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ViridianMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Net Gains and Losses (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Marketable Securities [Abstract] Â Â Â Â Net gain (loss) recorded on equity securities $ (12,027) $ 288 $ (9,702) $ (2,610) Less: Net gain (loss) recorded on sale of equity securities (2,012) 0 827 0 Unrealized gain (loss) recorded on equity securities held at the reporting date $ (10,015) $ 288 $ (10,529) $ (2,610) X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Debt and Equity Securities - Equity Securities without Readily Determinable Fair Value (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Equity securities without readily determinable fair value Â Â Â Â Â Impairment on equity securities $ (220) $ 0 $ 20,430 $ 0 Â Zenas Â Â Â Â Â Equity securities without readily determinable fair value Â Â Â Â Â Impairment on equity securities Â Â 20,400 Â Â Zenas Â Â Â Â Â Equity securities without readily determinable fair value Â Â Â Â Â Impairment on equity securities Â $ 0 20,400 $ 0 Â Preferred Stock | Zenas Â Â Â Â Â Equity securities without readily determinable fair value Â Â Â Â Â Equity shares estimated fair value $ 43,780 Â $ 43,780 Â $ 64,210 X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xncr_ZenasBioPharmaLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock Based Compensation - Narrative (Details) $ / shares in Units, $ in Millions 6 Months Ended Jun. 30, 2024 USD ($) installment $ / shares shares Jun. 30, 2023 $ / shares shares Jun. 14, 2023 shares ESPP Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Total number of shares of common stock available for issuance (in shares) 987,344 Â Â Awards issued under the plan (in shares) 787,474 Â Â Unamortized compensation expense | $ $ 1.3 Â Â Period to recognize unamortized compensation expense 1 year 4 months 24 days Â Â ESPP | Maximum Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Annual percentage increase in shares of common stock available for issuance 1.00% Â Â Annual increase in shares of common stock available for issuance (in shares) 621,814 Â Â RSUs Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Granted (in shares) 959,071 Â Â Annual installment vesting periods | installment 3 Â Â Period to recognize unamortized compensation expense 2 years 1 month 6 days Â Â Unamortized compensation expense related to unvested restricted stock units | $ $ 37.0 Â Â Stock options Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Options granted (in shares) 2,167,253 1,941,412 Â Closing price of common stock (in dollars per share) | $ / shares $ 18.93 Â Â Weighted average fair value of options granted (in dollars per share) | $ / shares $ 22.43 $ 30.65 Â Unamortized compensation expense | $ $ 56.9 Â Â Period to recognize unamortized compensation expense 2 years 8 months 12 days Â Â The 2023 Plan Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Total number of shares of common stock available for issuance (in shares) 18,721,104 Â 3,000,000 The 2023 Plan | RSUs Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Granted (in shares) 1,045,738 Â Â The 2013 and 2023 Plans Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Options granted (in shares) 2,380,651 Â Â Extended Vesting Periods Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Share-based payment arrangement, plan modification, incremental cost | $ $ 1.2 Â Â Extended Expiration Dates Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Share-based payment arrangement, plan modification, incremental cost | $ $ 3.1 Â Â X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAn excess of the fair value of the modified award over the fair value of the award immediately before the modification. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRepresents the number of annual installment vesting periods. + ReferencesNo definition available. + Details Name: xncr_NumberOfAnnualInstallmentVestingPeriod Namespace Prefix: xncr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the annual increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based compensation plan. + ReferencesNo definition available. + Details Name: xncr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorized Namespace Prefix: xncr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the annual percentage increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based compensation plan. + ReferencesNo definition available. + Details Name: xncr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPercentageIncreaseInSharesAuthorized Namespace Prefix: xncr_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xncr_The2023PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xncr_The2013And2023PlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xncr_ExtendedVestingPeriodsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xncr_ExtendedExpirationDatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Employee Expense (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total employee, director and non-employee stock-based compensation expense $ 17,190 $ 13,563 $ 28,611 $ 26,162 Stock options Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total employee, director and non-employee stock-based compensation expense 10,945 6,842 17,818 13,825 ESPP Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total employee, director and non-employee stock-based compensation expense 211 341 417 663 RSUs Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total employee, director and non-employee stock-based compensation expense 6,034 6,380 10,376 11,674 General and administrative Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total employee, director and non-employee stock-based compensation expense 8,469 4,471 13,168 8,747 Research and development Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total employee, director and non-employee stock-based compensation expense $ 8,721 $ 9,092 $ 15,443 $ 17,415 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Number of Shares Subject to Outstanding Options Â Â Â Â Balance at the beginning of the period (in shares) 11,142,986 Â Â Options granted (in shares) 2,167,253 1,941,412 Â Options forfeited (in shares) (485,918) Â Â Options exercised (in shares) (162,895) Â Â Balance at the end of the period (in shares) 12,661,426 Â 11,142,986 Exercisable options (in shares) 8,295,121 Â Â Weighted Average Exercise Price (Per Share) Â Â Â Balance at the beginning of the period (in dollars per share) $ 29.60 Â Â Options granted (in dollars per share) 22.43 Â Â Options forfeited (in dollars per share) 32.84 Â Â Options exercised (in dollars per share) 11.83 Â Â Balance at the end of the period (in dollars per share) 28.48 Â $ 29.60 Exercisable (in dollars per share) $ 29.38 Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Â Â Â Weighted-average remaining contractual term, balance outstanding 6 years 2 months 4 days Â 6 years 10 days Weighted-average remaining contractual term, exercisable 4 years 9 months 3 days Â Â Aggregate intrinsic value, balance outstanding $ 5,813 Â $ 9,977 Aggregate intrinsic value, exercisable $ 5,745 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - FV of Employee Stock Options (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Stock options Â Â Â Â Weighted average assumptions for estimated fair value of employee stock options Â Â Â Â Expected term (years) 6 years 4 months 24 days 6 years 6 months 6 years 4 months 24 days 6 years 1 month 6 days Expected volatility (as a percent) 50.40% 51.20% 50.10% 50.50% Risk-free interest rate (as a percent) 4.42% 3.69% 4.18% 4.17% Expected dividend yield 0.00% 0.00% 0.00% 0.00% ESPP Â Â Â Â Weighted average assumptions for estimated fair value of employee stock options Â Â Â Â Expected volatility, low end of range (as a percent) 43.00% 38.20% 43.00% 38.20% Expected volatility, high end of range (as a percent) 44.60% 55.70% 44.60% 55.70% Risk-free interest rate, low end of range (as a percent) 4.71% 0.13% 4.71% 0.13% Risk-free interest rate, high end of range (as a percent) 5.40% 5.39% 5.40% 5.39% Expected dividend yield 0.00% 0.00% 0.00% 0.00% ESPP | Minimum Â Â Â Â Weighted average assumptions for estimated fair value of employee stock options Â Â Â Â Expected term (years) 6 months 6 months 6 months 6 months ESPP | Maximum Â Â Â Â Weighted average assumptions for estimated fair value of employee stock options Â Â Â Â Expected term (years) 2 years 2 years 2 years 2 years X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock Based Compensation - Restricted Stock Units (Details) - RSUs 6 Months Ended Jun. 30, 2024 $ / shares shares Restricted Stock Units Â Beginning balance (in shares) | shares 1,490,040 Granted (in shares) | shares 959,071 Vested (in shares) | shares (550,972) Forfeited (in shares) | shares (119,483) Ending balance (in shares) | shares 1,778,656 Weighted Average Grant Date Fair Value (Per unit) Â Weighted average grant date fair value, beginning balance (in dollars per share) | $ / shares $ 30.66 Weighted average grant date fair value, granted (in dollars per share) | $ / shares 22.58 Weighted average grant date fair value, vested (in dollars per share) | $ / shares 31.72 Weighted average grant date fair value, forfeited (in dollars per share) | $ / shares 29.80 Weighted average grant date fair value, ending balance (in dollars per share) | $ / shares $ 26.02 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Agreements (Details) $ in Thousands 1 Months Ended Jan. 31, 2024 USD ($) Jun. 30, 2021 phase Sep. 30, 2026 USD ($) Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Aug. 31, 2022 USD ($) Aug. 01, 2022 USD ($) Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Payments for (proceeds from) tenant allowance $ 700 Â Â Â Â Â Â Cash collateral for letters of credit Â Â Â $ 384 $ 380 Â Â Letter of Credit Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Letter of credit amount Â Â Â $ 400 Â Â Â Monrovia, CA - office and laboratory space Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Renewal term Â Â Â 5 years Â Â Â Pasadena, CA - office and laboratory space Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Phases of lease term | phase Â 2 Â Â Â Â Â Improvement allowance Â Â Â Â Â $ 5,000 $ 17,000 Forecast | Pasadena, CA - office and laboratory space Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Improvement allowance Â Â $ 3,300 Â Â Â Â Â X - DefinitionAmount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_LeaseholdImprovementsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromTenantAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the number of phases associated with a lease term. + ReferencesNo definition available. + Details Name: xncr_PhasesOfLeaseTerm Namespace Prefix: xncr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xncr_MonroviaCAOfficeAndLaboratorySpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xncr_PasadenaCAOfficeAndLaboratorySpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Undiscounted Cash Flows (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â For the remainder of 2024 $ 2,792 Â 2025 8,022 Â 2026 9,238 Â 2027 9,560 Â 2028 9,076 Â 2029 9,331 Â Thereafter 57,104 Â Total undiscounted lease payments 105,123 Â Less: Tenant allowance (3,252) Â Less: Imputed interest (33,453) Â Present value of lease payments 68,418 Â Lease liabilities - short-term 1,262 $ 3,435 Lease liabilities - long-term $ 67,156 $ 59,025 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of monetary allowance granted by the landlord to a tenant for operating lease. + ReferencesNo definition available. + Details Name: xncr_LesseeOperatingLeaseLiabilityTenantAllowance Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Lease Costs (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases [Abstract] Â Â Â Â Operating lease cost $ 1,881 $ 2,020 $ 3,762 $ 4,200 Variable lease cost 310 219 1,140 453 Total lease costs 2,191 2,239 4,902 4,653 Cash paid for amounts included in the measurement of lease liabilities $ 807 $ 721 $ 1,877 $ 1,445 Remaining lease term 10 years 8 months 12 days 11 years 8 months 12 days 10 years 8 months 12 days 11 years 8 months 12 days Discount rate 7.00% 8.90% 7.00% 8.90% X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and Licensing Agreements - Narrative (Details) 1 Months Ended 3 Months Ended 6 Months Ended Oct. 01, 2021 Jul. 31, 2024 USD ($) Oct. 31, 2021 USD ($) Feb. 28, 2019 USD ($) Jan. 31, 2013 program Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2019 target Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Receivable Â Â Â Â Â Â $ 22,073,000 Â Â $ 22,073,000 Â Â $ 11,290,000 Unrealized gain (loss) on equity securities Â Â Â Â Â Â (10,015,000) $ 288,000 Â (10,529,000) $ (2,610,000) Â Impairment on equity securities Â Â Â Â Â Â (220,000) 0 Â 20,430,000 0 Â Deferred revenue Â Â Â Â Â Â 0 7,900,000 Â 0 7,900,000 Â Collaborations, milestones, and royalties Â Â Â Â Â Â 16,960,000 45,523,000 Â 29,765,000 64,485,000 Â Royalties Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â Â 0 13,300,000 Â 100,000 27,000,000.0 Â Milestone Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â Â 0 10,000,000.0 Â 500,000 15,000,000.0 Â Alexion Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â Â 6,900,000 11,200,000 Â 16,300,000 21,600,000 Â MorphoSys Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â Â 1,600,000 2,000,000.0 Â 4,400,000 3,900,000 Â Mabgeek Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â Â 1,500,000 0 Â 1,500,000 0 Â Vir Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â Â 0 100,000 Â 100,000 1,500,000 Â Zenas Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Impairment on equity securities Â Â Â Â Â Â 0 Â 20,400,000 0 Â Collaborations, milestones, and royalties Â Â Â Â Â Â 0 10,000,000.0 Â 0 10,000,000.0 Â Zenas | Preferred Stock Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Equity shares estimated fair value Â Â Â Â Â 43,780,000 Â Â 43,780,000 Â 64,210,000 Third Party Licensee Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â 7,000,000.0 0 Â 7,000,000.0 0 Â Option and License agreement | Alexion Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Number of different target programs | program Â Â Â 1 Â Â Â Â Â Â Receivable Â Â Â Â Â 0 Â Â 0 Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Option and License agreement | Alexion | Royalties Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 6,900,000 11,200,000 Â 16,300,000 21,600,000 Â Technology License Agreement | Mabgeek Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Collaborations, milestones, and royalties Â Â Â Â Â 1,500,000 Â Â 1,500,000 Â Technology License Agreement | Vega Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â $ 500,000 Â Â Â Â Â Â Â Â Collaborations, milestones, and royalties Â Â Â Â Â 0 Â 500,000 0 Â Technology License Agreement | Gale Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Transaction price Â Â Â Â Â 7,500,000 Â Â 7,500,000 Â Â Service agreement charges Â Â Â Â Â 4,600,000 Â Â 8,000,000.0 Â Â Technology License Agreement | Gale | Subsequent Event Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Payments for repurchase of preferred stock and preference stock Â $ 3,000,000.0 Â Â Â Â Â Â Â Â Â Â Collaboration and License Agreement | Genentech Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 0 0 Â 0 0 Â Initial cost-sharing percentage Â Â Â 45.00% Â Â Â Â Â Â Royalty milestones Â Â Â $ 600,000,000 Â Â Â Â Â Â Â Â Collaboration and License Agreement | Genentech | Development-based Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Royalty milestones Â Â Â 115,000,000 Â Â Â Â Â Â Collaboration and License Agreement | Genentech | Regulatory-based Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Royalty milestones Â Â Â 185,000,000 Â Â Â Â Â Â Collaboration and License Agreement | Genentech | Sales-based Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Royalty milestones Â Â Â $ 300,000,000 Â Â Â Â Â Â Collaboration and License Agreement | Genentech | XmAb24306 Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Collaborative arrangement receivable (payable) related to cost sharing development activities Â Â Â Â Â (7,600,000) Â Â (7,600,000) Â Â Collaboration and License Agreement | Genentech | Research service Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Collaboration and License Agreement | Janssen Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 0 0 Â 0 0 Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Collaboration and License Agreement | MorphoSys Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Collaboration and License Agreement | MorphoSys | Royalties Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 1,600,000 2,000,000.0 Â 4,400,000 3,900,000 Â Receivable Â Â Â Â Â 2,100,000 Â Â 2,100,000 Â Â License | Zenas Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 0 10,000,000.0 Â 0 10,000,000.0 Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â License | Zenas | Milestone | Preferred Stock Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Equity shares estimated fair value Â Â Â Â Â Â Â Â Â $ 10,000,000.0 Second Collaboration And License Agreement | Janssen Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 0 22,200,000 Â 0 27,500,000 Â Receivable Â Â Â Â Â 5,200,000 Â Â 5,200,000 Â Â Deferred revenue Â Â Â Â 0 Â Â 0 Â Research license term 2 years Â Â Â Â Â Â Â Â Â Â Second Collaboration And License Agreement | Janssen | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Percentage of responsibility for development costs 20.00% Â Â Â Â Â Â Â Â Â Â Second Collaboration And License Agreement | Janssen | Minimum Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Share development percentage 80.00% Â Â Â Â Â Â Â Â Â Â Â Â Patent License Agreement | Vir Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Number of different target programs | target Â Â Â Â Â Â Â 2 Â Â Â Receivable Â Â Â Â Â 0 Â Â 0 Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Patent License Agreement | Vir | Royalties Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â Â Â Â Â $ 100,000 Â 100,000 $ 1,500,000 Â Patent License Agreement | Third Party Licensee Â Â Â Â Â Â Â Â Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Â Â Â Â Â Â Â Â Receivable Â Â Â Â Â 7,000,000.0 Â Â 7,000,000.0 Â Â Deferred revenue Â Â Â Â Â 0 Â Â 0 Â Collaborations, milestones, and royalties Â Â Â Â Â $ 7,000,000.0 Â Â $ 7,000,000.0 Â Â X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire preferred stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaboration Agreement, Service Agreement Charges + ReferencesNo definition available. + Details Name: xncr_CollaborationAgreementServiceAgreementCharges Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the percentage of responsibility assumed for development costs, if the company elects to participate in development. + ReferencesNo definition available. + Details Name: xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts Namespace Prefix: xncr_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the percentage of share assumed by the counter-party for development costs. + ReferencesNo definition available. + Details Name: xncr_CollaborativeAgreementSharePercentageOfDevelopmentCostByCounterparty Namespace Prefix: xncr_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the number of different target programs under the collaborative agreement. + ReferencesNo definition available. + Details Name: xncr_CollaborativeArrangementNumberOfTargetPrograms Namespace Prefix: xncr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities. + ReferencesNo definition available. + Details Name: xncr_CollaborativeArrangementReceivablePayableRelatedToCostSharingDevelopmentActivities Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the research license term under the collaborative agreement. + ReferencesNo definition available. + Details Name: xncr_CollaborativeArrangementResearchLicenseTerm Namespace Prefix: xncr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCollaborative Arrangement, Transaction Price + ReferencesNo definition available. + Details Name: xncr_CollaborativeArrangementTransactionPrice Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe initial cost-sharing percentage. + ReferencesNo definition available. + Details Name: xncr_InitialCostSharingPercentage Namespace Prefix: xncr_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + ReferencesNo definition available. + Details Name: xncr_RevenueRecognitionMilestoneMethodPending Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xncr_MilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_MorphoSysMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ShanghaiMabgeekBiotechCo.Ltd.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_VirMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ThirdPartyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_VegaTherapeuticsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_GaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_GenentechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xncr_Xmab24306ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xncr_ResearchActivityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_JanssenBiotechIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_SecondCollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_PatentLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and Licensing Agreements - Revenue Recognition (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Collaboration research and licensing agreements Â Â Â Â Revenue recorded $ 16,960 $ 45,523 $ 29,765 $ 64,485 Research collaboration Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 22,200 0 22,500 License Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 8,500 0 8,500 0 Milestone Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 10,000 500 15,000 Royalties Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 13,300 100 27,000 Non-cash royalties Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 8,500 0 20,700 0 Alexion Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 6,900 11,200 16,300 21,600 Janssen Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 22,200 0 27,500 Mabgeek Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 1,500 0 1,500 0 Mabgeek | Technology License Agreement Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 1,500 Â 1,500 Â MorphoSys Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 1,600 2,000 4,400 3,900 Vega | Technology License Agreement Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 0 500 0 Vir Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 100 100 1,500 Viridian | Technology License Agreement Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 0 0 0 Zenas Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded 0 10,000 0 10,000 Third Party Licensee Â Â Â Â Collaboration research and licensing agreements Â Â Â Â Revenue recorded $ 7,000 $ 0 $ 7,000 $ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=xncr_ResearchCollaborationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xncr_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xncr_MilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type:

X - Details Name: srt_ProductOrServiceAxis=xncr_NonCashRoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_JanssenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ShanghaiMabgeekBiotechCo.Ltd.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_MorphoSysMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_VegaTherapeuticsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_VirMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ViridianMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_ThirdPartyLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Income tax expense $ 117,000 $ 0 $ 117,000 $ 0 X - ReferenceNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferenceReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Sales of Future Royalties - Narrative (Details) - Royalties $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Alexion | Option and License agreement Â Â Sales of Future Royalties [Line Items] Â Â Non-cash revenue recognized $ 6.9 $ 16.3 Deferred revenue Â 140.6 MorphoSys | Collaboration and License Agreement Â Â Sales of Future Royalties [Line Items] Â Â Non-cash revenue recognized $ 1.6 $ 4.4 Interest rate 17.50% 17.50% Non-cash interest expense recognized $ 0.8 $ 1.9 X - DefinitionCollaboration Agreement, Deferred Revenue + ReferencesNo definition available. + Details Name: xncr_CollaborationAgreementDeferredRevenue Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCollaboration Agreement, Non-Cash Revenue Recognized + ReferencesNo definition available. + Details Name: xncr_CollaborationAgreementNonCashRevenueRecognized Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty Liability, Interest Rate + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityInterestRate Namespace Prefix: xncr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRoyalty Liability, Non-Cash Interest Expense + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityNonCashInterestExpense Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSales of Future Royalties [Line Items] + ReferencesNo definition available. + Details Name: xncr_SalesOfFutureRoyaltiesLineItems Namespace Prefix: xncr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xncr_MorphoSysMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Sales of Future Royalties - Debt of Future Royalties (Details) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Sale of Future Royalty [Roll Forward] Â Beginning balance of debt related to sale of future royalties $ 20,974 Royalties owed to OMERS 834 Royalties paid to OMERS (4,448) Non-cash interest expense recognized 1,900 Ending balance of debt related to sale of future royalties 19,260 Debt - short-term 6,947 Debt - long-term 12,313 Total debt $ 19,260 X - DefinitionRoyalty Liabilities, Long-Term Debt + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilitiesLongTermDebt Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty Liabilities, Short-Term Debt + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilitiesShortTermDebt Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty Liability, Debt, Long-Term and Short-Term, Combined Amount + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityDebtLongTermAndShortTermCombinedAmount Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty Liability, Interest Expense Including Amortization Of Closing Costs + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty Liability, Noncurrent + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityNoncurrent Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty Liability, Owed + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityOwed Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty Liability, Payments + ReferencesNo definition available. + Details Name: xncr_RoyaltyLiabilityPayments Namespace Prefix: xncr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSale of Future Royalty + ReferencesNo definition available. + Details Name: xncr_SaleOfFutureRoyaltyRollForward Namespace Prefix: xncr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|%9/XY/XW,[(#]-+XHG3C3*U0#S'#>9C+ (U MP%P_<<(1;FG Q7'D!>:,XR'C^#]F3*A2HEPUW<(K3AAG5QG6 \$K9&^P-BG M(Z=,UL2&9()@M,#S4Y0S,L6@X[F>.[+DG,Z1&\G@1O*U;OP&>$>+M_JJOC8Y MD!BNARB(1J'/#3#3YC# 7#^<^*-SM33@3)O#/NAK:A";MJ&4),-4UT!&T:' MGO6V;=5&XW?=PUC"^PQ^U:TG_DNP;Y Q6;DDE2P1JG&PO=V]R:W-H965T&ULQ9U=<]NX%8;_M"L? =:9.9.B8^^)4ZGME()#:=;IM)=MN+3B\8B8XTD42O2,7)OR\H*Z(',%B M_JY2"S9!\A>0Y X"6.="E;KS\ULZIJ@R_+Q:IY=39KVYN7%Q?-9%8MR^9% M?5.M]%^NZ_6R;/7;]<>+YF9=E=-

MH^7B@H=A?+$LYZNSJ\OM[]ZNKR[K3;N8 MKZJWZZ#9+)?E^NOK:E'?OCIC9]]^\6[^<=9VO[BXNKPI/U;OJ_;WF[=K_>YB M3YG.E)6JF=>K8%U=OSK[F;U4\;;!UN+?\^JV.7@==*?
RH:X_=6_>3%^=A=T1 M58MJTG:(4O_X7(VJQ:(CZ>/X8P<]V_OL&AZ^_D8OMB>O3^9#V52C>O&?^;2= MO3I+SX)I=5UN%NV[^O:7:G=“4<>;U(MF^W]PN[,-SX+)IFGKY:ZQ/H+E?'7W
ML_RRNQ '#9@XTH#O&O!3&XA= V$UX,F1!G+70%H-9'RD0;1K$-D>CIUTO&L0 MVPVB(PV278-D&ZR[J[L-S;ALRZO+=7T;K#MK3>M>;..[;:TC,E]UJ?B^7>N_ MSG6[]FI4KYIZ,9^6;34-WK?
ZA\ZSM@G]: VNGGR:U8MIM6[^$N1_;.;MU^#9 M9E5NIG-M_3PX#WY_/PZ>_?0\^"F8KX+?9O6F*5?3YO*BU4?6\2\7Z<4 M_,A1_%:WY8)H-
O(W&]7+I4[G[8$2K+MK!N+/Y\%659EB1,7%YVDP0I-<<“2N0 M, 6“&:DA]JDA!J;&*>EPQXP/(ICP1&:Q&;^1:Q:'S(JQ:\/“A#/!3;O1]:=7^.LIM$W'D.NH11$\U&MVS],7;OGK>#;KD M(/W?=[J+!_I6?
5NNI_^CKJ]$=CC=#7,\GW.,LX3&)K M>:A !V;$C86],A-Z([>=VI]W.MNTN_7>Z!“6G5Y!RBNATPG'$H4FUN M#==CJ-\<2BN@-(6BF?G1RVK,KZM9^7%23KCB5YR**!7V4,)[22R ^W“6)A&
M<<3L/NX:GHN86[R“-,NR4%HK.T48'M%/6“]$L:%*U%“1TN]@<\3!J44+\Y ME%9 :0I%,U.DU]B85W?Y3K%R!ST,)*E6[NS\J&)^IL^)^S8J<0^;%MP5DL@UZ\[.OV8E8/2:E3“DUJRD&;5F
M)0R/=#G>“T2$$FD/U(BAM#*7E4%H!I2D4S4RI@ZU:?DWI<9[^^YT.3BU“ M=Y)1&#K[M[;N+ [N+!;N!YC#Q?OM3/NU\YPVP“XJWK%26(/],2F+3OT%>\ WAWBHU 6E*13-
C&@O=7&_U/7P9_Q^!X.[/*%[I*NZA=%(K1W#$&=YE!: :4I M%,U,GEZFXZ=O*/N.Y“$3QA7;&)?<'FR2^R<2),A9+$(U-BA-H6AF<'N-C?LU MMH&*/“P6HQZ3[.S\CTD(&/V8A#“D'I-0
M9N1C$L+PB&8K>H%- (LAZ6L+%=,$L2,LS+*494ZI'\@|(**$VA:&:*'-1$ M/K HDDX+0O**,R;LNZ\@RB*9$VL7UO4W'ML:&F7{[=0I'*MS&4N1.#W.-10B M.=+G>C5+R“=\3B*@RA:4-
H;2EW.CBU7+F-13Q. MN=W9H2H9E%9 :0I%,Y.F5\G$4Y5+“E?“8DEJ/RC96?GT#1KDC/)0\0I*4RB: M&=->O!*/70WI=S“XT[N“E4Q%RIQ.#]UD!J454)I“T+^LDCA M;C&S=
[L0E//([MO0RD@H3:%H9NAZ[4M JR,%43B&8_*$>KX.G?-#=:]0Y M,“EM\9(RB]/07FPHTNY !3 _[*17K“2N^%$2.[Z87NY;0?%[‘!J4TYSF4*<% ME*90-
#/$O>@D4<6/DHPZ=#.;).0L%@L9VW4R8ZC?'$HKH#2%HIGYT>MH\B'% MCW1.$%(7X\R9-DNB^)'9HB0!TSUC<$PK**A)G0BU,250!)3YB@ MRI0D“B!9$L>A/1D:0_WF4%H!I2D4SB\826 -
)'UYH360 MDJB!/+)NA:I(4%H!I2D4S?QPU5ZZBAY8 TFF143LBJ*6KA%1 ^DL70D8O70E M#(FE*V5%+ETIPZ-+UZA7BJ*GK(*,H,(1E#:&TG(HK8#2%(IFIE0O+D4_H@K2 M[W1P:E&?
OL6=3X>“.LVAM)*4RB:F3.]@A8]51%D1.RIDO;3/__1#!Y93G“9 M0UT64)I“TC^>LF=B6^+#“$YMQ]$^@]_<.B@DAJ*9H:NE]2B'UK:Z/<^N-\3I8TB MLS]K< QUFD-I!92F4#0S>7H!+GKRTL;
(E=$RX0P+]U/W.GA>!RULI,Y!9JFM!Y!:7>9\?CIE9VPU M,@/3BW 1KF(Q(HH'$Y8YW0FZ8^LTISG4:0&E*13-_:97D2+416+I)KFIP^] MY\:4-D<“UX#ZS:&T DI3*)J9'[TD&#^D8I.“;
<2D7RN0=BYSS4((_JY!F%(M/>@K,CG&I0A\5SCXN ;0;NOE/VU7'^M/7- M]DM“/]1M6R^W+V=5J6=-\[NO^NW*O_ U!+ P04 “ “0 M@059I['83+T(!&* & 'AL+W=O^
M9;7ZSXJ+#97J4CS.FJU@M.@:;;H9BJ)DMJ%E/5E<= ?NQ.*:M[(J:W8G0--N M-E2\?F85?[Z9P,GNQGWYN);ZQFQOQ:6/[(')[LH:YF^UZ*ZU]H\G=LNJ2O>D
M=/PY=#K9_Z9N>/AJU_O/G?/*F25MV“VO_EL60]?_X7&QR* M=7\YKYKN+WCN;5-EG+>-Y)NAL5*P*>O^D[X, W'00/7C;H“&!FC<@'@:X*$! M[ASME75N?:&2+JX%?
P9“6ZO>])=N;+K6RINRUM/X((7Z;ZG:R<4MKQM>E065 MK /4GVH.9(-X“MP2YLU^%G-

M35MBU+9O =3\/WA“WCWTWOP$RAK\,>: MMPVMB^9Z)I4>W>LL'W[[<_;R//;“?B5UW+=@*]UP8KC]C/EQ]X9M'/F,PIV M^.^V_@AP] &@“!&'GMOSF^. '+P?6]SUAWUCJP=PU0W@2O
-4&M/4%G6CWWP MEK)DSE'K>R7N7O6ZOFJV-&V&3Q][_!)/]'R^4+=78T &0_ “34 M^^(WE88JWCB=[%LF74N=:YX64X@3“-/KV=.A?H?=‘*4'9D?*XKVR.#@UGXK_ MJ;75A[KD*A_EO,
[+BH%ZD*SOZN^YGL.V48M#Q;IK]J2Y8)U.EKJ)LUE M9D&97_]L2_FJJYZU$.X6AEH]]<#EYU^N057F2CP#]%&P'B@N'S)+7332;UOH MV8@\H0(C [TH“'Q+%F< MC,0[C.*,>*0?\!H&I?
^3ZD14@X8JA4K[V\)[Z/QH1/%8MVWC&W!D5*.@ZMNU M&E2F0V5%2P&>:-5VZED?2R=$(TM0ED9H+-NV4L'N4VX8#H.$7'S;;)7B/E+J M, 5B6TE$\#BX'68^M0:X\
1Q>3WMD*7“F“D<2,]>=!YA3IW$$@“SR))I6_ED M&OK(“+06OVC]N%4>7K+523K4 BLMMB&REBD;0)QFGET&OK0!)%S!=6';C-C? M“>UH6)5T65;^.@ &Z?
K60N!2O1T/A@$L/$E8S=1FR/PZY3A]=B(TG5MIQK:; M9^G<,V6&H3 ,T6^[P#FBM+#;-=%Y/WOWP/QB&R\$33.VPZC>.ZI M3Y&A(I3\ M;,2'49 OVQ.K6'8PAK WB;),I0B3VE/G(X ^%\;?
75W93[I1G M VT*$PRMV;;M?+-MJ(?“F[?SMGW.D7;&[LI1&K_-TZ;+L-D/H>>ZA@91J'T M34L:':5G1P“Y4T1CVU08I)FR3B&7'8X MB^>^L3\X'@Y3]=@+QX;^A'Z;G5F66(%S]BX3&
[[BT^>2'I4Q#R5A8+$\O7L M5(MMJF9SC,=EH,,,)“GVU(‘8L!>‘3W[‘A%B5-;W$,V1?]$W54KT=#X(A/ X3 M_CCRRJ9IU1ATT:?JD8T^7=)'D:#=ZB./%R;RLL\0_6WZ3(7[>0^VN:XJ_‘'] M[+)*
(NB96<-^'-Z?GNM47:C-K1“SK=“<8+CCXTOU=CP !P^0PY7&[C3/Z:A=(:#Q:9?#QK?))*:$(.'M^ZF#&N(X MKX;6N;K#RAB1]:5Z
M.QX/4Q*0<$GPO5:ING^N]TX_U7\/'H?'9V=7V<1UG'V8IP9';;,XRGS ,=@G M)[“_/V(#?“F5]O%[,H-(F]Y_AE>W_2MMIIO^#;M?J5 \;D#%5JK+Z&.JQDOT+ZWU%Y)O
MN_>^EEQ*ONF^KAE5Q:\V4/]?<2YW%_H‘]]\.+OX/4$L#!!0 ()“!!5GE M;M(E>@\ #8O 8 >&PO=V]R:W-H965T&ULU5IMCQNM M$?XKQ*6-?8!.]V8]3F(;.#N7U&G=&KXX*5#T
[5+28QWEPJY>SKEU_>9&7*7 M>]*].'8+%#!\THHJ;P\-0+$VMP]2M M3(-?YL[7NL57OS@,*V]TR9OJZO#DZ.C)8:UML_?B&3][ZU\\>O#.+I8M/3A\\6RE%^;“M.]7;SV^'?942EN;)EC7*&_F
MS_?.CK]Y^8C6\X*?K5F[+,B26;.?: OK\OG>T?$D*E,T1(%C3^7Yl6I*B($ M-GZ+-/?Z(VEC_CE1_YYEARPS'L@U/CV[8^N!!C*#=7%W;1V+DM=-.JLZ)P M7=/:9J'>NLH6UH1GARW.HUV'1:3]4FB?
W$#[B7KCFG89U'E3FG*_Q!\]LR> M)&9?GMQ*\,>NF:K3HXDZ.3IY= N]TU[X4Z9W>@.J'5*]?YW-0NOA+/_>);#0 M>[2;'@70-V&E“_-\#Q$2C+\T>R^_.+XR=&WMW#[].?
VT6W4/]%4GXNV>JF# M#;3P+8G8M)JCZZ>E0805KE[I9D/KNT9WI6U-J0K7!&PN-7VQ36N\K=7<-KHI MK*Y4 6#,&^#0HY1_S1-X?Q$O6Z*J7K8@NPK(3KI?UH;A85=V%=+?6G4S)A& M0=\K[?
D YL.7(&\03.U2O9]>3-7“-;,KJMK0SV9%O.A!NI6WX&950;Z'/YR= MO=UG7K:9M8WD08@\99E'PNT4“H2KKH1VJDK\E>$M#Q_2%MMX.-=4['N&R)> M(=D5G??
T0[9A7[5+W2K22*T;)$QZ2ILR'4$7E367D *Z4(TI3 4O5A)&][FV M7JURJ\7=*TCIRI!^,Z7()CKM5][?CM(\UEG08N)=,+1[X/G+-+YZ>'_U;5 & MPD.7Q&T#:P04AA4=%D12/9\C=8/8RGDV5TW68M?
#6M/*MLKJF:UL2ZX9U4,< M)M'NSS01HQW]>1Z*;+K(G;E“&80_=R16V;%Q1JNC#EESD'[C*&Q$I8B6<6UO M'0O36Y N--6GQ'=:3><6[%LP(?TP[^!' MM“[%#Q//7+WW(M2“4W76-!T(O6-
K()P4E6QU?'3P5QQ387//R@7%5G07G'5^ M52QULV“RM0V,-1Y>G+_:9R)FYCN*GY.OI>9,D?3Z1 %+O>KEV9D#[Y\KTS7VB+$!$G/]R<([DMXDIY5T?,06@H'V':C'O[\^GR?
ME+=>VF))R9,\D,,>AB;I9DB-2/@6GZ=(_YPWX8CK1D%,#L8&JCSZ,S%&YTU& M*0?)“MDVP]];5;E 4=AZ.^M:Y@8&;%QS $VTWE45:24Q2-(KBS\C-67*P7%, M$“X-
K8%2S%4%Y:]%'HXOW&U+2@2P+3Q86E7V2GP(H!3<2!6XVS#^ZJSA5S7 M0@&O&Z Z[78HJ?KI2%/O$-OG)04-,W52:]65&<4\6U;B6L\\TX72\EMZ02X M478 E[.'Q_MRBEOC*:0ND4J+-KH(:
(GS1N%QI%“L'4P>AMI-604&BAO%%QZ$ M05G0(YA:#-6*[“I PJ MXM[58]8*SA$K1#6XX!*,?)&QFDR+#5/U“^=L5,7.=8&T2>'CS #FUC#JSBN M
Q$W5[‘.RETYWU5^Z0:*FJ43$1!S.F+@,E06S,0 !%K_0&*,YY< 9Z%=52^MHKK)*‘X_]^L MDQW%,-!CQT:AE.-?DEJU2TI ^ X_]J?9S\JJU(T2I0N_4!V=JG\ K$$OS<*1
M&F>$+“>Y8.925QT+0I[5BS6)>9,V#;*F$ZAF4“4I“M]1S4%P6ZJ6R$KXG_C! M“=T%C<% J20.16N,K\>G=1E?M)CG#I-,T19Z,#-#PAD\A[!A*3KWG_1.219N+PTI:Y<@PQD M8M[W5E2?
I\0A#89\._[*R21“95KQGPIN+\GG!A) 6R7%28Q/[3WEIFA,BH[* M?@“5I7,E4:&2“FO^3M3[NL[M J@P1=E5@-!&%I&/8“N@J6“0^B_B<#&“)7T6&IYI5;0VW?#9U#L%O' #O\[?“: &%“W?N40C$:]
<@%A8 M-;=7IDP9“8>X%?L9I=<8G:DC'-0“LX1DE4L;Q“#>$“O1H0T9TZ+2C'&“67VP MG\FY/V6@DL:)Y$V!O _YNS4'%&3E=H([HU(“TZC*KT*O +LJ^SOGFA#+6L&%DSK& M@D6*WF9]>
<#0+RZ%ICH?)PD(? 2)!5R@7IPKA_#%.)87M\@BD)@0*@ >5$/Y MD=)22(5H!?[$2TVQ;%SE%JGYR#,E$G?)%NQ;R-3D I\@D'S+XE!LDCHM#4 ,
MFD%%>H$?“KJGQ5FVN5)AB&77.3L!R#8“TR4&9(V#(J2DQ/0S'. MMC0Z0CE“4H&* G$1+4]M0.)TE-JG(],*H(LE?=NEPJ,Y]^\ X>R#ZIZ/I(U5;U$,:E#?\X&G_@-'- M+:Q^K(JV#S^]?
OB3>Q^>S6+N>3XL\T;[#T8:U. ,3$##N93.;#Z0VX^2G6XR M2(=^!O&QB2XFV36H16<)#E!?QU<.-&F,77F_,?0G3&BB;^NN5D YI6UCP[@A M#$S@%.Q0\U!3O1Y0'[6_L:/@)$+@8RAGXG;;?
%:VMFV(X\-(G+)B(],G(% * M_\C;AGL_NF=@[K#N]$E4:!PE$418C$D-,)@“DV0%“:U@;$%TF)$>1L1F![V]UT\AI. M+\.T6*MP L%4 OS#P3,S)WH1JVU2PA[*!)6R'76$ “-!)QR;]1;<)#:;/ O& MAC\#A';
<8?%DET!MQ0“4]>S[F5QT9P;;7#HCLP1JXS“.4 ;W0:E=C,5BGTM9 M%<=>R>N\]!&'9U)R3N;%C[FR DO6Z?27U'KI-/+Q1GL8WJ1W?N#]?> M&HIFJX>%T1S7VH2I.J8Q_$UL3U!WNXJ%B
M2F0T<8JC+PB:C*H]7:4T&BXE09A5.D-,9924.],F:=2%BX=?04U'2C+*W^ MR.]ECC#“VO>UR:())H5+ U]'JR2(4G#]G,K4XW'=.IY^W3^(L\U[*N^/<'MZ
M+VX7A#2(V^.LHC.WCZ?'Z8'DO^LR6JJNIF^N“&SE\UMIPTUS:;UK.$“(;,QW M<6.&T)C&J,REM)7ED5PCUUAB0>)0R69QUR>2VZ90GPG%Q6%G2'WVN.2A;C0F MN_E(.$]P-
%LWGS/R&O81=!TMA[NCQJY$3- ZT0YU/]X&(0'9*979E*T9TMH$!'PW2: MQ_1E-*OQ\!“TQ R'I=&E2\W7X\M2[JS74-U$“)*7>CX/$QY,6'N,X EAY7&68]FK“U@ODV/ 05]KG7“:K
G%'1)/WB>0H6WTB9=:3 MO'O:P@-W))H=>>,3[/9?ZVN1^/^6YJGJW1@'7L2(^%XN4]ZEJX)?Z&+%Q-A, M81-O7-[0-?&EC2-E3FJ!B^(DJ^8R->7[*Q[-25[/JT^<0Z2I2#;[D &'@=
M]B[.KYGALP4$))5,T?,9]7<'47;%;*)XKP%M* M-84N +VIS7J=E'TN62OEP'N[0]\#TJI,4?LW&J[+FKI!P]-3[OA-&5+-+7MP M+R G2(- 7 XWWHG+Y ZY$_2B3@>Q+.>?
KA7;“!89W(_+CFLBKKW!#:,'1NC3 M\]<;G&,,J89N#N=CX_22]?SFT[>[G%;>-N“AW3@F>G,SL]+];G.QI7V>+HSA M&C69T'#V,@QP:KH->“T%[3/D@O=5ZVKK27WC;!!/DM*Y.S%TJ“B!;H!2?$1[
MS#:,!SNN&UKQO*0WP)9K1>:O.6BOFIWV&;C^GZ25_]=TPE=%YMJ[A&@8\+F(M4$=*UG#+T]!U-MU0$E(8/-(S'1KYA#3I[*](!MIRP4VR>^1Y>Y-H LKQBE,R/R6G/_M'\I_$S>A1Z6RQOE;X!XZ
JI,G-L M/9I^]7A/KF;2E]:M^,WHF6L1R_QQ“7QE/“W [W.'Z(U?Z(#^5?D7_P%02P,$ M% @ D($%66SY$0[Z!0 “@\ !@ !X;“]W;W)KG!^&M8^V/-3TW@EM?A@F6NJ
MBMO=I5#F[FPP';0+'^6F]+0P/C^M^4;<“/^Y_F Q&WN-&5FR,N:6)N^%L&$“ DE38X'K!K'FC_$=S]>=([BP(+S?*A?_L+LK. ME@.6-\Z;*FT&@TKJ^,OODQ]Z&XXGCVS(TH8L\(Z*
LNWW//S4VONF“5IH-$@ MF!IV@YS4%)0);_%58I\ O^;2LB]<-8*9-;N6FNM<:>=M ^[=SKV4$3B MXSR!7D;0[!'0)7MOM“\=^TT7HGBX?PR“[.=6OY4N5\8U5CCVS\4*5B-1_CUD3-
$X3G'>'Y4^C_-TQ/@AZF_ N:>JNRMRIUKAK$&P/F2\'6G93S MW(L'0BSGKF1<%W$@OC5RRQ5)#)'=]E9XOE(“Y;7R08H$_(XYD3=6>BD@QO/< M-
1I12ZP&_*]Q9KOT@IV8]4V(“;NT!#N@X09=R2&=9*(// MUN2X+3ENQ#Z1^=V<'$D.;?AG>V[I.X]R4*@=XW5MS;UNT^0AX8/: “?]ZD M=5<:ZU][82NXS">N4?
>5J6JN=WMWH'N3GQJPU9M@CC;Z]7ZEIZ,2G*JA#5? ML 4H“[0F7[+KBYM+=A&!:>N-!QRWA8/60JYESD.[/M^')0+]PGMY M<7-%.UZ-
6!I19T6ZNAXS1,91R“2Z'2#ZG$LI++=YN0N&\Q%T>$MZST1R_5MB“#[UG!%“84LL(((M(>FDKAO*]:-V]=/(2BVR);@3^SN,7C ^1%[#^8FI<*>:NP“<&B MS[HS-
NHVNLO8M5$XM2G*OK2“TMV+C0&J.V%_B:U0;/KBV7$VS=[$4$<5TG7< M@;C:P2[]“.#0OON)$P]JWQM!/;64>TAP4J9K8SU8N5D_)/.Z]O-8@+ AY'@JG6 M9*SU+!XE3MFO>Q0JT=‘[V8K:)U$?
H5,&S!Q@;;=[M“$:F.%G!5'O8D /F0^1'D)_X@V#:_9T!VOB$/6(?A>(^!+UCS)4S'6U?(B>Z MG“1'IERTR6/$A=Q8F4(HI*]K2:U5<1P_6U*3:QQ<4ZJSC<“' J)BMJ-&QR%T4-#2&8,GW#
MQ&@S&G8FQ 8=#P+X%_1“>5*[11WG'LX/L5=*HOX+ D+T32Z#(:%%<[8!&=T> M8;N'AT+J7K$Y/3RE]F=32JA8)218XGI+$54A#)#]WLEX$CBCX>)=KXZ1“ZF5 M]'HF^3@=DDD-J@AGS
^]*IRP^TY%MJ7>N.^SW%4N%4N“/M;“2E.XY'!L?!EV MF<8A6N[5“<-U4G372?86]X=JA6R>3H/UV96P=\!'==' M7XEP] ;W)J3A&ELGHZ/%@-GX\HH3;^KPVED9C[=3&)9XK I+ OB^-NBB:4(*
MNN?O^7]02P,$% @ D($%6?N,UM+O P T@D !D !X;“]W;W)K&ULQ59M;]LV$/XK!ZT88D“U9,FOF6T@;\4ZK(§1M^N M81]HZ6P1H4B5I.+DW^](VJY3)!ZR+P,,^4C>/7R>
(WGD=*OTO:D0+3S60II9 M5%G;G“>)*2JLF>FJ!B6-K)6NF:6FWB2FT(5“.“”B M\6V'&1VF=(“]A[]@]=.6E;,X)427WEIJUDTCJ#$-6N%O5/;7W&G9^#P“B6, M_\
(V^.9I!$5KK*IWP<2@YC+\L\==‘HX“Q]\%9+N S/,.$WF6U\RR^52K+6CG M36C.\%)]-)‘CTBW*TFH:Y11GY[>T[K\K8V“!&JY475.FEA73.$TLP3NGI-A! M70:H[!6H(7Q2TE8&;F2)Y?/XA&@=N&5[;I?
92<#?6MF%/(TA2[/“;$\H#7W M>/DK>#=,2RXW0:L7“7]=(S5M#7^?DEO@.N_#.>.R[EI6(&SB,Z#0?V T?SG MGWK#])<39/L'LOU3Z&];F/\(!9?,\ (DC0LWWM!X$<:-'^?&M9O68@FK)RCY M
R\I@V K_!]K-5\5U5JV$@A6P9H“Z6=OW/;^G.!Y7OV@)J..TFBQI'5P M4S=“/2“TCLO6EU45!QA(9B$LYOE8M$!EV*I+'!9B)9* AE[K<_7H6“B:$58 M4O()N3“PK3 $>
“S6W#3%M5^SVQ5*TJH*/=$G'Z6OS\D#==KJOS=W1YWNLHW M;0AF:‘$$75KF'#Y7FJ0>ES=8\L?G':Y(N4]^9)UY0:HU-+V) 1\+;.QN+L?(M$0BMDMHIWY\W^MVWMCH+2YW!
[>K_&\%$677@'9\-!/!GF'6=FO7@RZ'NSE^?Q M9#+T]CB+1[U1!ZY1*KIR O[7'S?ZZZ>W-6&M0RI=S^KU-1CVXN%H&/?[?1A, MXG$ZB@>#L>NEGC@?^]Y)1HS(?,M2_EL:>MUTY-
6FW3P86;&ULK55M M;],P$/$XIR A)I4F2[LQC;92.T ,,51M SX@/KC)M;'FV,%VEHY?SYW3AD[J M“DA\;&J?[WGNQ9EB72KMQ5'A?G<>QRPHLA>N;“C6=+(TMA:>M M7<6NLDBC“I5G“;:5P*J:/)*-
CF=C(RM5=2X]R“J\M2V(<9*M.,H^-H:[B6 MJ*S(9Z,*K“'&_2?J[FE7=RQY+)$[:318'$YCJ;'Y[,A^P>'+)QJ;M[,&KF1A MS!UO+O-
QE'!“J##SS“#H[QXO4“DFHC1^;#BC+B0#=]=;]G>A=JIE(1Q>&/55 MYKX81V<1Y+@4M?+7IGF/FWI.F“\SRH4G-*WOJY,(LMIY4V[E$$I=?LOUIL^ M[#.DB< Z0:0AKS;0“'+-*+R73)95NDYJE
M!PD_U+H/@Z0':9(.#_ -NB(@6_P5T5>ZLR4“”^XV*,>?*+)-TNX%>L>3+VW MODT7SEL:H._[FM/&'NZ/S2_5N:M$AN.((C]+Z_O7SG@L4FQ23K(V“H=YMPO36T+!T+3WA=HV_,.)3=M M9J>C/M
[!“BR@K'D33^+&,!.KE^6/$!0H94F=X \1T!3@-T4!$]:#'H!;;IZ M“/&,Y@LBSC^FP!5PTK4F\5+R)T58D6AM3TDA2)7NL+W[!<>'&:UE5ZBZ\M ML2,T_-“&/#VE*A3)4J:$&ULO5EMCJNX M$?
XKA“\XK &=K5?+WNPNDdPNUQ270Y“]I$“+?N#*M$U$%AV2LN/^^CY#R;+D MU;ZEZ7VQ)8KSRIEG9J2+G=)?S$H(R[ZM\)<#E;6;L[‘8Y.MQ)]J;D=J(D\6
M2J^YQ:U>CLU&“SYW1.M\'K^9+SFLAA<7;BU#_KJ0I4VEX7XH)DIUVNN]Z]% MKG:7@V!P6/@HERM+“^.KBPU?BAMA/VT^:-R-
&RYSN1:%D:I@6BPN!Z^“\]“OWG/]15A^FPOV1MQ:QHLY^_5K*>V>W8BLU>*82[& M%]*(8)S5;%]7;,-[V$[8>U78E6& %G,Q[]*/H6*C9WC0\W7X(,_E\6(1;[‘ M0C^,‘^ 7-79'CE_TN-
U'.]F_7MT:JQ$I_^XSN>(8]W.D[#DW&YZ)RP'2PPB] M%8.KGW*)O[+!_2-&WWCA[A__SG] +;LSY5@UVJ]X<7^YY^F89“^-(C!AG). ME.:X?27R.>.&J07#L8GFV!SW-
R(3ZUNA612XU8AQ+6I,D/\12G8F2R87:G20(894O2)/:NL8V]+K+$7+ B\“7B] M8,Z(\%7GJGYXK?1&:6X[81*BX2SRV82=A>ELZ.XG2^.XM“; MQ0GMCM)XZ.Z3-(6,9#+QXMF,I(7X.9LDT=
M)]XTF;*/ J*M<+Z[YF;E ,)71 MA<“1;‘D.02T[6F?7Q/97G.9+$5QJYKPH.@NV?P0_P;)EX2^O?X MMW[8[]]PZD73D#S%SH*ANT^A5;]_XR#RDB1B@>=‘*3M+)T,LQ5X2T-%.)JD7 M)PEYR8M2Q!&
M#$*N8'VA$$V5YPS91FN3“D>AS/O#1(ZJLH M#0 _:=]*NB,]..1+# C_Q@&SXC[WIA(*9XFZ:)O65BT“86Q;H%“G4HZ((C^@
M$F^YS,GD7!4_&+@\HX+Z4#@*H2>%KFS84%QN*4XO, DY%VQ0O* MOG55GHY7\,(2NEIPZ#)_VPAGGX[6]*^>.+LWV“E_9YX?4[2>(0B&549/9XF# MA‘!X3]B'\<0+DA@)$F%/.O/B= H&<4@,
(F1V,)L2ARB>TQ-@E:^W^7:‘X\+K=8N,WNB MLIV,“*8Y;+6*9?#B$DO.5 I=N W!RYR=HMA*K2K=*2P+94\),BWFTK*O)11! MG:V! 1@J=+Z7Q;(MMB8AR$(<2S7JK<6BJM@=NBPOYQT+*
(<99]2YRWP/M(‘: M:“@=]!P3S DP)PD)VS.NM234M*W-%<^6>:U‘6F1J63A/“YZMV$9HJ>;.)_H MP36L*)BH266U1J$1WS!P&#‘T6“LB*‘W=BZP*RV$(S?RVR%N!767W7QU9 W8 M+-B+(!SYZ)SSW
T!H'\Q&Z7-P@YGYW35Q,D=PCWZ-&B$$+#.1T?G/EO-R,-1 MD*+)3@Z FOXHZFC)&SOA/KV[H\U<>GL“2:)RXUG3?EO“I^VFTXL^WQS[D/RX1X\[ONX;#XS51AEA![G>EU0,8V8
N26,::FT M*.17Z$Y5G _.0J2BYH?U!Z/HX5U45\3650AD @P;‘4.NF&0&GO+&CD9IF#AA? M;*LVEO(HQ7>#4#OE&aI#G#(“:NC“C M _;/5:DA,$+DRALQDAx,]3@BFN#!W@T ?
G\‘3Q’#S8,ANP7GKA6%HF*WO?K;5 M:N3P L51TM‘,M-X#ECE1,L4U A+YN**S^TEF%M(H91)07ERA:]/F D-7)9?F M@&=F'P9$F0;,CYTH“ID/-/-CXI$Z_M2SS.(DQ$V0.8E/[(,$[(-O-L4>N8;1
M!0(\9QJ1R,3)HL'*SOS,BLZ“V(W -%AY+/(3UD“?4Q))8X71OB/>8C8A&G“ M?-]) ,>O,T#T<3*0;,\.YK<8Y(#N-;0_DU!1V6H=9R2VM‘,\?K*8Y(#>2V&BP'+ MQ9HWROVBM^]%:\^4]&5:6?^?;=]CHWS+‘;^^-‘K+#*V&-
AIX4[TTP,F*G‘+O#&8EY-SU1P&3[.7801=] M&6>MW&V02[XC-V,_Z2$ MOK0W+/7ZTI.&L3]N5M89^/[/8S8&%9/C*B@?+FS-,W$U0,!;8;Z*P?6+9_$L M>G,“X*0‘.#FE_03S_T:.?
2H$6^JRYM4C4^&37J]E)ABOA,FD1RAV]A M^MEN+U%A!;:1%:2!^69CA$“-<2“/>6;9R_#H9UYY^W8()7Y;JGMN[[CEN:CV MN!VR;2&S K0IU9)*2W]L8%(2I=/ PL%NK“8?Y:“?
=G5;S:RH.;‘&ZJ+U*51J4PA?D\(K= MB]]%0&LKP,Q#E%6F&H*X‘UTGP:6C] G;A]YR,OMT*‘#HRTEGY[?=Q0:)@)C. M#Y“<39^8(-\B&CE ‘0>(>?&0P=R-Z%(&!AI/$\EB.^23@UKO[I;&P&D<0FT_
M<7I0N5!X(C1;F3UWH‘25T@?.3CZW@;“OKU8\$R&;?%KS3“KI‘@-#5/YDL.*= M6)D&‘9Q4I“';>-5]F/QKEJ‘I6Z))E*R FLO8]Q63?*8K71I??,D!J MWG^^62+ZK+,=USNY+0F!;RI2G:N.
[AL8O43RI9SI7<2).QTF.HN/ZY_F M7I2Q8T8?Y^\&,R#BE)KSI7[F%X47I6RCC%7;=\/7:/UJ17U45*_H“^,%;<$0 MLYXO!BAY!1Q‘9S34H3OF6V/%QR$^9CC:/5(XT=3#N80&(VHC“?NY;PC#T1)]
M)L[87Y;141QC.DN##8W!PTX#]M)XC?’_J1%EX3*T^P2LRPU7/3>,*4_8AF‘UJY-!^N[F3;RMK<+@1’4A,! MUF=2ML,#“1B_9%[^!U!+ P04 “ “0@059.39#6^T& !L$0 &0 ‘AL
M+W=OV$UOL%GZ78VITQ(TM66G^AEP_YU2 B M0$*)S)$&CL=7L11*D2+ ^*O5.>BW),‘=<:?]G;<=MJRX%4NM?I.Y*ZX&BP'+ MQ9HWROVBM^]%:\^4]&5:6?^?;=]CHWS+‘;^^-‘K+#*V&-
AIX4[TTP,F*G‘+O#&8EY-SU1P&3[.7801=] M&6>MW&V02[XC-V,_Z2$ MOK0W+/7ZTI.&L3]N5M89^/[/8S8&%9/C*B@?+FS-,W$U0,!;8;Z*P?6+9_$L M>G,“X*0‘.#FE_03S_T:.?
2H$6^JRYM4C4^&37J]E)ABOA,FD1RAV]A M^MEN+U%A!;:1%:2!^69CA$“-<2“/>6;9R_#H9UYY^W8()7Y;JGMN[[CEN:CV MN!VR;2&S K0IU9)*2W]L8%(2I=/ PL%NK“8?Y:“?
=G5;S:RH.;‘&ZJ+U*51J4PA?D\(K= MB]]%0&LKP,Q#E%6F&H*X‘UTGP:6C] G;A]YR,OMT*‘#HRTEGY[?=Q0:)@)C. M#Y“<39^8(-\B&CE ‘0>(>?&0P=R-Z%(&!AI/$\EB.^23@UKO[I;&P&D<0FT_
M<7I0N5!X(C1;F3UWH‘25T@?.3CZW@;“OKU8\$R&;?%KS3“KI‘@-#5/YDL.*= M6)D&‘9Q4I“';>-5]F/QKEJ‘I6Z))E*R FLO8]Q63?*8K71I??,D!J MWG^^62+ZK+,=USNY+0F!;RI2G:N.
[AL8O43RI9SI7<2).QTF.HN/ZY_F M7I2Q8T8?Y^\&,R#BE)KSI7[F%X47I6RCC%7;=\/7:/UJ17U45*_H“^,%;<$0 MLYXO!BAY!1Q‘9S34H3OF6V/%QR$^9CC:/5(XT=3#N80&(VHC“?NY;PC#T1)]
M)L[87Y;141QC.DN##8W!PTX#]M)XC?’_J1%EX3*T^P2LRPU7/3>,*4_8AF‘UJY-!^N[F3;RMK<+@1’4A,! MUF=2ML,#“1B_9%[^!U!+ P04 “ “0@059.39#6^T& !L$0 &0 ‘AL
M+W=OV$UOL%GZ78VITQ(TM66G^AEP_YU2 B M0$*)S)$&CL=7L11*D2+ ^*O5.>BW),‘=<:?]G;<=MJRX%4NM?I.Y*ZX&BP'+ MQ9HWROVBM^]%:\^4]&5:6?^?;=]CHWS+‘;^^-‘K+#*V&-
AIX4[TTP,F*G‘+O#&8EY-SU1P&3[.7801=] M&6>MW&V02[XC-V,_Z2$ MOK0W+/7ZTI.&L3]N5M89^/[/8S8&%9/C*B@?+FS-,W$U0,!;8;Z*P?6+9_$L M>G,“X*0‘.#FE_03S_T:.?
2H$6^JRYM4C4^&37J]E)ABOA,FD1RAV]A M^MEN+U%A!;:1%:2!^69CA$“-<2“/>6;9R_#H9UYY^W8()7Y;JGMN[[CEN:CV MN!VR;2&S K0IU9)*2W]L8%(2I=/ PL%NK“8?Y:“?
=G5;S:RH.;‘&ZJ+U*51J4PA?D\(K= MB]]%0&LKP,Q#E%6F&H*X‘UTGP:6C] G;A]YR,OMT*‘#HRTEGY[?=Q0:)@)C. M#Y“<39^8(-\B&CE ‘0>(>?&0P=R-Z%(&!AI/$\EB.^23@UKO[I;&P&D<0FT_
M<7I0N5!X(C1;F3UWH‘25T@?.3CZW@;“OKU8\$R&;?%KS3“KI‘@-#5/YDL.*= M6)D&‘9Q4I“';>-5]F/QKEJ‘I6Z))E*R FLO8]Q63?*8K71I??,D!J MWG^^62+ZK+,=USNY+0F!;RI2G:N.

M:%N)C:P\S*>T(%0^)<#>-Y5Y[O'#X*H]ZO@L/JY]W[2V!B"LB>=)S_-'X2@W M@7$)RU&.8;G/:4!0VN1=Z3I8Y9V7BXQ:%H-WC!?:-=>CV8\ZKJP^Y'C);8$%
MRI<(),0^U;M0NV1%O\@4NHA<2S+'(CG0]V7F\):1MM;K2UU9K63.:>*6*Q\V M]W1\VN]*+YXMDGC^QAZ6,+EB&Z',R\+B6AEW@#G5ZX:P3;(!<2HH)PS
M/1!JB1E(H?!M]UIKBEQ9;9CCZ8U3GMH.%3$F^HM26POH]31ZZ!*U=M9R$*\%+3YMN+!QO7UVP MWWU/1Q"2LCX&4Y23=RTH5!O0DH>X\"#.6#*?#.)JP3YJ*Y!X[P:Z:/P8?Q=%T&"-C
M/N)0<<$^A9+Q5"9>IL-DFKQJIS^4=>-" ER%];3X62:OF)W=.J#9!'KWWC[M;<[8;#& 2^AH$:N-> ^ _0[U-9LG194I7F[!J!NNFL]:Z;QW5/W8L MOP4L C7X^"$9"ZAE:+&(?
*U$2X9D.YV#LC$V&N%^RSS#.&[HC MD\8(F?@]27KN]9U'0>\,$LM 3MMK>$GA9+MS1]X5 MC1(:&].?$X_Y9A'-\7^>Q,&4^=P_)Y,IN_%'MCU20Q'>^ANCR%]S5$I<@-O4
M>6+&1X7O+8>)+BG$T1?]$7OH?7148Y<6Q3B./Y_ M@)*NQ>C\^>C8W6N\SY: ND,E^'^: _]3PDVX03\M#[]# _,2-[[]* MK"$*EJ<#9L+=/KPX7?O[]$H[W,[]L!
X_1M:@/FUUJY[H0WZ'UBN_P%02P,$ M% @ D(S%64#P7(?= P NP@ !D !X;"]W;W)K&UL1599;]PV$/XKA +D:;O:B#,9W#W)54C(Z7\QF%[F1RF;:5=2-6ENZ]"*TQTA]O
M2+O#.IMGP\8GM:LC;^2;52-W])GB;\V]QRH?42IER ;EK/"T76?7\ZN;,Y9/ M K\K.H23;\&>%,X]\.+G:IW-F!!I*B,C2+SV=$M:,Q!H?.DQL]$D*YY^#^@?
MDN_PI9"!;IW^0U6Q7F>7F:AH*UL=/[G#3]3[<\YXI=,A/<6ADSU?9*)L0W2F M5P8#HVSWEE_[.)PH7,Y>4%CT"HO$NS.46-[)*#WSA@5$>48A+25N'4V*KLC6RH*JSS"! OF90]WT\$M7H"[$!\!
M4 ?QHZVH>]J?@]K(;S'PNUF\"OA+:Z=B.9N(Q6QQ]@K>BT!DY>]X(-])5:&1)ZPR=$LCO*=N\?3. F+U_Q86S MT86SU]#_?"*A1\.$)4\ND(A/H(@]_*)L/54XZ =85F[^$?!CY0&+;1BZK
M1AZ[4',X:^4K[/C(D6[@>"MM8EZ2CQBH"&*)^4=*[CQ1TINP3=U6'#NX.@AL MB7#DW5%]!INDF#_:8A<**AW26+4T"'9779< 6=8<3I;GX \$*NQIUZ1MU@*$ M(5\B#NI;EURC-&%*(5-
3<1TZ+./:7AX5PTR!^!W9[O0[PT\U< KA1WS4#*74 M-]X5B3O+XU 97DU@HJP3PZ&<:[FGOEC(]H%#2GJ7^W2]?7.YF+]['$*$#8M['NBN%'[@4CF/(2\[W63LHK5&97UH%Y]OP8CTU>]5A;
[8$SH) M$=PY)LXD>08A^H'[;5#M_)H^-Y'RDPL%^=ZE:S-P<]K8W2WC[G@S7W<7TJ-X M=ZU_E'ZG+.8!;.$ZF[X$X3OKLIN$5V3KJ?"15QVZ;/&WP5Y%L#YUKDX+-C M^+^R^0=02P,$% @
D(S%6;A2EP@D$P X48 !D !X;"]W;W)K&ULO1QI<]NV\J]@7+=CSTBR#E]ICID<;9J\N/'8:5_G M?8-(2$)#$BQ!6E9__=M=' 0/R5?:#XE%BECL?8)ZL5;%5[T2HF2W:9+IEWNK
MLLQ_/#K2T4JD7(]4+C+X9J&*E)=P62R/=%X('M.B-#F:CL>G1RF7V=ZK%W3O MLGCU0E5E(C-Q63!=I2DO-F]$HM8O]R9[[L:57*Y*O"TZD7.E>:)+E_ EEP5<
M'7DHL4Q%IJ7*6"$6+_=>3WY\&E,R5^HH7'^*7>V-$'2"0B M*A$"AS\WXJU(@0$:/QE8>[Y+7%A^-E!_YEH!UKF7(NW*OFOC,O5R[WS/1:+ M!:^2\DJM?
Q&6GA.$%ZE$T_]L;9Z=/=MC4:5+E=K%@$$J, .7WUH^! O.QUL6 M3.V"*>%M-B(LW_&2OWI1J#4K\&F AA^(5%H-R,D,A7)=%O"MA'7E*Z FX7-5 M<,.C+&:?9(0\SY;L];(0
@10ZA=')>R%*XXB" >-@3O= O>47:BL7&GV4Q:+ MN+G^"#TB$X=HF^F.P% ^K+(1FXT';#]>'N^ - _.$SPC>[0L3;N >]\-%(_I1 MYSP2+ _? 2K0H;L3>JQ^^FYR.G^_ ^MAC?;P+^A.P_A9PV9>58
MX5*WQ"ZD9 M=]8,ĒJ"CON:T7BU8"4^"S8A"\H1%3>A%P;.EA2@S>K1>,'3(_!A-F*O$W&+X"Y7'*PS$E4I(Y[H ?N012/XCWWD68683<>3V8!V M>:O2G&<; R(6B9E0H@LL]YBVQ1$\T.<*7;S-
\^!#LM5W<@<6"_/ARQWX"6 MPI JBE0[%G7@-A%= J=*0!30=$\"NN(V2BH-SHRA@O$B6K'$H#TP6*4RE;A, M5_/$B[% _P28 :R4?S7,KK0(]_OAN_/IY.RY9G^4P'O -%IE*E'+#2X2-SRI
M0**TD,": 9: "Y2%U&!#9\?/1Z2#CC\2E:24 M96)X5(A($%O4AB>E%)H<=LR0;2P'M.!AB#3(_ S0T#P1) F_!],JB=E\XX@9 M$ U\L9")!-+AX8+N>,8*H1WN 7SI]14HLA2'W$\%BN82EGD^>UP;9#5,
(J*H?SS=!^)!E$P/BRV.!M^Q')A;WALTQH>W&;2VMU5N$2 MKLMAJ8;TC6 @4PF0$BY31)D[18I9#O2"]D?]!FP8U <7\SR'[D>%BU[-=L:L=6@&N4V;>C& >ATX,:V&W&[D# MW+ 6HU][Z&40
S\2E=/.QDVE*48$\#1_>U>4@8M(V(=/P\E)BP3K6#0[:.8D ME_;^(?H B\Q:J!8S'E28(42BZ_HOY(%9P<0@!7+> I<^B-]/9^-3PF1J_>G ML^GL<- ;\0B5HP^?)B=7/WSW[/CD^?
#G""]BV4,4MT:OWNX&C#%!:2X&;6A M3DEB2/.%EQ6(TF]J=&,-G@0R"A(S.S[Y'K>[FZ^1TB5AUL\Y#WJ->BT@VDC4 M9]B;]@JVRDR,7E#P0Y526H,/710J-5X./0P\! &@4$B>$QIJS1KP+ 8N "Y4
M58"._07:#(S#1<;^UE9!XY8.DO=6&8 H&2R%$@B,#"@.J4#$V! M 8G%PAB'<283YTM]^B 05:B9D&E0_I9C(E#?H$I) -.@P),^3GF$BBGUI6 MX%=4L6D)W=2S$H/;B/T7<&O)U.5"58Y7^Z?
C\6@/# M-?N3\]:3 :KU@\:MS]][4^IE^=]Z&"@BM^1#-TH'<2/UPX0J5I!^B2$E5)3. MRGA8"C"D(?3S;@'9@P^IZSC7[_;[C7HAT:78\P2;8VR,ZYPMG\6A#O02@HP M 4:HZ5Z]&P[
"S\,Q@M9@&6LP M:0SLFW,.%N@1!8V(L-W-EL5\0@K-W X&7LC52-JLH]J ME6E@U0\\S9_[]\@*^2/= AA([D.0C):XYVA=%L-W"D&. O80/HXM M"%X2)) I.%A=8LT78;57C-@?
(HOP005E'*B$I;N#W9*>-HKZ! G#'E;L.%+ M2-]!EPEA*CC0M#0BDH*H 6*2"3P&P;)*53&T]64#*^Q,8C% ^4)/#*ZK!LO& M3G05057DLA-8"=@N)-SS8;&'WC!QZ*A-4QO[9%OSC7B
Y9>MJP.V0:+2K-0# M/AJ&(.DM4>+UC437-?>& \CF5B\3$1:-?0@Y:E8\QC3494JL;K@JTU5!A&RW M (07*U>TW92O>G-J&W-DS; "&W+'^ML:-O0#]5^;AN78XBB-^07=E@+$.69 M!FB]@V
;H.5X8WB!"4,(AL VB5]@RD0:$AY*&N(#S9M@ ?AY1B=Q9> ;!K@:5$Q@^9^QS5"H4F4)3U7)4$[O M+X9 2<;L%O[,FGFW4Q$#LXN]CO[_3L0R>II#78$K[Q-[4&,Y*]=JN('OT$5(M%3\Z(H5AZ
V+!!AF&(1T4]0F'=\=@P;85_P3/$;8PK(\!6M2', M103U4E 1J3?*Y7S\O:D_ HSL5],QE<5.)!UX9MR +LN[*P]BS=%KV9!'3&_X=:PO989Q MH-DMK\GJ=+R7D* 74"5NZD"0V,ZD,0+]JO?H?
^UWM_FG0<-V=^Z%96K B% - M8?^NU^'U$+:VQFW*9!B%):U-': HN')Q9T>Z1=P.>IRFH':6CB%0IA2Q5+6T M/> L[F0Ŷ*!.# 8[O #MM6B8%1K7"C"76V.@RPG-R11@RRRNHDR$YAOT0&=LV
M+U1>2!J>X&=N^AQU(3(*7*6&KV1[;M^@\).A#Q(PWC\)>Z=T2P79[MNEM?1F#1/@ZW>/_0 ◆L;ZP63V==EK%9Z.31JOX<7E)IQ?\T%*WW4'8FG,\ MI2*^4$6^4M<;R&
[>'T%9N2F1347N7N22=PQW9 ?^ZM"-NU#:$*ZT M^*N"-> @;',LK'AX[5? 7EP^4T.^.Z/IRT[,9,HDZU\SM1ZNU-J8D^'B8$>KZ=@$_9(ON)9D'H?U((G<-C52_5S0 M&H\+&:@2DN0^:O7W4?%
[!.H'6S6#EHF:M^)?OY.MHTB +NS;&\%ZFHQF+AJV MY= 11RL]2*^F=N$ MJ?IN*@H&^ET7(W0?&OO,=/""Y7]6=W(^\P*NPGJ X>& M;DJWP-;QQ1IP4PA0+LX>/$RW:VZ=QX>"+ -OQZ/C?&
<9MQVD:-&U-'S<8&?9, MYQZ.R@,G<9T@.!U-/$*!'P:MDRE=U,*,&V/31M/_Z35G,.R[QDGQBDMVP>=+ M(;ZZ=B!P>#3 &1II?=TQF-ZI]IQJ?L[6]SU/78]L%\==B,M7KN%C:U?HU.G M77Y5(S;!1-
S$&3O9:,\#'9"ZX@WC0>?;03O>^VE9E4.>!]M:QT"'G@0!GRHP M,]J83)I:63LN\K4\-I[W7HZK5A=EYE>-=>.8QZA3;FC,W$_%VQ%W,TF M+BY.']*-%$$2=8W.!T[6"7(5BXCEJ>PE&H:VJH].RF,J@
MNMGEP1KY6.T%>PF:$US_5TL.0'D.=7(P0$RUR&ZLSVTTSRI(42[MM-M V[8^P"\.@[,NC9+4]6UI]0ZI8SUISG$U&L1V05EF\;/$9R@QJVW(CV4 M.$L%
^*FCWFYX@!^0G.D37_*7L3A4,_+!2UX7*O(=CT:[\[K[U*.^U8DN^=W M#XEAH$2R< [7<+E6HCM/<%R:@U;;% <@=_1FRVX'\,7A'4U%KS[WTIQ@KH#, M,PZW7"L[5]!-9=I=>=@>ZFYR;?
&TC>I_B#;,&&[-30"'\]-A(A>B/]@2-, 0 M#9L^FTY KI @G,C[T9DIK,'=2KH@]-]^_OW#NR'J0CUMUZI$E"D[WW+ I(\A M [J4NK/]T.YN1@C: MG(1K^;Q68OUOGF ;D49O&DET&$<]N8]*F?
\'A;9&EV:.4=?.\ [#^RW^Q$!N MNQ*Z>]?R*!E5 M];@X%'0==6W>N.!@,YASNFR(SN5A@\-^;R'%V!?"N9%BC4T'3H?7\:VO;'B!YA6C_X3>1I"P+P?1U> M[A+G Z79U[]"=/(6O"=ZHP-J0YV?30Y;
<@]#@3_6?PV\O,O==SHZIB65V4F] M;V&T>L$!NHV^#?KXW?[=J*H"/LF SUX$WH<:J;KX3!4-_(^U.4G1=FI"D=%, MAS8ED9F-W!($X
1H=@E6YH5S2<"$Z&M#ZJ&*3ILP_6,NFW26A@'I3DOKUUMS M$I/_,Q9'8]&:5L,OS_H^%??L,U..AC,!^D(BRPZ%'MH_ZT1,6',":QF6_M*YX)@&MM[5V"3-Y2.TN),26+_1?Q:R/NE:I&0+]]
XPHZ'C*7^ M1G!()?6>M:=^6&6V#1D(^]Y3TZLM*%O'P$C)FWY\0IG#;U*G@P\O37K#M-MT,P1&W@LI\?<2U/MN;\[N67/7FV<[+=TQJ^:5,[WZ;QN@N.0-%(/+N'G84/ M@);6S'CW>W-
+);N/f*$F_QV%(V%'RF;3Q4/UG\4.N(;N-?ZSF6L:2%_B61S_8 M [Q_&!Y&L>5R.Y$E3((§UBIJQQC/]&#FY"T&QS9;XWP%WBF"CG=F$VX:1V'\O}/2"G!C^@2 MWV %!ANX7U2);QE3-
$[.;/^X/4T[#ZPY..O>3_LCC+OY=IM[P\8<[8EMNJŪ5 M@G)T9UEIH'BG_VWG$%#D1)3RU-UT%)2_V\F4+9<,PV>AE[$G:OR<\\O*N[<@ MTWW\.4_#!0,[!Q.*9$Y'B7PZ4,][M^F90?
FW13$4! _^"#CAKN%O";!KV+YQ M@W.E'>M/[FWD?8;O.>XS>M40_N ЌCON,7C-TQ_6I.IL^9W3$Q%^@:KKY!ZR#_M MWW_9?NZ/M& <'%]BL_:)92<]T]YOYB@]M]QNY6?7]"_Q XW$?OFS5VW?7)
MI$D-'#$-Z=R@J.U:47N?G;6>;5X; P,(YO;Q"9$?38Z1P8?PQ7J3DE.<2YH M&D8 "P"1U!R!BJ7F2U#8I3^,7$>S)^O9-U*9*^?DFB\DAEPA%6G=./%!YSR0 M:_CYPN=_[@Y) M6 WK:Z\H'!?
S\# 455F"+#?VV._O'!$#PD_F6U^ MMJ1^W/SXRP6X;@E;)V(!2X&@DSW39'$710!5*HX39*SN!121Y-16+NWDY&I MG9(:[RU079;",F>HS'H<]./=PH-
<%LXQ)1?9;XB.Y[=6]Y%G,HXL(!@LH;X<1D9,T:K# _M;'X04@UH%B>U+\JCL[PK&>,?CW.6O2L0:?OH, @SFA7 M$'S6.>:O\3$KZ>2D.SFS]"#AMUKW8)"<0}JDPP\@RZ]0> ,?>)@>W$C*E*:
M(OR:SLE9OA"_WTJY81R^S>B;Y)(JD>$XXBX@M"N,)L=`_/DZH#>8:=W>(C] MPW+\$]IY-#P5"->FK(3>?;H_Y-VT(,I>86O M8IT$BC:KXZ.+M'}^1;X)T5HFV LGB-
#1"62& 8.T%!DX=F3"4=9,+:+:M>"YLS42%6"'-$3JQ6@6/!$6"^!0$KH6K1F(QB MEQ,ZP]Y,ER'>Z],2[3*X$,'&6KNF9,O5SO"F39__/=ZXY9VP2ZD)%"X8FO3.
M3R.PC0,U$V>JT/5SX]A#PK!@TT;K# _#^PABWF_@ W6]@\@)02P,$% @ MD($%67QC&UL MS59M;]LV$/XKA)H5+>#(DJPX3F(,<.(6VX!L@=_N-Y1H*63Q98B-9*RX_[Z
M'4E9E8/86(=]&!#$$GGWW'.ONNE6JB^Z!##DJ>)"SX+2F/IZ.-19"175H.Q! MX$TA54-QJKU4-<*:.Z4*CY,HF@\K"@3P7SJ$A[42"H;PYF !T5T4U54[6Z! MR^TLB(/]P9*M2V,/AO-I3=?
P".93_:#P;=BAY*R"H9D41$$Q"Q;Q]6UJY9W M;PRVNO=,K"P_[]$_ M.-_1EQ75<"?Y{RPWY2R8!"2'@C;<+.7V1VC]N;!XF>3:_2=;+YN, Y(UVLBJ M548&%1/^ESZU<>@I3*
(C"DFKD#C>WIC^2X:.I\]N27*2B.:?7"N.FTDQX1- MRJ-1>,W

R7))N\$-G6MG3K;>FVL7OZ="[P=)+C&$_F"5{@_1=8_@2O8BA/LZRWJVF/_M2GJWH-=/R]({M;%DSH?F1]<&22".'14$14!(C,N%$L7)*0*FO1Q&XK&LNS>CD#[L/VB M::3J.1<[*C7 &JK&W'@.$Q"+H@^1).!YJLJKKEZM6YW+XH7?6;^R!V.[8=W' MUJCL9'[3EWT5WH\+_4C&,$=7UMDY[J@H>Y5RHGA6/,8SKO!I+X81MG<@-"_ MSSE7ZXEV4#>,WB]02P,$% @D($%63H\G=[R P 3!D !D !X,"]W M;W)K&ULO9EM;]H($,>_RLJMJE:ZQH\X"06D)K,5 MGA0I"M>>U'>+/< JMI?N+M:(]^%O_1"#B>- .\J;8*_W_YOU_,?CL(RV7-S+ M)8 BO{(TEV-CJ=1J:)HR7D)&Y1E?0:ZOS+G(J-*G8F'*E0:E*(L-1W+\LV, MLMR8C,JQ6S$9\,5*60ZW@LAUEE'Q< 4IWXX-VW@0<;RZ/-P>?+,P*T%[K$1O%K'1MA4 L&QPK\6N"7N:^2568ZH(I.1H)OB2AF:UIQ M4-I5JG6"65Y4UE0)?95IG9K<4'$/BLY2(',%*%Y0L*?:Z8>R!3BM6"*@20? M.\:V3"UUJ9({7<\L?=!R!4*OL&1%E GRG:9K(._U!YV?$=?ZBSB6XW6LY_IXN=MU.W\6/?RSZ%&_/(!8R^TN>2N7 M,E.2;LESG^'5I2:?EIJH2RW9+[5Y46J;HM2ZZJ@*Y76'*MKV4*YH#&-#]V4) M8@/&Y-T;V{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{(X%]%:EKN M\.PYW6;H/_2NCE.N.BAQX9?:D-S5:AIF2!Q RRPRW9X<'HK)K8 M+7T.HE54Q\R:OFF\@!3S@<0,;JZCYZW.B2-U40 @]*!J/12:",]D&EQ[A{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v*$'M?UHQ'5*I,OK'$C@/UTZ HM,A@X%@1#>>+>;)J6/?+9E"4R M#&)XY$@D443Y^P.I;'_?P[U#P;=@LY6ZP)I=W0#3R"?=X}U!)4_7N%!82A M5E)Y_)N+]HHZ=>#Q]4'I\Y[3QJC$K*F#!PN^!+[?W/;>'?%C3))3?V/X7R!LT MTGH>"T7Z%^WS9P<]Y"5"LB@/5AE$09SIV\YB*, 8I\)(?D J07@5FKY(8:,1JOE!K-_[D^3JUT#%R=F3 M9-[+[8,BYZ,%BU1W$C1](;?HZRZ]F.LW$\AW=+4$28-07*O?TC#*$TB>$NG]^ M6J*K3]?H$[*0V%(. @4Q>HX#*6Y4H;K^8\L206-?3"V\M:U6UZ>XT.6(SF3 MHX.^L%AN!?H<-^WQ"-\9@8!"P%K*\=&#M0>B%'QMR3NH^'@!$!L1L26EP= M/FQJCSE\"9X*QTWAE=8,BSXP3/6&9_1^3Z(5<,36Z"E[=4_)ZA\U+I%DZ&LB MA52O+8@W>8=H?(%9!79S!7KNNA,[ZL%]3TU. O@K]&8__H"=P4]-\+H46W8D M5@%K%V!MD_KL@88T]@!1A7(+: 6,{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{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{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})'[>8\OW2@]]3C2]D6RESP\\7 M##=KB!ZR^-O=*M_Q>I20U9I)P!@3>+++UW\&8%$Q-@>_Q!%Z>7 -C9Gj,$GEX_J;^WYK69-9)XQ>F?I%35 MTIMYH,0;U%+UA>_X(,A"UAP*NTOV'=]4]VY:*7B]2@8$]2$=?_H^V$@3(@> M_$Q > @(?S8@.@1$UFA'9FW=(87RA>![{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}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j*:@+5)*HI5,M0+4Q:V]ZV>._9 MK1O.IF@S#E\([7-Y..\?5MU'W _MMPT(#],ZKFC;!M4$]DE44ZB6H5J.:AK5 M##I92G,CW;1MQB>_]-D8K>*@6HIJ M4DJBE4RU M1S6-:@;5+*4Y::X?OE_B MO/KZV[]%::"TS2S+I2PG6$ZRG-IPH9>.?<){,X6=G3YB=L8[NV'?]WX* M-KN=?,1,^0@W?,(%N@-GM\%%6N]A.<%RDN74AMN^5_5]=_F,'3AG.7WT[3#L MP!;C=K*6;&4MO(G-,6]?'C#:)PZMX+"<8#G)>/6AA*HJ\UY'N*]_']>UCA39E6$ZRG&*Y MC.5REM,L9UC.8MQ.6'M;80TW>O[,*ZBK=D+QQ^3NX954HP4@EDM93K"<9#G% M93Q]I.5-XG[=.7C@;FT#RU:)V(YR7**Y3*6RUE.LYQA.8MQ.Z$=;H4V7"SZ MLROOR>SUE3?:.F*YE.4$RTF64RR7L5S.U8&=Y??^R%O?G>.Q9 M8X_VUMAHYXCE!,M)EE,LE[%ZBK%:O7%]-KJ_+:O7X MO"RJF{)>3%?SFZJX6WT>_OD[_ERSC2V42UE.L)QD.<5R&*=83K*T&+>3 MLJTN5!S>;BG\NM"A*ZT&DS!!9MMBR%_->_>$MDS0?]'SJD9[H1IJX\4 MAW=-"JQ^?[F=5%?1IZ):?MW_2M/0=D^$LJE+"=83K*<8KF,Y7*6TRQG6,YB MW$ZTM_I(\}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

X$N%69'_GT3+T"_.W3*2>'R3OLL^_W#/K M[9MWUAO+#ZW/JVB;9+#D8IAF)YE/-9R7)W2].R%RX(1)QMO+BX'FQP?/XG! M[.>?G+'ljV[MD3"&A'$03(D2K:)$3?
39Z[4:9]=JK+^*KG>$<4'(_S=YFCGC MZ=B^&#[5U[=I14>C/)/J5JQI1::3\4BUXDVK,:5GTDIQ=52Y.FIQM4S!>3TS M=0X;."3B!N M!*ENUA2.8W3SU@]$IJ-";3DPCSTVTZ
T!J5Q%$V- I%1("T7A7(&5*R0- :E M<11-C944>8Y1G70K#&[K+8+&Q+'MQCV"QDQ3LD7WH/L&12LEID4K1BQ>D MOM GG"LT0F'I#$HC:-H:A2DB'-&O1<'J+Z#TAB4QE$T-
592XSE&<=*M.(S; MBT/3Q'=9GF0M#6+0].(3 X7!RF4'+-2^BL*W\^]9&7%QBIAA!R=>4@:@{X MBJ;&0XHZYZSW*@&5?U :@{)XBJ;&2DI QZA=NE6):2=MT;1J%(FF",$GS3)A
M(JE[U)#$;.&N@K$]P-?.)I"IMK4!J#TCB*IL9 "CSB]%T7"%0&0FD,2N,H MFAHK*0.)4;ITJ@LEHGZ=CJ>-NJ"QK# MJ%5=:$QTVQ/M)*XC30YN4!
IHXA91MUZ#TLAOFG]@VZ"06D,2N,HFAH#J>_(MI/?" !5_4:]J#TCB*IL9*BC]BWM+K5!C.M%\2[M>&IE6C+G0!<2-(=5/J)F+6 M3659L/ZS/HOY*HR":/E2MF0)V9"E=1ZZ9P:E,2B-
HVAJ!Y24?*[==]5PH=(0 M2F-0&D?1U%A):>B:]_ZZ5(T2T5(US!,=OK*+[M%WT*0S?CH#0&I?$438U"K>.R_Y9+;,\EMND2VW79A1)TI=)T3V^\+!'J%Q+- MADA&[406D<15/€
M(Q6FVWLWI@M5HE :@{XBJ;&2BI1]_2>3+>]*;/=A&E,-#<>)H[JHA1PKEG M:??5CK5?0'3DHC4%I'$53UU\J2[?WKDP7*C&A- :E<11-_?F&E)CT],Y,VMIS
M>:,Q:31/L"Y&7&=T\$M0*N49-A- :E<11-C9%4 M@;3WQDT*U8I0&H/2.(JFQDIJ17IZXR9M;]QL-V'M)MQHHCI8^V&;66#]{T)/ MGV+0#3HHC4%I'$53(R!5'^V]59-"%2"4QJ
TCJ*IL9(*D)[>JDG;6S4U)KH^ M[G82;R6ICDKY1,WRZ?/*CQ?6G1>GU=V#]M<>9LS1F0?=K8/2.(JF!D2*/=I[MJR:%"D,HC4%I'$538R6%(3V]5;-$U'^\/6E4@!N-5:-(=
%Q(VCGYK#VS(NU MB)?%PT82:QYMPW3W/(J:/5 DZOB,1Y{QZ^=\QM'A;O'DBR>Y-&F^*)&P]1FD;KXN5*> L1YP,9YX]1E+Z^ MR2>H'@LS^Q]02P,$% @ D($%628:&J=V @ IP<
!D !X;"]W;W)K M&ULK95M;],P$,>_BA40&A+,>5J'2AH;8H8T]1I M8__"\<)-KHTUQPZVTY9OC^VDH1M9J6!O&MNY_^]\=^E=LA'R7I4 &FTKQM7$ M*[6NQQBKO(2*J%-1
S=OED)61)NM7&%52R"%$U4,A[X_PA6AW$L3=W8MTT0T MFE$.UQ*IJJ(_#D%)C83+_!V!S=T56I[@-.D)BNX!7U77TNSPSVEH!5P105' M$I83[R(8SV-K[PR^4-
BHO36RD2R$N+>;RV+B^?9"P"#7ED#,8PTS8,R"S#5^ M=$RO=VF%^^L= 8.+W<2R(IF@GVEA2XGWCL/%; D#+,W8O,1NGC.+"\73+E? MM&EMH\A#>:.TJ#JQN4%%>?
LDVRX/>P+##&1:$G2!\+(B?$$2=(#K60]P)XF,] MG'4"%SIN8W>)RX@F:2+%!DEK;6AVX;+OU"9?E-OOY%9+\Y8:G4XO>2XJ0)_) M%A0ZR4
3RM1K[!;=W6;HY.7K!&OCQ=KBO"-.6V+X!#%"5X+K4J$Y+Z 8T&>' M]:,#>FRBZT,,=R%.PX/ 3PT_19'_!H5^& _<9W:\/!H*Y_^\S__9^X-D1'V] M(\>+_EIOE%&5,Z$:">C;Q4)I:?
ZTWX?JW1+C8.)M9&-5DQPFGNE4"N0:O/35 MBV#DOQ]*]G/"LN>$S9\)]J L<5^6^!!]5Q9MR@;;,P,4#!6B98P!YH=_;9AXK_4(%>NY2N4BX;K]J/L3_NI!0/GF9E
[=#XC6]'V!61*\H58K TKOS3<],893L6VHT6M>M[%Z%-%W7+ MTDQ2D-; O%*H7<;ZZ"?S>DO4$L#!!0 ( )"!!5G'TXPL00, -$+ 9 M ->&PO=V]R:W-H965TE$35 $#P#"$I\%)
MMP1T;;*%,IO6"59X/!1\A82)UFSFQ7ICT3H;PLPV3I707XG&J?$44V"(S]%I MKG(!Z)K?8ZJ(GMM#EU@(;%Q&NR>@,*RG9Y]B-A!A*$+0JG>#SETE99C2-VH
M7/JH6#IX9NDNNN!,)1)]9#'$#?CC=GRO!>]J&KHQ=K471T$KX>><=5#7>X\" M+PC1S?0$[>Z\:]+USS0;\KK55G4M;_@,[X3"G3GYO]&7K"@!%J-S$NF: H07 M D"7EVK:AU9>?
MUN_G.A2=*4CECR8+PFU:L"6R#0OV*POV6T_!)6=[$9:)OD.7P'+0SX@O&/G5 M6$)'!=G DIDK?3GN=0Z&[K*>SM,8O]?I5D$;,GN5S%ZKS!.8@Q 0KV4V:6ME
M>.V>%&1^4,\B]#J]YC3Z51K]UC0NN,@2/KV7NNKT/P7%,VZNQ$?%-VDKOM8% M7!OEEL@VO!A47@S^4_$-MFG!EL@V+#BH+#C89O$=/"VLVH$LTGD:$W,"YD/K
M>P]_ZEZKSC.F0&>OD#ZLC:57XGV_MJ[7\?O[C]3]/6Y38:WM\%_F)%E+A;O, M%E.I2!7M8$//X+'JTT^[=8K)+NUIBD%L;"]I$01SYDJ^J=JMNI?)[9+&PO=V]R:W-H
M965T12FFU3>I60;L] M3'LPR8%8=6QF.Z3=KY_M0$I'B/JP%_#M?!?;QR>CDHM'F0$H])13)L=.IM3Z MPG5EDD&.Y3E?],S2RYRK'17K%RY%H!3&Y13-_"\R,TQ84X\LF-W(A[Q0E'"
MX$X@6>0Y%I\3H+P<.[ZS&YB15:,,@!N/UG@%YZ-D[(+X-U@IRPJJ__+3=B+V (#@2$&P# JN[(K(JIUCA>"1XB819K=%, MPUJUT5H<8>94YDKH6.+C5#S'%"3B2W13J$(
FO%G3!718QTTA85JG#J=@L*$ MRC-T@@A#]QDO)&:I'+E*2S+ ;K*EGU3TP1'Z"-URIC*)KED*Z>MX5UNI_00[M/Y.@%?!+P%E)^G9[/9LW\5= O3W^0?
<(>U2S1V]D7V/2SAX=L':"..!PT_=K M_GXK_U?..@F6F4XD!?H** 1/^LF5^B0@X2M&_OR;%Y68_H$8?^AYS5H&M99! MJQ:=A/_QL@P:% ;1$8G#6N*P5:)]DSI(9ERHCMZPO{EY>,
<#<-^,[']OO;R4 MWENH*6>KH\Q;B%>F@ZI?/<*]|TK[K=SW7&%]3Z.1U3_(RZ:M=O?*1 YB98NA M1 DOF*HJ1CU:%|S+|LR\+*^]]2T6^FF1B,)2AWKG?>U85 6PZBB^MD5GP94N
M8;:9Z8\&$&:!GE]RKG8=0U!_AL1__5!+ P04 " "0@059T8]I!C@# #(M$P #0 'AL+W-T>6QEUY-B9X[)VOWZ^=H^X(L8#UN[5#3V/3[G'MLWQ#"HS4]PNSEC
M)EJ60M9#,C>F^A#']73.2EI?](D)BQ1*E]38KI[%=.49S6L@E2+N=3H7%(N MR6@@%^5-:>IHJA;2#$G;AB)_^YP/23=3R(O-U8Y&Y"LI<_%LI3= MR4GGX?
QZ/W!F@'.2!T4O7R!ZT<%U+89)IR^2?D89${I:%7:C3ZV.YYUBM'Z M9NUOF-#!R%F0O$5UQ+C9R=&@4'*SH0GQ :M,2Q8I4C$D8RKX1'-@%;3D8N7# M/0A,E5
Z,K:2,*HN1.I?'N[Z'A19HU-RJ;3+[3/X[TDS?]8|\ @%Z{UV",^ M,!I4U!BFY8WMN,$N^ 2*FO;]JK(.9Y]NNKU+LB&XFTTR43IGNDW3)>O0:"!8 M 78TG\WA;E05
VB,*FTCYW2F)'4>UHRF866G3(@[> *_%SO:RV)KSSJP8]M M6D--TU\OX#NAOJWGM;=GD5;I1Q1^5^;2PTY&N#X7-;C4K^.+UET5K %/OXNJT MJL3JH^ S63(_^1:_;#8HE:D-
.$VB1Z8-GVY'?FI:W;.E69?3 MLL]IX[0\]]=YQF33%.Q;=K6_B&O\]L=)U?_RK+[K:)O..BQ>:T>NLG+8S"9 M'H!)(ZC))#M\C\UQZM!-'N9*QLTA8^LDLW...:,1G!>'Y!NEUT_;P:G-
QF;.ER\=-5\\FKAG9ALW:7$#81V[<%48PCL?""&!8'LP!QO$L M+,__-)\^.A^/8=[Z0:2/T"5CN0/YP':BK,21+85DB3) MLC "6-A!DF (/(TX@CD #QB2).X]N/<^BM?OJ7CSO[O1;U!+ P04 "
"0 M@059EXJ[', 3 @ "P %|R96QS+RYR96QSG*Y;L,P#$[_Q=">, ?0 M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!Y!0.TXI+.:+J1C!$%)I M6M6X
4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6 MFD7)TZ{=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/[*X 4$L# M!!0 (
)"!!5F"GE]F600 #PB / >&PO=V]R:V)O;VLN>&ULQ9I+ M<|LV$(#_"H:GY.!*?$A^3)09QXI:S[B.QG)\[4 D)&(, BH VG%^?9=@U(*) MM=/+6B>)X.OCDMAO ?
+#L{&/:V,@+:=&:3=+:NlW%Z.1*VO1;V0D-;S;& M-MS#HMV.W.X*7KE;"-^H438>3T<-ESKY^&%_K*4=Q0O&B|)+HZ&Q:WB0XMG| MMfY;9$_2R;54TK_,DO!?B80U4LM&?A?
5+!DGS-7F^0|CY7>C/5>KTAJE9DG: MKW@0ULORE^95!WG/URZT>+Z^XP R2Z9C..!&6N?#%N'X'!B?!&S<+[7>+*3R MPLZY%[],T^ZDWG:'@:L819<1XK#_[8-X8?]/&,UF(TLQ-
V7;",W].%]A.D#M M:KES"=.\$;/DRCP)VUT/G."ZZ[_- U04*7LA886]K@(>)8IV1LD*SEZQ3UQO M70H60N@BP P!S&@!ATSLW9);V*$6X>%X'S'F"&/^AD%<=1#=#HZ9#;LQ+@YD
M@4 61X.\,LTN@IP@D).C0:Z*2/(*0(Y/5XDN:LCR%,$\06 MTT+>PG&[;LR6PG9=I3$:LA&DH3B#C[$4/J9^'AL0>"VT]W]G'%25"[$=OF3 MVT33Q!?^Z""9$,&\5\ MF%Y28K_<"$
.W%3.(RFY2)I&^CIE=3<4TJ&'2DI UQU"8AY)R46B%%;&|8$ MS!O8$7]WK+-+[:#XPDR2$JOD6I>F$>R>?QN&#A-'2FT.KD20V:+UK17LSKQP
MY7^ZMY@T4F)K+/D+>PKL.S>58=SZ4IE7#M,RI@T4F)K@,)D!<*XM[P*#YVU M'#I)Z#9Q98V)(R,6!UHC_)7%F)A%,F*+H%7"$!,=]!:,Y&"=P-[!&%3%F)A,
M,F*9H$X>1A.S3$9LF4-.[H,9=_,,\TQ&[)E>S3^@7#P>S3"O9.1#%$1_PYN, MJ28[EFI^[3*8<#)BX>!Y,H\Q,>5DQ,K!\V2,F6/6R8FM@^3).22F&!.S3G[, MLQIB8A7)B
M"^&89$$F9J&H%9]* >^QS&_+(;S(\6F(4*8@LAF(L'9F),S$+%%R@O?YLW@GG8TS, M0L6;3*0!U.76BA^S]]'HD&I0NQ?H>QIB!_T+^557TH7!^BZJW-5LH0Z.)H,AXS> :
>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V;EN MPD 4A>%707X AKN8+(0 4:=)&O(!%AD4LMCP3!=X^" IRK!1IHCF5-;9\ X_]OF ;8]ILNS0Z'?;'-*\V.7?/(:3E)AZ:-
&Z[>+Q<6;7]HL8=#*9AO[GC.IE]G/F:"NXE\FMJO5=AE?V^7G(1[S+X/#5]OOTB;& M7(T63;^.>5Z%T_Y^.H7K0<:7R=7H[6->]6\?4H7200I!6C[((,C*!SD$>?F@
M&H+]\D%3"}]6#WJ H(?R08\0]%@^Z F"GLH'R01EG! D#; FT%J0:R'P6A!L
M(1!;D&PA,%L0;2%06Y!M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706PBOJK01Z*^]M!'HKZJT$>BOJK01Z*^]M!'H;ZFT$>AOJ M;01Z&^IM!'K;8+.$0&|#O8U ;T.]C4!O0[V-
0&]#O8U ;T.]C4!O0[V-0&]' MO9U ;T>]G4!O1[V=0&]'O9U ;Q]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CM MJ+<3Z%VCWC6!WC7J7?^GWBF?]S'=>VYK?/Y_4ITO]\;
[XZ_+V\G!2[CB',"' M],LW4$L#!!0 ( )"!!5DHM&@3PP$ (D> 3 6T-O;G1E;G1?5'EP M97-=+GAM;,W9R6[",!0%T%!V5;$>(. C9MMRV+_H";/" BB2W;4/C[.F&0 M6M&HB$]]FT2)
[7=?;.EL,G[;6?*];576?I(L0[/C/EL297VJ;%4QY&Y<94. M\=$MF-792B^(B<%@Q#)3!ZI#/S0UDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$ M)FN2;&O+(M,ACK--
G7]+Z1\2TKBRG>,7A?4W<4+"SB8T(S\''-;]LBY(J?> M3+OPHJLXBVU+YL.N))]VESC3HYG/BXQRDZVKN"3UU!'_9(H5&6Z+WK3G1SB M#M/^RJ_.;\MT!<:9,V>LCR?
FZ/*XXY$T]_LV%B(7BNY//"7&TE=`'S6GG5/^ MR^RXO1_&K=KS\*R!7;`'7\ X5/_"/@1(*O*D#P72QQ"DCQ%(*[<@?=R!|'$/ MT@^DG= M[@ "L" 1 "_:\ !D;V-0&UL4$L! A0#% @
D($%66S8N\7?!0 LQ\ M !@ ("!#0@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ D($%6>*=,A"F!@ K" !@ ("! MI!@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
MD($%6;>QV$R]" 1B@ !@ ("!;R\ 'AL+W=O&PO=V]R:W-H965T 9 " @5Y5 !X;"]W;W)K&UL4$L! A0#% @ D($%66\G28<5"@ U1P !D M ("!#%\ 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0# M% @ D($%6;A2EP@D$P X48 !D ("!D'0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ D($%6:^A M)"Z' @ Q < !D ("!HX\ 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ D($%649MUOX& P KP8 !D M ("!=Z\ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ D($%64^UGJ0O!@ J! !D ("! MD+P 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% M @ D($%6;%@Q9G: @ 808 !D ("!\H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ D($%6?64WI*^ P UQ !D M ("!G>0 'AL+W=O&PO=V]R M:W-
H965T&UL M4$L! A0#% @ D($%62>LJ'4I P / H !D ("!EO(M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MD($%67'V?D&U! FAX !D ("!L@$! 'AL+W=O!@$ >&PO=V]R:W-
H965T 9 " @3<, 0!X;"]W M;W)K&UL4$L! A0#% @ D($%62+"E*9; P MB L !D ("!6A$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ D($%6<$#V[Z5 P)@T !D M ("!+1X!
'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ D($%628:&J=V @ IP< !D ("!\4(! 'AL M+W=O10$ >&PO=V]R:W-H965T&UL4$L! A0#% @ D($% M6=&/:08X P R!, T (!4$P!
'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ D($%6:&7 MZI3) 0 H!X !H (!(E4! 'AL+U]R96QS+W=O XML 65 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer
was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not
subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /*
v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a
{ display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px;
text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }
.report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white;
border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report
th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica,
Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report
td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header
rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,
.report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td
{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space:
nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding:
0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more
{ display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-
size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 315 302 1 false 76 0 false 8 false false R1.htm 0000001 - Document - Cover Sheet
http://www.xencor.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Consolidated Balance Sheets Sheet
http://www.xencor.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Balance Sheets (Parenthetical)
Sheet http://www.xencor.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Consolidated Statements
of Loss (unaudited) Sheet http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited Consolidated Statements of Loss (unaudited) Statements 4 false false R5.htm
9952154 - Statement - Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited
Consolidated Statements of Comprehensive Loss (unaudited) Statements 5 false false R6.htm 9952155 - Statement - Consolidated Statements of Stockholders' Equity
(unaudited) Sheet http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited Consolidated Statements of Stockholders' Equity (unaudited)
Statements 6 false false R7.htm 9952156 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet
http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 9952157 -
Disclosure - Summary of Significant Accounting Policies Sheet http://www.xencor.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting
Policies Notes 8 false false R9.htm 9952158 - Disclosure - Fair Value of Financial Instruments Sheet http://www.xencor.com/role/FairValueofFinancialInstruments Fair Value
of Financial Instruments Notes 9 false false R10.htm 9952159 - Disclosure - Net Loss Per Common Share Sheet http://www.xencor.com/role/NetLossPerCommonShare Net Loss
Per Common Share Notes 10 false false R11.htm 9952160 - Disclosure - Comprehensive Loss Sheet http://www.xencor.com/role/ComprehensiveLoss Comprehensive Loss Notes
11 false false R12.htm 9952161 - Disclosure - Marketable Debt and Equity Securities Sheet http://www.xencor.com/role/MarketableDebtandEquitySecurities Marketable Debt
and Equity Securities Notes 12 false false R13.htm 9952162 - Disclosure - Stock-Based Compensation Sheet http://www.xencor.com/role/StockBasedCompensation Stock-
Based Compensation Notes 13 false false R14.htm 9952163 - Disclosure - Leases Sheet http://www.xencor.com/role/Leases Leases Notes 14 false false R15.htm 9952164 -
Disclosure - Commitments and Contingencies Sheet http://www.xencor.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false
R16.htm 9952165 - Disclosure - Collaboration and Licensing Agreements Sheet http://www.xencor.com/role/CollaborationandLicensingAgreements Collaboration and
Licensing Agreements Notes 16 false false R17.htm 9952166 - Disclosure - Income Taxes Sheet http://www.xencor.com/role/IncomeTaxes Income Taxes Notes 17 false false
R18.htm 9952167 - Disclosure - Sales of Future Royalties Sheet http://www.xencor.com/role/SalesofFutureRoyalties Sales of Future Royalties Notes 18 false false R19.htm
995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 -
Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm
9954471 - Disclosure - Summary of Significant Accounting Policies (Polices) Sheet http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices Summary of
Significant Accounting Policies (Polices) Policies http://www.xencor.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 9954472 - Disclosure - Fair
Value of Financial Instruments (Tables) Sheet http://www.xencor.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables
http://www.xencor.com/role/FairValueofFinancialInstruments 22 false false R23.htm 9954473 - Disclosure - Net Loss Per Common Share (Tables) Sheet
http://www.xencor.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.xencor.com/role/NetLossPerCommonShare 23 false false
R24.htm 9954474 - Disclosure - Marketable Debt and Equity Securities (Tables) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables Marketable Debt

and Equity Securities (Tables) Tables http://www.xencor.com/role/MarketableDebtandEquitySecurities 24 false false R25.htm 9954475 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.xencor.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.xencor.com/role/StockBasedCompensation 25 false false R26.htm 9954476 - Disclosure - Leases (Tables) Sheet http://www.xencor.com/role/LeasesTables Leases (Tables) Tables http://www.xencor.com/role/Leases 26 false false R27.htm 9954477 - Disclosure - Collaboration and Licensing Agreements (Tables) Sheet http://www.xencor.com/role/CollaborationandLicensingAgreementsTables Collaboration and Licensing Agreements (Tables) Tables http://www.xencor.com/role/CollaborationandLicensingAgreements 27 false false R28.htm 9954478 - Disclosure - Sales of Future Royalties (Tables) Sheet http://www.xencor.com/role/SalesofFutureRoyaltiesTables Sales of Future Royalties (Tables) Tables http://www.xencor.com/role/SalesofFutureRoyalties 28 false false R29.htm 9954479 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices 29 false false R30.htm 9954480 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://www.xencor.com/role/FairValueofFinancialInstrumentsTables 30 false false R31.htm 9954481 - Disclosure - Net Loss Per Common Share (Details) Sheet http://www.xencor.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://www.xencor.com/role/NetLossPerCommonShareTables 31 false false R32.htm 9954482 - Disclosure - Marketable Debt and Equity Securities - Summary (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails Marketable Debt and Equity Securities - Summary (Details) Details 32 false false R33.htm 9954483 - Disclosure - Marketable Debt and Equity Securities - Maturities (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails Marketable Debt and Equity Securities - Maturities (Details) Details 33 false false R34.htm 9954484 - Disclosure - Marketable Debt and Equity Securities - Unrealized Losses (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails Marketable Debt and Equity Securities - Unrealized Losses (Details) Details 34 false false R35.htm 9954485 - Disclosure - Marketable Debt and Equity Securities - Equity Securities with Readily Determinable Fair Value (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails Marketable Debt and Equity Securities - Equity Securities with Readily Determinable Fair Value (Details) Details 35 false false R36.htm 9954486 - Disclosure - Marketable Debt and Equity Securities - Equity Securities Transactions (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails Marketable Debt and Equity Securities - Equity Securities Transactions (Details) Details 36 false false R37.htm 9954487 - Disclosure - Marketable Debt and Equity Securities - Net Gains and Losses (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails Marketable Debt and Equity Securities - Net Gains and Losses (Details) Details 37 false false R38.htm 9954488 - Disclosure - Marketable Debt and Equity Securities - Equity Securities without Readily Determinable Fair Value (Details) Sheet http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails Marketable Debt and Equity Securities - Equity Securities without Readily Determinable Fair Value (Details) Details 38 false false R39.htm 9954489 - Disclosure - Stock Based Compensation - Narrative (Details) Sheet http://www.xencor.com/role/StockBasedCompensationNarrativeDetails Stock Based Compensation - Narrative (Details) Details 39 false false R40.htm 9954490 - Disclosure - Stock-Based Compensation - Employee Expense (Details) Sheet http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails Stock-Based Compensation - Employee Expense (Details) Details 40 false false R41.htm 9954491 - Disclosure - Stock-Based Compensation - Option Activity (Details) Sheet http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails Stock-Based Compensation - Option Activity (Details) Details 41 false false R42.htm 9954492 - Disclosure - Stock-Based Compensation - FV of Employee Stock Options (Details) Sheet http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails Stock-Based Compensation - FV of Employee Stock Options (Details) Details 42 false false R43.htm 9954493 - Disclosure - Stock Based Compensation - Restricted Stock Units (Details) Sheet http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails Stock Based Compensation - Restricted Stock Units (Details) Details 43 false false R44.htm 9954494 - Disclosure - Leases - Agreements (Details) Sheet http://www.xencor.com/role/LeasesAgreementsDetails Leases - Agreements (Details) Details 44 false false R45.htm 9954495 - Disclosure - Leases - Undiscounted Cash Flows (Details) Sheet http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails Leases - Undiscounted Cash Flows (Details) Details 45 false false R46.htm 9954496 - Disclosure - Leases - Lease Costs (Details) Sheet http://www.xencor.com/role/LeasesLeaseCostsDetails Leases - Lease Costs (Details) Details 46 false false R47.htm 9954497 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details) Sheet http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails Collaboration and Licensing Agreements - Narrative (Details) Details 47 false false R48.htm 9954498 - Disclosure - Collaboration and Licensing Agreements - Revenue Recognition (Details) Sheet http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails Collaboration and Licensing Agreements - Revenue Recognition (Details) Details 48 false false R49.htm 9954499 - Disclosure - Income Taxes (Details) Sheet http://www.xencor.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.xencor.com/role/IncomeTaxes 49 false false R50.htm 9954500 - Disclosure - Sales of Future Royalties - Narrative (Details) Sheet http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails Sales of Future Royalties - Narrative (Details) Details 50 false false R51.htm 9954501 - Disclosure - Sales of Future Royalties - Debt of Future Royalties (Details) Sheet http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails Sales of Future Royalties - Debt of Future Royalties (Details) Details 51 false false All Reports Book All Reports xncr-20240630.htm xncr-20240630.xsd xncr-20240630_cal.xml xncr-20240630_def.xml xncr-20240630_lab.xml xncr-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xncr-20240630.htm": { "nsprefix": "xncr", "nsuri": "http://www.xencor.com/20240630", "dts": { "inline": { "local": ["xncr-20240630.htm"] }, "schema": { "local": ["xncr-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["xncr-20240630_cal.xml"] }, "definitionLink": { "local": ["xncr-20240630_def.xml"] }, "labelLink": { "local": ["xncr-20240630_lab.xml"] }, "presentationLink": { "local": ["xncr-20240630_pre.xml"] } }, "keyStandard": 266, "keyCustom": 36, "axisStandard": 21, "axisCustom": 1, "memberStandard": 24, "memberCustom": 47, "hidden": { "total": 13, "http://xbrl.sec.gov/ecd/2024": 8, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 315, "entityCount": 1, "segmentCount": 76, "elementCount": 574, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 845, "http://xbrl.sec.gov/ecd/2024": 74, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://www.xencor.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.xencor.com/role/ConsolidatedBalanceSheets", "longName": "9952151 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R3": { "role": "http://www.xencor.com/role/BalanceSheetsParenthetical", "longName": "9952152 - Statement - Balance Sheets (Parenthetical)", "shortName": "Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "longName": "9952153 - Statement - Consolidated Statements of Loss (unaudited)", "shortName": "Consolidated Statements of Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R5": { "role": "http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "longName": "9952154 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)", "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R6": { "role": "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited", "longName": "9952155 - Statement - Consolidated Statements of Stockholders' Equity (unaudited)", "shortName": "Consolidated Statements of Stockholders' Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R7": { "role": "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited", "longName": "9952156 - Statement - Consolidated Statements of Cash Flows (unaudited)", "shortName": "Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R8": { "role": "http://www.xencor.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.xencor.com/role/FairValueofFinancialInstruments", "longName": "9952158 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.xencor.com/role/NetLossPerCommonShare", "longName": "9952159 - Disclosure - Net Loss Per Common Share", "shortName": "Net Loss Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false",

"lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.xencor.com/role/ComprehensiveLoss", "longName": "9952160 - Disclosure - Comprehensive Loss", "shortName": "Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.xencor.com/role/MarketabledebtandEquitySecurities", "longName": "9952161 - Disclosure - Marketable Debt and Equity Securities", "shortName": "Marketable Debt and Equity Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.xencor.com/role/StockBasedCompensation", "longName": "9952162 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.xencor.com/role/Leases", "longName": "9952163 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.xencor.com/role/CommitmentsandContingencies", "longName": "9952164 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.xencor.com/role/CollaborationandLicensingAgreements", "longName": "9952165 - Disclosure - Collaboration and Licensing Agreements", "shortName": "Collaboration and Licensing Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.xencor.com/role/IncomeTaxes", "longName": "9952166 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.xencor.com/role/SalesofFutureRoyalties", "longName": "9952167 - Disclosure - Sales of Future Royalties", "shortName": "Sales of Future Royalties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "xncr:FutureRoyaltiesSaleDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "xncr:FutureRoyaltiesSaleDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-5", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Polices)", "shortName": "Summary of Significant Accounting Policies (Polices)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.xencor.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954472 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.xencor.com/role/NetLossPerCommonShareTables", "longName": "9954473 - Disclosure - Net Loss Per Common Share (Tables)", "shortName": "Net Loss Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.xencor.com/role/MarketabledebtandEquitySecuritiesTables", "longName": "9954474 - Disclosure - Marketable Debt and Equity Securities (Tables)", "shortName": "Marketable Debt and Equity Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.xencor.com/role/StockBasedCompensationTables", "longName": "9954475 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.xencor.com/role/LeasesTables", "longName": "9954476 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.xencor.com/role/CollaborationandLicensingAgreementsTables", "longName": "9954477 - Disclosure - Collaboration and Licensing Agreements (Tables)", "shortName": "Collaboration and Licensing Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "xncr:ScheduleOfRevenueByMajorLicenseesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "xncr:ScheduleOfRevenueByMajorLicenseesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.xencor.com/role/SalesofFutureRoyaltiesTables", "longName": "9954478 - Disclosure - Sales of Future Royalties (Tables)", "shortName": "Sales of Future Royalties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "xncr:DebtOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "xncr:DebtOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "longName": "9954480 - Disclosure - Fair Value of Financial Instruments (Details)", "shortName": "Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R31": { "role": "http://www.xencor.com/role/NetLossPerCommonShareDetails", "longName": "9954481 - Disclosure - Net Loss Per Common Share (Details)", "shortName": "Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-5",

"name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails", "longName": "9954482 - Disclosure - Marketable Debt and Equity Securities - Summary (Details)", "shortName": "Marketable Debt and Equity Securities - Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "xncr:CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R33": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails", "longName": "9954483 - Disclosure - Marketable Debt and Equity Securities - Maturities (Details)", "shortName": "Marketable Debt and Equity Securities - Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails", "longName": "9954484 - Disclosure - Marketable Debt and Equity Securities - Unrealized Losses (Details)", "shortName": "Marketable Debt and Equity Securities - Unrealized Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails", "longName": "9954485 - Disclosure - Marketable Debt and Equity Securities - Equity Securities with Readily Determinable Fair Value (Details)", "shortName": "Marketable Debt and Equity Securities - Equity Securities with Readily Determinable Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R36": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "longName": "9954486 - Disclosure - Marketable Debt and Equity Securities - Equity Securities Transactions (Details)", "shortName": "Marketable Debt and Equity Securities - Equity Securities Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:StockIssuedDuringPeriodSharesNewIssues", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R37": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails", "longName": "9954487 - Disclosure - Marketable Debt and Equity Securities - Net Gains and Losses (Details)", "shortName": "Marketable Debt and Equity Securities - Net Gains and Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R38": { "role": "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails", "longName": "9954488 - Disclosure - Marketable Debt and Equity Securities - Equity Securities without Readily Determinable Fair Value (Details)", "shortName": "Marketable Debt and Equity Securities - Equity Securities without Readily Determinable Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-131", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R39": { "role": "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "longName": "9954489 - Disclosure - Stock Based Compensation - Narrative (Details)", "shortName": "Stock Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-135", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-135", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails", "longName": "9954490 - Disclosure - Stock-Based Compensation - Employee Expense (Details)", "shortName": "Stock-Based Compensation - Employee Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R41": { "role": "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails", "longName": "9954491 - Disclosure - Stock-Based Compensation - Option Activity (Details)", "shortName": "Stock-Based Compensation - Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-160", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R42": { "role": "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "longName": "9954492 - Disclosure - Stock-Based Compensation - FV of Employee Stock Options (Details)", "shortName": "Stock-Based Compensation - FV of Employee Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-150", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "longName": "9954493 - Disclosure - Stock Based Compensation - Restricted Stock Units (Details)", "shortName": "Stock Based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-170", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.xencor.com/role/LeasesAgreementsDetails", "longName": "9954494 - Disclosure - Leases - Agreements (Details)", "shortName": "Leases - Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-177", "name": "us-gaap:PaymentsForProceedsFromTenantAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "us-gaap:PaymentsForProceedsFromTenantAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails", "longName": "9954495 - Disclosure - Leases - Undiscounted Cash Flows (Details)", "shortName": "Leases - Undiscounted Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.xencor.com/role/LeasesLeaseCostsDetails", "longName": "9954496 - Disclosure - Leases - Lease Costs (Details)", "shortName": "Leases - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "longName": "9954497 - Disclosure - Collaboration and Licensing Agreements -

Narrative (Details)", "shortName": "Collaboration and Licensing Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "xncr:CollaborativeArrangementNumberOfTargetPrograms", "unitRef": "program", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R48": { "role": "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "longName": "9954498 - Disclosure - Collaboration and Licensing Agreements - Revenue Recognition (Details)", "shortName": "Collaboration and Licensing Agreements - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-269", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "unique": true } }, "R49": { "role": "http://www.xencor.com/role/IncomeTaxesDetails", "longName": "9954499 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails", "longName": "9954500 - Disclosure - Sales of Future Royalties - Narrative (Details)", "shortName": "Sales of Future Royalties - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-181", "name": "xncr:CollaborationAgreementNonCashRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-181", "name": "xncr:CollaborationAgreementNonCashRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails", "longName": "9954501 - Disclosure - Sales of Future Royalties - Debt of Future Royalties (Details)", "shortName": "Sales of Future Royalties - Debt of Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "xncr:RoyaltyLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "xncr:DebtOfFutureRoyaltiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "xncr:RoyaltyLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "xncr:DebtOfFutureRoyaltiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "xncr-20240630.htm", "first": true, "unique": true } } }, "tag": { "xncr_ABruceMontgomeryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ABruceMontgomeryMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "A. Bruce Montgomery [Member]", "documentation": "A. Bruce Montgomery" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r33", "r682"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "verboseLabel": "Receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r831"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accretion of discount on marketable debt securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r63"] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r36", "r77"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r36"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive (loss) income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r12", "r13", "r51", "r116", "r493", "r528", "r529"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r7", "r13", "r376", "r379", "r434", "r524", "r525", "r807", "r808", "r809", "r819", "r820", "r821", "r823"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r739"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r45", "r682", "r948"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r543", "r819", "r820", "r821", "r823", "r890", "r949"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r752"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r752"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r752"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r752"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r24", "r25", "r306"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "xncr_AdvanceFutureRoyaltyAndMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "AdvanceFutureRoyaltyAndMilestonePayments", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reduction of liability for sale of future royalties", "label": "Advance Future Royalty And Milestone Payments", "documentation": "Advance Future Royalty And Milestone Payments" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r785"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r711", "r721", "r731", "r763"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate

Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r714", "r724", "r734", "r766"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r786"] }, "xncr_AlexionPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "AlexionPharmaceuticalsIncMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Alexion", "label": "Alexion Pharmaceuticals, Inc. [Member]", "documentation": "Represents information pertaining to Alexion Pharmaceuticals, Inc., with which the entity has entered into a option and license agreement." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r752"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r759"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r715", "r725", "r735", "r759", "r767", "r771", "r779"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r777"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r367"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r76", "r87", "r109", "r144", "r178", "r182", "r190", "r191", "r233", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r369", "r373", "r408", "r489", "r583", "r654", "r655", "r682", "r702", "r853", "r854", "r904"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r105", "r117", "r144", "r233", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r369", "r373", "r408", "r682", "r853", "r854", "r904"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total Fair Value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r386", "r387", "r671"] }, "xncr_AstriaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "AstriaMember", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Astria", "label": "Astria [Member]", "documentation": "Astria" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails": { "parentTag": "xncr_CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r202"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r203"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r199", "r241", "r488"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature within two years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r837"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature within two years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r207", "r484"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in one year or less", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r836"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r206", "r483"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesMaturitiesDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "totalLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r200", "r241", "r386", "r475", "r671", "r674", "r832", "r894", "r895", "r896"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [

```
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r774" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r775" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r770" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r770" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r770" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r770" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r770" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails", "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails", "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r772" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r771" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r771" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "xncr_BassilDahiyatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "BassilDahiyatMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Bassil Dahiyat [Member]", "documentation": "Bassil Dahiyat" } } }, "auth_ref": [] }, "xncr_CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Cash and Cash Equivalents and Marketable Securities Amortized Cost", "documentation": "This item represents the total cost of cash and cash equivalents and marketable securities." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets", "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Money Market Funds", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r107", "r645" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r61", "r143" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r61" ] }, "xncr_CatabasisPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CatabasisPharmaceuticalsIncMember", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Astria/Catabasis", "label": "Astria/Catabasis", "documentation": "Represents the information pertaining to Catabasis Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r750" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r747" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r745" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r100", "r113", "r114", "r115", "r144", "r167", "r168", "r171", "r173", "r180", "r181", "r233", "r269", "r271", "r272", "r273", "r276", "r277", "r281", "r282", "r284", "r285", "r287", "r408", "r535", "r536", "r537", "r538", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r571", "r592", "r610", "r634", "r635", "r636", "r637", "r638", "r789", "r817", "r824" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r751" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r751" ] }, "xncr_CollaborationAgreementDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborationAgreementDeferredRevenue", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Collaboration Agreement, Deferred Revenue", "documentation": "Collaboration Agreement, Deferred Revenue" } } }, "auth_ref": [] }, "xncr_CollaborationAgreementNonCashRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborationAgreementNonCashRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash revenue recognized", "label": "Collaboration Agreement, Non-Cash Revenue Recognized", "documentation": "Collaboration Agreement, Non-Cash Revenue Recognized" } } }, "auth_ref": [] }, "xncr_CollaborationAgreementServiceAgreementCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborationAgreementServiceAgreementCharges", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ],
```

"lang": { "en-us": { "role": { "terseLabel": "Service agreement charges", "label": "Collaboration Agreement, Service Agreement Charges", "documentation": "Collaboration Agreement, Service Agreement Charges" } } }, "auth_ref": [] }, "xncr_CollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborationAndLicenseAgreementMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and License Agreement", "label": "Collaboration and License Agreement", "documentation": "Represents information pertaining to the Collaboration and License agreement." } } }, "auth_ref": [] }, "xncr_CollaborationResearchAndLicensingAgreementsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborationResearchAndLicensingAgreementsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Collaboration and Licensing Agreements", "label": "Collaboration and Licensing Agreements", "documentation": "Collaboration and Licensing Agreements" } } }, "auth_ref": [] }, "xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of responsibility for development costs", "label": "Collaborative Agreement, Percentage of Responsibility Assumed for Development Costs", "documentation": "Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development." } } }, "auth_ref": [] }, "xncr_CollaborativeAgreementSharePercentageOfDevelopmentCostByCounterparty": { "xbrltype": "percentItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborativeAgreementSharePercentageOfDevelopmentCostByCounterparty", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share development percentage", "label": "Collaborative Agreement Share Percentage Of Development Cost, By Counterparty", "documentation": "Represents the percentage of share assumed by the counter-party for development costs." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and Licensing Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r92", "r94", "r99"] }, "xncr_CollaborativeArrangementNumberOfTargetPrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborativeArrangementNumberOfTargetPrograms", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of different target programs", "label": "Collaborative Arrangement Number of Target Programs", "documentation": "Represents the number of different target programs under the collaborative agreement." } } }, "auth_ref": [] }, "xncr_CollaborativeArrangementReceivablePayableRelatedToCostSharingDevelopmentActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborativeArrangementReceivablePayableRelatedToCostSharingDevelopmentActivities", "crdr": "debit", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement receivable (payable) related to cost sharing development activities", "label": "Collaborative Arrangement Receivable (Payable) Related To Cost Sharing Development Activities", "documentation": "Amount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities." } } }, "auth_ref": [] }, "xncr_CollaborativeArrangementResearchLicenseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborativeArrangementResearchLicenseTerm", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research license term", "label": "Collaborative Arrangement Research License Term", "documentation": "Represents the research license term under the collaborative agreement." } } }, "auth_ref": [] }, "xncr_CollaborativeArrangementTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "CollaborativeArrangementTransactionPrice", "crdr": "debit", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction price", "label": "Collaborative Arrangement, Transaction Price", "documentation": "Collaborative Arrangement, Transaction Price" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration research and licensing agreements", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r367"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r41", "r78", "r490", "r570"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.xencor.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r69", "r262", "r263", "r640", "r846", "r848"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r692", "r693", "r694", "r696", "r697", "r698", "r699", "r819", "r820", "r823", "r890", "r947", "r949"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r44", "r571"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r8", "r44", "r571", "r589", "r949", "r950"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 200,000,000 authorized shares at June\u00a030, 2024 and December\u00a031, 2023; 61,766,054 issued and outstanding at June\u00a030, 2024 and 60,998,191 issued and outstanding at December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r44", "r492", "r682"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r756"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r755"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r757"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r754"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Xencor, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r14", "r122", "r124", "r131", "r479", "r504", "r506"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss attributable to non-controlling interest", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r28", "r32", "r122", "r124", "r130", "r478", "r504", "r505"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",

```
"http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r32", "r74", "r122", "r124", "r129", "r477", "r504" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.xencor.com/role/ComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r50", "r128", "r476", "r502" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r29", "r650" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r289", "r290", "r293" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r289", "r290", "r293" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r294" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r662", "r664", "r671", "r683", "r689", "r944" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r146", "r147", "r278", "r283", "r435", "r453", "r486", "r647", "r649" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r268", "r851" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r268", "r851", "r852" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "xncr_DagmarRosaBjorkesenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "DagmarRosaBjorkesenMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Dagmar Rosa-Bjorkesen [Member]", "documentation": "Dagmar Rosa-Bjorkesen" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r111" ] }, "xncr_DebtOfFutureRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "DebtOfFutureRoyaltiesTableTextBlock", "presentation": [ "http://www.xencor.com/role/SalesofFutureRoyaltiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt of Future Royalties", "label": "Debt of Future Royalties [Table Text Block]", "documentation": "Debt of Future Royalties" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r88", "r243", "r657" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized losses, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r88", "r243" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r88", "r243", "r657" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized losses, Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r88", "r243" ] }, "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleGainLoss", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of marketable debt securities", "label": "Debt Securities, Available-for-Sale, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r811", "r812" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (loss) gain on marketable securities", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r834", "r835" ] }, "us-gaap_DebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable debt securities", "label": "Debt Securities, Current", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable debt securities - long term", "label": "Debt Securities, Noncurrent", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Deferred Income, Current", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r795" ] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "calculation": {
```

```
"http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income, net of current portion", "label": "Deferred Income, Noncurrent", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r795" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": {
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order":
17.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and
amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of
tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r178", "r187", "r191", "r654", "r655" ] },
"xncr_DevelopmentBasedMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname":
"DevelopmentBasedMilestonesMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Development-based", "label": "Development-based", "documentation": "Represents information pertaining to development-based potential milestones." } } },
"auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of
revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r856" ] }, "us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.xencor.com/role/StockBasedCompensation" ], "lang": { "en-us": {
"role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based
payment arrangement." } } }, "auth_ref": [ "r304", "r308", "r335", "r336", "r339", "r666" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] },
"dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation":
"Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year
statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentFiscalYearFocus", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label":
"Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial
information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype":
"dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": {
"role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the
report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or
transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref":
[ "r706" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport",
"presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r738" ] }, "dei_DocumentType": { "xbrltype":
"submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": {
"role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The
document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings
Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r749" ] }, "us-gaap_EarningsPerShareAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)
per share attributable to common stockholders:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/NetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Basic net loss per common share attributable to Xencor, Inc. (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net
income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r132", "r153", "r154", "r155", "r156",
"r157", "r158", "r164", "r167", "r171", "r172", "r173", "r177", "r363", "r366", "r383", "r384", "r480", "r507", "r651" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/NetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Diluted net loss per common share attributable to Xencor, Inc. (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of
net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have
been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } },
"auth_ref": [ "r132", "r153", "r154", "r155", "r156", "r157", "r158", "r167", "r171", "r172", "r173", "r177", "r363", "r366", "r383", "r384", "r480", "r507", "r651" ] }, "us-
gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.xencor.com/role/NetLossPerCommonShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Common Share", "label": "Earnings Per Share [Text Block]",
"documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r163", "r174", "r175", "r176" ] }, "xncr_EllenFeigalMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "EllenFeigalMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Ellen Feigal [Member]", "documentation": "Ellen Feigal" } } }, "auth_ref": [] },
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Period to recognize unamortized compensation
expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over
which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r338" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation":
[ "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expense related to unvested
restricted stock units", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of
cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r885" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr":
"debit", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation
expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for
option under share-based payment arrangement." } } }, "auth_ref": [ "r885" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails",
"http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "Employee Stock [Member]", "documentation": "An
Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-
gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails", "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails",
"http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option
[Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at
predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } },
"auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2",
"presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line
Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode",
"presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-
digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r704" ] },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding",
"presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock,
Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership
interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common
Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
```

the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r704"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r704"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r788"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r704"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r704"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r704"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.xencor.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r704"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r743"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r784"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r784"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r784"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r102", "r125", "r126", "r127", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r179", "r234", "r235", "r258", "r288", "r352", "r353", "r360", "r361", "r362", "r364", "r365", "r366", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r409", "r410", "r411", "r412", "r413", "r414", "r416", "r419", "r434", "r502", "r524", "r525", "r526", "r543", "r610"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r230", "r231", "r232", "r359", "r791", "r792", "r793", "r886", "r887", "r888", "r889"] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Marketable equity securities - long term", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": ["r407"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable equity securities", "verboseLabel": "Equity securities with readily determinable fair value", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r110", "r407", "r646"] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 }, "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) on equity securities, net", "negatedLabel": "Change in fair value of equity securities", "terseLabel": "Net gain (loss) recorded on equity securities", "totalLabel": "Net gain (loss) recorded on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r511", "r842"] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less: Net gain (loss) recorded on sale of equity securities", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r509", "r842"] }, "xncr_EquitySecuritiesFvNiTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "EquitySecuritiesFvNiTableTextBlock", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Securities with Readily Determinable Fair Value", "label": "Equity Securities, FV-NI [Table Text Block]", "documentation": "Tabular disclosure of equity securities with readily determinable fair value." } } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesNetGainsandLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on equity securities", "verboseLabel": "Unrealized gain (loss) recorded on equity securities held at the reporting date", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r510", "r842"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity shares estimated fair value", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r228"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 }, "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails", "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment on equity securities", "terseLabel": "Impairment on equity securities", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r229"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity securities without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r839", "r840", "r841"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities without Readily Determinable Fair Value [Table]", "label": "Equity Securities without Readily Determinable Fair Value [Table]", "documentation": "Disclosure of information about investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r839", "r840", "r841"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Securities Without Readily Determinable Fair Value", "label": "Equity Securities without Readily Determinable Fair Value

[Table Text Block]", "documentation": "Tabular disclosure of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r839", "r840", "r841"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r753"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r711", "r721", "r731", "r763"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r708", "r718", "r728", "r760"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r759"] }, "xncr_ExtendedExpirationDatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ExtendedExpirationDatesMember", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Extended Expiration Dates", "label": "Extended Expiration Dates [Member]", "documentation": "Extended Expiration Dates" } } }, "auth_ref": [] }, "xncr_ExtendedVestingPeriodsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ExtendedVestingPeriodsMember", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Extended Vesting Periods", "label": "Extended Vesting Periods [Member]", "documentation": "Extended Vesting Periods" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r386", "r387", "r397", "r671"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r386", "r387", "r397", "r671"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Recorded at Fair Value", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": ["r671", "r892", "r893", "r898"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r279", "r296", "r297", "r298", "r299", "r300", "r301", "r385", "r387", "r388", "r389", "r390", "r396", "r397", "r399", "r440", "r441", "r442", "r658", "r659", "r662", "r663", "r664", "r671", "r674"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r386", "r387", "r388", "r390", "r671", "r895", "r899"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstruments"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r392", "r394", "r395", "r396", "r399", "r400", "r401", "r402", "r403", "r474", "r671", "r675"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r279", "r296", "r301", "r387", "r397", "r440", "r662", "r663", "r664", "r671"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r279", "r296", "r301", "r387", "r388", "r397", "r441", "r658", "r659", "r662", "r663", "r664", "r671"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r386", "r387", "r388", "r390", "r671", "r895", "r899"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r279", "r296", "r297", "r298", "r299", "r300", "r301", "r385", "r387", "r388", "r389", "r390", "r396", "r397", "r399", "r440", "r441", "r442", "r658", "r659", "r662", "r663", "r664", "r671", "r674"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r671", "r892", "r893", "r894", "r895", "r896", "r899"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r236", "r237", "r238", "r239", "r240", "r242", "r244", "r245", "r280", "r286", "r381", "r404", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r503", "r657", "r671", "r672", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r683", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r838", "r839", "r840", "r841", "r891", "r894", "r895", "r896", "r897", "r899"] }, "xncr_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Patents, licenses, and other intangible assets", "label": "Finite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items]", "documentation": "Finite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items]" } } }, "auth_ref": [] }, "xncr_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]", "documentation": "Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r472", "r473", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r643"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r715", "r725", "r735", "r767"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r715", "r725", "r735", "r767"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country

Law, Amount" } } }, "auth_ref": ["r715", "r725", "r735", "r767"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r715", "r725", "r735", "r767"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r715", "r725", "r735", "r767"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r748"] }, "xncr_FutureRoyaltiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "FutureRoyaltiesPolicyPolicyTextBlock", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices"], "lang": { "en-us": { "role": { "terseLabel": "Liability Related to the Sale of Future Revenues and Non-Cash Interest Expense on the Liability Related to the Sale of Future Royalties and Deferred Income Related to the Sale of Future Revenues", "label": "Future Royalties, Policy [Policy Text Block]", "documentation": "Future Royalties, Policy" } } }, "auth_ref": [] }, "xncr_FutureRoyaltiesSaleDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "FutureRoyaltiesSaleDisclosureTextBlock", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyalties"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Future Royalties", "label": "Future Royalties Sale Disclosure [Text Block]", "documentation": "Future Royalties Sale Disclosure" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r815"] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestmentsTextBlock", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Gains and Losses", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": ["r811", "r812"] }, "xncr_GaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "GaleMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gale", "label": "Gale [Member]", "documentation": "Gale" } } }, "auth_ref": [] }, "xncr_GenentechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "GenentechMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Genentech", "label": "Genentech [Member]", "documentation": "Represent information pertaining to Genetech." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r54", "r594"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r54"] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices"], "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": ["r246", "r256", "r257"] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": ["r5", "r248", "r256"] }, "xncr_InProcessIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "InProcessIntangibleAssetsMember", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "In-process intangible assets", "label": "In-process intangible assets", "documentation": "In Process Intangible Assets [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Loss before income tax expense", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r52", "r81", "r86", "r481", "r498", "r653", "r654", "r826", "r827", "r828", "r829", "r830"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r259", "r260", "r261", "r391", "r393", "r398", "r521", "r523", "r595", "r643", "r673", "r917"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r260", "r261", "r391", "r393", "r398", "r521", "r523", "r595", "r643", "r673", "r917"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.xencor.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r145", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r354", "r356", "r357", "r358", "r540", "r668"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r90", "r98", "r160", "r161", "r178", "r188", "r191", "r343", "r344", "r355", "r512", "r668"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r17", "r142", "r350", "r351"] }, "xncr_IncreaseDecreaseInAccountsAndOtherReceivablesAndContractWithCustomerAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "IncreaseDecreaseInAccountsAndOtherReceivablesAndContractWithCustomerAssets", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts and Other Receivables and Contract with Customer Assets", "documentation": "Increase (Decrease) in Accounts Receivable and Contract with Customer Assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedInvestmentIncomeReceivable", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest receivable from marketable debt securities", "label": "Increase (Decrease) in Accrued Investment Income Receivable", "documentation": "The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r470", "r814"] }, "xncr_IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities and ROU assets", "label": "Increase Decrease In Lease Liabilities and Right Of Use Assets", "documentation": "The increase (decrease) during the reporting period relating to lease liabilities and right of use (ROU) assets." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInLoansDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInLoansDeferredIncome", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred income", "label": "Increase (Decrease) in Loans, Deferred Income", "documentation": "The increase (decrease) during the reporting period in net unamortized loan origination fees and other fees that are collected at origination but recorded as income over the life of the loan." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r715", "r725", "r735", "r759", "r767", "r771", "r779"] }, "xncr_InitialCostSharingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "InitialCostSharingPercentage", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial cost-sharing percentage", "label": "Initial Cost-sharing Percentage", "documentation": "The initial cost-sharing percentage." } } }, "auth_ref": [] }, "xncr_InmuneBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "InmuneBioIncMember", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "INmune", "label": "INmune", "documentation": "Represents information pertaining to the counterparty, INmune Bio, Inc. (INmune)." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r777"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r707", "r783"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r707", "r783"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r707", "r783"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Patents, licenses, and other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r247", "r844", "r845"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r186", "r813"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r136", "r140", "r141"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r178", "r185", "r191", "r654", "r810"] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares owned (in shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": ["r555", "r560", "r615", "r624", "r628", "r694"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Debt and Equity Securities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r508", "r531", "r532", "r533", "r534", "r617", "r618"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r556", "r557", "r558", "r559", "r560", "r613", "r616", "r620", "r623", "r625", "r626", "r629", "r630", "r631", "r632", "r633", "r694"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r556", "r557", "r558", "r559", "r560", "r613", "r616", "r620", "r623", "r625", "r626", "r629", "r630", "r631", "r632", "r633", "r694"] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails": { "parentTag": "xncr_CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": ["r486", "r487", "r688", "r691"] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Marketable Securities", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecurities"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Debt and Equity Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r83", "r101", "r196", "r197", "r405", "r406", "r913"] }, "xncr_JanssenBiotechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "JanssenBiotechIncMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen Biotech, Inc [Member]", "documentation": "Represents information pertaining to Janssen Biotech, Inc." } } }, "auth_ref": [] }, "xncr_JanssenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "JanssenMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen [Member]", "documentation": "Represents information pertaining to Janseen" } } }, "auth_ref": [] }, "xncr_JohnDesjarlaisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "JohnDesjarlaisMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "John Desjarlais [Member]", "documentation": "John Desjarlais" } } }, "auth_ref": [] }, "xncr_KevinGormanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "KevinGormanMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Kevin Gorman [Member]", "documentation": "Kevin Gorman" } } }, "auth_ref": [] }, "xncr_KurtGustafsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "KurtGustafsonMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Kurt Gustafson [Member]", "documentation": "Kurt Gustafson" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.xencor.com/role/LeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r424", "r681"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.xencor.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Lease Costs and Cash Disclosures", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r902"] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "presentation": ["http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Improvement allowance", "label": "Leasehold Improvements, Gross", "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r68"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r423",

```
"r433" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r423", "r433" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.xencor.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Liabilities Maturities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r903" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "For the remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r903" ] }, "xncr_LesseeOperatingLeaseLiabilityTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "LesseeOperatingLeaseLiabilityTenantAllowance", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Tenant allowance", "label": "Lessee, Operating Lease, Liability, Tenant Allowance", "documentation": "Amount of monetary allowance granted by the landlord to a tenant for operating lease." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r901" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.xencor.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r418" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r11", "r35", "r36", "r37", "r39", "r40", "r41", "r42", "r144", "r233", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r370", "r373", "r374", "r408", "r569", "r652", "r702", "r853", "r904", "r905" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r49", "r80", "r496", "r682", "r818", "r843", "r900" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r106", "r144", "r233", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r370", "r373", "r374", "r408", "r682", "r853", "r904", "r905" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "xncr_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "LicenseAgreementMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "License Agreement [Member]", "documentation": "Represents information pertaining to the License Agreement." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r34", "r38" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, net of current portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent, Excludes lease obligation." } } }, "auth_ref": [ "r112" ] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Abstract]", "label": "Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "xncr_MarketableSecuritiesImpairmentLossesAndRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "MarketableSecuritiesImpairmentLossesAndRecoveries", "crdr": "debit", "presentation": [ "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss or recoveries", "label": "Marketable Securities Impairment Losses And Recoveries", "documentation": "Amount of impairment loss or recovery related to marketable securities." } } }, "auth_ref": [] },
```

"xncr_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "MarketableSecuritiesMember", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable securities", "documentation": "Primary financial statement caption encompassing marketable securities." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) on marketable securities", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": ["r55"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r264", "r265", "r266", "r267", "r302", "r340", "r390", "r469", "r520", "r522", "r530", "r561", "r562", "r614", "r619", "r621", "r622", "r627", "r641", "r642", "r656", "r660", "r665", "r674", "r675", "r679", "r680", "r685", "r855", "r906", "r907", "r908", "r909", "r910", "r911"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r751"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r751"] }, "xncr_MilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "MilestoneMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone", "label": "Milestone [Member]", "documentation": "Payment for achievement or success." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r264", "r265", "r266", "r267", "r302", "r340", "r390", "r469", "r520", "r522", "r530", "r561", "r562", "r614", "r619", "r621", "r622", "r627", "r641", "r642", "r656", "r660", "r665", "r674", "r675", "r679", "r685", "r855", "r906", "r907", "r908", "r909", "r910", "r911"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r48", "r79", "r144", "r233", "r269", "r271", "r272", "r273", "r276", "r277", "r408", "r495", "r573"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r770"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r858"] }, "xncr_MonroviaCAOfficeAndLaboratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "MonroviaCAOfficeAndLaboratorySpaceMember", "presentation": ["http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Monrovia, CA - office and laboratory space", "label": "Monrovia, CA - office and laboratory space [Member]", "documentation": "Represents information pertaining to lease office and laboratory space in Monrovia, CA." } } }, "auth_ref": [] }, "xncr_MorphoSysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "MorphoSysMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys", "label": "MorphoSys [Member]", "documentation": "Represents information pertaining to MorphoSys." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r778"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r752"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r139"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r139"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r61", "r62", "r63"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Xencor, Inc.", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r53", "r63", "r82", "r104", "r121", "r123", "r127", "r144", "r151", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r169", "r233", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r363", "r366", "r384", "r408", "r501", "r591", "r608", "r609", "r700", "r853"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Net loss attributable to non-controlling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r31", "r75", "r121", "r123", "r157", "r160", "r161", "r500", "r809"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.xencor.com/role/NetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to Xencor, Inc.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r133", "r153", "r154", "r155", "r156", "r164", "r165", "r170", "r173", "r366"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://www.xencor.com/role/NetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "xncr_NonCashRoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "NonCashRoyaltyMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash royalties", "label": "Non-cash Royalty [Member]", "documentation": "Non-cash Royalty" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r751"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r715", "r725", "r735", "r759", "r767"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO

Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r742"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r741"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r759"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r778"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r778"] }, "xncr_NoncashConsiderationReceivedFromRevenueContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "NoncashConsiderationReceivedFromRevenueContracts", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity received in connection with license agreements", "label": "Noncash Consideration Received From Revenue Contracts", "documentation": "Noncash Consideration Received From Revenue Contracts" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of non-cash activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashProjectAbandonmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashProjectAbandonmentCosts", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Abandonment of capitalized intangible assets", "label": "Noncash Project Abandonment Costs", "documentation": "The expense charged against earnings to eliminate the capitalized costs of projects that have been terminated during the reporting period, which is added back to net income when calculating cash provided by (used in) operations using the indirect method." } } }, "auth_ref": ["r5"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r26", "r288", "r819", "r820", "r821", "r823", "r949"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r56"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": ["http://www.xencor.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Unit Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": ["r10"] }, "xncr_NumberOfAnnualInstallmentVestingPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "NumberOfAnnualInstallmentVestingPeriod", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual installment vesting periods", "label": "Number Of Annual Installment Vesting Period", "documentation": "Represents the number of annual installment vesting periods." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r86", "r653", "r826", "r827", "r828", "r829", "r830"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.xencor.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r425", "r681"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 }, "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease payments", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r421"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets", "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities", "terseLabel": "Lease liabilities - short-term", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r421"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets", "http://www.xencor.com/role/LeasesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities, net of current portion", "terseLabel": "Lease liabilities - long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r421"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.xencor.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r422", "r427"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Right of use (ROU) asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r420"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.xencor.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r430", "r681"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.xencor.com/role/LeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r429", "r681"] }, "xncr_OptionAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "OptionAndLicenseAgreementMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Option and License agreement", "label": "Option and license agreement [Member]", "documentation": "Represents information pertaining to the option and license agreement." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://www.xencor.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r64", "r65", "r66", "r73"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r108"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) on marketable debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r118", "r119", "r120", "r502"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0,

"order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r57"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r751"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r713", "r723", "r733", "r765"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r716", "r726", "r736", "r768"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r716", "r726", "r736", "r768"] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Paid-in-Kind Interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r5"] }, "xncr_PasadenaCAOfficeAndLaboratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "PasadenaCAOfficeAndLaboratorySpaceMember", "presentation": ["http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pasadena, CA - office and laboratory space", "label": "Pasadena, CA - office and laboratory space [Member]", "documentation": "Represents information pertaining to the laboratory and office space in Pasadena, California." } } }, "auth_ref": [] }, "xncr_PatentLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "PatentLicenseAgreementMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Patent License Agreement", "label": "Patent License Agreement", "documentation": "Information relating to a Patent License Agreement." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r740"] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": ["http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments for (proceeds from) tenant allowance", "label": "Payments for (Proceeds from) Tenant Allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": ["r15", "r58"] }, "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock", "crdr": "credit", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments for repurchase of preferred stock and preference stock", "label": "Payments for Repurchase of Preferred Stock and Preference Stock", "documentation": "The cash outflow to reacquire preferred stock during the period." } } }, "auth_ref": ["r60"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of patents, licenses, and other intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r59"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r833"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r59"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r750"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r750"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r742"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r759"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r752"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r741"] }, "xncr_PhasesOfLeaseTerm": { "xbrltype": "integerItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "PhasesOfLeaseTerm", "presentation": ["http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Phases of lease term", "label": "Phases of Lease Term", "documentation": "Represents the number of phases associated with a lease term." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r743"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r787"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r742"] }, "xncr_PotentialMilestonesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "PotentialMilestonesTypeAxis", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Potential Milestones Type [Axis]", "label": "Potential Milestones Type [Axis]", "documentation": "Potential Milestones Type" } } }, "auth_ref": [] }, "xncr_PotentialMilestonesTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "PotentialMilestonesTypeDomain", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Potential Milestones Type [Domain]", "label": "Potential Milestones Type [Domain]", "documentation": "Potential Milestones Type [Domain]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r692", "r693", "r696", "r697", "r698", "r699", "r947", "r949"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r43", "r281"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r43", "r571"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r43", "r281"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.xencor.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r43", "r571", "r589", "r949", "r950"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at June\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r43", "r491", "r682"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": {

```
"http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense
and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and
amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r806" ] }, "us-
gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices" ], "lang": { "en-us": {
"role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for
reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." }
} }, "auth_ref": [ "r803" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": {
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order":
1.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of
common stock upon exercise of stock awards", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation":
"Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r2", "r9" ] },
"us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities",
"label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r134", "r135",
"r833" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of marketable securities",
"label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through
sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-
gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of equity securities", "label": "Proceeds from
Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value
recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r89", "r137" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": {
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order":
2.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of
common stock under the Employee Stock Purchase Plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from
the stock plan during the period." } } }, "auth_ref": [ "r2" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ProductOrServiceAxis", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r192", "r471", "r513", "r514", "r515", "r516",
"r517", "r518", "r519", "r644", "r661", "r684", "r685", "r686", "r687", "r690", "r849", "r850", "r856", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925",
"r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r945", "r946" ] },
"srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r192", "r471", "r513", "r514", "r515",
"r516", "r517", "r518", "r519", "r644", "r661", "r684", "r685", "r686", "r687", "r690", "r849", "r850", "r856", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924",
"r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r945", "r946" ] }, "us-
gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": {
"http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 },
"http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 },
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order":
18.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited",
"http://www.xencor.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited" ], "lang": { "en-
us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The
consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r104", "r121", "r123",
"r138", "r144", "r151", "r157", "r160", "r161", "r233", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r363", "r366", "r368", "r371", "r372", "r384",
"r408", "r481", "r499", "r542", "r591", "r608", "r609", "r669", "r670", "r701", "r809", "r853" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset
[Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r432" ]
}, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet",
"crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment,
Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and
services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } },
"auth_ref": [ "r6", "r432", "r485", "r497", "r682" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in
the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of
furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r68", "r432" ] },
"ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r740" ] },
"ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text
Block]" } } }, "auth_ref": [ "r740" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r295", "r302",
"r331", "r332", "r333", "r340", "r390", "r443", "r452", "r469", "r520", "r522", "r530", "r561", "r562", "r614", "r619", "r621", "r622", "r627", "r641", "r642", "r656", "r660",
"r665", "r674", "r675", "r679", "r680", "r685", "r694", "r847", "r855", "r895", "r907", "r908", "r909", "r910", "r911" ] }, "srt_RangeMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r295",
"r302", "r331", "r332", "r333", "r340", "r390", "r443", "r452", "r469", "r520", "r522", "r530", "r561", "r562", "r614", "r619", "r621", "r622", "r627", "r641", "r642", "r656",
"r660", "r665", "r674", "r675", "r679", "r680", "r685", "r694", "r847", "r855", "r895", "r907", "r908", "r909", "r910", "r911" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [
"r708", "r718", "r728", "r760" ] }, "xncr_RegulatoryBasedMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname":
"RegulatoryBasedMilestonesMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Regulatory-based", "label": "Regulatory-based", "documentation": "Represents information pertaining to regulatory-based potential milestones." } } },
"auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails",
"http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name
[Domain]" } } }, "auth_ref": [ "r146", "r147", "r278", "r283", "r435", "r453", "r486", "r648", "r649" ] }, "xncr_ResearchActivityMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.xencor.com/20240630", "localname": "ResearchActivityMember", "presentation": [
"http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research service", "label": "Research
service", "documentation": "Represent information pertaining to research activity." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and
Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold,
leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both.
Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } },
"auth_ref": [ "r341", "r643", "r654", "r912" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in
```

which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "xncr_ResearchCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ResearchCollaborationMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research collaboration", "label": "Research collaboration [Member]", "documentation": "Right to collaboration or assist on a project or agreement." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r709", "r719", "r729", "r761"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r710", "r720", "r730", "r762"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r717", "r727", "r737", "r769"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r804", "r816", "r914", "r915"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r107"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets", "http://www.xencor.com/role/LeasesAgreementsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "terseLabel": "Cash collateral for letters of credit", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r91", "r805", "r816"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.xencor.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r46", "r70", "r494", "r527", "r529", "r539", "r572", "r682"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r102", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r234", "r235", "r258", "r352", "r353", "r360", "r361", "r362", "r364", "r365", "r366", "r375", "r377", "r378", "r380", "r382", "r416", "r419", "r524", "r526", "r543", "r949"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Collaborations, milestones, and royalties", "verboseLabel": "Revenue recorded", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r84", "r85", "r178", "r183", "r184", "r189", "r191", "r192", "r193", "r194", "r291", "r292", "r471"] }, "xncr_RevenueRecognitionMilestoneMethodPending": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RevenueRecognitionMilestoneMethodPending", "crdr": "credit", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty milestones", "label": "Revenue Recognition Milestone Method Pending", "documentation": "Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "xncr_RichardRanieriJune2024PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RichardRanieriJune2024PlanMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Richard Ranieri June 2024 Plan [Member]", "documentation": "Richard Ranieri June 2024 Plan" } } }, "auth_ref": [] }, "xncr_RichardRanieriMay2024PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RichardRanieriMay2024PlanMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Richard Ranieri May 2024 Plan [Member]", "documentation": "Richard Ranieri May 2024 Plan" } } }, "auth_ref": [] }, "xncr_RichardRanieriMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RichardRanieriMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Richard Ranieri [Member]", "documentation": "Richard Ranieri" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r428", "r681"] }, "xncr_RoyaltyLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilitiesLongTermDebt", "crdr": "credit", "calculation": { "http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails": { "parentTag": "xncr_RoyaltyLiabilityDebtLongTermAndShortTermCombinedAmount", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt - long-term", "label": "Royalty Liabilities, Long-Term Debt", "documentation": "Royalty Liabilities, Long-Term Debt" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilitiesShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilitiesShortTermDebt", "crdr": "credit", "calculation": { "http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails": { "parentTag": "xncr_RoyaltyLiabilityDebtLongTermAndShortTermCombinedAmount", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt - short-term", "label": "Royalty Liabilities, Short-Term Debt", "documentation": "Royalty Liabilities, Short-Term Debt" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityDebtLongTermAndShortTermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityDebtLongTermAndShortTermCombinedAmount", "crdr": "credit", "calculation": { "http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Royalty Liability, Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Royalty Liability, Debt, Long-Term and Short-Term, Combined Amount" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts", "crdr": "credit", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense recognized", "label": "Royalty Liability, Interest Expense Including Amortization Of Closing Costs", "documentation": "Royalty Liability, Interest Expense Including Amortization Of Closing Costs" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityInterestRate", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Royalty Liability, Interest Rate", "documentation": "Royalty Liability, Interest Rate" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityNonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityNonCashInterestExpense", "crdr": "credit", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Non-cash interest expense recognized", "label": "Royalty Liability, Non-Cash Interest Expense", "documentation": "Royalty Liability, Non-Cash Interest Expense" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance of debt related to sale of future royalties", "periodEndLabel": "Ending balance of debt related to sale of future royalties", "label": "Royalty Liability, Noncurrent", "documentation": "Royalty Liability, Noncurrent" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityOwed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityOwed", "crdr": "debit", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties owed to OMERS", "label": "Royalty Liability, Owed", "documentation": "Royalty Liability, Owed" } } }, "auth_ref": [] }, "xncr_RoyaltyLiabilityPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "RoyaltyLiabilityPayments", "crdr": "credit", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Royalties paid to OMERS", "label": "Royalty Liability, Payments", "documentation": "Royalty Liability, Payments" } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": ["r857"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r778"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r778"] }, "xncr_SaleOfFutureRoyaltyRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "SaleOfFutureRoyaltyRollForward", "presentation": ["http://www.xencor.com/role/SalesofFutureRoyaltiesDebtofFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Future Royalty [Roll Forward]", "label": "Sale of Future Royalty [Roll Forward]", "documentation": "Sale of Future Royalty" } } }, "auth_ref": [] }, "xncr_SalesBasedMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "SalesBasedMilestonesMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales-based", "label": "Sales-based", "documentation": "Represents information pertaining to sales-based potential milestones." } } }, "auth_ref": [] }, "xncr_SalesOfFutureRoyaltiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "SalesOfFutureRoyaltiesLineItems", "presentation": [

```
"http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of Future Royalties [Line Items]", "label": "Sales of Future Royalties [Line Items]", "documentation": "Sales of Future Royalties [Line Items]" } } }, "auth_ref": [] }, "xncr_SalesOfFutureRoyaltiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "SalesOfFutureRoyaltiesTable", "presentation": [
"http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of Future Royalties [Table]", "label": "Sales of Future Royalties [Table]", "documentation": "Sales of Future Royalties [Table]" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r303", "r822" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r162", "r303", "r790", "r822" ] }, "us-
gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale
Securities", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used
to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198", "r199", "r200", "r201", "r202", "r203",
"r204", "r205", "r206", "r207", "r208", "r209" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and
Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of
information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r367" ] },
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.xencor.com/role/NetLossPerCommonShareTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Basic and Diluted Net Loss per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation":
"Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-
share computations for income from continuing operations." } } }, "auth_ref": [ "r825" ] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Employee, Director and Non-Employee Stock-
Based Compensation Expense Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular
disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and
statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r23" ] },
"srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r230", "r231", "r232", "r359", "r791", "r792", "r793", "r886", "r887", "r888", "r889" ] },
"xncr_ScheduleOfRevenueByMajorLicenseesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xencor.com/20240630", "localname":
"ScheduleOfRevenueByMajorLicenseesTableTextBlock", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsTables" ], "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Revenue by Licensees", "label": "Schedule of Revenue by Major Licensees [Table Text Block]", "documentation": "Tabular disclosure of
revenue by major licensees." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"presentation": [ "http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails",
"http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails",
"http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails", "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based
Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } },
"auth_ref": [ "r305", "r307", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327",
"r328", "r329", "r330", "r331", "r332", "r333", "r334" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Assumptions Used for Estimation of
Fair Value of ESPP", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular
disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b)
expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r72" ] }, "us-
gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Assumptions Used for Estimation of
Fair Value of Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular
disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and
similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [
"r72" ] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Summary of Stock Option Activity", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in
stock options." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "presentation": [
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Equity Securities", "label": "Debt and Equity Securities, FV-NI [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r404" ] }, "us-
gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "presentation": [
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
Securities, Trading, and Equity Securities, FV-NI [Table]", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "documentation": "Disclosure of
information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with
change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r404" ] }, "xncr_SecondCollaborationAndLicenseAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "SecondCollaborationAndLicenseAgreementMember", "presentation": [
"http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Collaboration And License
Agreement", "label": "Second Collaboration And License Agreement [Member]", "documentation": "Represents information relating to second collaboration and license
agreement." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle",
"presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation":
"Title of a 12(b) registered security." } } }, "auth_ref": [ "r703" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r705" ] },
"xncr_ShanghaiMabgeekBiotechCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname":
"ShanghaiMabgeekBiotechCo.Ltd.Member", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mabgeek", "label": "Shanghai
Mabgeek Biotech Co., Ltd. [Member]", "documentation": "Shanghai Mabgeek Biotech Co., Ltd." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
"http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order":
19.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited",
"http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "verboseLabel":
"Total employee, director and non-employee stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount
of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] },
"xncr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://www.xencor.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorized", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual increase in shares of common stock available for
issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Annual Increase in Shares Authorized", "documentation": "Represents
the annual increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based
compensation plan." } } }, "auth_ref": [] }, "xncr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPercentageIncreaseInSharesAuthorized": {
"xbrltype": "percentItemType", "nsuri": "http://www.xencor.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPercentageIncreaseInSharesAuthorized", "presentation": [
"http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual percentage increase in shares of common stock
available for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Annual Percentage Increase in Shares Authorized",
"documentation": "Represents the annual percentage increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of
directors), for awards under the equity-based compensation plan." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"presentation": [ "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in
shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation":
"The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r325" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
```

"http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value, forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r325"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r323"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value, granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r323"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r320", "r321"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value, beginning balance (in dollars per share)", "periodEndLabel": "Weighted average grant date fair value, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r320", "r321"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value (Per unit)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r324"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r324"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average assumptions for estimated fair value of employee stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r332"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r331"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, high end of range (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, low end of range (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r333"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, high end of range (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, low end of range (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails", "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails", "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r305", "r307", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324",

"r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total number of shares of common stock available for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r667"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Exercisable options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r314"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r314"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Options forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r318"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate intrinsic value, balance outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r21"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period (in shares)", "periodEndLabel": "Balance at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r312", "r313"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Subject to Outstanding Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period (in dollars per share)", "periodEndLabel": "Balance at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r312", "r313"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price (Per Share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, plan modification, incremental cost", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": ["r337"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Awards issued under the plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r21"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.xencor.com/role/StockBasedCompensationEmployeeExpenseDetails", "http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails", "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails", "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails", "http://www.xencor.com/role/StockBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r317"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r318"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r316"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.xencor.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Closing price of common stock (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.xencor.com/role/StockBasedCompensationFVofEmployeeStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r330"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate intrinsic value, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r21"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [

```
"http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average remaining contractual term, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r21" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual term, balance outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r71" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r100", "r113", "r114", "r115", "r144", "r167", "r168", "r171", "r173", "r180", "r181", "r233", "r269", "r271", "r272", "r273", "r276", "r277", "r281", "r282", "r284", "r285", "r287", "r408", "r535", "r536", "r537", "r538", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r571", "r592", "r610", "r634", "r635", "r636", "r637", "r638", "r789", "r817", "r824" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r44", "r47", "r48", "r102", "r125", "r126", "r127", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r179", "r234", "r235", "r258", "r288", "r352", "r353", "r360", "r361", "r362", "r364", "r365", "r366", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r409", "r410", "r411", "r412", "r413", "r414", "r416", "r419", "r434", "r502", "r524", "r525", "r526", "r543", "r610" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r148", "r149", "r150", "r179", "r419", "r471", "r531", "r554", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r590", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r610", "r695" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/LeasesAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r162", "r303", "r790", "r794", "r822" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r148", "r149", "r150", "r179", "r195", "r419", "r471", "r531", "r554", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r590", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r610", "r695" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r712", "r722", "r732", "r764" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r8", "r43", "r44", "r70" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r43", "r44", "r70", "r535", "r610", "r635" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r8", "r43", "r44", "r70" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock awards (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r8", "r43", "r44", "r70" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r43", "r44", "r70", "r317" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r8", "r43", "r44", "r70" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r8", "r70" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock awards", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r22", "r43", "r44", "r70" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity attributable to Xencor, Inc.", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r44", "r47", "r48", "r67", "r573", "r589", "r611", "r612", "r682", "r702", "r818", "r843", "r900", "r949" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.xencor.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.xencor.com/role/ConsolidatedBalanceSheets", "http://www.xencor.com/role/ConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r26", "r27", "r30", "r102", "r103", "r126", "r148", "r149", "r150", "r152", "r157", "r159", "r234", "r235", "r258", "r288", "r352", "r353", "r360", "r361", "r362", "r364", "r365", "r366", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r409", "r410", "r414", "r417", "r434", "r525", "r526", "r541", "r573", "r589", "r611", "r612", "r639", "r701", "r818", "r843", "r900", "r949" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r415", "r436" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r415", "r436" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." }
```

```
} }, "auth_ref": [ "r415", "r436" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "xncr_SupplementalCashFlowInformationCashPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "SupplementalCashFlowInformationCashPaidAbstract", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for:", "label": "Supplemental Cash Flow Information Cash Paid [Abstract]", "documentation": "Supplemental Cash Flow Information Cash Paid [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r758" ] }, "xncr_TechnologyLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "TechnologyLicenseAgreementMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology License Agreement", "label": "Technology License Agreement", "documentation": "Information relating to a Technology License Agreement." } } }, "auth_ref": [] }, "xncr_The2013And2023PlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "The2013And2023PlansMember", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The 2013 and 2023 Plans", "label": "The 2013 and 2023 Plans [Member]", "documentation": "The 2013 and 2023 Plans" } } }, "auth_ref": [] }, "xncr_The2023PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "The2023PlanMember", "presentation": [ "http://www.xencor.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The 2023 Plan", "label": "The 2023 Plan [Member]", "documentation": "The 2023 Plan" } } }, "auth_ref": [] }, "xncr_ThirdPartyLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ThirdPartyLicenseAgreementMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Licensee", "label": "Third Party License Agreement [Member]", "documentation": "Third Party License Agreement" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r750" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r757" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r777" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r779" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r280", "r286", "r381", "r404", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r503", "r671", "r672", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r683", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r838", "r839", "r840", "r841", "r891", "r894", "r895", "r896", "r897", "r899" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r780" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r781" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r781" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r779" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r779" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r782" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r780" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/SalesofFutureRoyaltiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r367" ] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.xencor.com/role/FairValueofFinancialInstrumentsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesSummaryDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Securities", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r482", "r662", "r683", "r689", "r944" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r776" ] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": [ "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrealized Losses on Available-for-Sale Investments", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.xencor.com/role/SummaryofSignificantAccountingPoliciesPolices" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r18", "r19", "r20", "r93", "r95", "r96", "r97" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.xencor.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.xencor.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r426", "r681" ] }, "xncr_VegaTherapeuticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "VegaTherapeuticsInc.Member", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vega", "label": "Vega Therapeutics, Inc. [Member]", "documentation": "Vega Therapeutics, Inc." } } }, "auth_ref": [] }, "xncr_VirMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "VirMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vir", "label": "Vir [Member]", "documentation": "Information pertaining to VIR Biotechnology (VirBio)." } } }, "auth_ref": [] }, "xncr_ViridianMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ViridianMember", "presentation": [ "http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritiesTransactionsDetails", "http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Viridian", "label": "Viridian [Member]", "documentation": "Represents information pertaining to MiRagen/Viridian." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/NetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted weighted average common shares outstanding (in shares)", "verboseLabel": "Weighted-average common shares outstanding used in computing diluted net loss (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r166", "r173" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares used to compute net income (loss) per share attributable to common stockholders:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.xencor.com/role/ConsolidatedStatementsofLossunaudited", "http://www.xencor.com/role/NetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": {
```

"terseLabel": "Basic weighted average common shares outstanding (in shares)", "verboseLabel": "Weighted-average common shares outstanding used in computing basic net loss (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r164", "r173"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": ["http://www.xencor.com/role/NetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "xncr_Xmab24306ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "Xmab24306ProductMember", "presentation": ["http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "XmAb24306", "label": "XmAb24306", "documentation": "Represents information pertaining to product XmAb24306." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r744"] }, "xncr_ZenasBioPharmaLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xencor.com/20240630", "localname": "ZenasBioPharmaLimitedMember", "presentation": [
"http://www.xencor.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
"http://www.xencor.com/role/CollaborationandLicensingAgreementsRevenueRecognitionDetails",
"http://www.xencor.com/role/MarketableDebtandEquitySecuritiesEquitySecuritieswithoutReadilyDeterminableFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Zenas", "label": "Zenas Bio Pharma Limited [Member]", "documentation": "Represents information pertaining to Zenas bio pharma." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r446": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",

"Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name":

"Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",

"Subparagraph": "C" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r789": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r790": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r791": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 72 0001326732-24-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001326732-24-000043-xbrl.zip M4$L#!!0 ( )"!!5F^%:UOY3 ! #$/$P 1 >&YCEWHTB6[_?Y*WCJ>=.9YR";32"<67K'Z716NSO3]MBN[I[YTB<$(8M* M!"H6+_W7Of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|<>>=WI%1E=@-P;S\9O?\/O M+<A!NT%;W5DXA\](INJ,KG\[FG%GC)51P$Y W?G-!" [O|@%%Q[|E>BUE!" M0N9?6H0U%S;Y!#TB3QFV;30=@!'JR0JA_NZOSY3I/W?R"?AY W=5@^H7]8+ M[LGMOCW_"K/5^^\|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{0[@O@ /X6DO^,:S_!%N M#"\J=Y0KYL4#CI#C8?L:!9[C/8>-(7SEKGG%A+_U/9A1X+LNH?L-F1N)L:/& MD+_R^*)9G>/R%6=8= ^;I%<>1AT+$::6:O&-G508?*0[MC]&Q88%SEP6CC MW2 6N-3T6/E0/A,+O&IZD'VHO,8"S?=Q:I7&!]8U)#;*I'_3@^FZ$QME\J+I M\)?5!$QME$K[HD74- B8TRR<_8\F&94ZL\RFRR2\' PJ;2^/"WKIQ-'LC+ M1*ZB#L8U/0H^?*ZB#BXU/?ZM*U=1 Z_4IL?-!\Q5E%7EIC8^5]XG5U$;_9L> M'S.0JRB-%TT/F0^=]RB-\$U?9*XG5U$;^7E GX_F2GF%+RJ/T>NE/P^[V>$% MCZ1K(CP/CNLDOU9Y0%O?U)H>5AYNC:#8=I>RZD*TQL>=M:P1U,0L%G99LD"' MHL>)|:^5U,2XID>8!UXKJ8E+38]}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{$]LVI.YN/P2 MQ!;^0<;_[(l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`ULYG1@KHFUD!UK>[AQ_"9V+0 M/-^[C8D!=BPAM7L/H%BMMMP2/ 2.@HV=BZ^^%8/AA>,*6M3D#<@-/5EJ_S+!,=\^<'WW_(^&AX=Y]"*-"O&KUXIB9-=! MNAT5\FK)_>_?+A^>KA^^_X_P<'U_]_ DW/_V\C;Y>V3\'0G$#/]X(A(*O" MW8,@=S[8'X6[,\+37ZZ%&0LZL9Z75T]P6395;8Y$;#DT^33:-S:0HB$6_L<@M(B31C$ "26SOH.<OZ=>ODS!T'G4V^:0]{H\8PM?;-GIOOV.4M+&7H5!M]2"# M]5]_DG7!DRJ) @1?.UH(5BCL!]Q6<%O!M*UX"LCK' B1UQN+ 7+#B;70"*R/ MV5H\/5S>/MY0F\#-Q2IS$4T0D]F+0>"/A"R>$2)?V!K;"&LQA#'KOS1R DA MFRH,'&)Y0>B<.-9BS0Y8R?7LEH0/ER_(2NBYTEHVS.C)3XJIU.RPF F0%DD0T*!@VN: M@GY'(D,W("GC-#?_&)'@@)X(§KQ?^?9\Y$ &9,$B6(3'@?\"SYF&#$:K]Q6[MZ!4%N%R/I/B?)D)O-^G:FT6)/*^_NZV>(K5E75$ZTGH%/O%42D1!!8[=5@U' M*?B!PDP@3HQ/O)A ^#T.G-!V+.K(s)7GS$*2WA8\(_Y-_W[8Q5XJH\4-VPW5!W?!/3$K M1/:G:Q,* <9PO-SNUIVI54LK=^\0@N__KC!-KG=)-,?5,69:,SG*2W =(P# M B!GC%P!OV$KCIP7<**).L7AD1D.PG,!F+["/#0LF_$A/_9!'UT&&,VA76OU M=$5?Q/K' LKHNT\X>C_TO878&BJQ5*G3[IC+.I7Y,'(:'/_7G[]*;'P*A0B[M> S33/,/(KA:;@R0%XCGC@B-[*R+]M-E<,<#C^5"//>P=7%;!A\:+ MQ'6J4))5F<44,JB;^>RQW"6:F? ADMRBTT1_"KZ{?)Q$<5/DM9TWV#'=]=U=A M'X4%Z<_^NV-L?53&$$UX^L0TUPHN*;3)9\+X8/\41BBD*X;V@)R77(5B@/ MV?TC=L#%5)1YN'Z1+,(KT.5 G$=)!T$&B,!),2;#1>WA6 M./ET%05Q2; $:(D)1'$XP:,9Z_X/#1?@)&?Y*JB,)!YJW@F\M$[#"K5_/ MI/U"Rl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|@EPBJEAX&(MW)PQ9LY,,LZ.V)Q!U?R<.9OZFV#'OOOA=']?Q$WDJ;JYI@ZF")FKT!!Z=MV9/ M ,Y&'(;ILFJC9P)NDJ VUUC#%)C#6(!-GG6:G/[W C[#%S4N7T^6OO:@RMTZ2'W/71H M]#-5LT3[VDG#/[CG 8>QFP1(=V.<#(F7>3=#YP(*E#T7WKGXUB"^LF2F2E?E M2K=97/MO:&;]1+2##U6@¥ ,W^QOTK^N',30BO.S[<92>ER,\..%/KE0;H50I ME]4]UT>Y?-8AGW V-=6J&M>JS>(:]_,*"&.H1KT/? O;H$2YRFR&R@06;E.9 MV92R]VH';YBS:UL78.1L13DVG?\C-S$UZ7G.7)GMRG*LLN593/%#@D[M2Y3E M)=>6S6(;)%\B*_(KRH8H2N ;5Y3,C*4(Y[1447;XGFP6U^]H$7 W7G*(M"D45Y8=49$Y;- %#l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|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|S'1AMI:0+D\G7^4!U]%X.%DK2!9;(3)\<5;@)2NK MM"L=K5[F!;@98]7U!;B\EO9X:VFYIMDS YL6+(*M2 N::"[5"V%3QJ0ZB<0U M,;9%&V,GB4# B%. [GSAD'L9VLHHYLW:6EH-XSTVL:YK6'JVK4*3;1.C.#Q_* M6=/6R]0U3:LI?2(C_F^CQ@V*7G07IMN8#Y;Y-3 MPP9.","D.T:!D%0$?\46= <7^ZT^R+GU293$YA2AQMI<51NM8;9]6BE&*1ZAGPE_LLPQ2M@"83BF'I#?=[.0A# T'L/B M$2P]T!QW.$R\W1=G<[T;75$<0#YTH;.9?-MR BL>A30I1S^8N1E8Z%L)W:QD MJT_LS2X(}H_A.VXF([J5LN-&Y3MN3L!+8&7'3=)"EB\\6?DD?+NYO;RE6W#F MVI,N2GA.*,NMS90XA#5=/>VT%^3*4[5VGJZY?;K,\'UV-^A:#<[*8.<.0ON" M7+I>\3C$>!6S&!O[! [JAP8_),VSP'MY@$8SX*^"-I57&Z5^P%OTQKUL*S1JH M&IJ83>+T!&U:MC .\47VRR?;"8G/\W[A>'1L]$N?TH>EMA9LQ6(7!:!>7S\BE\^7/#?G,5%=? DL[DE9^O>Y2LG$=U5]9]ZCUGVN2 M7MZ@c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|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{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{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}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~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{IG4+BU1-,]ZY#EC/W0 SA:4B^Y/%&9U*B$%,W*GUS>OF,7#I?_ES3SM2.MO*2="[O_'S= MHV3E3.JN_LJZ1ZW_7)-T/JC##ZJS\5%;G/2-4:,Y=-N'<#'1!(>)%]NYU,.3 M,9]8^$'N&X;"-;&]]N=^<-!|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{>9"?+A5B<)"K)6^PL"%F OQ"0MQ M^2%H82'NP()+1S17-&;G4LREF$MQ'6M6A;58+WW]Z>!F "S!L+5M.KC3<6G"&% M44ICP2YO+'CXL1Q?8T&S07T%\XUU0UO!Q\BW?@Y]E[SI-EFXY-P_4?L1.^L M3XJ}]H+YABILZBYXE/T$%?E,-A3&6ML99Z;Y^@H?T^SGYIG48:XM(;F@L#8H M\XS8-3ZF'&/]RIN:BZYNQZ5H^[?C:E;?12/O(B6<)T5M=PF=\0+_=7'UORGD MH.;UDHP5O%+DT@:4]\BQVXY'?[H"8X@0.9%ZEY85CV(77$!*&;HS+]'1:,*# M?G*3=]]XGK-SQ:G1{BL>.):SOB#U="ASZWOMJYE:W9MMM;JG0YHG/TH5THH8 MBWZ^$&=M:$NIY+'"#M2:0\]FM',F\?=WS4DJ>@P/[_":FV"7(S_VRM-[3-VV MZ]Z0G9C*FKKX@ESD65@4OF(+PR%5@BJ+0LYVT(75X2Z<_+B,]=V*N^LOX^#BQL4MA[B9AQ&W@14; M=*.B3/P+15_N\(EDDOD$4ND++$HDHH$(JFL< :Y.')Q;)@X%JLWSEMP7)-@ M0N-871-5HX1NBEPJV0#H24IE(:%4:@H3%.754]7E/O[<"G)Y.V)YTYCT2>D& M69,$BF4U=F6HK11+N_7SX>DF#&-8(8!"5BNIB0D!%F(\)K_B-QQ83DBO)A^C M5Q38N1;5JCY*X@B7"&1UVQH\ !8ANVO<0"'2H;EV\G2 ?WY!878AG(4{6T MSKSH*H*BD9QBHXAZ=]DUK8SM.3H%LM0SI0+72,VAJY<9,W? DQG@=WY=5+^R(MW%?IKI9"UOM,'CEZ\ECZ@N@I:-5U>C9%=^_$+X?78>"5MD7BW.'0[!4;*5W*?;=M-);+]J4:16]>/=BU@"UF\/.N<,YP{G#N<,R M=PX5[!9WOCR*THK*0X[9B-P:0/RH1"X##(-SE0OX4!"UC"F$%;" M64('T7&=5L^01+E30K]TOI:\%4,T&]+N0Q4 E$]/R@#X"G+UD?7))OUX2I9E M[H19N'MI_QZ'$>TT_N1/>W1">\X;+VW,2:LC^HMU2 _XC]@G0@_XN#%L?"2 MRWW EO_I+F*TU+R

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|.239-M7"|\^.Z'89[B_%.CW5<\<"PGXI3IW?I>^VJZOB)D"RR<-+TG/TH5TNR:%=WY M9GRBGR?K5W.D6FT',\]_(OV96AI=;;=6$$)8082]H/U..W;80D|"*KK%)L|& MF*WS/0V"78{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}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{\;LXA/A=C;Z+0XC?MQ2'$[V(0NE74)1$Y&G&T_BL'9-=&4G3G23'[M$T8+60Y'-63%'N@*,F5;T\Q^5]5,6^E8 R0KFJE+_U+E5O:EX>1(V3%ZQNU^_M@-'/-AJ0"5X@]Q6IAP#L6103",\2?9%>:ZDR&%1&E426;&SY 2U$Q["M8.$N M,B;$S%B$80"9L3]MYX_1ZCV!%H$>MU>05//@J!'46\7[U1I&5@ZK8M:5$U/, M_A-[A!RB<,-9ZR69E<$2>M,D'8*C7AXC\@^MA:>L0.%0^.;ZKR'SLUA5JLWL M6!U/B(9^3)YAA\O#)=;7RL)$=!.$*AFCKZ!?^J2*1*KP M06$MY%,I$9++4UUV)B7Z+'4'TS>GE_(I?/ESPWYS%177Y+.Y)6?KWN4K)O) MW=5?6?>H]9|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|K\>N#0V_3Q=G"LN(MD<@<;Z1T9*#:..]\P|ZIVEW'2A)\ORPK?1V\595Z]XD>(T!M/XE:I3Q,Z/P&9 M=W4]3$@B&-WE;3@\B\L:MJIV8?,@:F/%8:>\C9#<0B,G*U_H1G=A[O? M3C*?6UV1!*7SC--QZ=D\.*[P6\ASD]I{APT(+T(\0OAL:HA4&GP48J=7 M6&F>A*T:"5DV70B2WE6GY<]6FH-=5=B32<9[$;]#9H(FH=!DI>3LFQG6A@AP8GI^7'5EN7\-TG(\OHF\1^A:4"5L)T497W22%P MMY8]'G;%=GR2I*[A 5722?' M%\?&H=W$@82Z;G+&'$YX4-AS0RG22J2V#%+<%ARGUS,NJ!\LH#,ZT57"..AN MJZ=WQ:Z\7#7#$!YA"QKAY9L._PLZ\I.?&3\U_[.+"&L'PPWY]VNA7GQ$H/ MRXRZ[M$|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|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|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{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|%$T#2%GR&@]-&3,!FTM=>]; MQD$FW5'IEFL&C6XPNZM,[]'JE>H?0^D2"=@5:6YK)-503R1?OKC?/M M$45#1%GC2JF-VX-][52_&IO=_+S@:*?<_EAE)C:Z$5BT M#"61S1Y$*7A9LQ7PSV6IZJK(H\OC7D3(Z41R^@VQ \L/L8PB*;>+4THI:A; MJ]RRX>LFB)+Z*F4FD"06$7]N(4@$X;5V2A<++MPIV0M62#S,LB21ZQJ(U-4X MIS$Y.IR,%>DR"I;Q.DJPQ&H)3-6,K7[(UH^BH.GB MF>DH'<9%ND+?4#TV+.43N$'YT=)7DJPE.BXB M(7NDZVW$\OI9K4]DPZ9OEV$873BMDKQJ6!W>X')5-0DSKV/NN5H4S96I"'| M$U9=!IG,[86S)*.!?Q-1':\-072EE!SO#D#V2/OE.<@IZJ064^@?2;.%B+UB MMC@UD%*HGCFPX5HL/[W+" E!K@E_1#H,C7B="|'5%?P%44O\$7MP/-JBS(ZLN8 W -_1PG05;")|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}4JH)0#3E[GQ4"C](@U]O_#OHD_1 \K7L><>E&2<@,? M!7-@V]>DCXO2 TR-.4QF32H]N;\=35J(\V]>EUKY-/2G],%?4/?W]S^TM: M?[R-E:8WWC2N%%&&]^S[U!HS8E$*2;X,7U(!$>*M1\S?]N\N+E@!![V57$ MOWA# A9DLAGB/@%HUF929&U0\?S)7'0Y+^X,+]YXA=HY'/P'+V,Y'>>"O M*C,(,1?L&H?@O1]LLHSK_?*,FK3R.W:*4-1XONOQ2.)\.")[0R)G)I+H_Q"GT@@,PI2N!({$JR8#^2=2P M=A(WS)F$I=/=4+";PL^S'><]C"/A4P5B]%><:X7^<'KGA-+[N Z5?1DB1I14 M58@6!<@$^AB_9 -V)06&J0-0+SIZ=S?VWMK)CBE%+NE5CGZ*B&&F^'I'Z F*X M%P3C@S=E#O:KP\Q(*\BZT#G;?+:,9,T7WWV,$3EP.^23VW;S#6#F_F%3:&M\\ M#[JPJH6I3I-4]);3BD"/&(66;NJ.G&B&V%#5F[DZT6@Y%DC&!SG8?/0>1(>,M M=P?Y=V_1%SH7\OI/5>EN5PEEZX(P"3)N:+|/4%!?:VP[GVWDVF5CGB-VC]@ M'$]+412CDBD*AC@1.8X-LGZ*+P)B\B\V%:4E@QYT#YMXQPJB55$,.UG6= ZY MO-0C7:8>M6 O!TT](O](D==$/PFO2=FQN..HP)VDK?1\2U48K'@7$I^"$-E) M.'P..T"9Z9!0H-8@6;X+U!%XF,+YG-([K7CB0CK7')/Z"YN ;,.=NX^V?;MSI MJXEV(2S=Z6?W:V3MPP\^>6YL_-/$-4*E K|<$2 +9NA1)#}]CQ=E*V1+ZOV, MK25*'SA(TO1"H2=E22Y1\XX@J4%_24MP3$F08O7VTUDH].L,%=+]H(!Y. MLYX!L1UK$;!7T3]>8^F(8SV_LEU"3WKHM7B9$;(_%=&/1/|*\3WMCMU7YYT:O+S M3>EK7T4#V 4= JDC1Z%<^E@)XO/=>SC=7;PG_AFV6%KYG9@#GY]*6S("?I\3 MRLM'U2KQE-H[_^?"P;OA|%* TN-Y5!/V< <6M*[R:H8,('9!D^1G0K:0Z%F$ M"M7Z*7BRUZ<"*AYVP#PGPIO$S5X!;3:?_NS!UTOY6R7$;D),VY4UG1-<)"%* M0FP'(6X0C7?6Y/N]|RW=Z;78Y&3"V&RV[N#H*#[,L3>[']^C<'SV7/8O$!^4] MG"505K%FTW&K84!/.05P_'U/AT\?FOK@IL!^"TR7!28*[4((;-DYP:[M:Z,;5.([*2V*3Q'91 MQ#8ZAG0SK\::W3&UGB0X27"717"#WC$(KB\)3A+F!U5C?>/Z"4E6+YORL.N:U>FG*YB;+1WGL^]I5(@(ICE9*_M:HNH(8@H='F8@UW)IAA)]R:)5I8KC-=(O!KH^\"K]9QXU!@GEBC51I0RCL.J ML%F"9%5GC%?FD?!*!;S2AIV!E!T*?']#/!J0^AV#R+0T*0(/&N4VA"A7/?'!_?L:,L6'/X&&L-#>6%5?LJJSQJL-T8^]X=7@:RHH1+4MF\I@DWC5*KS:2YA@O0@<2A%XUBBUEPA!!58U:ANKVC4L6RD90CPC@LNBSX , MNYUZ2^Q:0 'FRTR5:|(T9T2?F\(MU+]CH,]Q78(T>U=CLV]VAF9^4O-VSJ4F M;O)(SDY)OY)^&Z+?36&MQNA7;:IX19*O)%|)OH)\-T4/&R-?#<2O:70T7=*O MI%|)OTW1[Z90;6/TJU^-^_UA9|!8>I*D7TF_DGXW!9,;HU^CJ6(=2;Z2?"7Y M"O+=%+-OC'Q-$+^&#NKSJ8M?K=F*^YWEXRB#X OS;^>67|!1V^SG.V];,'9M*R

MES61#]M0.CV!+,VQ),HU[W!N">2ZV<;.$GFZSLAT9+"KT.V\+/[&%;X/Z@8Y@[MYNN=9&RSY$DP;,2X"\U-M_!']^7K!V

Y)CI(<3XX<:QE!>Z+'33:0V@,,&]7RPY_DM1.B=0:1+3MJTE-M546%D1W^>9(>_MH_MDC<9\LNWK\"<.]&GY%)XD^\)>,TKA0'0%_#BT?SHZSM8*R*V^X4EGRE M]\G3?*

&#$IDY&W^9,>>!' UU"\69")<\|1Y@+\|4LSUX'<-O8MU\"LI'2D%7_M+'KHMZ7+, ,;/>]M9BB6S_#+!F>SR_X7L'"G+\&BU?S4VC%%GH.Z< M!=V>>AA)/Y) ^]M,/JBC;!*

*<\&G';T>]#[_;:S\2^>6Q@,.K\9JS^P M;4DMB-QIX1P;WO>C\4J_M-/:,$=Z*<9.AH5WHO^F&)UJ/+$!*N)t@,#/:*1'+:GZ5*FZ-MJ40@36UIU&?IH\'X-T+==I<6G3*

*=@A0W9V"|<.,$%-O[@E<|<^.4C2|*$/V4# MNN*8O>01ZPX.M0S+'\G(%*HX4]47W5CH6 M\V0]!PCQ=/S6=[_J_%P]>^D)9[.]G9#C#] ^=OO%FP%<93{^"O9DM68ORMQ' M#O*

*W6Q^HVG36UZR1.C6,T=U0-T93S9S,+)%4S1OW>/P=78THZP%@}B7P##)K M7'2-*Y@>=9P>C*XUSGG@&S:]":-/];N:R1+9"G>L[OWLIA(H2K(C-*UB=@1F M ,0I/6(9'U=Q:/Z5*

*D"U(]9\4SW.@#6FDINH'<*3$=IdD\1&X-$9AOX>T;A:.MES,!CT53ZL178E3=N:=3R.F6 W<M.C/B:OMMY+4+:GL(+*FI-<2]L FHZU?C$4Z%U!*S<M2?X4!/H6-KL! KV7=X2?C$*

OJ,>5%6H75G;%Z-AYU> M8\|C$W "2UIJT|EJIE(=E)@]N&7]8&:QV>M0C-=M#>#;4Q+4-BGL2\|=5=0VL, M(LK"MC8JZ#(G=C>&8+19W39TT'Z,3E_-%[W(<'4)]+DMI-

R#DKS%6P< ZB\ M@9; DK@E<9\E<;>&MG2W"6Y2W(_$6N^?R[47V$$97$)W#MP^YF MOO> L^R*1MX%,0[1?+KIDBFAITQ S;N'CRC5%^?BAN'] Q.?3>U0^?<2-*

A(^XZB\D':&8Q.?X9+2RXI^IX?SN VO6[5P7AM M OH;[P%6?B9&+P.%/;O)1X\<\R)LYQF /YDAW/%4N"ZIK K(`> \H/M4BEE M,FRP]\ "P7[-ERR%:9^S-^9NHW45SZ;>/5<-*

MX5T#++OJ!G<,2P$[>+A;.U?WM-/AU7C4S5M2\4:?@=H@GT$/Q%,R27& MXRR!$S-"K 0CM!M;O0-(C+:-)/4Z&KI-OCVASOQ M"R^E9-2MJ>8&{<)G^+|L-*

QW.3Y?C:EWE>Y#3R8,_*0W7I^,68K4'YGC\Q1-MU$@NIACXW&;^Y4_FSP(D-[=OE*$&1)C,JDW/|,T6ZC0SLG9U)G=:4A=/+>9@-M.X?V ?*

*U1=]@;-5,UKG=50VM;*3MN2C]@*7OKR_Z28LD_*Q9+7A($+A$9]C1; M],2 L+Y_Q**#&^"$%0LM/I -59N0U -=MG1S7+2O[W*\>6IO@S^O2#>M&U0W M-, B.KJ:+W':R1-*

WTIYV25\]70E_F >A+OQJ,':V?=QBUC;XNH8#CPZ<'5,;6 MR6"9'IHBD)AV!-2EU+2)4)DBG$K<6AP !PR<8YH1]-WUF);DAU\"KST M3]NWIS:LNS,WK5HV>^J4,#P)?

*2OQJ..OCLS;4^UM42A% J-#H!"&.$T&TRS M/K9B6LD"%_ (7*O](@N:,;%'=,,>V$5H<@F(S[&B#IA2;MJ=)2M*5I'L TMTP MK]\1TAU=C0VMHZE-V,4MRW%,A^U/+,,.H3-*

*52C$FF%L^"_)(DVD-|^'3^U6L M(0/H0Q LV?0M((YI_X62Y6[I=7 *^]IBU5LOQJ-^;PUREVU5/\Y654!Y0^^, M>GG5L>"#BTI/XC>%V303;BX'> 7XMX@+*

*GIZUH(M@0B#CO+!G725%_RKEY1M_M,V?;X*RQ 1$^Q FBGY|<-OW%/X;23+A^,SIX4-EX_K)4HR| M CYVGD5*,+A*Q_B!SOXCV4DX7@=RBDN7(NR8I/?S6'Y"EFU4:ICLIY(VHVS*

*MG6TW.A!=F!46YK6F#Q'GK%GN:AYV[51#5=TE[37}^U^3=MC7P3S"79)G MJV&#>376NV:3^=SJ<. ^;[N.F\U+V0E$XE9YNA\$:GKP-KNLKN'[*I28*()H/ MVP$1-P?1&=37)T:'U"?*

0$=D9#LV.J1?(FW*-0D1Y?[&|2)'BG[SD?*K=AQY6 M/+0X9.;LE!GN6$%@SVR>&)ZO:1.0+1EQ4ZA9M. (-!2>^>!8+";S0H";922 MGDJ;'H!U:*PI*

*LGRKHZRPBF3^C!DDAREMBH!V73UJ 9N<_/;GO3 9JK:X3H M-A>N!VNO&B*G5O&>+UI&;8>T>0?8DT@=<2CP)XHEU!QI+S(ZH^^%.(J>4O\ MU-Z8?OH>LCBTUN4G[M+*

2IJ%!=_1:P&T#$IH/DI6I(C/)FIY!'K#BSZ95C^ M2"[^_4CXJO97H)/Z!IQ/.O3OV?4= /W!M36#S;ZRG"?K.4"G;IHD@1[3 %P] M> ^D)9[.IG9#SA2DR<;KM5[P,&WX%>*

[):LQ<%!!00 =!L?:.!JTUE?LT;JU#!& M=T/=&$TUN|-L@#,=UXCM,52,G%NL\4V;5^/^,@!?]SU&VMXI1@,< M"+/F4B^,YK9 X;WIQP:#!?

*ZQ)AQ!G96N")14M>Z*1E6!C\"1'36SVZB00;Y M$O3!<+78 _24-U^8XST3(@_ !PFMF-SR0N@C'M$0S%"&\)#A9?!U7'L^=4C"S-M/G.BW^$5OZIJ.9U**

,IA='73./-9ZG)353>UOZGSK9NA/]Q4E_R-V 3O;;\ M0_9 @WJCFNVSFRQ?#2JWP#*KP:29@O[6CWNN!K:*!?[G/QVI,KCT70GL'($B*

M<6@'"#ITZ=4Z#IU>,UX_U=&,5_QEIS+=|E[XEC8IUETMKV'2PK%2#DW%T)$0VQ%>0PGW7:MA83DHPD&34KLG% M/*

<064.5:ZP'O7P0HL26IG2VJY/AZ'(#7J3M8OJ%K$:D=NG'2T2Q.',,T M2EEG=])X &]6U?X\\SXY!S.^ON8BHC7)3$D\S(SUN+1VKLO0 M.-N45HE-C=;--%>-?PQK\;#*

O>/Q)C3QY@M>K_MPG^:FRMUHGW@CJ8;_K@52 M[5IL6R>]D.85U3A-)-WIE;(=@17R XP%SDH[V#:=E$&8DU|&RL;>Z!PYZO- MY)Q;2<2G@]@YZ5)(TX1ZG*

/@15)]D)4SXM4#Q:R:4#ITCDCTFE]^.$"*7DG/ MDIX/&A?:G9Y'O;8C1&UIL+AYB'2;BGC2Y7R "1YU5$N/'I:+/ -!8E^XMP[JE MZF\4L?<8'2SOPK$M%YUB3Q9T/8F!M9A)R"9?*

*VH#6MN4 0@=\ M+#7#Q:P0=A8L)_/5AV@"INX"Y_G1.+^2X:>C@N&GH\K#3ROA0&ID*KD MTDU0N$2DN/3H=K.TTLC7@[2A)4#9)^_NH1Q1/^/N2"^O_ALQGR?37<;L"K-*

*MWHLT>^LUL;@YBJ>":GWS`/;UO VM78T#N#8<,C)]5,2!+W!=.%N\O&B*G5O&>+UI&;8>T>0?8DT@=<_5>C7!O":=K#;3M-RB[MA<=_K%|KL,+4#-J!$E??RRHUCH MN7JT0J;-*

*'P.UD[^#@(&X.7/Z1;UQ9X&METDZN1_%'TWX4<7@K MY*Y%8 3+(,,87#CP >R?QJ.Y! %02X=\B[2K [L.WR;-DRKUJXO\LZ)14,.7(PBW+A KTX=?*

*IOT#AL9V%6@8#X$/W_402SCZ<6;\>_)@6B) M6\0?<&28.!YAI*7< D'#];U19K!]=T+03NX/D^0^6L^*+@:?5&G BGO>W/W2 M!!6Q2D>K8YC6_;H^Z[=V@! %2OP\0S(%>B> ?.7=V-*

*X P074S/<7*V#3+X)K M%B*BLS0*/M9GW6),AJ=#+E/1ZVWF(:8&"9;6:+\8W+B W Y?)N>-]25W!Q+'^* MN/[6!F80>GZ@O$ .0I_SR47$YE\"):=4C"S-M/G.BW^$5OZIJ.9U*

*;

*JI"+L*T*^3(E5_M8K51K2O>!BZ"B12P",R>\1IBN,D(*)03%(/A!9W_]\@(O(F_>LP*)BVL9T2CFOE& .WR?*,LV44WB"YIEB0>?9ZEG-/HLO[E^0TFX#*?BJB+ M\I) 0Q\/"UH:Q47I$2BW/9->]TSIXWS-&&,W/)?GO>>O'#,H/-F -Z0IRK@J MJNFG>R2#DW*)DB9=$02P4Q%HE=R^)MK,&)&8NF2[:'1FJP.3=#II4@=[9ZY MS+<U&"YTYP'-MB-J T0|BU@24S>BC5>'SHLLGS.'EN!:A(;I#=A?!+4'F@_!K.C*BR\|V%,U-M M*_[,XAE_B4UCNJ0) T%"$B5;|R3|%%'(,%47 !"N%4#4>CN5-.3MHN'5V%Q; MME)[\)6%!5YT'K'_PL!P<7N14X M4UGA&UOY%CHY8;UM59[6;|@-E@>0"E)9:[202^LU|!'+,U]#30^Z^?3M'7*765O'WC*M+I|))O,JS2 E!?Q7R^CO@G(2\$\#]B_E[QAFR@@2/[J>>T]}(VED3K<7WH5/#-=& MW PAB6#)/,,U><::S#-NP5X.G6>L%^89&VOSC(^$H2|\R_B,!*I[_/CY*R@M M7&NS9A:0'2KL+Y,&'>0]H-*

*JU!%4@5^W8K[}]AX3IP9J>W"NH6.E((R*MX>9Z5]H>AV:,W^!NS%4U!6)=KSY6K* M,.N-BSE.SVRMWS7FH^?^:_EH5^D9DX]'U&P>$55]0;8)TAQ06+1SK-]61FS[M|&ZHDX6XG6J_A4'A>>&<&&>NRC>N:5>]>NYT,>`>,5V.@:QVQVDfU+NO7'UJGMN-M9C/LX4CU@LJW7:YWSSUX:ACV0|OJZ!CP%W4^YO-5M.IWWLYB=4-Q1]U/,3#GM# MO-_|=*X85BF#F;?Y#3-%C--,RZE,B773*27]H9P,59\/SZASRBTV6YM;MO+1 MNKMG|'N4G T1U%14CQ-Q_(.H*K#97B5Z2I+*D_0RY;SNK#MJXE1=R,?,!*

*MCI%*2]OQ(9H9UB|:"]AJ=Y1FG^F.XV %X, E)))**G7"/$23[$PCRUROB?(^_ME*>&DFF)'|5^G19?FLC,R8?,! 2*$Z')$65-)BP@M=HB)28QNU*^I$CCCOQ'-M41YQ%''F;BV:*@ */47++)1I*V4M5*A_T-M_\X)BE;;CPQ3SLQ/5K1N['+ZA3?X+Q.G (B<-"T& M#DA3VW^YH0@D%JJ5Y&FJ>!>QE-O1I7R'UP7D64_&O7O(>1U#L".P/*)L7L?I M6=|IC69]7H@I,5J/72)SJ S)IH1*Z(7|P3^UV#EFO'GK&D=VZ[' ,W(<^C M-O'!9=8K", RD|KM2C5M M0@D+P^BTP?&F)VA6<\R'IFW('SG:0D.A5Q^,%#!];&2KWT?02"@ G5O.9]*

*MQZ6T48E2LC;JD\|JW#+NLWU@0S|0J9))>$M0YYU*E;W;,GUY_P;Z"D9>&G9IN M2KDHSTG8L'Z"4Q$4' !MD|-V!^DDD2OV=S|4"BA%Z-$K0*7 MW9JJ-5$MK&-^P4VM6"X-*

<6T\H6|;@9+>9RG-LN@A'-R]/8/Z?3K2%22G&NKD M+KCB.>-IX0/8P!V R|O GMJ6]Q1BJ&@O,#/?Z:;;9HM$RM5((PE4=%^G"V5L M4?^:GA2S0Y4Q;2;_N9#F|&5<{D- _90*P^2!1)\K>N;YC%F|2B^FF44DGL914 MQND"7A>6Y&"U@C6$+&I6)OXC>.#P$0I[7>#P0'W1#7ZV"D@J&:/>D) BH=S&/-M00R!QR+G-2"\Y:UB#H//+D*WG8%*

(37Z\;DYW63[WM\3/L6'G18QYCXRYO79<+,E3;_.PC;NR&,I M#]; /!]I%T%H?2=,XR?^Y@&G$2Z08 L1M&YD=Z8%7I)=G-|(_/<;OG;1N0?8 MR:71[C-&B1NEF?

V"C3UW52K228P=`K7"N DU#I^*8&S@.4BD MMAC+17V7-MHHJQ&0Q1(# ,V23TO4F"\;2Z.*A!M"VHR-OB1OHA>7>\|_RN+ M=0!Y]B7;\2UN^,:=\@\PDD:?%-W;'"%O*K%-*

\9'[@0O^8'MF OA\X/C- OS M_O'!9=8K", +%ys/N/)<|Z+HQ-=DA~;>3.9LN'9H@06(11,06+_! MX[\XQ&D$?T&APX#K+)I]_24[F=`U'2@.5_5BQREE7+0#HQ#S2-

CJQ%S2-{0[' MS4 $>T^I;G\X>09DB.#$PT2$.BAU^)E@BTC*WID/@W2$2R7;HE_G7"I,H]SJM"'_S^-5A9?=^&KG_.? M&T97-XW"KWI=M?#ESI>I6KHH!//S]F>CW, ^TQ0_\X>N<)K&*

!!S/FV9$PTW.N\?Y$':_MCYS#O$,.\S|W_LIC*IP#!A.S@W!Z25"Y!:Y,#2:[H$SR,\$)B;DNP*I&6T+!`M4|X^*:"A-*J_9M/>S'@TB6X)'8="+L$JUJOI%63*W#/95\;7B#7V;3.!CES*

*M9TV^W_L>V*O7-KTF$\;_5%Z#L@Z;Y?3N_2#L9IN(,/;&83]2Z9<1C=C?N%_2TYF;T+G>!5%OK3LI9P:,E MTJQ$4L3Y4L2&O,"&*-(K%M2"@6Z2)%]#-*

I(D(1+8D!#:$$GH0!+]KBY)0I)$ M^TGB('E\0'ACK6@=2"5%(8H,)% 4.8.LG((N\|5<2MY-]5M9KM"+ M*-%+,58DZ#>D!?5+AI]+`#H"-10/,Y%G%C60+,I\T>L@LQX,'$18E,)^':!PZ*

*M=*QJ7>;]7E%!#/1:R>R48:MS=[^8^YAJD?]DB[-TB'9&JR1%!%1Q(9]DOV]-M44"/3:E1DEHDM>R?6@Z2]F"6S)F4%-$:K)$4$5'$/M(>]LL/K6WRXQ(IN1SH.+EZ9PJ7?D1)$?NGB*-*

*ZW0=&V_R(DEHDM:RA MEH-4RPY,*3\D19P(11PU#C5H78[#)<2AOGFAY=0U5,5013%;7 ?03KTE3BJG MP8K5AGN>&V]H$C3GPU,.8Z,-KL9J*

*T*VP2ML14=3$]XDW&J$>Y\N1(/AU=@P M&TOTEX0K"?2B"'<6@9#*T=58&W6'DG EX4K";89P#^:,&O:NQGWCY"4N6>8_ MAQ0L%4?*

*\^($^+0$8]B2"O/@SSR.SP\UK[!,]O<_N+03&YYD !C=BY<)_#07.92BR^%?OWZRI^$< M":?;X\0K7#]B9?%U%[IZ.?^Y871UTRC\]M=5"S\O>Y6]=7O#XD?*7E7^N=*K MRTT=?*

*E/FVE=M<"RN+4(?Y7Y6H!Q,@-DP_S"B<+C"?@8E*1O(-#YR9O$.F<7_ MW/D_CY%A*, K2AO+G#=4;H&!5H/)+BB34FVK2N1V@P%2P6,V7S:BP&7OBN! M_?*

*_VOK0[<219]*_HU/2[#|\%)[54^=XW*YNMU3V[5QND"7A>Y6"U@C6$+&I6)OXC>.+_9;XXTE;W2>#3Q2R3^*6Y9S M2WU,>EVU2(&5I*[_O%-&-# ME=S), KQ*KMDYZI#]M'=+U2%27N?5NUYI.J1N(8]"D5"&A*

*[:*Z:WO>YIBKQ*_M25YI2MKV^GK8VBH5+2T%Y.(_4--?WO9$FHMY>SHGX3Q%"[-&+H M"K!.[TIBS4WIZQD(*M2TE>>SE'Z;=!N#;K345#)TE# M>SF$Z'?*

4I+_3):%='$(LDE#WU3MC>ZTI5!SO>2KXXKDUDP4CS7^-1L7 M#DOZVSDL4=YR*4GHH(T=EBCR*B5YI:-Q0+_1P'|J@>E?1T$G2T"$/|_8; MVQLNH6)IJO.C.F=3!IFR#[NYWS!4YT?

5ATHQ[E68=Q^=' N-INK\|A?,>XV M&7) $U2?S A]SWN:5)0 M?$=T=58&W6'DG EX4K";89P#^:,&O:NQGWCY"4N6>8_ MAQ0L%4?

*\^($^+0$8]B2"O/@SSR.SP\UK[!,]O<_N+03&YYD !C=BY<)_#07.92BR^%?OWZRI^$< M":?;X\0K7#]B9?%U%[IZ.?^Y871UTRC\]M=5"S\O>Y6]=7O#XD?*7E7^N=*K MRTT=?*

*E/FVE=M<"RN+4(?Y7Y6H!Q,@-DP_S"B<+C"?@8E*1O(-#YR9O$.F<7_ MW/D_CY%A*, K2AO+G#=4;H&!5H/)+BB34FVK2N1V@P%2P6,V7S:BP&7OBN! M_?*

*_VOK0[<219]*_HU/2[#|\%)[54^=XW*YNMU3V[5QND"7A>6Y"U@C6$+&I6)OXC>.+_9;XXTE;W2>#3Q2R3^*6Y9S M2WU,>EVU2(&5I*[_O%-&-# ME=S), KQ*KMDYZI#]M'=+U2%27N?5NUYI.J1N(8]"D5"&A*

*L

*M;@\\"/$1<1TYA0R?)K8HL-4LN)$JT?F?D1U.-?,(?MC?AXXGA3#E_CCQX M1VC[HC#!$G;ET.;/+U!(;&U&Q>@R+6*C U>5.&%X;$%".56*CS9 _:?>&2! M]E.E76]<;$;.54"V;8Z L("'9). "R 62=6!E%E^/H?C!]>Y<^H3X7 M^"Z3O"V!.4#^>+-@%%&[P-JC':[WVN]4JT8]KZ6 [1BV+?RR _57H'J!>8/A&9%(7)G/A\$ M;F>=]1R;?EGC J$7^0()>&!@4&$DAXY!0 <=>"D#IS4@5.1(MOS,DL=-ZGC MG71[3B0fL]+ M*AY/+>*>M\5RQ)5?-;'R"|+%%;65:6^&L6GFMB(U16H%[&!UDZ^'' 9L#4Y M*N<0@/]DFWC]H++!9,=;,-S;- +NB!#D4)XZ:S0P=A9Y3YYRSFGHM0"Q^?K8= M'H2>NY"^:NA;E'6^;GL81FZ GCA]} M'A9M]V=,8H#16>_IH(FS>E#F8XG9F MK:V.1KVG+++.2XJ:[:5]=A9N=''^5.W5#-K78 V+BYE3B#>XF%_(+2@_+1F]$O M+*<+@>$(3+>3PF>G]<).*@J?I<)GI=G:H =MB?J('V&BQE>1WNG>)P4T+TK9 M.'3Z0^GN/_ W;+.2V<6J=/U7KEVD$E18[1+CRW0B%G7W9 MXA?6,98W7$(-MZO5[@IQX(**Y<5\|\%23;N=-->7% KW.P)-\7'N:@@7L$@GK?@GZEP7FS#M?]; MCA-2\9]2{K2M;SJ[2R&TC BMZ/6FBN?M-YZ?:90QUT/D5(SZBMZN]_9^O*B, MQN?PTE('\F5%347O\$E]FW.KVH"L]O. B\(M_$?>CZ/)73(GF+#_@4E!Z=I M.S3!O2R1]: ,P1<@LI?)=%&%RU+BLMW<(#ROK/?3?>JBW.PYAQU!&E946- M*DTK- 7H.QCGG$*/_PD/JEKH;,7BB9?@GT=$;W)-.O5$B,V@/+2(4U1X|U9Z> M'Z:(1N2)%AS.$SQ&.HY,L=C"T5@+8^O8@$EUY0T|S/1?VYX.^YSB8GA#W3#\S MQ[1BU'5UR%0ZM"BGM- 3H.0C7G)-#NB"N_.^"NZ?E5G)\2WU"5OFPF^TD;6"\# M3Q%DRNU2*XX3WYXB0^MV$&OPXFQ R;M'@T[%)IZ6)KA=K?S MG3R.9-)0O.YBDX-\GIG&YE _5@PPR'8F8A;=9S:XY_R'*%V#1]N^57?3H*YML/CFW.+I M\7Y<#CWS4IRR%'#3Y^-U92Y$J_LK!J@O0=[D9OVT#9?2)OK%)ZE-5.!\/MOKUID+6L2"K>:CI7&?N9:*@; [=TK7+UZ<.7CO;'MYH)^7?OJ6>$&NJY15*RH^*BN(-(MD|FO,%&^EU MR.'1;>?B;*,F7|ON\+ 4@>0YI4S4I>]M/^S2>PZ.!L+Q/V]|+0S!^ MJ/$&@..%D^@A1Y904// &VM>$L3YH[U-G_MOGS-T$GX^+\;DD*$>(ST3K;!>^Lf$_*ZS4L^*('6$ M(ZX]V -NBG'-52VTK4C^BFN@YNHM/7GV6M323 CAW<\#'WEQR3T2("T,V"WB M\-&VPI$4,- F[I,!HI+>P 7A+4;C\EHS8, &UX,^)S||+$A+/8-[NF$-.P;KZU:KU1_TFJV^9;3-(=.-5K_3^-\N M.**H0I"_KN"%*#%_?LW>Y.%Q%3.0'DH)F!0?@,%ADX"_B7]Y;]G!Q&'3-[9+ MFZ&;WLIG2:K/B6W3/L77*\4&X(09)1 OEE^78>O7B]^WN[5]9:1^U6CKN=^ MONQ1NE%OI/)O62:HY9^W&IT37U1KY.,>"?>L##$H87K%M \]>DRCO[2?L,5XT" {1KXUB)%\EOD4KSBX4H1{\H1;O!1"$6ZY4'B>A*N73^^>UGE\/MAOW$V- MH.-/_UF=F=55>71EQ0TH.56,45+<5#KU]K&VIRBUI+X+/?.'AN=IX[5=D);- =4K+6ZZ"C=EQ4VQFNIR==THB5PN44;K>?]fVP1-N;EU9UFP MAX_R[*RS4/"$B?/$KG)}%4\HGCA2GMA!ANZ.XZEKY^YFLU Q+?5 N7W/YVY: -MW/0YN>6#]? 83(&2#93C@F6M#SZ=4S,/1^TL8BZX5CUHN&&]+D5U4S.S0/ MP'8N9F,N4SHQO1-S&3#'$ #F],LB&_^UWA,. AKM)V97;/972>T6X1^3E$ MC14@2TGBP<6; M2@TB7+DIE8RD6I=$F5+JG2)56Z9,G!=:,IDK\L-2=4>N2Y M)>LT]4V')1T^UJ*RS,Z8<#<((2K"+1<*SY-P-QYXIL)Y2T-!RX(B;70, WH M^3T$]-)WFIX_P=I6KC$3UF6'- L^6=@>8!E1,3 .2!>-49@U?P2/QW0!TN "_ M|H;. P|"?$1<+TX!OJ>)+0II-0MNI(S_F=DAU.-/3+?BB/IXXWI3#UX\C M#|X1VKXH0+^$C3BTW^,+"E+ !:^W&!2ARK2(#@1=5>&%X;-% L15;;H4G6\%V M$X\LT'ZJZ.UZ[R*A8\3\3ZUZ8R/"CN. U#E\P!%(N3.M:V(1\N7BW44>:WI MJ++G 4#0'D^8[5.DW1P!U#E&/|^NRRH4G13$JGM(E7398I\/.*B4&.P+F81 M,W'9+@*CD-XG/; G(B+'@B1"Y_>I4^H-0=NPR3/4M+-@^?1C=+-A4%RV+V<#4*$8S9[X+BP.H9%X08T% <-M,X>$'#F4 #T52+'"%M5Z5O\H,5!&OZX-10FX19CF"Q;;^_NKY{G]#[_=ACT:[MW>_KKTHIF/*C?E_Q-$XE>$A*! @?D2\{;0]&2.2;7"BA*!"*Q\)2- MD[YAYHAZ$X|XH]TF>##EHFX; <'@!G4(@P\-Z+74,<9P1_U(N2AU#]&,(=0RA MCB%*#]BQQ#'=-H 3I@P!R:^]V!;PA>O1 &YG1EMOT,ZV1HY[?T]VYQF7/XI M5F @,HIKI/&2E]0YG&@4]{ABG16P.]KM? H$RPO)$42E*.RZ_2]/.VE"'T. MR#AI0FOKU6Y//|8"Q..P!&<[+<(1C TM@W8K[TNVZ<%G$$;%-OU=M-C>L@SN" MVAU%;&7:6ZM3I3;/=W"H{K9C(C;P!\#4_ ,{#WRT7>;:*CQP0K9TM|U5 M'EL9,'"*5&94>ZT-.Q{I6E.T5DRB-;N=QNEWYUDUO63GATEQQ32F'>'!4OZT MZ.>VKKHMG'6W!:-9;>B|HVEXH-J/*{;0\4E=OVHTCZ<#B6((Q1" {MN2ZO>)# MXLO9D>?|\YOBUU1R_$JQEGW/\|D>@EJ=&*4ENNER,7AY)40"5,\C,/BS^9+U"'^H2XTBYV!%6(61$\8U#"%MT# *(Y_+6T5=G|@,KGP$,.-^VI&+ MZAO6 LH+AOV6AM+3P OCI?2|\{2XQ&J^PBJM"<-N6LS_P459BL4'H.Y&?GB M=O; ; >_)6&7U)"0JC@9VAPQ63ICUMRS[VV\EP58;%,%D^@A1Y904)\BA M;"0R W1@22@L4E2.XFI"RL2VYIJ"\S$8>13,;?% I.W!VA:#KP',CZ_ !%I[6J"PG+HU\ I M?C[@?A">UX{IJ*M[7C)*Q=8100A[++$H30'0{I=A<#:,.5JPTX90K>$(=.<_M1:WJC|5UW[730. 1Z$)P*?@_DGE*GD5@VM(10J M\)J$DTFU"&YWP+A#%|CSA=9:.D@"MOQ@F]29 -F:?6]7LHP%80%F>"]0A*"=@ M5KI?K.=>2(6I+-NG;@>Q!U+7OL(R8@V? O^SDV>D&ECP\4S@LA,BZX.C2X'71 M:|(#(;:)}+_->SY^YZ3_^UC/TIEOYM2VPQ#03!"D#/;G(&CH>V%>P%'PS!S!SD*Q@U@H$!T"I6W<;*#? *J_N_A@)A_(6I9\OZ/S89'^LL$%[MRL;&(37N2/WOQ%R+G6VI&X.8)(2Y&!$Q6=1?!\G%HT>F+ P?!!Y01V@J]%.\ M =&(S^|C!YD4[))\6I_%M2GA)KPC- $^I*X7&G()4/,824O]=#L>L9BGK$UX MA$V==^H:Z#=X(TI^D)7 Y:$SC8,)D $(B:.,4-3\X\I*K9V/W$<,0!['X, M=B IPQ]$Z(]9 14S$1*\D 1P*!]^R@WA"/@!|\'V1? 30|6TP(ROE6^0+4JF9 M1&15N'"QPHQL6]^/+@GG73K890,L8$$IECT< MVB;&M@&!; %4+#"C:X%'|*&3\G>3;IR7AW)?>)W@K SF 5[VIUFB11!26;UDRUB M*ME\B;9)38.[MD#'&@\:BL18:B$$TEJXC[7;IN3+$ND#\S[Z'M+,R 9E|NA% M#KX?_'PIM"+)%O&;_-C[J;'G:'""^3QF!4? J@O<$F[Y55K7X#VGOFD{U M-^+#NE|FWO)MC8S,@'I FI(R(B*S(IQXZ>1UP!)$#HJ7V2O&-MU9)+8)C61M(-MZ 0$G1GG;U.'T!N-\E(${'@'Y8/1%P!Q?P;V^9VF8Y@ITF!T>)6E\1Z,5T.VC M^;.A- /%1I(DV6CCK(0QLB\=G#9X/8A@[++)D@'$18:A"!|\\#$B(H0/!(Q 8I M3IHW!IB7 5B&^,*1S_GF!Q#G=X,<67Z&7(3-F[_4R?/)GSP?2DZBK826*4) M0H*\>.V;Y]CF$9Z'? 1GA(]#,PHB!N=HHQ;$)/H.<3[9NF^)W+?53 BN8.1 M!Z/QH:C#)D!#UAF'GD)$'H.OUM$HG3RQ:)NZ-10'34> #Y*@^B M*-1$!%;]M8,?Q\$PNH1#A7G,J]H(Z.C?V.! O+@SPQ,&.5_!*E8((#X !#T MOC;@%M8UDB%IX,!VAT!,XNS7\SA,Y4Z6(WA"_/(#@CZ'\!C8RI0S7UIM2\XE-N86W2@YMJ3/MD)ESQ$>P#<\V+4(L(?O5;UR^2D-+- O!L3'S91!'32@(>QN!Y:0W64UO5P87 MM#?Q4=N2'TG%K_JY'-AW _-R/B MJZ\8MN*^\ 7!NU37Q-!5Q)$J<)<|H9A/?+.7N3G]?I@\0'X_FVYV4=4X]C86 M_=@QCV X%-^1+R9W:/$ %#0].3E_CO=@I71@9NE@DE)RA6%\U8BAS$67GE0 ME@#F%Q?RM#+'EZ,3H35>C<%.L7IQ)"J3,K"|=>")IM88\/(1!$'A+CH6GQ&N MDB1$|$N^*Q9@QHBBN0?%E @<8!XN) [W*0.1M+6@\P=_M=@=6:#2."F2(4X2(@Q1RP,^\^2>#@%81]?/T"=F)G@:P_[,M%OJ06X2VP09 M39>@)26"XTL6),2<1NSW4=V(_/((+34R8']T#FE\]HS9>Q7R9DF'L;O\4 MA"I5[6LKR9(&WE,#C<%"H;O^21,&?6?KHU_D?] Z[@E"YXU5>+PO MPG=T_$S/CRU8<8B2WNB((2#I&R1 2WQLE&_#?(X_7L,Z%L E&4+Z7<|Q(IP MQV3&Z(8(TF;"M)4KGEBRL/*1K>3]EBBZN<(W)))4FP,VIQT-^G-U+A#)*>|SV. ^<$5 M\ 86Y8GAC#(@ =!?+*= KFO.8046<,E|GI!VIR?(('*)76+!4@#D;)@FM M+0PE2M>%TX9HQ#CP-MZ$65"(]Q2V&T+R]R66+90L&/.P(9V.9(11O D:2:$ MG_$9YM,O9@SUA+CY,%)$+<@W5(2YCOOOP6Q C&JB++)E'@3.XW9C(!N/\W)BX MQ"'J5B@*E'*6EPF$.>*'2G+8 Z7-RG5D#)O,F]'/QOS1\W_DAXG (?CA>H\. MMT3*#NK]9:LJL7{/)?/B51'5\;DTU6)D3'#FA3;)="Y]=N[]/JX^V#[GCN. M;U-B=8?(6-RE<,/R= T@1KHQL!T7S5UA,,;N8$)>F)EV!2A_(\..1)"*=$%38H3I%-W96|\YZ M =4DIST4U45X1>H,]SD#+>KZH!+L);3.XW-EZ0B42RCF'DV&2T6GEB^CF#I+Y M)%/&'OBZTH)?""|-Y- '/23'2K7BK3S%#S.F,"9Z5V6Q:*IYM@_4)N'WN(-U6(+5QE)-MJ3;K;24C26^KC*33UX&+,Z\.)->_7=Y^VVNZ/-/7V_M7WZ_^?!E\X/K7LD/KO6Z]@G\24>$[CBZE<<4*4TF@6;.$;- $]5[9$J4R:<$R M35@6M9UD;E0:G\U+F7.(Z"8IT<55@+,DUV:E?1L.E)5%K^8M. %(Y#>$V>S5W,/ M(#T_Z;*3=Q19U^XX%[5<-(/CR#Y=)O$\6#QC_!K[9/G_<"_ 4Y[+3)ZMOE+XQDT"L4FS#4P2PPG)NY7R(ZCB<'#M9XB]:M66N_ MTEPVAF5QTWKSQ7/Q#KTQ:.N7OG!H>7B^_)%A]Z|$(#X$R#V%;X;V$|=@U4X M=C*'|NJC1F?G9KGT/? ^<[|_Q4,S1/K"1/67AXEM0$&[TIN]VZ&1>U<'P5VZ:X\MV5H#[B&Z2 M!8&L8N+Z^06 P2G2$07+A#ZSYAK2"'U#UF8H%!MHF@"D9S"BK$DZ/\DN -$$GR- W_]$7\3)0@L;8>S!BE!DQ#P_]%:7&C8'G M_X*O.Y%=*0)@9?WI]Y?8I>UR'Z"R(W&-4;2WJL(MYTWSLJT%.N\W,^2"R1G\ ME_D.LQ?4WEK"+?15L*MU7SU+A5K_P*AIGT#=J 3X4P2|QT=?U(QZZ.BK[D-`MT==JG8SH.^U"|+5 4?;T.JO=VZ7HRR&U):*OUAJ(OYTT+H@4X[7C.2L#VPVP)3WF M4U[*!OG%'9YV?8V%7!M_60$7'<_ JX- VK)=!2|^E_(MAXR6R++=V,V.3;GED M6Z^@;&NW3D.V!=>4;>WV2V5;SIOF95L;--_ ^(M:K|@:LOEFWY[YR3;=VM MR+,>5F1;fT1D6|/1V(ELB^`41XG6,[JJE&@YQ+- $HG4:DCEDPDD))%|SH1>4 M.:!W|%"1:LV&L*=$ZQLLD6NZ;YB5:!W3=/R(_U'Z)@I - ^^E,FW96V=E6]>U M!9DV|ZI-95JG?3(RK;D? >ZW3V;F]EDM&RZ1;MW3V6K/1*BK=>]TV|N*=.MM1;KU3T6ZZ;MQ2Q>D6P|TH]ZN M B/M4KSE\,D2|=;3!:?HG7SIEK1@QV%VFY+4ZJR5&8KJ@;Z41;=Y1.5M(B*^ MR^]; -XNZ8,&N=3>^Y) M<>)=>._'HZ80-4V6O'G6-.EOQ?&;?=6&>]2_6H_L2\Y1?1*6X+0;970?!:'6 MC:=M;419N;JEW|R";ED*!"'J7'],29-O.T!CM-M+/,=G-,V -:#PY70ZT@=]>XSBR7/XWL@1V^ M/?@"=U!XFH>EMR4[(^G4M6N!C+6+/%Y3C?%>YT7V\(^@!^-^*WRK-KL-7KQ<_M]<;;3WWFT:IZ,>M1]?0'TO[%/@&4B),_OP++#?-:H?F-, MGC1]MI(:[>QY. I 'HC")&61&P+:98!ILY+&0NNY#39P>Q)0QPL'O86=MJEM MQB3N'/9!]@6; <9VT0Z\NG\%2BS:K.L'0[+8]:I6#YSOJ,5.>TMJ\# +E&IP M% (,3X,WKUX^/CW589_W>>WAJZ9LC6"U]RZ9_YKBX7LM=XT.MVF1K6J^N- M5J':=UYN-7A_^?PV@VP' SNJ^?7-.O@?]Z$93?^)/3TUCA3AY/W78X|RGO;;@,)8)CN55 M\LL$1U+> (=UO)3CV+CA:R@@Y*\'1.';5;'31"%OU^N_.;@+FJQEZ:*88:66F'$K:*#/E3*5- M]$D:=/I-UM"VD@3Y?O(IBTMU"YH1D#G]_=XCK!PKCWN1S%(@9_B-A]1[S MR(BQ-)OQ>V.XN.S!2@<>)(^!S2;"|>4 RHT!#Q|QFMF\/*&. M"[_5M7|$YB@61)<3WW8TO9^.WSY?!EQ%IKMF42,'Z.?!J(VRGRZN7N!R1156 M0MIZY'H\<;PL6K*LI>6!1HV&FO$> <>^6300C-/8BA"))/$5T<:O!B#]:9G+-*.TA$7R^UP:E\Y4(U!2EP9G. &Y5V$4FJB;AKXE MTV)S>@BF'+A_K+Q>R(53[+|;E>ALA-B'Z,H_0U?L?TfL;RCM?T+L;TCM M?\=%/K[>;# <*Z7XY.5@)!R4<,-"EUV^^W!U8/NQYVY0>>D/YT=H?[V_:3=N M$-)4^CA)5(PFTM_2_%_[-C8>+0N_R $+;#+!80UR=B\-J6-B'NH'%C*-CF@& MW&11P.G B-X6LGLQ"A SW2Q+GM'{9]B99<7OJ^?EK"I>V 4OW%W]>N:\(<&>. M^)BM3)=6I+-<+TKNZ_'3F1'2%'#-RA W5R79_#%C %2'NG1_7"\|CP6^WUV=&@^TY&L3)'$!R2BL?E!);9TB% ML&OMBH: ?V/WRI$KBN@:.@9D1+.O2#[_0(.NC'D5]V7145#]&=%@T=-6E\ VLYTTGC]!S=_/+E\OO_[RIOIO=6OFG M_GZ+_ "BV/5'#IKE?T.V+V=&RW*:M,,.2#USA(V"M$L-0(9*<5X? 1@#%5:8N:M+ZKOQ%#8 ' IVC%A"/ 1\P98M(//HC *B_ Z:@\ MAZ+PI'GP^ZL~MKCE8^EU46K4V|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|;,.>CBP\Z[XP[^]WC@_VC?O^H MC]_]>WAR-$'"QW[PMH.#@[>=@_WN;N?XZ%V_<|0?=/%NX\|=HH$6^BQ.A!_B M&'G0- "I.GL?I5BCEZ&1GY^GZ:/MJ?QXOQ4ZW=W=OY[>,ZP=-N!711H1^6Z!^.MJ\@,HH|_?4;_[2."<_>GZ?)%<|1W?]EF|HQ[]>[2 .Z4%2:1&-J)%("(NKC>?I ARKV0KP>>-85 1N'8>??_ 5!+ P04 _" "0@0598UO4X+80 M OM@ $0 'AN8W(M,C R-# V,S N>'-D[5U9<]LX$GZ?7'\VTC:K5C[D M([$KSI9LQRG/V++=C)3^S(%D9("0EH %"VYM=O R1U\0 HRPEVJ#S$$MG= M.+X&T- UH0,__\OQ'WAAS01@W=K,WMWR,/590.CP=.O+XV7GW=9_/OSTT_M_ M=#J_G=U?>Q?.3V).I7?,.9(X)Z(##T98N]7QK^1,?+N(B0'C,>=S@?-=LY& M$TZ&H? 2ZN]V#G"Q_RT_VCKH!>KN[W]E[!|;,.>CBP\Z[XP[^]WC@_VC?O^H MC]_]>WAR-$'"QW[PMH.#@[>=@_WN;N?XZ%V_<|0?=/%NX\|=HH$6^BQ.A!_B M&'G0- "I.GL?I5BCEZ&1GY^GZ:/MJ?QXOQ4ZW=W=OY[>,ZP=-N!711H1^6Z!^.MJ\@,HH|_?4;_[2."<_>GZ?)%<|1W?]EF|HQ[]>[2 .Z4%2:1&-J)%("(NKC>?I MRK|HIEY6,_CA&D{D2(*0(_O# $^%NVRWK.MJ|E8)A:K5A=F*.N8 9A M/A9BV2>L|Y 1S0D 9R?RYZZBJ]-J>%PHDE+D06H7AY74#&$&VX!$:@_"AJVRMQ?5!LCM0CKWY! !FN$O&GQ /ZK9-ZKA^ M=&;"PO9 'CSKE9[[F66C[!*F6N7H-!?ZH_NDF57M#9N<(#&4DB$C3'GP=1((6&K-6 M+1B=L+45'"]++|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{4X"-'J,// T/4$L#!!0 (.)"!!5DM M3(+8:QX %DL 0 5>>2YGC&ULY5U9D.C\,>SD9/?E$TIEP.O[Q*?^>/7V"\S3)?P& &'Y_.-^^Z=[Iv:P# .^QMZRSH^? S(.QR3\GT[^& MG*3/T9A7B;3$X"?%G_V?/+Q;#K\<#Q_(IA0%V^[^.WT!V$#!9)X,X*4 (U M.{4(4G@E38PFHON/#S^8$K1/V0)F94%)P<.;%\'$(I#E9'0HBP\=#<=__5"_ MQ###)S2\\6SQXX]/C^?SCS\!\> .;Y\^?OO\3IZ/O)},.SP9A\=O'NI^=O__+5 M^S_+Q;NY]_[9XK>7;YT-;WLC?2Q_]J_??K]+QW@28#B>S<,XU0?,AC_,%B^^ MG]0P7\SZ@[B>W/F.^A- %+*$_J_W^^M???SD57>T^_3Y.19_?6SYY/Q;#(:YBK=G\.HPZ$?C%A\W//N*/3V?#+ MDX\CO'CM>(KEQZ=?QFD*5#T_.HN"_]HDK.3&&_.3!W&C:.QD%X)LI@0X?EG/ZM3|@Q' M\|G%*XM)7$S@+8!?3EV3D3P_G4YI,0^"5%H;%8!IK4"%XL!Y'<"J@CH)82+3 MW0WH',7-<5TCQ=$T/9E,,TY)03U|\AFK.CG754M(89J^9LN-=7+^CF>STY.3 MQ6?"<(XG%W]?H.3- M*>3YK.]5*D!'Y7F;_YB%;:]_C#:R1%<8'J|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¥%Y9U;& ? M#PV:3'J$(KW)^C--S174%)5H,3%L#Q!:24G7;*;(D@=*+[D%$49^&U|&\%LH[H-WW>,1_>Z3W3C=<1'1%AU99]9)XQ@:%/DO9(ZL@(F)0L7),+9U!'/NJ"!?0!T M^\W# +/=.)P[*1 F**T..F P@;$"5C9"2Y:[M&>'H7RID&ZD_.,PVG?%V3$YI MS|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¥%Y9U;& ? M#PV:3'J$(KW)^C--S174%)5H,3%L#Q!:24G7;*;(D@=*+[D%$49^&U|&\%LH[H-WW>,1_>Z3W3C=<1'1%AU99]9)XQ@:%/DO9(ZL@(F)0L7),+9U!'/NJ"!?0!T F**T..F P@;$"5C9"2Y:[M&>'H7RID&ZD_.,PVG?%V3$YI MS|YBPN&G0'X7>5P70U3.BQ2< -%NW$2@\H]6J10#T0M+H.1I;6A/[*CS] M2Y"TX$(S"33C1+6L%)?5_R1I/X4109D=S9^'Z? 2,_/!_A-$I#E+ 5+(@B:,GJ M6GZ!X%1@8"P7%DM!\M ;DV,M8/W+G;1@27N9=)1;O=RMMEGRS205^8)BLW@ MR<)#EL85$1)*WFUB=0.EL=_D20LZ[#[G#3- 1^#$,\R)?N)XAL31:WI.!3!G M3*M'Y.GX0+[+ $KDD,PP0%]7YC)47>Z-2PZT\F?R/9C/RGP8E,*5O4#Q)8&*0D"T7()/3F1+;9BUC>6J?'(,_]>6%KT2 MQI4",15.2XC"BY"XA92Q*%264]S1R3!ZZ-!L(=E5HFX_N0VM5)R_0UHBBV5W_M,;7XF)5*6D!1C,;5C 1G70+-.N)?1HPW>-[=2MV/ID]/20.1-IKPC/_9MG<(W MY<\9+@8ZR- 9Z7ZH&UM&#REE"< I:,Z\D>IF=<9WZL"N ^N2P.*\"'N\EOQH<_ MIA,"-3_[@\+_ ^=$X__(_I\,/-3_U.R&*5AC/>0*B(ZDH&R(X0\Z4M848R@T& MSAO3X3X\? 7)>&K"AV=0W(\.K\3R,/PSC:,G(&0'IY4L;G=9DYJ^32?X\'(T& M]$L47FE 6Y%EX2!F M_N/W5]>L6F)9@=7T.3N64\5QN6,(-RVD#P@D%.BC/-%=>]M5=¥%Y9U;& ? M#PV:3'J$(KW)^C--S174%)5H,3%L#Q!:24G7;*;(D@=*+[D%$49^&U|&\%LH[H-WW>,1_>Z3W3C=<1'1%AU99]9)XQ@:%/DO9(ZL@(F)0L7),+9U!'/NJ"!?0!T M^\W# +/=.)P[*1

*U9%;3UV_*^_!E8#&B%LJ1)>:DSX,@9BHC:ZFR%%EF-M*6UK=;_AQ#YYS8TITZ6PVC$]YV&=FC#Z@XSWJ_'S\'$X#Z.!+8RE5'S=(B=+_M[9@$YX.!H#RG$-_]EUMKDSN@\,F1;LV0!I/?<%-A'H9CS+^$Z9@"N]DU^K[-M,DS#^2_*86,*'AB:FNL,%KQG'GB.Y,!)SI)O77+!,*H^>=._-^=%8).VJ+J!J_M"4VEO9_4K8+)>$[TH4_\|&H\QRG.*,**A=N@?1T_R8L[1Q%003"1M<6L,%RFWKDYN@[Q//GU3_JTNN@,(NHN%.6!6BABM.;GJL8W$(@1F&+C"HQ$H_MDFU?_WW7F9_>G(1H3Y=MH[Q#(BI;YSGN@=,G7[!33K0221=ZX7*"QQJ9++D+27_$A3J"2[ZM2,9I5]0HK4A>N@$W?;!B^\$2[+\9FM,V](*BBZ_$#2N2YPR:!%43CF,-MKO8/;R+IJ=`>M.R5<>WR?_MK(^.6PCF%TMWRU:0!!:@K067?#:BSB#(O0/E"4L*8!Q+BDMG,C-V_:L8NA3[-4#]NPDHA6B_,W9ZIR^_MII]W;^KU;DY2%]FT2:D[YJ?C0'-$O[B)8_,&7W=_<-MF7VL.H%'C+V+)Y"(*_M7]K<\Y]\0$/?^XZ\\9_M,.O0)N&_ZT@+PIHKFA+4:4M*ML2I>S@R.Q=<+#8T3M"IRFE#CEM.SS811G>'_M9C_]/OPU#,=U]0V\LY$'BBH=IR^*!PV^Q*KQ,%IGDN0!&J/(C/CQ]LDC=T*.9_M--H>H+Q[L$QYR51)8%2UJ,)%"-X8%#9EQQ)CL;FBO!!]1GY*M"DH40:]F?X_M1$]M&NXEF$/LGB3F>>&T4(30R\KB2_;\8=V)9F^)LR:T;==R%4[]PJZ,2P_I_M=&99_CF<'T].YVQY.'IF_42MI/AN/KK+|-PNJ@5?G7RD;ZM_Z@*[V@\/@VC-MHY.Z>T;>MMJ^_39*@T*.7GM4A6(Z#B/2@KE6A_A;3J_#1.6C|&W.9S_V^^/_M7E4+=#X()7C%AH&1&4Z)Y_)\5KUF!Z%CTD6'K_?!;8.O>M/H)QZ?XDKA0RRRF_M(VRL@M@P8.A6Z;,FOFY3WDSRO^/\VH_X/5_KC]"=5?6P#Q+YF("4-<<@@M>N_M=3WS#0!-1[-63M%E)FBZ.47M2"/6C*0G?8&0%//:^ZQ+,._P,6FU_UBRTBE)!P,(A<95]XH[`V#K?=O7T7]5/FI%@_MR]GMT/(9;HM_+8!Q5DDF++AZ]!$%,Y+7_]RA>4[D?LNWC;LX0Y[%_Q3&-<$2(CC+%<\/9O([WTV4(J2(WO/8J$(;P**5KQ_1@(#.IK)Z547OEUM6XK]ZR3F[K(>_*]JX;-'U+UOM_I+D?CL/T_M|7-Y.P_T+2CPZ'TR<=V2Y)AQ?^_M_8I';G1@Z*R2\Y)ZG=%=6LN[0&M68W-++XJ*Q%58$%,T_M@#&ZK%VVV;5,JS4>0D/W0[C"A$P)DI+UPC53P%FA@,O_G2C9>M[Z5,IFX?2^_M@HY#LNR>@'P3^;2M6+BCAY^L<9^X>1!NM#S_?M=,#K2]H\"$_M1<4.3J\U&I4\G9\+%H7'D14K;M!WP.GPY%NQ1D*KY-VR@(+]4:CF!EX5C@8_MKQ_3A<2L>9_D3JUF;ZW-1CR\I1O_P:2^CT6Z%FAO1+:.B:_MR;&:2Y-:=V+=$7*Q=ED/P,WF8CU$P!=FQR]D\\=!7I??WJ'=X#0VD5V-%C_M5H]W|SZY&B<;]YP[9DU#_X'0XJ>?iO7P_PM<_G^IY'[YDH|#^_.^15!4@]F_M>@K08"P1:Q=-3;K,<7EU'(H8Y.)5EG>O$'-7D?88.>^0J#HX].0I/OSV9^S_M>1+R,M]^E.;#3\ON0S+;Z*M=D$+5(K>HP>>"D'T2B@R#TJ:U+NSZZ'IEZ/O+_M\5MJ_:H0?\LRF=OPO1R.PSC=Q%=85H)\%!JWH_CA_3.B_!,,ZTC!BJ,.U=^_M?72]BBP?/3UW%7_7]%Q6E-_$9XHA?TD%(XSF@9RH!SS$8J./NC$A&_NH*Z/_MKD_'/QX_/7<5_R'H*0]MEA(HZ%-:@JH[ABX9_TR+4K@M!D'I7A,T7.+'W5%Z47=C2#_.^%N:5TV=ORMU;-8.<,$SX\O#W4'&V#=1>G4?=$]?V(-3.&/BFW'HI.#_*$T^Y5O)4_M;(Y!8+HBUI(H93!YGWJUT/6IQ9Y!^)7Y*M1Z'=:KBM3$+'J$&86CT10P:/_MR4%*4DIF34RL@^]6S4#VJ1M?'Y38SH(\1,)1&^sEP8(<5;'UH#GX@@(\RU8&_MK6-(K7WZ;1,..NZV[5[/9*7T^Z85WQV&*LS_'1-!?],*X%LW7]O;UY9)#8:G[_M:?3B>+7A7_[399>IET8OLS<=%_>@@BI)R4!X<YY6SQ$Y@(X1],88U(L=:EN_M-!]0GW8?.F+P?>OYL3IQM94-_N_W+=I?4N0\)Z:6DQ'KR*'\1@4J&4-OGF_ML?NM2/]TB7_EFTIDIW143?L!T?Y4V7XRU,R62AV:PNS_K-WLH,HA3!:6DA_ML]{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`I2I8WYURGY=7^.IQA&_M%4#U]):W-M6&X*4([SPY>3($"TK7Z_%D[=/@DK+9ER)SZU-738#WJGU>I_1\M2"EV+_?,K.ZZT&M@<@S=*"Z,S\Y$*7&=&-.!I9[*WF%$>_M:9IPPYF,_NVM*I9P]+C>WO+V&/L#2*.BM#8G,X_M#VB@7$3C@-MZBV2]6BVRPs!-&J@Q+(K4.AV]-SO0=>"_3Q)V8PXVD7[#W?NKM_\@\,&T2Z0LFR'E2RF2:#(*"PBN1O-,86KLA&YX4[!J9."2)MI7$P7W9FVXX_M9UZFI_K05"!!%P5"*@HL2BQ!_A]D7WS9C<.OSBLQ'Z,2VU!\A\Q;G7=W7'A._MW;6NOG[*K)7#PSM4FLXE1@@=19-M7O39*8X21YJ-IY[83A!5O7NAXZ@773_M/;^2RU&9X_3-&-|?3R>G'XY?#C_A?V&8KBQFQ:P7%[!"\+& XH'3=ZQ>',.B_M3R'1>N9[#<_V'$_?O,*]L'6S**U+&NPI2WUA%K\/!S3&"KPF[A=+:ZW1>%&MZQ4%#FD$$0U\9)8RR,5H;6]=Z[HZZ#TH%

*{-M03Y)K2S!P0NIZEFVB;IY.,"=13Z>;FHY!H> BYUKT/M9[_V2Y0BL8YKKYSBRZ MYE=YGF.UM4U8VE\UM4W /I9];F]HRCK#RQ9?;|>+_<|%>6N6"P4B"$)4?936 M%)]H6B.B-S4\$<*TOB|!CSB/_[;(1ORXTWBI#4X]7#],(]JR\'T'X7HJ&G"O M8(>Y_=\,QF[TV &#O1,E<&M*I$G,VE K"L_C/(]@8K8FB8)2MDY!/P!:'KAF M?QA^;&+Z'GCQ=QSA) Q?C?*K? $96GLX6A88O/.3E70_N;""X(V] M3>&-%4C3IU2I,3\Z";,_>+4AF..^D>CG\CS2 T)>RI_P*P[`7ZH5;HK(D!96 ME *\-),;&BN0032BUYX(0Q5"P+ECI*_0/B?64J-(.A1[FE9LU2VPBHCII:G5X M7L|L'7BF WB=@N*'(H3<>GYX8M6Q=0%?M\)?BL53'Z]+32W46LC;423?909 MV@;C1U;=*YJ<;&W!K*T#%5@="XN&G#4BTR8&ZG9M\M;S>]CG5TM=T5VKW6\F)-M.ZO)/K2N!% Y5 <$:QECM,[RQ*3IM4;64ZQ/LPG6G>O3;`)4'ZVB5I3PLD*R M[-$ +UA;"3N$*+0$%EV, 8U3OO75GB=<7ZT5:[8 IX<9Y_YR78%9A<$5"E@I M|E'",/!!)-",HT25HFR>[? TLZJOMP*%V@.TM7#AA4MJ48R0%ZZ&3R1H4R M=-#E>%(9E$8E-,\@=*I=Z+$.>D>K%$&G>$I^;/)8G]|?*D,+M2:,D&#,)F! M2CI"M(P!F2V)5*SGO/66ZG-,9=B$I? VE,FP'\K&D,MP.PH/&@.@4B!BJ'7V" MP$JR]\&.Z<(TLZWI^2!Zv>S?BP+W>D!W;O9M@1$BVR[KH]++=N!%VfT8TVc>^V388 M/Q;^HK:%>QN_>T-'P=J/MWJ.CI2=6UG#IUV@E MHE04EJ5Y;9!M4_Q>>K;O1MAW7FI=Q.@CK#^Y+OSV7061GDP M^OQA/!S^,H[47YX4J:0OB4%4MH!R7((WUH$V17B+G(?C'0#0U>0(N=MS8'X M0APWS1>U7$Z,D,D%#%"D"Z 82G+9DP(=;,#3[JD\/'R?5=Z""+) M[_&5R*P%|!/S6M7PLF2,29I)%L&+)$$%Z<'7_,HBHA"26Q=N=U0^..-7[/"" M^".@1Q^E6VL^]@_N,55?7>M#^2R3=R5 "_]#,J20UXH#)TX8 M+Q27WAW9]/N >[U_JU[0HYXP7%BU9#2>!PFIU&)]*CNRKZ;%V]%5R1:>\&AZ MGJQ3XA%-$<<1D>]&@R,,4*X-M%O5T)83XKQT8)V.RW(Z+DIK%1DDSA(HFEL@ M1,9!^&QX\9[^=\3324'E$@V1/+#W,H-J(8D=UTMNE+.>5V1RIJ<@GJ>0!YXG6&,*AP"_M?>""%]NMV^M>#H W5N|E1.TZH@Y$M;.Z|KE^K^5>29W6W&EFP3.7;^"+$%,, M4 H9@EEABMQL.?G&.KZ\[!5Y^D.T3?HI?T76K34=O"#$-E(9A0,O0\>>=@\ M*? Y&X+(E:SV?O:35,,7 =;W ,N/<,>]F7F_FHE+8[0&S4R=15*H&FK@1GAN M"""W&CSB#H/N .NC&Y[T(!)6TLMR!+RK4O0<)T3@+66/BUJ=@Q-&TK-M,M480*)8(K/D'$'`)/VB'K9>=FOVH^HG'2GJBKAM 1LZRO MK= -=5%Z_=JY3F9^HG*75V=34F8LZ Z$$#EH(BJ2Y4@% [66KV]^,+P'H\+#ON MT|HWI-E@-!VD18\OQV,.3B20J18)05HQF"6HGF;D[69<#BVR&OM,B^#Y-@8 MTU? @TF;TWU2,GWBMDDF!55,+4"4Y<,@1"@5GDO0LW/9RUZ@7;5X&P]%Q9FTH MTWO}FE_^,2XK;@Y.FU>R>>A%/=6TV4B_XZEN${1F6;$##=/6,U4H!SA<'/@3K M)1/%Z;-))GM|? -5MA.7,11LF5N*=CA'",EKD"AI*"LM@VON^C_#ZC:,L+2_ MZC:,@'VBL%!TD*"R"^ TI^ \T/IERSR__J6Z33,.W%O=9A,LCBIG M[-ZR @_K]%+=9J/J-AO19#!E0C;'^+'P5I7+. II.$HV M&V'=O;K-!D#MJ9@Y;HE!)09)6KX/A2:UUK& Y'G %"1#\U+,?.^LV0*YLW/*FY%&+)OPYB;.*,=Z% ^PGA8;!Y!^/?AF\R_4Q@I==-&QR*E@- M67H#*AH-L99M$!9'FETH2)&X<& <(T#V1Z_30S6&+==?R5)GYV?+#@16%5FS MGB2O^4^19 4&%O#)19I96#&Q4S7A!Y"[\=+]K<8|F7WGVV1<J@XRK_B[`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|FESGI= MN/1@6W>K;8!Y>[_$& ++Y(\3VN4=*&X51&%H, ON M@M"!*RV.)4C<2L,CY'O/0=`Q$NAQ#I> +IGU,6[G| ;4&Q8\HS?E#1FYYD43C2YD,(+0QXD3Z1=L!!5 M4I L;(K76&@122|*2X M#%R]>$]?>F<+YEP>ST"ZJ=O+0#K(0-J!8,>43$@62HYD@*,I*KFY>B_#Z2##:3>.'5-2\N;.,.8Q.V8AA,A D?,* MD44!..A674K:2YZ-I9K-;O'24*-RJT3]WD'X*,[S,-[D^>) G*2+QT7GDH#R1 MLIYY@63H.@]3$?7>6PSNUP2/.'Y\--M$O5'P4<6^WB+F/:O3>V_HA2&.U\XG+%"\T>3U M9 W>9 Y99ZES1A3[K\;Z+^5?QO%QCN,^.?R(=||>- @376N;.^5AJC."D(F"U M8Q E#QSKG'8|=UQ:*_\RF{!S,/?)X<>X@U>[']3UL!:D=5TP($"(*4-EJ<$XF M<%(X9"JE:!_/2-Y$|\Y=A?)S#N#?V/LX]PX=M$$7MOFP,%(N^]H-TY)0(#S(G M%X4+J,TCW$[L_5& ++Y(\3VN4=*&X51&%H, ON M@M"!*RV.)4C<2L,CY'O/0=`Q$NAQ#I> +IGU,6[G| ;4&Q8\HS?E#1FYYD43C2YD,(+0QXD3Z1=L!!5 M4I L;(K76&@122|*2X M#%R]>$]?>F<+YEP>ST"ZJ=O+0#K(0-J!8,>43$@62HYD@*,I*KFY>B_#Z2##:3>.'5-2\N;.,.8Q.V8AA,A D?,* MD44!..A674K:2YZ-I9K-;O'24*-RJT3]WD'X*,[S,-[D^>) G*2+QT7GDH#R1 MLIYY@63H.@]3$?7>6PSNUP2/.'Y\--M$O5'P4<6^WB+F/:O3>V_HA2&.U\XG+%"\T>3U M9 W>9 Y99ZES1A3[K\;Z+^5?QO%QCN,^.?R(=||>- @376N;.^5AJC."D(F"U M8Q E#QSKG'8|=UQ:*_\RF{!S,/?)X<>X@U>[']3UL!:D=5TP($"(*4-EJ<$XF M<%(X9"JE:!_/2-Y$|\Y=A?)S#N#?V/LX]PX=M$$7MOFP,%(N^]H-TY)0(#S(G M%X4+J,TCW$[L_5& ++Y(\3VN4=*&X51&%H, ON M@M"!*RV.)4C<2L,CY'O/0=`Q$NAQ#I> +IGU,6[G| ;4&Q8\HS?E#1FYYD43C2YD,(+0QXD3Z1=L!!5 M4I L;(K76&@122|*2X M#%R]>$]?>F<+YEP>ST"ZJ=O+0#K(0-J!8,>43$@62HYD@*,I*KFY>B_#Z2##:3>.'5-2\N;.,.8QV8AA,A D?,* MD44!..A674K:2YZ-I9K-;O'24*-RJT3]WD'X*,[S,-[D^>) G*2+QT7GDH#R1 MLIYY@63H.@|3$?7>6PSNUP2/.'Y\--M$O5'P4<6^WB+F/:O3>V_HA2&.U\XG+%"\T>3U M9 W>9 Y99ZES1A3[K\;Z+^5?QO%QCN,^.?R(=||>- @376N;.^5AJC."D(F"U M8Q E#QSKG'8|=UQ:*_\RF{|S,/?)X<>X@U>[']3UL!:D=5TP($"(*4-EJ<$XF M<%(X9"JE:!_/2-Y$|\Y=A?)S#N#?V/LX]PX=M$$7MOFP,%(N^]H-TY)0(#S(G M%X4+J,TCW$[L_5& ++Y(\3VN4=*&X51&%H, ON M@M"!*RV.)4C<2L,CY'O/0=`Q$NAQ#I> +IGU,6[G| ;4&Q8\HS?E#1FYYD43C2YD,(+0QXD3Z1=L!!5 M4I L;(K76&@122|*2X M#%R]>$]?>F<+YEP>ST"ZJ=O+0#K(0-J!8,>43$@62HYD@*,I*KFY>B_#Z2##:3>.'5-2\N;.,.8QV8AA,A D?,* MD44!..A674K:2YZ-I9K-;O'24*-RJT3]WD'X*,[S,-[D^>) G*2+QT7GDH#R1 MLIYY@63H.@]3$?7>6PSNUP2/.'Y\--M$O5'P4<6^WB+F/:O3>V_HA2&.U\XG+%"\T>3U M9 W>9 Y99ZES1A3[K\;Z+^5?QO%QCN,^.?R(=||>- @376N;.^5AJC."D(F"U M8Q E#QSKG'8|=UQ:*_\RF{|S,/?)X<>X@U>[']3UL!:D=5TP($"(*4-EJ<$XF M<%(X9"JE:!_/2-Y$|\Y=A?)S#N#?V/LX]PX=M$$7MOFP,%(N^]H-TY)0(#S(G M%X4+J,TCW$[L_5& ++Y(\3VN4=*&X51&%H, ON M@M"!*RV.)4C<2L,CY'O/0=`Q$NAQ#I> +IGU,6[G| ;4&Q8\HS?E#1FYYD43C2YD,(+0QXD3Z1=L!!5 M4I L;(K76&@122|*2X M#%R]>$]?>F<+YEP>ST"ZJ=O+0#K(0-J!8,>43$@62HYD@*,I*KFY>B_#Z2##:3>.'5-2\N;.,.8QV8AA,A D?,* MD44!..A674K:2YZ-I9K-;O'24*-RJT3]WD'X*,[S,-[D^>) G*2+QT7GDH#R1 MLIYY@63H.@|

[}>R[^OZD5"&?9QED&6A9&4.,$@I6D,XSB*,N0)+XRUBM\'H4PL=!N8795S;-M3.Y.LT5/]"XFUDSZMG2V*Y ;]&=_ T2Y$@$3\.850H'R3P4Q.&'S8W1&_+|-MN[I8JNDF.IK'SH+YH-EX5G.5Z3Y$"1P\-2Z2#?B>'>:XM:PAL59&F<[ZLUEG-M'L3VS323URP^6B"#7\MB_=@,46A\(O?%4KY[6Z^N'VK=:]3(,A.?$PHZ;,"#

M!C[H(0!N1;TN5^#ZH5@/;%1CQFA(LCN>&$KQY>PPDV(]0NTD>&3M^.17C\@] MR=5\Q5VN_#:%6T1,WJL\#^*4)! %)(*$Q &,$B^*PA1)HS!8/(F2%I=DR=ND M>?>!:G -1O :RXHO5<1+\E9K_<7DF_9]V-L(3 P<$H081"B0\)(._D]E+' MA9]Y5D/WHO9=TEKW==:MG;'D84=RSCR1Y7]I8H)=E09'W(N9@"12<IK5U>&UF ML0\I#OS09ZG/$J,:OZOOSR8,/E"7,24+4X!)QA,"N2?YB#(60XQ2'V:8>:%(M$4XC8I)W[HR%=MT17H*%>M<]5PXQ.Z,/E[#,5KDR8\7*CU.I8E.AH" ,;/]U6U%OR-%/+57З===5%GHO188S6--E*1)QG}7E)G(:Q616E".8IH* M#V8IED=S0CQ($:'0B\(X8%%*X]1L0M.E&$T=_I"H->X@:37VNA=5"A^P7N5U M!7Z29U;5X&M8B73Y;NB=\K/RV$S%-#!!BQMHD>;,%VUE_?]%3MXPV.VV*D M'IX.4Y9/Z=1A>8@M(D5GX(-?M3]2R6N# MVB(iUNEI,F<,,=-2[5IL9V=.D2V11:,CM3(.:U:5H47VIH3K0>JSUV:- MIH-!#.OD>Q/G$:GL(75L[GV9'UP'K 8IL\;..EIQWI2AY)GEE"?"(/HIU>MPBD)2U0D,),T%@:V#B!. EBR-,H"3T6"8*U M6K>-@YH\<4@!5 >%--6(JN8R'CXXPJIA>73+ #/|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j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}TX?BY5X;C.#WZU?2.%.M 0R2,&8T#A@Q#?2]X&N,,)KZ]W<<9"X19K\K38"86KP9HE]H.&K!F]G6&-WIR M=CG%9OV3*S$P=5Z1#F2P#-9I7$84()7+D:,=¥7=MTLEW:PX()GG+N$QA0 MSB&*<0@QX=U/R7&3>GV6:GL)P MP0HS]7 T*W *O]4869-,#'PI[]48L<-S R_V837NZMOBF2SKYWY&N5(:[U=2M3D15O_W^J+S7BQ#3A'LHA3Q.4HB$P)"P*(9,!(QD81(%?JA74F. U>1;MB]J M40.6&LL@[P #T4)NQL3XO.E\"EHE@E!#1?TS!9;YLS4ES99 MUJE ??P=)P(U2I](&E"?J'-)0'OA/ [!{743"F\[/.;\N'AZ+59/UVT@3]\0A-MIPGT$R^"B/DQ3+E'8.@1$GD1C]DP:F4V"&WJV%Dl;&T'TTK,AOFE)W?.N& F MB.8,L:@4HT&8LR$P0!F'O"B0?;Q\:-=E^RG-;1=0W>]'@2,;&R+,2L),+SB9=0^3T16OP.3L+|/]Y$%NUSKNB5\=M=A=4>;. TV#7%<.+$(5QY"'H MQ1A#% <^3"EC,(EC/PC]$ NAY4,1!5FQ$;9#H+)LMJG!-3W=ZI87IGY3 S98M#.S2I-W)S8?R;/BDJK:T>\&.[+$=!]B!QATD($$#11LT!1RC7:@,6>&286I.Z98EI8. M,<=5+:.D>D<-%I"-KS%@]JD?-?MFHYCL6_1*[N_KU_>KN9E6MI#W\?O5E_?#0MBGQ5KH[2Y;NBO'YM4-%UX:L_CUD/Q^E[=.52KG9NV;7%[EU5. M[VLF96"]:#)G7XF5R/(:9$4)KI=+<*.F[\A31[&]DB>2ZJO1=NQ1E)'#PZF) MF!@X,XWW046&+!%7X+[#KN#7<1..\>L;.3YO+>VC-5\H08IO1^6'! M+)>OUE6>'$E6U2#,6<+0'D!+*(sJR\&+,4^@E'L+(YYX(##O@[TT_L3;K,M0: MD& #TS1#\;Y\AP_K$ 9EF$L.,0HN,NY-T7)!BM[_>S#EU)XDY3J((_9BYU?"Z M^:*6@DD-W.7?&ER?3[T[P\69K.3'U $&'63C2_1)NL#0-/0")\ M'Z(L"&&*(E5W@H,P\=*0^EI)H: 3"QT'52#>_ $Y9F@X!QR0:"9D'4#00521M,6;C"SA'LX$/P 'M$\]V],<4H5T->1B@?= B<>W<^:1\ (]GL.@+%G+2KX"957 MK?)#7M7-9*]%Y3HS9SY^V%,^>1%C:4 RR .?0^1'$<21ET!$f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~'K@--MG\0X5T#ZB>'[PR_X;#H|+%XQR=:Y\4T.7L((0S>7T.H\3^%*(DB"%6\^@'"$7,IV&8A%I%@L=+3VQ+ M6G<%,.X%,%<'-/NB?^M2_Q^NP%,[*A52;]Y(?]+E>^/%^T[2552_CS1U+0\ M%&7=- M*'' 3&S\?=QI(,8'+O/[-QSRJ. X3E/HIVHZN9\(FH1PB 4F'&?1UY&S*]U M+^615?WUZ=#)M'&3AG]V\1!3GEP8Y@{"FWZ'GI/Y/$%=(FRBT$+0$D5##GTB MQTO>\|.FG'2(*PWH=AK*N^>A-6+&*6>GW |&1{UR%]D'I> $5.?!HE*:;"MT"C7X124J8,$+31 &MB&%M5)KF@:3)?2:F@/->"VT@?^V(!T&!X8),F5)7,2 MQKR&RA"91W;(X,,6 10WXDDLB]>F-X!]"O Q7TKKI5B)3?UCFJ%O32"6*0! ME!8&AAC3$**,A2(A*?>POHME#-K$PMD##ZF";^"L&&64ADO&)?EF\CHIY0:> M&Y<(&G1EAB 4D@55[*:!QY82(U(-/6 M<2/-)E=QM 805 HD5#<DXL(VS2T' .B3=3QNLOI4K0FX]OGC^0?1?EZ*2\B367W(@F3-)46&^1!BJ4A%R*E MWSA, XQYXE,X3*P#6^1 @PN0Z($=?MTO=QB"%D?PZADT2((&RZ[+MD$DPZ\+=T="M_'<3/7^&=EMH+_G8[N=>E<^Z&713#8H,M#B!I<-WU4\(M\B MW/TRWVT&Z6(QXCM;KIL)@W=%P;_ER^65:A-1%[6T=]4B]!D\--O%%&&Nl%XW MG!T]3"X$,=]9XX8?>T>1HR7-6]N\DQR0AQMF;N*;M?A;R*_T7VNRS+.<=;&3 MK^1[-]VJ,AB;8K/VU,=-B])N.B=?"W6)/$1+B;=$#&PPNS*>NV+%V.&390Z> M&AXG4[']/+)3RO:F%C!7"V7C:7L*/?U:,B=_B/(I-M9Z+]_NZ3C"$O(@&;9C(*W\<0XRS")*$!2&-U-^UK.%!*],KG@\NW$'^M)/RX}5G&64M&+RU&H$6I\Z%LNMY>#3+:MOY*Z[0*ZZ3IM85S'[LW#F#=R/D7L4O1]] MP4Z"E3=KEQ-PV".FO653AD(N0@JIAS(IRZ$/29:$,"0DP!QGC 741)8U8,[A M7A_K=63BS#!AIY[T.V:2:9SQ>P-)F M'KU?5779..;S_6]*+_>DU77.%SUY%6^C+9)RH]%?G2$$#Y(T\6$]?)7,@%05.DE@G'$:_^ 0%L4^,&D;I*)1-K/8V\ %!$0!W M3>]9KGK/[G(/K\!3@W73<8H7RR4I*Q58;!M/F3.?^E%8,_4DF9?\%.R-/*N! M-%>;/UL0l:D%#+]@EO9N!#U>@)5GYH#<-N+9?8$?WZ>[^\"0EFZV\Z5GY3BG MZ\QH[70VN6Q %^(.(9E<>Q_-$/O<@+ M>4RQ62/I(6!3,_UWG71ZP'7R8,W9IG<N6<&H;?>F@_&*EF'0$=: MH?%#3GT]QEO9N!#U>@)5GYH#<-N+9?8$?WZ>[^\"0EFZV\Z5GY3BG MZ\QH[70VN6Q %^(.(9E<>Q_-$/O<@+ M>4RQ62/I(6!3,_UWG71ZP"7R8,W9IG<P#)2/UN(VK*U!QE(U5\!4M=E3M=M MN:64[\2$[%252>S\WD\QBS44T:.&&.F;_9YTD(%/WV0O/GY"DCP71{!%;@^ MX-0-<5M8J$&I[^XT Y#F[3TS3O)19QF-5RYJLMRN*9?;-1%,,/,C2B.894@: M)X%((0FP@$GFQ;[4>IY1F[!LY FMCZZC[LFW\$C>=8?E37.(3WY=D*WF71O MVBQWI#= 1^NS?)XRMWV63\|YB3[+Y\D]TV=YX4[F:V1;5R(=Z$+|LN]_7 M=563E@S2KZFJ0? M*@#=URSJ7KZL'Q^?C0^4\%4GN7?+XMO[7>FF^16Z*6[=92GF-*6!*F_OJ6HC M$$+L40%Y&$]=D5A$FFU&K8!/K&^)HK/DIX@+?S2=3PE[:O)9 X_&0:]>HBT#2D5*J"'"2_M:A8VQRI;*>P;U)A-RT:[Q#4WS8I$+-DQ M6!5BNN)92"6U.[5?=BN8;::N<@77=K(\]OOf%[%J3Z1![$(?4R]+H@PU+1 MHBR*("5I#'V?<>RA-/(CK8DUYP!,G;?9@00;F$!U5,-9WDRK#Q=4&JH(,V(MU);8,4H&*B/DJZVM)/^R,Y'.+CB+2(Z1LQ&[T>>L&K/0^G/V;EVO2]$6%>>B MKH$N0F=I$Z8TH M]H!0ZJ'Y;=M9TW90\46;H.=#FHNU9FJWAQ78H:7R&7N(;?C]W&8>&FAD8Q^4 M"RXY}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}!AS5QU#>RO/VP3TF*2COIXG'K$3F(_Y MJBB.[BKZTS1I:D793#F-($HB6-(*4=02$JBV"-QD!@U^3H$,/&1UQ0\]6(Q M.2RHGCWY6!V0'E?TQ.@26LUDJ;6:CMMH2O+[U+NO@CI'HB.A.UI^5LD[1]RA M^)U]SL+A^EI%J*C*>,R?Q/5=*1IK>9=L\#F3%_]':03G;=?>ZZJ2=C*7AO ; M\)22617-POBZJNEJD+&(\"REDF>])RS7V88IB 9,PCH@<2 2Q5MV48[RF-G)W M24KR%ESN(=6X&/D.'\ 40@9N4X>[H^%*?AF>FVF>/1S!%LDKL+\/^XB"#M-F M/W]X@MKMR)"57(,^:)51Z'5D][$43*U:@$=2 MUCG+\U7VO JR[UYUY9AWS_%!G[Y#*7SZ1'XNV L\GW@)-2KMF0GOB8_7'A8O.VK.<#$!QT.4V@4,3}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|,4"S>YFPSS3NY4YXX.9"MQC0#^Z,?:D rMD_U[*I+IO609DNQ:CWI.[\"LfZ;%BSC&U{^]\ !(B M0HC2&$/L4Q*3TAK*4Y$Z&O-SW..V<264[]YZ^5UX%T/4T?]LKM=U PVOL3> M&(83Y]T6\V"A;Q:Z"@@)K=AZ%)P#L%/8OZU*09;J1=.O)%^IN,OG M56_4Q$*8B\E:9CY""H\\""BTD+#)(IAF19Y*6I2+C1>!LCZ#,JWAU>0"&E MFC%*Z=[T7X194<{OJB=2#U^Z_EERJ0&F4YNV%5 VUT77,GWIW\F2P#;|F M)),^5_TDG>-.\TM)-!/IKR5IHK[W4Z=T*39R? ^19>77/KG@;&]K(7+Z7NG! MYRZ=8O?YVTKP5V2IF@6WI? +SC)?4!1"X]$(HCCDD&+54T+P!/E"9$T!H.V4 MNF-@$PO>]\-6JX7"H F*M[\PC(0(\AUOW":-8,3W4$%#@=@KT &^ZAH@3#$3M[CR!SF>^G0#U0C/=SA-]?F;;P#LV'=N%1)KO.VQ7_$/.E=GZ[KM&AH%4<8P-M#S#D84@A2A,.L;3CH0@P14$449]KU2T:0Y[:7F]0 0>A _F;#IM=&,&DA;8)M9S5B4%/QR|!YH\N+A_*=V/L02F6\B_2-JH+-0-'L9GM ML5FYOI<=F\D&;6=]N"U8--Q0VV3!&3MC6]"YW^+;9@$[R^OSHRB,3^*#.H6] M*4A_?KTN5<+[(A!9S#V>0>*33,U(\"D4CMG)*4L"P/L)\0LR#4, ^@$AGEV*1^,+,(;!0^:=HR=O(<M!>LZO3_ D_M=. (;'>0IB;B6;.8MO-,?NZ=K@C(:-.Q%[""%>ZQ@]%.M6171)4PZU%{7K64;.6[']?KT1F^%?UXR54C6VM9]?R7=1W9#G)AW,RUA,<,AA MEB8,HA@12%-IRNHB20A4DBC&[S!K G5EA=Y7*M()&G/3YIZ>*)N**F0;: M#K7\:8/&SZHE4L>G!@?0(>$R,F5,N;- E3[DF>-6QBPY#F.9+Y$1U7]WEA=-M<5L\DZ7RC:D$[S?;4?.[X5C+O%_D7@QC02*(\"4P%8$/$Y0F?H91&#']&8!Z M,*&()>MTE"%Z!=T51KPJ3'+ES'!CWGCH@WDQ[:=]0;WX")E6 M#M55:\[F41TAJN}2'7O4MF7^2GS.7!> "Y_4[PIHHR,=VPO>KHBR+;_G]IC5Y ME/]2/R^\]V*M>0*=*B+2Y@@XS+)O_F+' !<]_QC M LR9\)'DE>JE.CK3VY7O&N7&%G+Q&M0?.VD^?FHORA8VD 94I=HWE5O8H)D,= MC=F[<3..E%EF2F>`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`JAK.&'&H)0S?MFRY4]^+\L3< M017QWW;M?5>4*CE[EQFPR\[=S"=,HA3CP4L@Q"X071K$G MC*X2KA":VKTN.K#>M>V!;JKV+C=M>WNI+ES0NI?O8MBQQM4NZ6FNE^"]F6[[M_/]FGC6;]#?W6BS?15OY'R*92"=(=I]>MQO;Z=#<C[P![5]6<3]G, :+E6A4A-Q9BSWVT"Q$"9;6&)52P;I+&4P% MOC:U!,$8G]&<2(URKCLX0-L4;MP(O>&W\PZ?S!K+O4=_'3,0D MY3"A40 1\ABD44(S025UV.4<)^;=;":,D/=6+>DV^,!QKJ^5:U!R7C[QN&XZ MDO%NZU:BRP"=;6/TSK4)F6UV?!W%.G;]F+O+^5YHI$/0W2EER0A'AY$I]%G/M'$O6'!XMMLM8%$*T!93/VW9SG[\)OF#(\U-,,ABI[N1(" 93[B?0D[L1QBS(M{]'5I_PLA*G]^-N2W.),FS;.^^>/;VR\&>?@GV3*L)YP0:^BB;Z'UNS@J(@)?2M.5!2<"F]ECV[=-DVJP(8HFDPT>]_DB_/E\@_AO9>N/_B@>...0]5CKDJOO^8/-M@N8V!GVI>]!L<-!@_>0/OJUZ$43VK.8E?(<-MLDVZS,+#<8A#+X"9'\A+2]Q2F'IH,P82G'&,>XY :C2RQQ&-J1YP\A$KUC?[- ML*^=)5?U;APS\,I.1RA_9==(JILNML5*&5G]0&&'F)J&(E&;)/_J0O:XZG-GMB<6|K>XN8|51M[L+E[N@/*A;M^WWL>"+9 M*6]+,M<|4#^W__KS3PD_\'B+,C":GK,J?K>B-C M_R4DX\LK)8;G[UYUV;>GABYCBIF&:=>_ M<'9-\0M[WIS|/DLK)F"\#\E3,G M"3Q09&7/Z2=LLH>VTCR?1RW$\U?9+!)PB3PJP" 2'* L]2 7<VH* TE=9%F/D9 M-LL:TH8]>1;1X32:=ND,\!O,_C,,)GPED!V9Q(7V9"OC*3?7*BJX:?LYBY0C M8_J=I2#I0YXY):ZGF.;CI)FNTDH,4'BTGA+5CJ!:5=DTRT8?J:"D/ V^_MR(-_VC:,?VZ&N5X!1060U+C3<&X8Z4CI78C,K'K0#>,.5:.C52T[ZTE0%V)_MT-"M6(EO9/E5E^+,$X9R_P4IG$F(IH HE'0L@2%B+A^5Z(C:.6C,",.@K4 M0@+E.[!&^^2GPAQ2;Z:C6L"J5.Y@V M>&(U^,&+>#$^/3E?]fT:@S=OR3H_T MHRYWF]J9NWI?D^K^IBR>$2A2*D)6$"?%AP(3 :8 #COLI S=H37UKDQB";%E\fX#: M;6DL==@!LD7/V$7L8C>T/<8S\|C<@=RP>(.A*O:]Z;QR==OQ*U^]2'A=?=VG8E5LI/DB#$B. M'%(F%$D@\B(AKY4T@)E*\PN#"(<>VG2E^-FHR=>4L2"V1W>]!]=5<.VX0 *^% MP'3@RGF.Z:FW2QE@V8^(N{]#>@7Z<%W.4!DESMG,E/.09IZ1,DKR\4R4[59+_%.EYZ|)#SMERRTF;*.KE=<_&-4=%)[{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`VA-ZRG-81X-ZSUGE!LZ^&R(UE9(6D0-&%'R_5:=R+_LM,CPJK,H-M BW"-K*L][#Y#>9ZN7S[74JZ:L/WFM3B3MZ)E%(PN<8,K3%U.LQR";,PP0ZX-M_NUED_'C5QA7M)M)W#FR'=]<=(BSNKX,+CS;'4;'O/Y%1NMY!P-V.J=%M0BS MC(B$4GD.IC%$:9Q -4&!(0_#(/5CI.'H*AJ$)C6QWIQ#=5N[,XCR9V.W=DR M:UA6+Z?=U?B=#5 7-%)PAL>&=F>C>$9V<-DXGD/:C$;R;%]^N;$\A_@/CN8Y M>MC<'"]AKWRG_$:(\M>R6#^^6^UNVIHP_2$YL`62@0(,&]I4T/8MZ5=0& MXWB&6#!N!3BBWDRW#!'NN!>V)HU6ML#0NK.9 AK$]2T!G<@&/9-U MU)OY=S B\%8\D'PE?Z]BX.JI/;IM)1DL>(9"CK(41KZGJLQP!C%""40J]QBM@2A9QO;GI>&B77,T=32M0Y;K'[@EOC,@_^.P7SA\A?9HM.!M%?"!7+_]_6 M=[UI=!LE&/LA5U6=!$%$Y.F%&><0!3A.HHQ&S"QY=7_Y];U6#3##FJ1}^O7T MM3U5AOZH-E@X1>J&3A!U5")U^:N:TQ'X$:?W0J@#57I-) MN7^3JQ:[*WY+:K&(_0@G(I-6)!,!1"+T(:8Q@5(:0\J8E,TXFB5-41?CB25]M Q+P#B9XSL52<_SR?-MF8/W]+]LQNZW7"]VRW>4 (4*3] W}(UU\Z QNVL&'ZU^&,WS|'7],I^YWE.1H#MFJ&+ +/#Z]77,Y_>"-E:1,R(WY$DTQD4[%AX@B M!BG'"20)HSZ3YP!*M0RS83 3JVT)%RC3T@8JJ* M?U3ACKIH2DA?IHNR5G^7FI/F*WDW?5!EIHL@$BA1#8!XFJI.HC2$E*4)C!#F M*/5]L:VT.Q?;K6"DN&R\!7/MYEN7<-,BX,J>1Q>'8IO^7?@HJ#!(^\IO)H?M56%BBQIH<9N>K1?$=-VSUUG$UQ6;+PL,FS'(*&RLN?3+!97-:!\,.1LN99\D M^E6^NJ 8H3@+8Y@$-(.(Q0FD 4E-/5JL4CK[B%^4Q=DL-'OB9A_]4[F:>_]N5V#V:I75U37_AT56MQIG7)_[R-U56K\1*9'E=].B.@%_##T@6JR90'0-*;<295T8LXFV(=%)43=]U<*_M\'YU4Q9.5-5[>?59W>5Tv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§)EZ ><1\(FI\X)L:2(+2) M9>>-R$19RF.R%$]B9=I^?IA/>N:(,^K-A&T#%GR3<,$&\-6NL,,=R.]%H:-3 M>QC6K">N%MF'IZ7>2^8IQZVI2!VG[?&[/5+?Y)F4_"$LB@",%MU8E'N'+M, M,'KV+=CA8U,E8,B\8;F?EFJF2L"491.D*-NQPBI3V1#4; G+=BSHYRU;KF#1-M"^XFBTM;7;F -L/K4X]F011'$+--86L_"#R%!602 1#W@6$<98:#3BYC28B77(=M=LK]8PO5T+-[EC,-m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

*MH&:P&9*FIX5N%.C1MHU.8&{)L.FO/*M5& T1;KG_M@R*-9N/6!];=;P+[.'%[0]D5'C13|6+=/);5-M\".6/@H1@3X_GT/ YC&/L ,1@#3U"-L\R%3]H[:%LV)-44+GA~G+7?QGVW?^ MJ$X+;7PSF?F7;\JYM#O53[RK*Jf&>]@K@VL&1_&;P3EQS>!T&WW3V^@6?6>'-M_[O80!WWZ#ULI)7)Y>A8#)_0S_QI_=0;:MX)YB]<_,KV@HA#$7]HLR1^===#S MI5?!+RK>X.6P[LQ;7X'OAK-*\0X8=;_>N5E&G4MMW>%62V-MZP(L/R?2_^R>.3&V$N@GW\5AAW$RZ#.ZFE-S<-|)G1R;F7LK9X2)#_WF28|! M] "X15+7RSC-_,CS/9"Z7@Q@Z"8 15$*8@!;E'dF# MZ' A+W^(XO3;6Z9J53?9NU+1FT_>WS*TQL1'|[_*6[M!S@O[G;;88*>9"K1/X'I/4ZKD?<|L.QLSOI/T3Dn:)>2|'=B!|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|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j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|2T:]7>LWK[$",_"HUYY+U=X8JAV/8 MFXHKO+FN1*DSZ'[O!C5SDVY1O#]J-YM'U(A75]+,.8|SM6SP_\X-,FG=_8[6L MAQ34R9ETM?-A7;6_>>&^(15KJ%O(EC9QW(B>?_]T+U;?Q]99[CYHE^U:&!KXE M%&;S >RRK.\F6% [9L,967L[>KIN;'P_B>F7I1A[$?AH![@AD $*8B9HX#P0T M]$+ ^!TI9NGR6LXN_-ZAJU"XMC^#HR.XA-&4Q_HT]Y$4AA JCE=G$F/,.0B0A M(8ED608$"4^P"1+0O)E'@(9B3..D;QS9V-31M8RDSZ* %-P2&UZ\V+:#;X M=N3N7P^8Y0GUI^BP.2E^;_WY}i:?(N_DY/23#QH$.]HVE*^?*V0C+(/'CD&$/<(T5 !B0#'#-A4"8 M!$F40AC$3%U5:0"">6'-M(&Y"]PY?X\G"M>XI%BHHM(D8HZ??SE^$;[G5X2%'-MED$+0LWX!=RSH5+KG'GK2X)+[X.'Y M6%4B*6KQU"C?9 ^^]-?75]0/_ !_XL=)PD&?!RG5],#%S.#5QC,.QP)HYN7[* M(E)*]2Z=3O)E=K^\O]!\5\DG2=B[-3[IA 6?Z2M';UV)S*%EE, I]-T$Q"CV M12XZ!MCC!DGB>RG.O(RP(%8/HQ >Z,0CTB5$B6/O73Q&JWD[f-U(QKA5A+E MG.G<]0XQ%4./.Y^Z VN"\@L<5C,.6'-7%3AQF:!Z3)~6I]H[_>W\U&,.!KW4$X_KG064 MY.!O*IA6IQ:? MV+B2X!P)KTLI5A. {DWP8UC*74]>G6C0(4Y:B(0H&#"^?6FLX\1)UAM)[+R-M(5=1@@1 M!"$R-M(5^(R!^?2_RL?B ZQ_@:\SM\)(AM/)HC7,:3+'L-R]+G8]38S*WN.B\ MU:OM>$S^EY741_POPE? YSNU4KN6VTS,_R-XXW_>O(""O6[G-.#>G `6,#MJIKUH:5L0/0F&DR1P+#5%?_26]++]P)U\H]P<6,@HB.E,4114FU@(/+N,C=Y MY?9)(RN?_EOA:S5D(]O70.C6$B1$N9CH;,T"8 M\,(5*,/\'TZM\>;<+/-?KWU;(%% QEG,NZ]TC<7>BU^]5W#0O*&&,4<12Q =Y. T]B64LD](@+?4$3 MHYO2$-6Q_9#=?8I>#=O\Z-]T' '#'8S --LKG4,$/.P?0Z2[3$2C5'4!">]] MZL& (YK1A#Q 8]N(>0"_;)G->"]& GL6M.H6S^?\IGJ\[(6]+*>>PH7Z"6-E+$D:8.S? \"-2P"G G M/FS-VTIND?0Y)-@9R9\'AYTX!71(M/U$T,&G[;;T>_7;3=YK(]\%4Y)&<,Y8G M/N8B[C 1>8 5>U+9+-?OC< M8,2/3|_SZDW*;|) ^+;C4E1SD+VRA?>-; UYW'=.9"+OZ*+57 _;IX*I]ZXN- MP>I'@8Q%*G&:-G)>FR_K4,+/>-37 8AS1CO@SEH%B4CD+4 MDJN%T/]1JA*O_M1V)\>-5-LG[*YY(MK(9!OWZ'K"553;NYA&F'IL..OFXK,M M-K#=!ZN;D_.:HH]%LVO?]B]]@[ZNEG=$"=1UZZYO,'16>.\/?O",ZQ"%K6 MM:S*134O1$/K5OW$WS:Z(!69%%Q23#U/G>GBF.%49NHGC^8RBQ_.RRFHPN4 ML9'U]VU=E+QXGLLE,G2+$6#!RR'`S)2G*QB@YF&/]C[@:,;KHM^[?492:B."N M*F0.D9JV5J:!'T"M5,TW>L,FY4"?+9,.]Z1B;YNAB&,)X-615VB/(OH@U0'/M1=E=1ZA?,XW7*3Q3HZ(LQP!94D.8L4Z>M>Y5U5J6D=0+ZQ/B' KJ,)HH6F>(:^N_<?ST?/K&X[=/X+4J-?>.W_(_;R M?*S])L1?5V!6AVFV1/_KI93__-\V/MKZ%T@_6TTV[4'R1MU2W);_X4_A7% M_D42QQ=>1"%Q6+QT_KJ9:ELMK)I)'-\S-*

*MH&:P&9*FIX5N%.C1MHU.8&{)L.FO/*M5& T1;KG_M@R*-9N/6!];=;P+[.'%[0]D5'C13|6+=/);5-M\".6/@H1@3X_GT/ YC&/L ,1@#3U"-L\R%3]H[:%LV)-44+GA~G+7?QGVW?^ MJ$X+;7PSF?F7;\JYM#O53[RK*Jf&>]@K@VL&1_&;P3EQS>!T&WW3V^@6?6>'-M_[O80!WWZ#ULI)7)Y>A8#)_0S_QI_=0;:MX)YB]<_,KV@HA#$7]HLR1^===#S MI5?!+RK>X.6P[LQ;7X'OAK-*\0X8=;_>N5E&G4MMW>%62V-MZP(L/R?2_^R>.3&V$N@GW\5AAW$RZ#.ZFE-S<-|)G1R;F7LK9X2)#_WF28|! M] "X15+7RSC-_,CS/9"Z7@Q@Z"8 15$*8@!;E'dF# MZ' A+W^(XO3;6Z9J53?9NU+1FT_>WS*TQL1'|[_*6[M!S@O[G;;88*>9"K1/X'I/4ZKD?<|L.QLSOI/T3Dn:)>2|'=B!|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|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j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|2T:]7>LWK[$",_"HUYY+U=X8JAV/8 MFXHKO+FN1*DSZ'[O!C5SDVY1O#]J-YM'U(A75]+,.8|SM6SP_\X-,FG=_8[6L MAQ34R9ETM?-A7;6_>>&^(15KJ%O(EC9QW(B>?_]T+U;?Q]99[CYHE^U:&!KXE M%&;S >RRK.\F6% [9L,967L[>KIN;'P_B>F7I1A[$?AH![@AD $*8B9HX#P0T M]$+ ^!TI9NGR6LXN_-ZAJU"XMC^#HR.XA-&4Q_HT]Y$4AA JCE=G$F/,.0B0A M(8ED608$"4^P"1+0O)E'@(9B3..D;QS9V-31M8RDSZ* %-P2&UZ\V+:#;X M=N3N7P^8Y0GUI^BP.2E^;_WY}i:?(N_DY/23#QH$.]HVE*^?*V0C+(/'CD&$/<(T5 !B0#'#-A4"8 M!$F40AC$3%U5:0"">6'-M(&Y"]PY?X\G"M>XI%BHHM(D8HZ??SE^$;[G5X2%'-MED$+0LWX!=RSH5+KG'GK2X)+[X.'Y M6%4B*6KQU"C?9 ^^]-?75]0/_ !_XL=)PD&?!RG5],#%S.#5QC,.QP)HYN7[* M(E)*]2Z=3O)E=K^\O]!\5\DG2=B[-3[IA 6?Z2M';UV)S*%EE, I]-T$Q"CV M12XZ!MCC!DGB>RG.O(RP(%8/HQ >Z,0CTB5$B6/O73Q&JWD[f-U(QKA5A+E MG.G<]0XQ%4./.Y^Z VN"\@L<5C,.6'-7%3AQF:!Z3)~6I]H[_>W\U&,.!KW4$X_KG064 MY.!O*IA6IQ:? MV+B2X!P)KTLI5A. {DWP8UC*74]>G6C0(4Y:B(0H&#"^?6FLX\1)UAM)[+R-M(5=1@@1 M!"$R-M(5^(R!^?2_RL?B ZQ_@:\SM\)(AM/)HC7,:3+'L-R]+G8]38S*WN.B\ MU:OM>$S^EY741_POPE? YSNU4KN6VTS,_R-XXW_>O(""O6[G-.#>G `6,#MJIKUH:5L0/0F&DR1P+#5%?_26]++]P)U\H]P<6,@HB.E,4114FU@(/+N,C=Y MY?9)(RN?_EOA:S5D(]O70.C6$B1$N9CH;,T"8 M\,(5*,/\'TZM\>;<+/-?KWU;(%% QEG,NZ]TC<7>BU^]5W#0O*&&,4<12Q =Y. T]B64LD](@+?4$3 MHYO2$-6Q_9#=?8I>#=O\Z-]T' '#'8S --LKG4,$/.P?0Z2[3$2C5'4!">]] MZL& (YK1A#Q 8]N(>0"_;)G->"]& GL6M.H6S^?\IGJ\[(6]+*>>PH7Z"6-E+$D:8.S? \"-2P"G G M/FS-VTIND?0Y)-@9R9\'AYTX!71(M/U$T,&G[;;T>_7;3=YK(]\%4Y)&<,Y8G M/N8B[C 1>8 5>U+9+-?OC< M8,2/3|_SZDW*;|) ^+;C4E1SD+VRA?>-; UYW'=.9"+OZ*+57 _;IX*I]ZXN- MP>I'@8Q%*G&:-G)>FR_K4,+/>-37 8AS1CO@SEH%B4CD+4 MDJN%T/]1JA*O_M1V)\>-5-LG[*YY(MK(9!OWZ'K"553;NYA&F'IL..OFXK,M M-K#=!ZN;D_.:HH]%LVO?]B]]@[ZNEG=$"=1UZZYO,'16>.\/?O",ZQ"%K6 MM:S*134O1$/K5OW$WS:Z(!69%%Q23#U/G>GBF.%49NHGC^8RBQ_.RRFHPN4 ML9'U]VU=E+QXGLLE,G2+$6#!RR'`S)2G*QB@YF&/]C[@:,;KHM^[?492:B."N M*F0.D9JV5J:!'T"M5,TW>L,FY4"?+9,.]Z1B;YNAB&,)X-615VB/(OH@U0'/M1=E=1ZA?,XW7*3Q3HZ(LQP!94D.8L4Z>M>Y5U5J6D=0+ZQ/B' KJ,)HH6F>(:^N_<?ST?/K&X[=/X+4J-?>.W_(_;R M?*S])L1?5V!6AVFV1/_KI93__-\V/MKZ%T@_6TTV[4'R1MU2W);_X4_A7% M_D42QQ=>1"%Q6+QT_KJ9:ELMK)I)'-\S-*

*B[IH#2|*D_|.YAPM!3_LX\FY[L M[><.:BHTD_:MG;15V'.#B56C19<#F3>< MHKIAU3A)% ,T\+IVCYMEF;F&]2R@#H>T*5NT[7B8G6G,0I*@$8!8Z!EUS3 M#6]PI[@%0Z0<[^1@/-EU7 :A\6QT&P"];A[5V@;(W>?l.Y4[.M:YJKD^:6Y=, MW[JLB*XKYH8^)U+&"8Y[*I5%%S!.HRS#DD9>0$7F X-ESF-G[&OMX4M1DVJY M8\R!F;4U';(P=>T 5)OH60=8N NK/8>9J>- M'0!W(!#?Q:B6AU2V>-2-$=4_ MNA:!.LT"$P[)W:02l;5G+JU/;GJNY7@;F7)2N7.H+GNS9W9UF8^B1) MI-*L"5%G>9I@1BG'5)) 4!ZR),U!E9R.R(X=3],QT1S8?WKNUS#Z&2T;5A!; M\0*L[F0&]YD"<0\63(-LXW2[C5/+:;H\B1.\N!-(;%?%GZEK1GB52^HE09B9.0F6GQ1G<I2"HE09B.0F6GQ1G<I2"HE09B.0F6GQ1G<I2"HE09B

%X4+2:D$/-5WEE23@Y4(P/RR3*?3&@=$GJ,EAXL-MZB8 :L+L@T'S%9=Q,4C,Y^9.BK(&782L&.TDU*Y9Z-7DHDMP#+/(3U5T'Q_V-MV1,V-YO,36#3A-D=Z)\[D8A_?*

_OZQFZX$=YKZ4#(6)/"4@"O# -&YIVQ3G@5-M!X__W**H!Q.Z"8 :,KX#&+TCJR[4.K%?^-NMI>RA,CEVI^DJ!Q6B4. *)V;_B!KL1;[BI4:-QR1D%P3KR*

M*!DFLD6Z563/9;+"YO!4Y)@3^-H[,,*#Z,V;:8C3V>;F?#'/FP*'SXL9-M,7VUO5BO6!,M5!SZ#$0G!T4:D2[20CL,/FEFF%/-C=]=:1LW]C-X0L\@(NI-M\|S8U|U@:B0-J@4R*+

[64&B;P*&LIEMP*3L20VEM+C\,5:N@)&L-(_W&'(2.*-M#D'U^:+W/GRKSWF7.77I4:5L-6#,-M9HO*.]%4Y#HDE:Y%$;]6N=-I M*#D_\HQZ!-/(@.

[RG%;]QZ,)>I2>&P_!U(8TVALR"U@"E9,T9""HP 9XA7^8-MF'$ON^$_U(#U_6"H=M_PX_AC^N-<-+(R@=R!I@EM\!Q \%; XR%6#07@9N! M,'2?F"%?

+8;%T)&L]P!#MX,1E]RZ](0T82QQ+XN!'*6H3WPUT2DX*)GKB$+G-M8%M[:D]3-.X3QD!H:BB$+D)"KRX6WAZ/]Q2GB-F)'6!U[8G"!;^I!@&IE$$LPH#,C'[35B3&M-MWR<.-)

'>Y08""=',KN#0..C%^J-P+I'Y\]-72:-4-1)N4N#I*(1ENC(^>I-MM7KY+E'=>%O@Q7[:."J9#8^?&3@JWR>5L0*9FZV1=A% 2,4NC<+0GB^:,I0:3'

MVSM{(NL4/MAPR&HBAAYNNL7\]TT=1!2K!QP 8,4!\O@AZ =,VJB4"738D6$0)2JY1]+G0!0,%]S)-MOK1VO6XLWXW#=9(WC;V8W8&M5+O-3==GF_K9>7ZYF-?

K&>>I;@6#=T45#BE5-M*Y))!MYC@)PQ&9N]#=@Z_/,$,-TX9(M1NBU]YDKI%YT1I-#Y Q=],7-A*^7UQX%+L]0,R-9]I;^DMD0F1=0UV> MU]Z(9-

"YFBRC0W*QI$);&N!.NTG#V#E$@V#E*$9WX-ODZM8NWTO\C//5|"MNHQ)O%JM:Z_:N? Q_3)*6B(4KNL8% MN0F":?#":_^ IRV1U1MV^S=1^)(!KZ@^%M@'%U $*/^ Z3.>8?

PI+,,D.]QO; M?3:EFJ;K";H@E)("N*QSLTVQX(R5+$9)W0B6E!6]?@)#JL:-$0R$M<;"Z !>M|QDUT=D(;BT"<^2=]%)$/2 ,R%T)Y*7DJD9XQT?+G M\\7R"RE&,I£*O

MT%6\;0CPOLI[B(^&LU\MI/%_7G-^/BQI67\S71 5]XI>K73M=G*D3W;U2Y)NJ MR"#Z8B#Y4*BBCB*Y?G)K0.Y56HGTU^#*[4#G?>]B-XD2"F"I_V0\VR]7V.A

MUN(O,B:%-6BR*]U[$G^/IG'A=^H7FN/%T@QF3?NAW^HL_G[#^L^XG]8PNTWW M;@W1G_BT!AW1=Z7UE"W1LR%MHDBS&.D$]%I6&TO)X&P)/"5EU)/S47MMB7X[-MB$N\?K?

<+)LW8;KWN-P,F2+3DA5O:;LE;M+O*I&:53E *L8EG8KFL75<=#?* MQHZL-7L.TS'V)N+IP*!O;OM&+,Y7^O/9*7^,>9:N,R4R!J,8&2>]E*¥(9Z

M+\ZR@D:6(%NW!WB:HK%#\B<%V5'BZ!1K<]]D4<@*XPFI*S5]T'.R$;P" MR;4U26A+_M)@+6E9NQP_0B@.D .G0+IYM!%[J7GCAS1$%+M#X4:?(H)&-F*.MFF>FO&W] O0=DL:.S8\

K4,%T@&^;KR-/GK!\Q"\T59 -+Q69)"O&S-',-H) M)UU*B;6N9]B!K+'C\@/CK+5@^L+:O7M>%&.%BQJDD+7+N*QTI.0TF6N,Q2KI MY8'Y#P?97 ,&

[4^K.,$T2.F+]YYGZQ@P27PV6101R0?PAA2RX3;F(*1.(:8C\ MT =(&3AS6G@<%7ZAA*\'ZNVYE#L9H%'HRS?'#EM*^% M-6!(_M2(.E04_<^&O.+E:E%];L?Y/)SGZ?

INMO3^,*93U!T+C*]9'0[P^L."2!+BHE_H)S MXM*,=O,BGTWGT\]A]?0K7FY()(/9!00BOW:@#05"!5)#"<)AIE.G6D/J.R2- MJ*VV& 55+*70!JWMLFFC!4>FL09,S"XHG3K'6/B'%?\8:!

MSG&<[B#+]FH#UR4;$\Q&%^,X"!^)(=KX6K1AP03.@E;>9-LZL>X!,L:%RZ!V MT(&\[@ N;Q?SQ>U=7 [,O&2082E]?74=%;8;9D8, 46"]I=.]23QGM*V#&|\E

M:MQ'WB&@U%8.'9C6K~=?<;5IV+#=SE76,@9KM7 &.(N&\&G(+R/(%GF*GO.-M??.;ZS%:QC6H&XO\WBC!!OSO

D=;NB]XS,*Z25R"FME3V_A.ERDU+S^NP+_;$]ZVI#OIC/S\EI/;O3'"9TMH(2FMQ4 M6=NFARPA($,@,]+7Y-34/L.NZ0;&-=6&Q>UXDNY'C]Z,_/CU[?0O83K?.$,B

MDKMC/*/SZN)V;D0P.D%,ECE7BM:A],B%I^@9-V?OM%@\6 Y=!+P>OPRD*.F7 M&(§78I2*U7PU9,@RQSS+44?O6]M\Q]W)@^7I#8NG-A+H(,)Q'9NY?]=SLJ

M4Q?!F\5\]1.6Q1)OC"SY^A_B'XF/=/?RVVOR\E>/5,!&:4M*<5-R*%5,8'+ M@3B#1+1%UAN"W]$E'&UZ7#P.X[G'4#G_7)!5&\,B>2>TE%(\+H^ MA@B'X*U-8!Q*K@N=*-

F^I>3EZN.F,@\!D ,YV\&M^A,7U\IUIVX5W1/5058H MY.C(Q_$L763VT\XQ*-*6J;4OL#>1XZ8V#_*N,*B<^O 5;FYQ$LD(+8PQD,A] MD_$2(;*2:S/ZB-HEU*FY?

W"]@'$G:0\,H;WXVX&>NNPP=UFTIE-83=,$T9@< MO(48.?G#B 4<4P+0VVCID(;MWZ#>1"0W1Z@V'-"R_$,[\#BN;N)5]/9^1KS

M)*NDHTX,N*ACY6N);24>$M,6(VE&GEMWB'R$E-V0\ZRRXELPO0/L_VGGSX3 MW2_HC@N?\.WY6<3ENW*OENB*9Z*D$"0M#]$LOR$]D]G*#%Q2ILCL->G5Q]#:

ME\;=I?:L%@!AS3SG@&/ 19>"!IE5!;%_KL M1>"XN1K#HN5 ;.XON'[5XX6ROU(Q>6)66NH"$;M?;#."\X5#G>$HG2PN-I]' MN">)X^9]((#,)L)[7N6RMI[#U8[^0]

Q;2[KJW)BT{MQ?]9L#3O>;SU\7= MI-I*M!(8#[M>2<[UQHY)M!41\)XT]H(WY/$A@'7**RW+A=@O Z5B2;60=4& M$'-*&)CAIG43\3T#K]=H,-@<%T\$8O?A> ?

WZ5.S&EY\)#=/9)OUDL?PMS/ Z M.^!%_H_S;7;HU3P')[7!J!)(011:23*KO2\%L@_(HN9.N-;'JA7MW?0H'!RG MHTB[Y0_L.7+K1S4.EN87)+T!F2I)4+H%&V?6Y

QLF#19*T:*G2<@O=M% < M'/-CRKZ#"/83Y]HN\84DRS*5/H'CM$F^3H5!B.4;+C3/9#Z2Y&Y;.(X) M[>.R[5N+3ZS3TC.K0+N:$\%8 L?)0]+1>]Y"0/O3P?3;KH[C@G!O6329^?_

MQUS<^V,.!O'?GUIF0 =^Y]VU]^"?&E*AK;&Y/AHS9Z#"!V*=P9.'''"B)S@=E-K M'6'>B;#C1_1<+/*QZNI)\BH8$SP442=1.8$0.#&PJ61CM4C6MLYSN4U!-UYI M(RSVQ=_3%?DEJG,.D-

(F2Q255L+.FXR,,R6 MVVRUM:VS5YXD]!,L'2#IQT!S--L[P-"=/;Q:G(7I?)*=MD&) !X9 Y70T9^2 M!7)]N-7.6FS>\^I!0CK!S/&"?K#"YABN=P"=&]U-?\7Z>C-1-B'G1';*FDY5 M'6

>HI<685 0_8 +G< DT=&3U[L)A8G'#D D'T= M,A"-AI43! R1;5+0Q>;66>|/$<1N_+<]?-IQOP2 WXW0%/THZO?NS%RLS11@E"1%9'1LO* MG@@@%M32!TV^I=8G4-2,&YMLCZ!FO.|

1U?>QQLZ$YOJT8F1%H//1KWB\UGY+ MO-1NS@F"M))%);WKB8VE^U1T\D+>T(_C,$=0(0NUR6&%;["[>^OY_?C9!_H M+/RR6/X>EGD24\S&BWJJ-J43!2%R4J<:/4,I8W!&@:!KS?

4CLQ,$_$!'W:W8'M$T\'Z+N?HZE5L;XP"4XK8A;6MB F:|"T.O>&3B-K'G(*(5VR&*6X41^5W\= MQ?^# ?0%E|-%?2-;KAO=@XJ"'#+6OD=11HBUFT)"Z^E ,11O;96W MH7STGOZG

^SI)=T7RK<#Q5Z=+^N:MPMLSO!E=2-NGN;)<=2]?X%S7 M:K4B-42K,I@8O!E=2-)%3.!9-:!S$.(/T7LRGQ>^,NSA3G]KBQM=OQC='L,/=$,1IVE],=7X

M1>7G)@F)>%MPNCZGGYDD9:-1V4+U_$&91/9\3 :TI;W;[!DO)X+L[D2/WE%K M;0/)-]^,;TYLCOMEQNI7/$,= R"+IG$P7MA(->\31&B9[V].M1Q-(_>H6ML M.

\CW7[1O#V^/Y]]F2V^(6ZG@9\OTV?B_OM9F-.A#3E*%1D$K(>VCESU046P MS@B4+"F.K4/C:\Y(Z>O.PL;';5);]0G9S1!_=Y.1$I:P+%K(V=OLNY9.28@5F

M7DKM@;&=@<1.GHGLK'AVE".'8"U=0T3(Z;BMA9D*L1U]S,$YCQDYYPLG"'= MW"\;HWYMR#Y]D?XF++O /K7Q;>KCXM;ILV=U.\ZC^-^0)++#:KK&WW#Y=9IP

MJQ@^8%#\!FF\^9:,C)C$Z);PD+J22@"XP#5$(#\X+5"YIZ6-K0WKH/8W?%^YD MIZ,K>'1P7.X_$+F2)4^.7 E161Q$@5BB :N59]+R:%-SD^6P!#[_T!>Z?01P MY-

O%S_/*B=5NBI^AIT$*Z?N;]Y>+KE#CWTI>_D]WQ>GXUW_5%6D^__M;E]I/#1#XHHK1800BM7@);FBJ[@$WM3D(QE%#FA0\M:I6FTH[R2#ZUBD/=''Y M^M1B[<""O-

'+RA*7G"H27-;UUY]1X 0ZD-S(VE:?N>;Y-;UT#QM#]H\W%=M' M$!U Z)935CVJ>9K.\%8C^(^+'=E[Q4I)YK*0R@#&34D >B#7*P'7UKG(HM2A M]2#I(?

8Q\IC7\6$!.C@Z,'"OD%9.TPU?Z<\SW,A_GE^<59/IO[8I&D8]3AF1M MGV(R6?6&]B_/#5G8)9ABZ4NZV!H#?A>ZQM7+XZ-G,; H.X#GBT1^YV8^S91 M^_2N4ATUNJ+MO5_BV?

3\;'4])WPU\98GQ9J?K\BO/F"]K8s1O-(VZ1+(,6WM M[A]&Z;@ZN#L(GT#<_0RP&0B(S*V664PK9\]2ZHV./ MJ;7=8;.!N$94J#4&M"E0)(!5> QQ;'GQ^)!P^A5SG2OY

;_B_!RKP579M9IP M3(DADY WQ.\8.VZFMY 3AN22=47?R0&_'VLZ:.,5Q,V:[P=[P4NM"5YLDUCZ M'YC6+V*8Y\6\]RN#E8D6;8D@GJ4Y'(4^3U3P)!2%R"]8E'F0*S,O6:O%IBL9-

MB>T&H@.(KP.[\Q7&]8VVTW<:4E^-(T]*,%,2@,"T!N6):SX(!]DE%##4'9M' MCW>C;-P$U^[.8 X^U&RZ~W']O7M]&I+(8M0?Q&0+60@ Y<_M$5K9&$3KF5Q/T3-

N\FIWN&PFNF/1. @0_S9=?UZZB?#AP=F!/)+)+#_,9WG]S0%6X1+KA0P&D5!2(E O/50 M,*#U)K+L4^L7K7M4C)N[VAU&CQ13!'T"[O#5>S5]-5U\6]^DV@/9BM<+UBD]B

M,1X9W2'%ATA72F(0C#%0VS;F+!0=]J:C<9ZF:.3\T.X0V%!^79@$]_/'KCAW MD1)!G1^1(SF#Q"S4&I:1 $$:8AOM3-8VVMZVQN;NU(V<-MH=3@>2Z]@!TOO;

M>I&N7AXVI26W@:=]#JPVLRRV,:=]S+PD"9$LEMNS,JEEZXE9?!I]+.I>*(WF5 M.0#M-Q<59.9QM]!I.YIZ;TI4!C*+\>773RS@008LSZL]N'TOB3&

AV^80HC%%U&IS$U,]A$Y!X,F!,3$}:T1 ,)UP\EVB>NLZ=#]- M>;,!H.O#@'[T"WDQ#G,XV)OR$.Q&#"P:L]^/RI'''[1'@+B1'19*8H451']7>-A MJ[]HP\54, ^@VUH;'\,?>'6>E&'62BXA*%=

>26V&;=2Y!2+4]HUF//-M]B"OM\X^I583CO)7?^[NF,K;C8-%EL2'Z:?/ZW?EKV16;,T)GXW'VN0%M7'@ M!&H(]3'K(,A.;0\PRWO%?=O:T=UB^MW0$\IW"]6TNE2PWX4&S@-%GR2Q-

X;IYQ($I836Y>H?+,(\]6E>[55 M]Q.R-40H$8&GVD)(:D4]'C.(D+7TAEBH6Y=G[$18;YUQ3H3 8T743Y!F]QJM MB=8F^1I[4J3T007&

(=1I)YP5D:QW6LO65N'NU(T;C.F@TFT@038;E=T[,S2IPKAPY:-IK.I\[@PM8FU>@\$$7SUSKH>UM*,]D'LZ)"MZ"%&L'USWY M,)?]HI)_GD^7^&M8_ATW[4ZN$Z,7V9

MJ[]M3$#0V4N9E$[-$XQVHZS+8O>3@K.['O4F*])]O/4SIR%W$(%[SPM0[*M>-]&DH5L>UNG^D5/]HSD(36?E_E=HK]T1?5E$>)K8LWPGM;(OX2T];?:!?? M8MYKL?M2_V1"?

JP1FVT$ MV0=({UP"M)M?P[KJ_V_ORMVRJ!LV2U)>DO,7R&81Q$^M(P0>+6A6I/$Q,(9# M7^L[DCKN$V0\#V!B'NX^),.YH-V=[0R6!TT^$*[5!+),54UY]4;S4P1$F7K

MGG9I$SGNZV7OZ#U:K!W@=G<>3SS9VIEA!BY#]35.#"'+6?L^.U4EN26C9NLW8 M[M2-^^S9 5(*$F2_(=5?!O.P3[LS5]E4K+82N!895%02',<)T#J.BB>12_.& M#4TH']

<[.W5(=4BQ=]!O:UXH=38+[17?E6UK]+_.292OZ1NTW;_UJGFXQ<]F MJ-!5*^L=M GV(R6?6&]B_/*

VW#&%2,-HE''XE4(:NS^@8·M!Z|$+,,H4+GCK22R#O$,·]-@C0#Y";RK+#UX#'.'O=:NVJN"D8(63R@,)P.I1% M00&&<~%>$D^6.M?8F#B1U7#8|N.A\GO·XUZDYFU-6N)X99GVI:JL(:9>-& M@,/:U#>%:$0V(H36LS2.H_AYE.M'PJJ%{7R8C)\1HA\SD*XWKGF0B3$&4M6I·MB"@MA, TD,L0DPG,2W/:'K5[$/\|S.-Q<-Y6\MU#_L:CB,O2LV·R^&CH**>(MM*7"P=8X=\|&17%;IV_//ZS1S>|3 O9 N;?79ZO:[,?S;K\G#OE(\MM8IWBIV·MVNW*G8O0$+(4^**M3:IV,,7:,C9*5<_6$>A?HK&I6·MAWM+,K#DPW*A@RZL--[R\VZSL0|&#FFSL8| .KAG'ZO^9|PH.JT.G'"JULEP M*3_P0I5K'>&R>;7ZK·ML|&7R'=LL{$/_SN 4=;.:++Z+$4K|-/9,_X7"??&0@Y M/(@@1,Q&6R5:-)W >-W_G@>?3>. :|[8?36 0*0\PHKTS;7";JL75(,=!V4K())$ M"*7>*2()'5V=V-VZ*O,^%?W7_AYC&A{)}>YP\Y+T\:?%1"!9 EA-H52X,G3QT\ M%S%I;\BD:)W?U:[ARF"O6D,;7CH_7YS?>=!YOUA--V]& MN%I]_!SF7/Q*/_EY-=%TWFSV#IQ*%A13Y!_5 5M>6,K<85.[_<*B_43)L*BT$W M])QZR/1S)HY!11<%X\>QXY(-[Y9O%O-/9*&E8(Q#Z<$:121"2U(1-;M#&9:$ MM5D7T_KYL.T.GE,?F_&.P5%R? _97P]W=WU4",4=:3 J@4VTP*H6$E,A+Z;00·M3J·PS5NQ#{JAY10.IY\S<0P|&EX-ITU|N_OU|{UYP\8\G16AS#A\FPZW|#T M,O=PR-2X0YDY1>I<$Z= (K7.&BN"8$BH]07(A<0Z1L@4A$Y:.9C;-W 8\C4 MNFME\G$9ZCS)&TO,\|OU9UQ>_,6+U0K7]VU@P,>>!2ZEM|P"'3A@7, ^ M(Z+QG+5^:SV(T{[3]_;!T>,QF:&$-])\LEJN)R\7YW/Z)&+$^MO;<+9]^^&* M<89TB6'D9%(5GB%(2;P+*DNNC+-RIWHD6N &X.BK;[ ]MG8O\9'!Q+UHR/N1 ML?,!OYPOT^>PPA>? EH@U6GYW2Q=1#1BM"J:FO%HRB%1$!(>F=B\WGLP1KI7; M*<#|\'4#M3- X*&LC||70 AA[\, +TMO3<+#FTR!;/C9.@%5=D5-?RH5HJ75@(·MF@>133+?,}?N?>IXXA{8HL6[!M;]J_G9~=S_&FZ>#U/%^0[:TPNJA;%_,+H MDQ?@<B\Y.{)'ZKO7SB/3O?_8X0<<38>!(5HZ-A'^?+]=Y&BY?=7WA27+, M(6GK2#U]NE\=!\A,<;.;:7=XNA;=6V4ND M7C? IOSAHT8;()48HWI)1N871"UK[!THTQ]<=6K=;.\^%2,!/VW$>S===ZSA>.MI"6Q=G98K[9P&4Rs·TK63$'C#D#RLD$T0<&TA0?@\.@3.N@S#TBQL7*L5*]·ME]-W# (L!P,B^ROCZU8!9Y942M4D"%Z"$)PO=);KA$QEDICCFQ'"Y5WL2V\L+ MY"(G%0/+I%&MT2C'El,FDJ':%$LE"S,% PE0PH(Z&MS;K'Z+C M>5GTPV%K+WDTG*TVI[HOQII(O1+KJH(U3=EEWC)?@<[^_%^<^4;N4+04$XH"38 M\1C 84%2)9$I"R]+|W9A ;WZ:I5X5HEL:65(12N4$)BMQG# *+64G@\W ?4? MX]5W'QRU>? 7=1V@=W,.UB.9=>;&D0 \)KWHVV'"*1;I((CEE.;-,,@B;M;Z2*·M/%A>HFB=0/8@(<_+RCL 'J[?1PMC0X@=8\RJ>WBWFX_L[-V^6J7.M&:|&! M<+&^3FD'CC8%)? OH;>|2A^,3H/8C<>3F%I>#XFZOO $E-/:KT9MIPOF-)Y6+ M+>C ;6 ED#14ZJE,"2): [%P85U**:3T/9/NB<\?N17ND/)5/15FFC*\ MQSRY6+3UKI+.I0.5]DZ6,=61S\P5$0W3H^,)=1.I.- P^:L+|9Y,GYY2TQ3#:.ME#·T*CR=!9\R@\2C"\G\H#RY?00PIGUV*|&+D=5G#;JE MYX*,0D9WL$?2V4KSA#XBUSO>7<!M3VXOB3V:) [HZURMYK6+2$1A/#%2NE4@V2&!&">0F5S4LW3X2·(UC809SN·M\4PO;X31D3L(DO'ZD%C(N"+^,"&T*(E+'E[_OAR77ME9MLDQ(>_V4ND_7@\E MAR$37/,"6E7+W:5<^[=$B"FH[`D.4,6NY7P^Z95[B7>'],H]>-T#6N|G_D55 M/%l,F^ &\O60DU6%"9@3Q)$@O%*Y-5CZ3Z_<1ZK?3Z_<@\4=8.3PS!CO"M8I M&+]*:]MCP8ECUGC@F1M6-".3I7FE5YZ@V<7)+KR32+4^~·;3]WJU.L?\BC8X M__0>E!-%_HW<2ER|Q=!W?I6:Z.Q*$61^BAC)BB33%.C4DS=AK2HR>AY#ZQ[$ MW2A[7H_Q0!\+DGC767&8=(/&ZA^J[W^>8?PJS,$^XW=1$J.1E8H&<5DV7 M.; M*JGHZVB")H%V;RVZBEZGM<31QO4-9-/!UA[*+'TNG_15?IRQDABCX0*"(2M$ M8>TQ[ED$[85D(@E;>#Q!ZN]HRIZ7_]D&?P/(K\D23YL<_;,?=;LK^JOA1RD^·MNM@ITH!WV^DIN9WOU4US5"Q5^,/B)H-@^V+9P^W-7, M2BH7K?9@D_?5"B5F:48V O/.YFBTVJU3*G>A:UO;[J3P.DMDS!=LLRB%D{|<·MG5C;KBK/R1A-&K0(-K/$-.K6)0K/P6P[*=2.%,6;G&Y,-%_WU:US1W+& M:OAY"+=.4OTEA$X1-5A2C: X7!06.LB2KK3&^]? 5U2@OP;]]G_3:LBMYG M@2I_';HK1U;CON@Z7OZ=A#1=7#=/_XLB9G[M$!@#R14#Y0M=*DQQ,,H:E|!&\O:[R@48#&2GP<+.Z0#["*8#A#WPF%FXC2Z$ M"-+)N U1A1@49).8%E+++T-S1?S[!`N}]_OI·/OPN@.TO+]<]^9SM47'3*B* M/"!9SYF\IU#'B2?/M,R\""5,S_9XB([ND@+VDNVB,.·[K,B11C.BR(5Cl-%]N2@3?3L^D:\X5R%<%D Mj5T$YC@=M40\H\O= MS6W=2MKOL^OF)IWf((I6[]JA1?.C[CV"[9R9D| M+RI<)9Y07·HDY43GUT^#(F5=>%DD00)44I5*',O&0G=_W>AN-+J5E%B:W&"<·M@R_*(W)<)W·BE? =64N9)54Y[$>Y10/KO.?O2%\C1XEU\7]IR% MG3("JLP$@2B+Y&8(ZIT$FSGS9YHH_G\|`|_,KE·N5#@; MC6[M<$X\^A:DKT(.<47S6T%P)#FS7% MLT3Z3W82PYON^B:.)K/U/N7N6M@/|]WU*4']N7*":9!<:"A6&O!U,_+":W(XA·MAGK\|?,XFV3\|IM.)[.7$"YO[XN]N^]@MKCLEX0)ICA&EN<6+DH0I.,,R8EK·MY2A+JG3IR'X[+O_ MS+I9-P.,,JQ+/[@MMOFZGL81,;OZ}>0QQ=^_[_%E:$<_1F"L 11X7·\XOD7>71$);FN19!A>(A*42-·M@=T;JI:F5",5K S&2)]XL5-A#*!*134$·%P6_-P=KX^#=/(CY M+4ZF#Z_]%X0(AU7@*8>EE.62/\ZS,PDQ{*W)%O(?C?WZY2]#]T%|'.$5 M0+S[+\V8PGHGA+;CT"TKRX&S#9$(3 +AZ"%T2D1+9*/U+/T+M* V)_3G9@,,=X[S3#'YXY2=12KYG7*%&2&_]I#Q8N>3CX>+2<)R·LZ;YF3S;0·M2H^,FO"{A)I·$Z[_^X'V:/P3%,E(D0PXE!0WB$>A4;&2H%5]XGQ2\|JW0^·MYP!T5!ZML3N\LGF=]·LNX 9R_N[X9=G"PJ[:R=Q|S:W4_G3QM^`0VFD_.OORXZ-0=G M%&9PMLC4T M6,4=EM;F3L·;YTO)W·>58^HCBR+V,DU]·%.[JG9'83T7]PZ=>/<;·NM"8$&T6PC]<5 )+X;R18"[·4C@C. K12I94GLOR+,,!:<7=\A,TVGALZ MC#(TB803UXPU7$?&>8(ZIT$FSGS9YHH_G\|`|_,KE·N5#@; MC6[M<$X\^A:DKT(.<47S6T%P)#FS7% MLT3Z3W82PYON^B:.)K/U/N7N6M@/|]WU*4']N7*":9!<:"A6&O!U,_+":W(XA·MAGK\|?,XFV3\|IM.)[.7$"YO[XN]N^]@MKCLEX0)ICA&EN<6+DH0I.,,R8EK·MY2A+JG3IR'X[+O_ MS+I9-P.,,JQ+/[@MMOFZGL81,;OZ}>0QQ=^_[_%E:$<_1F"L 11X7·\XOD7>71$);FN19!A>(A*42-·M@=T;JI:F5",5K S&2)]XL5-A#*!*134$·%P6_-P=KX^#=/(CY M+4ZF#Z_]%X0(AU7@*8>EE.62/\ZS,PDQ{*W)%O(?C?WZY2]#]T%|'.$5 M0+S[+\V8PGHGA+;CT"TKRX&S#9$(3 +AZ"%T2D1+9*/U+/T+M* V)_3G9@,,=X[S3#'YXY2=12KYG7*%&2&_]I#Q8N>3CX>+2<)R·LZ;YF3S;0·M2H^,FO"{A)I·$Z[_^X'V:/P3%,E(D0PXE!0WB$>A4;&2H%5]XGQ2\|JW0^·MYP!T5!ZML3N\LGF=]·LNX 9R_N[X9=G"PJ[:R=Q|S:W4_G3QM^`0VFD_.OORXZ-0=G M%&9PMLC4T M6,4=EM;F3L·;YTO)W·>58^HCBR+V,DU]·%.[JG9'83T7]PZ=>/<;·NM"8$&T6PC]<5 )+X;R18"[·4C@C. K12I94GLOR+,,!:<7=\A,TVGALZ MC#(TB803UXPU7$?&>8(ZIT$FSGS9YHH_G\|`|_,KE·N5#@; MC6[M<$X\^A:DKT(.<47S6T%P)#FS7% MLT3Z3W82PYON^B:.)K/U/N7N6M@/|]WU*4']N7*":9!<:"A6&O!U,_+":W(XA·MAGK\|?,XFV3\|IM.)[.7$"YO[XN]N^]@MKCLEX0)ICA&EN<6+DH0I.,,R8EK·MY2A+JG3IR'X[+O_ MS+I9-P.,,JQ+/[@MMOFZGL81,;OZ}>0QQ=^_[_%E:$<_1F"L 11X7·\XOD7>71$);FN19!A>(A*42-·M@=T;JI:F5",.

8#^[VN M@-B'B6W4GCZML\2:$>5!0M1YB-*2T\B&*!"U(LB$/7;B5P[!9(J:#^;FL,W> M-N"QL"":-8C9P;=`%GB7QZT%X(CVR&EN L...%`'"E3V5TN2M9-JK-'D;!K=P M7_"D8(9(&AC3%/DDP91:19 V2J,H+0?#JI(6I;.(VY2N!KBU"VX:[M#4!C>3F#5N"Wl@'2PUZ)`]{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`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{O[$"(GI8 MJEZY]B[">79=$LI8[OL\9=VZ]8JT=Q'86MZT6];];CSK3W*@ MOJDO5R!2E+UATP5JU?.TSN!Q?/ZCI?=?&9_6\MERY8 M+1>_C7P>;`HZMM2.V.(&>'<_]A/^N_>-T;+UJLEK+=Z!7DSX^ZCMF<,M3R M]V7CMNF,3[$K(92G*S7]/FEX0V=*W%;,%>Q=N%J1FU7SZ /FVJ;O,O+Z9RI MO9L"%VJVEWPKM):SHK*\EEL:&2'=Y//I$R%QE]G?[^ M9>P_C[I-QN\FT\&UO>|5*XK=Z\/5+M8WE6JV!"MLH0_WT|!QH]F&9URIG3U MJM5NFW>5Y48&M7, ?NJF_XP)W4LU3;ZSP>J74T7."PWLJVRA-_#HMTH+B@M M4?6V8LEJU\:[2G$]:.]J2VJO;^*V;#U %.D>I&_N9:[VOL=WF.I4NN0M>\3 M&Q3[:K.\^2^[^]ZZ_@FCYD;WWVT?QO"]FL_5N_:0"0"^O"S01@ Q?-CM<-I_M&OCY[K_9/W^*HY@&T[!UVNWTP7HW|R7AT)>O;4&"S-C0CN8;_G:!]DV== @'W MHRK+^&Z[?;%>34 A4&S'V78BL)(NWIEZY40% C"VO3UEFRP0FPJ MU[691PW="G1Q G'A>?S7[6#\8%?*&.4M/M-+R$VEOK;G8:M50%^^'ZH"Z.G* M1:I_UFRV0.7/%WOWV^1+'*=9?QT?2Q?^!%E_#[T&YNQ?Z_.P2+4+URVD\%@C MGU-?^T+HS^AOIX/O\0Y8BN)Z3F_NY1$UTXD#X?/MS>(A8I(M5B] (Q3Y[_ZQ/_KD_<3C;A/[!ULWA\7_5XNE*U.JIUVK&4V-H"& X? MME5&-9XO5^]87\KNK@_MM85R>3F=#9<834;_65#>Kf?7U_=Y]\ET],T-WW?C MLYNA&_YS7$)F6W^MIJ>V2F)=_? 8U(/:)9R!Q\O6[?S-9VL5]!^DN7;2F9]=3 MB.N843OX*2VGG65T&5?;Q/VN'RL:D=*7],BXH)ZO64^?=1#5"H;45M+]:WIW M]LY8V_ QSGN_0PNCP;A5]'WR#34 .W^T#=?? 3KY=.697ODH.KSZ.YOM_OM/G M\("S|<|QB?-\JZ^V831V1LO>[*X,E]^ P.NWTZ5X!SK@QP^P+P"3[;]6S2DL M X^=V=N.%3F;?$YS,CZG&8(?R"B,CIT_6NV99W$;LA.S:Y'EN MWAN^]\,PH^U--PJ3MV/X12GD%-I"M8>E97!45A"54:?V>PB3S^//TZOQ.]CA MY$OX/'J@YM,T__X?D_,T))FL;]-A9A!$;LA@5>+!U1ZWEL%301'4GNP0;.Z+ MY_LJ_$ZU0Z^U=1>92PBMG>B=[!9,K?3+U>]56^Q?7:MG;LY,WW=|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`]K+,YE>N7K%W>5[

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|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p"K0=@BG\!?*2.D&?);1P4+K0F4YD!.%#C/ K8%E#;_R",&+ M1L-C5\>]^E&W#Q'>/TVX3;W,#.J-"B3S7/"(A0+!LELOFRH1.]\.@B.MC/&^7=]5]+B!-^-|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|TM=(6X MZZ/--!'OME*9U6-!XW?:A[GI3F1HXD[3_ZW9>5.3R*5&0Q6H+/[Z72L:N+% M"J,RCO-%C09<6?J/)&CK&/GM^54S<0#E:BBL^W9ORZUU".>RF3:^6$H4Z'9 MA9BP:Y7R[(>:YIFN:U'(REJ^.N C1C$7DZ<_4?0D\A,S.,3;-$D^G>0[*5A M!\U&_X,UK,](.=%\8V;/^M?#P]X>#R@EU^8,,?^^S]>G!Q-KCJ?63] MS_VS3\/[SWTT0:L_S:X^?=]\ZET,V?"2W?3/;+<#KU5UGA4V#\S M^,-^O.E=O^]=[&_JE\'_]G]EO,A>:3E>:UU(?'5 ?"XUP8U]IYK+1,V:+!S M'LLI-S5V%3?.&S46B,+(.,I.S,W.!N%Q=VU\YSP,P47U1$08Z7B&>)F%0'NGM3G>^T82;C6\'T@=N\1]'Y(8!B_E8L$*,I9B Q4TL-?NIY 5H(9FR:Y&KPC"5 ML0^J2%G3J__$5,0^BRQ018T-L@"1VC6Q8#O;QZV6USU3:O M(7"MC0L<%@["A<"D4W:,J4DBPI&HN?@5+FJA@@F90HK&"%QF#(%A96:*4F & M2-HV?R.#!OP>"@D4R0Y)+XN@UH _B*.Y M6&J7601FX49"C\R"I RA$\!9BF -H)$1CGB3I E*"?) L.5'/2#H0'14)+B M&DF4"00 16TV.&TM2?@.F91HB9ZAM**PABG.\IHB,AN@30|LV3%U-<"MO;& M@6VXB PEF^915U=8J@H%((@<511*7NWK/AFW >"$L.A!MZ2>" LD$(.DG4L?4M@\12<"/Q(UV'4@>)TB7Z$6L6*G$PR0L5B!"W-=L%,$(!F+GH]^^"F&;A[O"6=$\#-V5NY14<6<.GJ2?$6LMH=8!B6Q9>Z#HWD 1!J)Y MWL,RFBG1OZ"0.GBS0?CD>QN$SU:;_'-N-'94")7-95_&48W2;,!+O7X7RG>^ M ";]D5P&564!!6"FL=26[" E,]N':N<%32Y3;2$2;D%6I=_**+6*@ZE%@B]AMB%)#.T.7Y>^EJ'DA23KIG^+6!C06P5B&1.9EY2]*KH@B5(5RC+CHA]7=O(98@W7= MY>,%GP4K.H(TM:LI?56:IX=?)R_PN;2@@CGZ\AZ'^;-2W*X_X=P >RS6.(!7 M@+*=P8_VYTL7S%504,E5%NV915VSZ!(RN$J"_J"XKZ4-!^ }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{\6A=WATI/W?WT%7B+L^2L]3JG8GXWDS86;\ M7O>PT&_W:LW,5Y+'*-P20ZNTNG8UT3E1,HTZ+H^6UHTNQ>-VG* M)WG/SF_'J:K%0Y$*V=OU[+\ST]*,:<;3>>^[6YXQ1:[8C(Q%1O/O&HKFJJF8MY+$35/QW\ALQB+V=.:N/HI?E.:OGX[?-)(,W"0^X)AV_U7XX@\UL#^%YO\F MXP?#\>WH0&HD)QY_& M-S_UKV[)36Y&0YLMX[7KKO>],?O^E?#F^,U+Q^&OY+^X-:TM#UO8[=\=4=T MGW3J'>4:G)#S3'BI$Y2[E2+&^0D$G-XSG1"=5O=@\/SC,.<4&C",NQF.(8 MHYS44>=YA(CWFN;)WS19OU5/XMN/_L@M7NO0N&%$$CIE1+(I9S,PF4ZX(C^6MB B3Z9R,62$0')&32R$SXGO-'XF(R2\L#X5LD%$>MAID3R>,O-D|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|-'-MLHXE^**!D#-+<0"-/?>NT-5P28_G4Y%,FR8D66%:F8,[3.$N%X MD#[+K#V\FJ@|8S7>=KNDJKF -ACL@D_]I10K%=?G(&LBY3,>SRWWK*=SBIE M@=!:9#WS^GAJ2!\U0O7RU*+)-2_?+++<\]W992_R/ZI&KYM.M#1>EOW!'7]-M?;K9:_F?;/M":@^LRS8A.&]W.CMUAPHV/8_XUK.UOC\1,1?W1GCUA;,! MW9H?1?'MUZ'?QL3?[':!//M+WO7'M^2'_A497(^OAA]&-S?#]P70O]Q_*AQ: MF!:8M#E=(O5L_S'.> ^]5]5=RV#;YQ&KL<8VAP@V\-$@XB\GE@L6N7;7XKZ,>M,VKOHSL<@H_6O+7_E+MJDRLMIXIOOY0'%AN&*!G>7WQ^=&W7K?OD=!MN4[Z MY;14^LVN?^2='3;L)U]//H/Z*WXZLGSB>R\^B56(91]+=ESA_!3MO9MU(L M;?[UEEUH,8L]7]7SWS.5?VZ+\L.[!=M?P!02P,$% @ D($%6=Z3TN.I M!0 B1@-!@ !X;F-R+3(P,C0P-C,P>&5X>#,R,2YH=&WE66UO&CD0_GZ_MPD=T:2*Q9)>WD(5&4H2H5!5)2HWGTYF[66M&GMK>T.X7W\C[_(6V@NM[MJD MQP'$[MCS^LQXOG02, ^>7G81BU^D6=M*(I;M1CTB 1)N>!3^(_@Q)LA>7Y'FV6G+XLS9GPM$FKEA_5&:MH+1DP2![K[_6\FMN^S$4A@0IF!S_C/GL<\)JQDP,S(-@RIP,O3> M>)B5F0B=?:6;3.D,@UPCD4DH4O13QA1U&:"!0;%4 M)D%,H%'&*0IJV O)]-3)&.W?$RC3#'#0*^?91@,;.H&QE++#BY[]3+"&F%@ M1B"13NR&XZ-6M>JWMQ>[5T'[%!8+8CD:)@6(:OB632_!*802-6OV:6)S"06M ME?P/@MD<'1M(50U922@Z >J'RKC2]X"PH'G>MIR ^2NL->-H4$&O<<*6V)31 MC;*:$6O]\5&MU099C,9@"\AEV!U%UW',I -PGZG(I*JC 8BJNQ8TI/S%(OE MKA&OL#*@C1*4,ZVI*!>LKYC (F*8;[.VS HN941QE*"$*CI=(J ;%EO?FL2]M6X1H2K4][G&%/@JYX)3.Z/%1H]4^.%=23 C4-8 3V(2UYBI[F+#N"#WI[@=E M3U!9&?']\V'7+=56I6'=,-D$R(8Y.&IK]#Z#$%%/$VEAS4\@1)"]DFJ-.M[M.[/&A2H%)21!.?I?9H):1/KMFE]VYX8+Z2)A$'*3,,!O'O (NPR %]@8P /L MQ3;_-B5Q!X$W3@B+"DTV2(PS#OI%H#FW(%HPDSS,<6V!MFYPR9K38O&B=D MG>]J*=NX:%ND_P1XJSY)O#$!&)KG0(B"X;=Q-9A&XH*$4.@6;K,P9)! MABH-/17 +\%P*.]N(#]ZH!P0[0XK*&-XC90&E!F"E_8Q#X%S_=< Q^ IG/(% M>2H5;."!U1RGFH:K'VW"=,KQ,F3"Z>XVM0MF4VF,G(>V-!ZS137"O.@,7=G) MR9NVN>+GK,.!?MF0E>2"7'&D,TAV:77(V(OF%\E^)?A&6MW_-JZ/*MLZB.V9 MMI#MN5RFW!\.!%6PYOBH#H>U^T;O MNN/QXV3WK_IO!G]T]VM.%M!X!T-]:V;IH*7/S'>C"7K;'.+>]6C8?S<8C_O# M';<\ H0B-UWJF")Y(R@E0G/QB-[D\&_BXR?Q4G0:+S%8GNL^1JH/!M##QP*.M_Z?5XPMS[-%@N,8,@.BH@.L/[E1#.Q.P?]0)S^0(CX=B_M>5T'REGKG-[.M DWYY!O@B9W,HYW)'$>1FX;R]YGJ>6P!U<.XKBBW=U-E.\X+:.1"A,'@3F,$X M?*]'\JU[-#N)%)5^(@<]KV%3YI_1"U?>N:N2"+$,#?&.1]+U%N;=TNH(;,PWJPWSVGLRK'2C J5 MK40BV&13@NCF=DMD\%G"#;>4 P.^J;ADNX2 +$I+%%)>F;:NA?ALNZ%C M#9Y[^3P";TDGW/C:I/7B^>Y:=MK1WL/+$ ^N(#7# _<^9)3,'2,=>3RK]0H:"[23]@WWZAUB(O],/4SMU=LGK?I+ M_=[)V<:9N: >%&K^4$;,&^V5I\+:QOZMY/_%-]?N8 .W@HXX;7^LI;PT'-]@ MNC%,+]DKH'-WJ7]Q3?8>]N^*M77SI=_CKX@C-W-?QO"MO!OG._:2/R\EM8Y8P]?5%KQB= G:SCF_%>ZIXU^[^KM[R>=U?\]PWNYK_4MC%K!?]C*E?%W8SV-@CFK=SY=S;5FM6LM55AHF*"#V -?N];RV.F;QC^ZIPZ7+_1)NO_)9?$P_]5\]Q_ 5!+ P04 " "0@059A0-3 MD?\' !R)P & 'AN8W(M,C R-# V,S!X97AX,S$Q+FAT;>U:[U/C-A/^MWK]"A7DIS"3!">\@$HZ9',2FF;D!"KGV^ND=V99C#;,E6G)"^M?W6 M*+U>RI09DMA;K5;[CYY=R3Z)39JA'#.9OMN27'AOVF$41MY1T'L,YL?^871\[+4/?%^(H\/@_|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|LV3%U-<"MO;& M@6VXB PEF^915U=8J@H%((@<511*7NWK/AFW >"$L.A!MZ2>" LD$(.DG4L?4M@\12<"/Q(UV'4@>)TB7Z$6L6*G$PR0L5B!"W-=L%,$(!F+GH]^^"F&;A[O"6=$\#-V5NY14<6<.GJ2?$6LMH=8!B6Q9>Z#HWD 1!J)Y MWL,RFBG1OZ"0.GBS0?CD>QN$SU:;_'-N-'94")7-95_&48W2;,!+O7X7RG>^ M ";]D5P&564!!6"FL=26[" E,]N':N<%32Y3;2$2;D%6I=_**+6*@ZE%@B]AMB%)#.T.7Y>^EJ'DA23KIG^+6!C06P5B&1.9EY2]*KH@B5(5RC+CHA]7=O(98@W7= MY>,%GP4K.H(TM:LI?56:IX=?)R_PN;2@@CGZ\AZ'^;-2W*X_X=P >RS6.(!7 M@+*=P8_VYTL7S%504,E5%NV915VSZ!(RN$J"_J"XKZ4-!^ }3)4VZ$='NE"D M VCYS1WDN!..A_(1H O.>B!.V8MMD,!' W1JD)5SB_:Y@85I9%,<%+1)/+ %U0M%*K&:7&_7!U;AI'S6I4H>>IW=Z OC25Q@CQ%/W!"I4#-828EED-N\ PV%83 MF^.,:N;9DA._E1*&VQ569H$!1=CI;T_UU?)Y+T$IAM)0 F8<-M%N.) "H*C2M\GQO,Q\EO*L*\ULIK5%I3W+G)WX/ MJU5;&G2 \0F<\1$/1@[^7E,4W;]?30[*."O!%#2$7EN(&GOL M7*&KYI*>S,8J&OO*?!D?5:?G1<6*(LT3-15HG<3*\2"_AUU@[>750.,93_2,MW255S3ZP)XHZ_)SP?(O.[$<79)TG?-J1F?66[=2ME/G*&)5VZ,GYF$@?=4+U-MW-BBR34O'JHW//=@W13X#V"\VSK8FG6H8-/Q6--Z=J;O3T1;^1T)+S]K)]"M^%'EWV@=[FRW@3S[MR=[W:FX&'^U#\V-Z@U!PSG*_E!G5'"T&,TQ8SI98K,]_FL\]0CZZ_D#5WR MB]78D09#!6MXZ@K;64D9A^UL'QQWV5DL1<3Z=R(H:5 _+EWY^)_C'CIN]\J= M%H'Z5[RU]U?<]2P?S%^,^@=75K.%:9\CW]]FO7*4:G-SG,SC=<]K-F7QQZ\ MH/7EN-^#B/73OLUNCR3/Y7?$&5X>#,Q,BYH=&WM6FUOV[86_GY_!6^"VR6 [4BV]^:D M5S7P3P42>=DV/;I@I(HBX@D:B1EQ_OU>TA*MA.G]I.TG1>L0!U)/#P\/.?A MV:ZY1=U'K.#]SJ^8$=Y#P0T?SB/.)3PJ.W:IQ# MC[O'1\%)3$\[W=COTH[O1<>!{\6A=WATI/W?WT%7B+L^2L]3JG8GXWDS86;\ M7O>PT&_W:LW,5Y+'*-P20ZNTNG8UT3E1,HTZ+H^6UHTNQ>-VG* M)WG/SF_'J:K%0Y$*V=OU[+\ST]*,:<;3>>^[6YXQ1:[8C(Q%1O/O&HKFJJF8MY+$35/QW\ALQB+V=.:N/HI?E.:OGX[?-)(,W"0^X)AV_U7XX@\UL#^%YO\F MXP?#\>WH0&HD)QY_& M-S_UKV[)36Y&0YLMX[7KKO>],?O^E?#F^,U+Q^&OY+^X-:TM#UO8[=\=4=T MGW3J'>4:G)#S3'BI$Y2[E2+&^0D$G-XSG1"=5O=@\/SC,.<4&C",NQF.(8 MHYS44>=YA(CWFN;)WS19OU5/XMN/_L@M7NO0N&%$$CIE1+(I9S,PF4ZX(C^6MB B3Z9R,62$0')&32R$SXGO-'XF(R2\L#X5LD%$>MAID3R>,O-D|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|-'-MLHXE^**!D#-+<0"-/?>NT-5P28_G4Y%,FR8D66%:F8,[3.$N%X MD#[+K#V\FJ@|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|TM=(6X MZZ/--!'OME*9U6-!XW?:A[GI3F1HXD[3_ZW9>5.3R*5&0Q6H+/[Z72L:N+% M"J,RCO-%C09<6?J/)&CK&/GM^54S<0#E:BBL^W9ORZUU".>RF3:^6$H4Z'9 MA9BP:Y7R[(>:YIFN:U'(REJ^.N C1C$7DZ<_4?0D\A,S.,3;-$D^G>0[*5A M!\U&_X,UK,](.=%\8V;/^M?#P]X>#R@EU^8,,?^^S]>G!Q-KCJ?63] MS_VS3\/[SWTT0:L_S:X^?=]\ZET,V?"2W?3/;+<#KU5UGA4V#\S M^,-^O.E=O^]=[&_JE\'_]G]EO,A>:3E>:UU(?'5 ?"XUP8U]IYK+1,V:+!S M'LLI-S5V%3?.&S46B,+(.,I.S,W.!N%Q=VU\YSP,P47U1$08Z7B&>)F%0'NGM3G>^T82;C6\'T@=N\1]'Y(8!B_E8L$*,I9B Q4TL-?NIY 5H(9FR:Y&KPC"5 ML0^J2%G3J__$5,0^BRQ018T-L@"1VC6Q8#O;QZV6USU3:O M(7"MC0L

gaap:USTreasuryAndGovernmentMember 2023-12-31 0001326732 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001326732 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001326732 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001326732 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001326732 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001326732 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001326732 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001326732 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001326732 us-gaap:MoneyMarketFundsMember 2024-06-30 0001326732 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001326732 us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0001326732 us-gaap:CashAndCashEquivalentsMember 2024-06-30 0001326732 xncr:MarketableSecuritiesMember 2024-06-30 0001326732 us-gaap:MoneyMarketFundsMember 2023-12-31 0001326732 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001326732 us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001326732 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001326732 xncr:MarketableSecuritiesMember 2023-12-31 0001326732 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001326732 us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0001326732 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001326732 us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001326732 xncr:AstriaMember us-gaap:CommonStockMember 2024-06-30 0001326732 xncr:AstriaMember us-gaap:CommonStockMember 2023-12-31 0001326732 xncr:InmuneBioIncMember us-gaap:CommonStockMember 2024-06-30 0001326732 xncr:InmuneBioIncMember us-gaap:CommonStockMember 2023-12-31 0001326732 xncr:ViridianMember us-gaap:CommonStockMember 2024-06-30 0001326732 xncr:ViridianMember us-gaap:CommonStockMember 2023-12-31 0001326732 us-gaap:CommonStockMember 2024-06-30 0001326732 us-gaap:CommonStockMember 2023-12-31 0001326732 xncr:AstriaMember us-gaap:CommonStockMember xncr:LicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:AstriaMember us-gaap:CommonStockMember xncr:LicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:AstriaMember us-gaap:CommonStockMember xncr:LicenseAgreementMember 2024-06-30 0001326732 xncr:CatabasisPharmaceuticalsIncMember xncr:TechnologyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:CatabasisPharmaceuticalsIncMember xncr:TechnologyLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:CatabasisPharmaceuticalsIncMember xncr:TechnologyLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:CatabasisPharmaceuticalsIncMember xncr:TechnologyLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:InmuneBioIncMember us-gaap:CommonStockMember xncr:LicenseAgreementMember 2024-06-30 0001326732 xncr:InmuneBioIncMember xncr:LicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:InmuneBioIncMember xncr:LicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:InmuneBioIncMember xncr:LicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:InmuneBioIncMember xncr:LicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:ViridianMember us-gaap:CommonStockMember xncr:TechnologyLicenseAgreementMember 2024-06-30 0001326732 xncr:ViridianMember xncr:TechnologyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:ViridianMember xncr:TechnologyLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:ViridianMember xncr:TechnologyLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:ViridianMember xncr:TechnologyLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember us-gaap:PreferredStockMember 2024-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember us-gaap:PreferredStockMember 2023-12-31 0001326732 xncr:ZenasBioPharmaLimitedMember 2024-01-01 2024-06-30 0001326732 xncr:The2023PlanMember 2023-06-14 0001326732 xncr:The2023PlanMember 2024-06-30 0001326732 xncr:The2013And2023PlansMember 2024-01-01 2024-06-30 0001326732 us-gaap:EmployeeStockMember 2024-06-30 0001326732 srt:MaximumMember us-gaap:EmployeeStockMember 2024-01-01 2024-06-30 0001326732 us-gaap:EmployeeStockMember 2024-01-01 2024-06-30 0001326732 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001326732 us-gaap:RestrictedStockUnitsRSUMember xncr:The2023PlanMember 2024-01-01 2024-06-30 0001326732 xncr:ExtendedExpirationDatesMember 2024-01-01 2024-06-30 0001326732 xncr:ExtendedVestingPeriodsMember 2024-01-01 2024-06-30 0001326732 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001326732 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001326732 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001326732 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001326732 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001326732 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001326732 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001326732 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001326732 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001326732 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001326732 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001326732 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001326732 us-gaap:EmployeeStockMember 2024-04-01 2024-06-30 0001326732 us-gaap:EmployeeStockMember 2023-04-01 2023-06-30 0001326732 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0001326732 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001326732 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001326732 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001326732 us-gaap:EmployeeStockOptionMember 2023-12-31 0001326732 us-gaap:EmployeeStockOptionMember 2024-06-30 0001326732 srt:MinimumMember us-gaap:EmployeeStockMember 2024-04-01 2024-06-30 0001326732 srt:MaximumMember us-gaap:EmployeeStockMember 2024-04-01 2024-06-30 0001326732 srt:MinimumMember us-gaap:EmployeeStockMember 2023-04-01 2023-06-30 0001326732 srt:MaximumMember us-gaap:EmployeeStockMember 2023-04-01 2023-06-30 0001326732 srt:MinimumMember us-gaap:EmployeeStockMember 2024-01-01 2024-06-30 0001326732 srt:MinimumMember us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0001326732 srt:MaximumMember us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0001326732 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001326732 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001326732 xncr:MonroviaCAOfficeAndLaboratorySpaceMember 2024-06-30 0001326732 xncr:PasadenaCAOfficeAndLaboratorySpaceMember 2021-06-01 2021-06-30 0001326732 xncr:PasadenaCAOfficeAndLaboratorySpaceMember 2022-08-01 0001326732 srt:ScenarioForecastMember xncr:PasadenaCAOfficeAndLaboratorySpaceMember 2026-09-30 0001326732 xncr:PasadenaCAOfficeAndLaboratorySpaceMember 2022-08-31 0001326732 2024-01-01 2024-01-31 0001326732 us-gaap:LetterOfCreditMember 2024-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember xncr:OptionAndLicenseAgreementMember 2013-01-01 2013-01-31 0001326732 xncr:AlexionPharmaceuticalsIncMember us-gaap:RoyaltyMember xncr:OptionAndLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember us-gaap:RoyaltyMember xncr:OptionAndLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember us-gaap:RoyaltyMember xncr:OptionAndLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember us-gaap:RoyaltyMember xncr:OptionAndLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember xncr:OptionAndLicenseAgreementMember 2024-06-30 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember 2019-02-01 2019-02-28 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember 2019-02-28 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember xncr:DevelopmentBasedMilestonesMember 2019-02-28 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember xncr:RegulatoryBasedMilestonesMember 2019-02-28 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember xncr:SalesBasedMilestonesMember 2019-02-28 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:GenentechMember xncr:CollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:GenentechMember xncr:Xmab24306ProductMember xncr:CollaborationAndLicenseAgreementMember 2024-06-30 0001326732 xncr:GenentechMember xncr:ResearchActivityMember xncr:CollaborationAndLicenseAgreementMember 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:CollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:CollaborationAndLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:CollaborationAndLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:CollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:CollaborationAndLicenseAgreementMember 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:SecondCollaborationAndLicenseAgreementMember 2021-10-01 2021-10-01 0001326732 xncr:JanssenBiotechIncMember srt:MinimumMember xncr:SecondCollaborationAndLicenseAgreementMember 2021-10-01 2021-10-01 0001326732 xncr:JanssenBiotechIncMember srt:MaximumMember xncr:SecondCollaborationAndLicenseAgreementMember 2021-10-01 2021-10-01 0001326732 xncr:JanssenBiotechIncMember xncr:SecondCollaborationAndLicenseAgreementMember 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:SecondCollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:SecondCollaborationAndLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:SecondCollaborationAndLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:JanssenBiotechIncMember xncr:SecondCollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:MorphoSysMember us-gaap:RoyaltyMember xncr:CollaborationAndLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:MorphoSysMember us-gaap:RoyaltyMember xncr:CollaborationAndLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:MorphoSysMember us-gaap:RoyaltyMember xncr:CollaborationAndLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:MorphoSysMember us-gaap:RoyaltyMember xncr:CollaborationAndLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:MorphoSysMember us-gaap:RoyaltyMember xncr:CollaborationAndLicenseAgreementMember 2024-06-30 0001326732 xncr:CollaborationAndLicenseAgreementMember 2024-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member xncr:TechnologyLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member xncr:TechnologyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member xncr:TechnologyLicenseAgreementMember 2024-06-30 0001326732 xncr:VegaTherapeuticsInc.Member xncr:TechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001326732 xncr:VegaTherapeuticsInc.Member xncr:TechnologyLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:VegaTherapeuticsInc.Member xncr:TechnologyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:VirMember xncr:PatentLicenseAgreementMember 2019-10-01 2019-12-31 0001326732 xncr:VirMember us-gaap:RoyaltyMember xncr:PatentLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:VirMember us-gaap:RoyaltyMember xncr:PatentLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:VirMember us-gaap:RoyaltyMember xncr:PatentLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:VirMember xncr:PatentLicenseAgreementMember 2024-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember xncr:MilestoneMember us-gaap:PreferredStockMember xncr:LicenseAgreementMember 2023-12-31 0001326732 xncr:ZenasBioPharmaLimitedMember 2024-01-01 2024-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember 2023-04-01 2023-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember 2023-01-01 2023-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember xncr:LicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember xncr:LicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember xncr:LicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember xncr:LicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember xncr:LicenseAgreementMember 2024-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember xncr:PatentLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember xncr:PatentLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember xncr:PatentLicenseAgreementMember 2024-06-30 0001326732 xncr:GaleMember xncr:TechnologyLicenseAgreementMember 2024-06-30 0001326732 xncr:GaleMember xncr:TechnologyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:GaleMember xncr:TechnologyLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:GaleMember us-gaap:SubsequentEventMember xncr:TechnologyLicenseAgreementMember 2024-07-01 2024-07-31 0001326732 xncr:AlexionPharmaceuticalsIncMember 2024-04-01 2024-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember 2023-04-01 2023-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember 2024-01-01 2024-06-30 0001326732 xncr:AlexionPharmaceuticalsIncMember 2023-01-01 2023-06-30 0001326732 xncr:JanssenMember 2024-04-01 2024-06-30 0001326732 xncr:JanssenMember 2023-04-01 2023-06-30 0001326732 xncr:JanssenMember 2024-01-01 2024-06-30 0001326732 xncr:JanssenMember 2023-01-01 2023-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member 2024-04-01 2024-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member 2023-04-01 2023-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member 2024-01-01 2024-06-30 0001326732 xncr:ShanghaiMabgeekBiotechCo.Ltd.Member 2023-01-01 2023-06-30 0001326732 xncr:MorphoSysMember 2024-04-01 2024-06-30 0001326732 xncr:MorphoSysMember 2023-04-01 2023-06-30 0001326732 xncr:MorphoSysMember 2024-01-01 2024-06-30 0001326732 xncr:MorphoSysMember 2023-01-01 2023-06-30 0001326732 xncr:VegaTherapeuticsInc.Member xncr:TechnologyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:VegaTherapeuticsInc.Member xncr:TechnologyLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:VirMember 2024-04-01 2024-06-30 0001326732 xncr:VirMember 2023-04-01 2023-06-30 0001326732 xncr:VirMember 2024-01-01 2024-06-30 0001326732 xncr:VirMember 2023-01-01 2023-06-30 0001326732 xncr:ZenasBioPharmaLimitedMember 2024-04-01 2024-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:ThirdPartyLicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:ResearchCollaborationMember 2024-04-01 2024-06-30 0001326732 xncr:ResearchCollaborationMember 2023-04-01 2023-06-30 0001326732 xncr:ResearchCollaborationMember 2024-01-01 2024-06-30 0001326732 xncr:ResearchCollaborationMember 2023-01-01 2023-06-30 0001326732

xncr:LicenseAgreementMember 2024-04-01 2024-06-30 0001326732 xncr:LicenseAgreementMember 2023-04-01 2023-06-30 0001326732 xncr:LicenseAgreementMember 2024-01-01 2024-06-30 0001326732 xncr:LicenseAgreementMember 2023-01-01 2023-06-30 0001326732 xncr:MilestoneMember 2024-04-01 2024-06-30 0001326732 xncr:MilestoneMember 2023-04-01 2023-06-30 0001326732 xncr:MilestoneMember 2024-01-01 2024-06-30 0001326732 xncr:MilestoneMember 2023-01-01 2023-06-30 0001326732 us-gaap:RoyaltyMember 2024-04-01 2024-06-30 0001326732 us-gaap:RoyaltyMember 2023-04-01 2023-06-30 0001326732 us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0001326732 us-gaap:RoyaltyMember 2023-01-01 2023-06-30 0001326732 xncr:NonCashRoyaltyMember 2024-04-01 2024-06-30 0001326732 xncr:NonCashRoyaltyMember 2023-04-01 2023-06-30 0001326732 xncr:NonCashRoyaltyMember 2024-01-01 2024-06-30 0001326732 xncr:NonCashRoyaltyMember 2023-01-01 2023-06-30 0001326732 xncr:BassilDahiyatMember 2024-01-01 2024-06-30 0001326732 xncr:BassilDahiyatMember 2024-04-01 2024-06-30 0001326732 xncr:BassilDahiyatMember 2024-06-30 0001326732 xncr:JohnDesjarlaisMember 2024-01-01 2024-06-30 0001326732 xncr:JohnDesjarlaisMember 2024-04-01 2024-06-30 0001326732 xncr:JohnDesjarlaisMember 2024-06-30 0001326732 xncr:EllenFeigalMember 2024-01-01 2024-06-30 0001326732 xncr:EllenFeigalMember 2024-04-01 2024-06-30 0001326732 xncr:EllenFeigalMember 2024-06-30 0001326732 xncr:KevinGormanMember 2024-01-01 2024-06-30 0001326732 xncr:KevinGormanMember 2024-04-01 2024-06-30 0001326732 xncr:KevinGormanMember 2024-06-30 0001326732 xncr:KurtGustafsonMember 2024-01-01 2024-06-30 0001326732 xncr:KurtGustafsonMember 2024-04-01 2024-06-30 0001326732 xncr:KurtGustafsonMember 2024-06-30 0001326732 xncr:DagmarRosaBjorkesenMember 2024-01-01 2024-06-30 0001326732 xncr:DagmarRosaBjorkesenMember 2024-04-01 2024-06-30 0001326732 xncr:DagmarRosaBjorkesenMember 2024-06-30 0001326732 xncr:RichardRanieriMember 2024-01-01 2024-06-30 0001326732 xncr:RichardRanieriMember xncr:RichardRanieriMay2024PlanMember 2024-04-01 2024-06-30 0001326732 xncr:RichardRanieriMember 2024-04-01 2024-06-30 0001326732 xncr:RichardRanieriMember xncr:RichardRanieriMay2024PlanMember 2024-06-30 0001326732 xncr:RichardRanieriMember xncr:RichardRanieriJune2024PlanMember 2024-04-01 2024-06-30 0001326732 xncr:RichardRanieriMember xncr:RichardRanieriJune2024PlanMember 2024-06-30 0001326732 xncr:ABruceMontgomeryMember 2024-01-01 2024-06-30 0001326732 xncr:ABruceMontgomeryMember 2024-04-01 2024-06-30 0001326732 xncr:ABruceMontgomeryMember 2024-06-30 shares iso4217:USD iso4217:USD shares pure xncr:installment xncr:phase xncr:program xncr:target 0001326732 --12-31 2024 Q2 false P244D P243D P364D P367D P364D P364D P358D P364D 10-Q true 2024-06-30 false 001-36182 Xencor, Inc DE 20-1622502 465 North Halstead Street Suite 200 Pasadena CA 91107 626 305-5900 Common Stock, par value $0.01 per share XNCR NASDAQ Yes Yes Large Accelerated Filer false false false 61833530 30768000 53790000 449372000 497725000 28271000 42210000 22073000 11290000 23986000 18145000 554470000 623160000 63868000 66124000 18778000 18663000 384000 380000 104862000 145512000 43780000 64210000 39527000 33995000 498000 648000 826167000 952692000 15838000 13914000 19557000 23564000 0 5782000 1262000 3435000 36472000 31682000 6947000 6332000 80076000 84709000 67156000 59025000 104081000 125183000 12313000 14642000 263626000 283559000 0.01 0.01 10000000 10000000 0 0 0 0 0 0 0.01 0.01 200000000 200000000 61766054 61766054 60998191 60998191 619000 611000 1162726000 1131266000 -652000 1291000 -598368000 -464372000 564325000 668796000 -1784000 337000 562541000 669133000 826167000 952692000 16960000 45523000 29765000 64485000 61531000 60060000 118404000 125612000 17746000 11460000 31533000 25613000 79277000 71520000 149937000 151225000 -62317000 -25997000 -120172000 -86740000 7681000 3771000 16229000 6670000 844000 7000 1921000 14000 -4000 -9000 -4000 -23000 -220000 0 20430000 0 -12027000 288000 -9702000 -2610000 -4974000 4043000 -15828000 4023000 -67291000 -21954000 -136000000 -82717000 117000 0 117000 0 -67408000 -21954000 -136117000 -82717000 -1445000 0 -2121000 0 -65963000 -21954000 -133996000 -82717000 -1.07 -1.07 -0.37 -0.37 -2.18 -2.18 -1.38 -1.38 61676444 61676444 59807558 59807558 61444384 61444384 59922784 59922784 -67408000 -21954000 -136117000 -82717000 -498000 1765000 -1942000 5093000 -67906000 -20189000 -138059000 -77624000 -1445000 0 -2121000 0 -66461000 -20189000 -135938000 -77624000 60998191 611000 1131266000 1291000 -464372000 337000 669133000 152682 1000 1786000 1787000 483812 5000 -5000 0 -1445000 -68033000 -676000 -70154000 11421000 11421000 61634685 617000 1144468000 -154000 -532405000 -339000 612187000 10213 140000 140000 67160 1000 -1000 0 53996 1000 929000 930000 -498000 -65963000 -1445000 -67906000 17190000 17190000 61766054 619000 1162726000 -652000 -598368000 -1784000 562541000 59997713 601000 1072132000 -6952000 -338285000 0 727496000 34388 924000 924000 349499 4000 -4000 0 3327000 -60763000 -57436000 12599000 12599000 60381600 605000 1085651000 -3625000 -399048000 0 683583000 145003 1000 676000 677000 18148 0 55309 1000 1241000 1242000 1765000 -21954000 -20189000 13563000 13563000 60600060 607000 1101131000 -1860000 -421002000 0 678876000 -136117000 -82717000 6059000 5130000 10037000 4345000 28611000 26162000 0 10000000 784000 594000 3000 0 -9702000 -2610000 20430000 0 1900000 0 -6000 -1379000 10783000 -8978000 1705000 -420000 5691000 -1127000 1924000 4009000 -4007000 -288000 -5782000 0 426000 582000 0 -22455000 16312000 0 -120595000 -68814000 259130000 276715000 4236000 0 1549000 1490000 3158000 14636000 347966000 339580000 9969000 0 98334000 46739000 1927000 1601000 930000 1242000 3614000 0 -757000 2843000 -23018000 -19232000 54170000 53942000 31152000 34710000 21000 14000 6100000 0 -1942000 5093000 7166000 0 30768000 34710000 384000 0 31152000 34710000 Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of consolidated interim financial statements requires the use of management's estimates and assumptions that affect reported amounts of assets and liabilities at the date of the consolidated interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period. The accompanying unaudited consolidated interim financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2024. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Xencor, Inc. and Gale Therapeutics Inc. (Gale), a variable interest entity (VIE) in which we are the primary beneficiary. Since we own less than 100% of Gale, the Company records net loss attributable to non-controlling interests in its consolidated statements of loss equal to the percentage of the economic or ownership interests retained in Gale by the non-controlling party. In determining whether we are the primary beneficiary of a VIE, we apply a qualitative approach that determines whether we have (1) the power to direct the activities of the VIE that most significantly impact the entity's economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to the VIE. We continuously assess whether we are the primary beneficiary of Gale as changes to existing relationships or future transactions may result in us consolidating or deconsolidating Gale. Use of Estimates The preparation of consolidated interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive income (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these consolidated interim financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets. Reclassifications Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. During the six months ended June 30, 2024, we adopted a change in presentation on our consolidated statements of loss to include loss from disposal of fixed assets in operating expenses. The prior period has been revised to reflect this change in the presentation. Intangible Assets The Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There was no impairment charge recorded for the three and six months ended June 30, 2024 and 2023. The Company capitalizes certain in-process intangible assets that are then abandoned when they are no longer pursued or used in current research activities. We abandoned $0.4 million and $0.8 million of in-process intangible assets for the three and six months ended June 30, 2024. We abandoned $0.3 million and $0.6 million of in-process intangible assets during the three and six months ended June 30, 2023. Marketable Debt and Equity Securities The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The investment policy limits the maturity of any individual security to a maximum of 36 months. The average maturity of securities in the portfolio as of June 30, 2024 is less than 12 months. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale because it is not more likely than not that the Company will be required to sell the securities before recovery of the amortized cost. These assets are carried at fair value and any impairment losses and recoveries related to the underlying issuer's credit standing are recognized within other income (expense), while non-credit related impairment losses and recoveries are recognized within accumulated other comprehensive income (loss). There were no impairment losses or recoveries recorded for the three and six months ended June 30, 2024 and 2023. Accrued interest on marketable debt securities is included in the marketable securities' carrying value. Each reporting period, the Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if each security's fair value has declined below its amortized cost basis. During the three and six months ended June 30, 2024, the Company recorded an unrealized loss of $0.5 million and $1.9 million in its portfolio of marketable debt securities. During the three and six months ended June 30, 2023, the Company recorded an unrealized gain of $1.8 million and $5.1 million. The unrealized loss is due to the changing interest rate environment and is not due to changes in the credit quality of the underlying securities. The unrealized gain (loss) is recorded in other comprehensive income (loss) for the three and six months ended June 30, 2024 and 2023. The Company receives equity securities in connection with certain licensing transactions with its partners. These investments in equity securities are carried at fair value with changes in fair value recognized each period and reported within other income (expense). For equity securities with a readily determinable fair value, the Company remeasures these equity investments at each reporting period until such time that the investment is sold or disposed. If the Company sells an investment, any realized gain or loss on the sale of the securities will be recognized within other income (expense) in the consolidated statements of loss in the period of sale. The Company also has investments in equity securities without a readily determinable fair value, where the Company elects the measurement alternative to record the investment at its initial cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There was an impairment charge of $20.4 million recorded for the six months ended June 30, 2024 in connection with equity securities

without a readily determinable fair value. There was no impairment charge recorded for the three and six months ended June 30, 2023. Liability Related to the Sale of Future Revenues We treat the sale of future Monjuvi royalties as debt, amortized under the effective interest rate method over the estimated life of the Monjuvi Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future Monjuvi royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Non-cash Interest Expense on the Liability Related to the Sale of Future Royalties The total expected royalty payments less the net proceeds received are recorded as non-cash interest expense over the life of the liability. Interest is imputed on the unamortized portion using the effective interest method and is recorded based on the timing of the payments received over the term of the Monjuvi Royalty Sale Agreement. The actual interest rate will be affected by the timing of the royalty payments and changes in the forecasted revenue. Deferred Income Related to the Sale of Future Revenues We treat the sale of future Ultomiris royalties as deferred income, amortized under the units-of-revenue method by computing a ratio of the proceeds received to the total expected payments over the term of the Ultomiris Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Recent Accounting Pronouncements There have been no material changes in recently issued or adopted accounting standards from those disclosed in the Company's 2023 Annual Report on Form 10-K. The Company has reviewed all recently issued accounting pronouncements and does not believe they will have a material impact on our results of operations, financial condition or cash flows. There have been no other material changes to the significant accounting policies previously disclosed in the Company's 2023 Annual Report on Form 10-K. Basis of Presentation The accompanying unaudited consolidated interim financial statements for Xencor, Inc. (the Company, Xencor, we or us) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. The preparation of consolidated interim financial statements requires the use of management's estimates and assumptions that affect reported amounts of assets and liabilities at the date of the consolidated interim financial statements and the reported revenues and expenditures during the reported periods. These interim financial results are not necessarily indicative of the results expected for the full fiscal year or for any subsequent interim period. The accompanying unaudited consolidated interim financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2024. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Xencor, Inc. and Gale Therapeutics Inc. (Gale), a variable interest entity (VIE) in which we are the primary beneficiary. Since we own less than 100% of Gale, the Company records net loss attributable to non-controlling interests in its consolidated statements of loss equal to the percentage of the economic or ownership interests retained in Gale by the non-controlling party. In determining whether we are the primary beneficiary of a VIE, we apply a qualitative approach that determines whether we have (1) the power to direct the activities of the VIE that most significantly impact the entity's economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to the VIE. We continuously assess whether we are the primary beneficiary of Gale as changes to existing relationships or future transactions may result in us consolidating or deconsolidating Gale. Use of Estimates The preparation of consolidated interim financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive income (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these consolidated interim financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets. Reclassifications Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. During the six months ended June 30, 2024, we adopted a change in presentation on our consolidated statements of loss to include loss from disposal of fixed assets in operating expenses. The prior period has been revised to reflect this change in the presentation. Intangible Assets The Company maintains definite-lived intangible assets related to certain capitalized costs of acquired licenses and third-party costs incurred in establishing and maintaining its intellectual property rights to its platform technologies and development candidates. These assets are amortized over their useful lives, which are estimated to be the remaining patent life or the contractual term of the license. The straight-line method is used to record amortization expense. The Company assesses its intangible assets for impairment if indicators are present or changes in circumstances suggest that impairment may exist. There was no impairment charge recorded for the three and six months ended June 30, 2024 and 2023. The Company capitalizes certain in-process intangible assets that are then abandoned when they are no longer pursued or used in current research activities. We abandoned $0.4 million and $0.8 million of in-process intangible assets for the three and six months ended June 30, 2024. We abandoned $0.3 million and $0.6 million of in-process intangible assets during the three and six months ended June 30, 2023. 0 0 0 0 400000 800000 300000 600000 Marketable Debt and Equity Securities The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The investment policy limits the maturity of any individual security to a maximum of 36 months. The average maturity of securities in the portfolio as of June 30, 2024 is less than 12 months. The Company invests its excess cash primarily in marketable debt securities issued by investment grade institutions. The Company considers its marketable debt securities to be available-for-sale because it is not more likely than not that the Company will be required to sell the securities before recovery of the amortized cost. These assets are carried at fair value and any impairment losses and recoveries related to the underlying issuer's credit standing are recognized within other income (expense), while non-credit related impairment losses and recoveries are recognized within accumulated other comprehensive income (loss). There were no impairment losses or recoveries recorded for the three and six months ended June 30, 2024 and 2023. Accrued interest on marketable debt securities is included in the marketable securities' carrying value. Each reporting period, the Company reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if each security's fair value has declined below its amortized cost basis. During the three and six months ended June 30, 2024, the Company recorded an unrealized loss of $0.5 million and $1.9 million in its portfolio of marketable debt securities. During the three and six months ended June 30, 2023, the Company recorded an unrealized gain of $1.8 million and $5.1 million. The unrealized loss is due to the changing interest rate environment and is not due to changes in the credit quality of the underlying securities. The unrealized gain (loss) is recorded in other comprehensive income (loss) for the three and six months ended June 30, 2024 and 2023. The Company receives equity securities in connection with certain licensing transactions with its partners. These investments in equity securities are carried at fair value with changes in fair value recognized each period and reported within other income (expense). For equity securities with a readily determinable fair value, the Company remeasures these equity investments at each reporting period until such time that the investment is sold or disposed. If the Company sells an investment, any realized gain or loss on the sale of the securities will be recognized within other income (expense) in the consolidated statements of loss in the period of sale. The Company also has investments in equity securities without a readily determinable fair value, where the Company elects the measurement alternative to record the investment at its initial cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There was an impairment charge of $20.4 million recorded for the six months ended June 30, 2024 in connection with equity securities without a readily determinable fair value. There was no impairment charge recorded for the three and six months ended June 30, 2023. 0 0 0 0 -500000 -1900000 1800000 5100000 20400000 0 0 Liability Related to the Sale of Future Revenues We treat the sale of future Monjuvi royalties as debt, amortized under the effective interest rate method over the estimated life of the Monjuvi Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future Monjuvi royalties is based on our current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Non-cash Interest Expense on the Liability Related to the Sale of Future Royalties The total expected royalty payments less the net proceeds received are recorded as non-cash interest expense over the life of the liability. Interest is imputed on the unamortized portion using the effective interest method and is recorded based on the timing of the payments received over the term of the Monjuvi Royalty Sale Agreement. The actual interest rate will be affected by the timing of the royalty payments and changes in the forecasted revenue. Deferred Income Related to the Sale of Future Revenues We treat the sale of future Ultomiris royalties as deferred income, amortized under the units-of-revenue method by computing a ratio of the proceeds received to the total expected payments over the term of the Ultomiris Royalty Sale Agreement. See Note 11. The amortization of the liability related to the sale of future royalties is based on our

*current estimate of future royalty payments. Royalty revenue will be recognized as earned and the payments made will be a reduction of the liability when paid. Recent Accounting Pronouncements There have been no material changes in recently issued or adopted accounting standards from those disclosed in the Company's 2023 Annual Report on Form 10-K. The Company has reviewed all recently issued accounting pronouncements and does not believe they will have a material impact on our results of operations, financial condition or cash flows. There have been no other material changes to the significant accounting policies previously disclosed in the Company's 2023 Annual Report on Form 10-K. Fair Value of Financial Instruments Financial instruments included in the financial statements include cash and cash equivalents, marketable debt and equity securities, accounts receivable, accounts payable, and accrued expenses. Marketable debt securities, equity securities, and cash equivalents are carried at fair value. The fair value of the other financial instruments closely approximates their fair value due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosure about fair value measurements. The ASC 820 hierarchy ranks the quality of reliable inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets or liabilities. Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in markets that are not active. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by the reporting entity - e.g., determining an appropriate discount factor for illiquidity associated with a given security. The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024
(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total
Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total
Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money Market Funds </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,657 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,657 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,723 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,723 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,577 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,577 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414,514 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr>*

<td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414,514 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">565,858 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">554,234 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">668,757 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">643,237 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Our policy is to record transfers of assets between Level 1 and Level 2 at their fair values as of the end of each reporting period, consistent with the date of the determination of fair value. During the three and six months ended June 30, 2024 and 2023, there were no transfers between Level 1 and Level 2. Financial instruments included in the financial statements include cash and cash equivalents, marketable debt and equity securities, accounts receivable, accounts payable, and accrued expenses. Marketable debt securities, equity securities, and cash equivalents are carried at fair value. The fair value of the other financial instruments closely approximates their fair value due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosure about fair value measurements. The ASC 820 hierarchy ranks the quality of reliable inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets or liabilities. Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in markets that are not active. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by the reporting entity – e.g., determining an appropriate discount factor for illiquidity associated with a given security. The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date.Our policy is to record transfers of assets between Level 1 and Level 2 at their fair values as of the end of each reporting period, consistent with the date of the determination of fair value. During the three and six months ended June 30, 2024 and 2023, there were no transfers between Level 1 and Level 2. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024
(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total
Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total
Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money Market Funds </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,657 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,657 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,723 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,723 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,577 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,577 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414,514 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414,514 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">565,858 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">554,234 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">668,757 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">643,237 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 11624000 11624000 0 25520000 25520000 0 211657000 0 211657000 228723000 0 228723000 342577000 0 342577000 414514000 0 414514000 565858000 11624000 554234000 668757000 25520000 643237000 Net Loss Per Common Share Basic net loss per common share is computed by dividing the net loss attributable to Xencor by the weighted-average number of common shares outstanding during the period without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to Xencor by the weighted-average number of common stock equivalents outstanding for the period. Potentially dilutive securities consisting of stock issuable pursuant to outstanding options and restricted stock units (RSUs), and stock issuable pursuant to the 2013 Employee Stock Purchase Plan (ESPP) are not included in the per common share calculation in periods when the inclusion of such shares would have an anti-dilutive effect. Basic and diluted net loss per common share is computed as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(in thousands, except share and per share data)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(in thousands, except share and per share data)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to Xencor, Inc.</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(65,963)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(21,954)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(133,996)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(82,717)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding used in computing basic and diluted net loss</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">61,676,444</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">59,807,558</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">61,444,384</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">59,922,784</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic and diluted net loss per common share attributable to Xencor, Inc.</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.07)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.37)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(2.18)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.38)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the three and six months ended June 30, 2024 and 2023, all outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share as the effect of including such securities would have been anti-dilutive. Basic and diluted net loss per common share is computed as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(in thousands, except share and per share data)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(in thousands, except share and per share data)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to Xencor, Inc.</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(65,963)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(21,954)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(133,996)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(82,717)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding used in computing basic and diluted net loss</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">61,676,444</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">59,807,558</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">61,444,384</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">59,922,784</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic and diluted net loss per common share attributable to Xencor, Inc.</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.07)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.37)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(2.18)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.38)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.18)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.38)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -65963000 -21954000 -133996000 -82717000 61676444 61676444 59807558 59807558 61444384 61444384 59922784 59922784 -1.07 -1.07 -0.37 -0.37 -2.18 -2.18 -1.38 -1.38 Comprehensive Loss<div style="margin-top:12pt;text-indent:36pt">Comprehensive loss is comprised of net loss and other comprehensive income (loss). For each of the three and six-month periods ended June 30, 2024 and 2023, the only component of other comprehensive income (loss) is net unrealized gain (loss) on marketable debt securities. There were no material reclassifications out of accumulated other comprehensive loss during each of the three and six-month periods ended June 30, 2024 and 2023.</div> Marketable Debt and Equity Securities<div style="margin-top:12pt;text-indent:36pt">The Company's marketable debt securities held as of June 30, 2024 and December 31, 2023 are summarized below:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money Market Funds </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(279)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,657 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,945 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(374)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,577 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">566,499 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(653)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">565,858 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reported as</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total investments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">565,858 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money Market Funds </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,382 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,723 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">413,553 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,037 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(76)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414,514 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">667,455 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,379 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">668,757 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reported as</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Marketable securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">643,237 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total investments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">

</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">668,757 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt">The maturities of the Company's marketable debt securities as of June 30, 2024 are as follows:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
Fair Value</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Mature in one year or less</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">449,715 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">449,372 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Mature within two years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105,160 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,862 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">554,875 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">554,234 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">The unrealized losses on available-for-sale investments and their related fair values as of June 30, 2024 and December 31, 2023 are as follows:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">12 months or greater</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
losses</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">119,044 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(217)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,895 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(62)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">246,154 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(132)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,478 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(242)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">365,198 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(349)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid

#000;padding:2px 0;text-align:right;vertical-align:bottom">91,373 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(304)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">12 months or greater</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
losses</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,073 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66,546 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(76)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">74,619 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The unrealized losses from the available-for-sale securities are due to changes in the interest rate environment and not changes in the credit quality of the underlying securities in the portfolio. The Company's equity securities include securities with a readily determinable fair value. These investments are carried at fair value with changes in fair value recognized each period and reported within other income (expense), net. For the three and six months ended June 30, 2024, net losses of $12.0 million and $9.7 million were recorded under other income (expense) related to these securities. For the three and six months ended June 30, 2023, a net gain of $0.3 million and a net loss of $2.6 million were recorded under other income (expense). Equity securities with a readily determinable fair value, which are categorized as Level 1 in the fair value hierarchy under ASC 820, and their fair values (in thousands) as of June 30, 2024 and December 31, 2023 are as follows:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Astria Common Stock</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,311 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,360 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">INmune Common Stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,630 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,231 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Viridian Common Stock</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,330 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,619 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,271 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">42,210 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company sold 443,909 shares of common stock of Astria Therapeutics, Inc. (Astria) and held 253,958 shares of common stock of Astria as of June 30, 2024. In July 2024, the Company sold the remaining shares of the common stock of Astria. The common stock has a readily determinable fair value. For the remaining equity interest in Astria held at June 30, 2024, the Company recorded an unrealized loss of $1.3 million and an unrealized gain of $0.4 million for the three and six months ended June 30, 2024, respectively. The Company recorded unrealized losses of $3.5 million and $3.9 million related to its equity interest in Astria for the three and six months ended June 30, 2023, respectively. The Company currently holds 1,885,533 shares of common stock of INmune Bio, Inc. (INmune). The 1,885,533 shares of INmune common stock are classified as equity securities with a readily determinable fair value. For the three and six months ended June 30, 2024, the Company recorded unrealized losses of $5.5 million and $4.6 million, respectively, related to its investment in INmune. For the three and six months ended June 30, 2023, the Company recorded unrealized gains of $4.9 million and $5.2 million, respectively. The Company currently holds 717,144 shares of common stock of Viridian Therapeutics, Inc. (Viridian). The shares of Viridian common stock are classified as equity securities with a readily determinable fair value. The Company recorded unrealized losses of $3.2 million and $6.3 million for the three and six months ended June 30, 2024, respectively. The Company recorded unrealized losses of $1.2 million and $3.9 million for the three and six months ended June 30, 2023, respectively, related to the shares of Viridian common stock. </div><div style="margin-top:12pt;text-indent:36pt">Below is a reconciliation of net gain (loss) recorded on equity securities during the three and six months ended June 30, 2024 and 2023:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Net gain (loss) recorded on equity securities</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(12,027)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9,702)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,610</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Less: Net gain (loss) recorded on sale of equity securities</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,012)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">827 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Unrealized gain (loss) recorded on equity securities held at the reporting date</div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10,015)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10,529)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,610</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company also has investments in equity securities without a readily determinable fair value. The Company elects the measurement alternative to record these investments at their initial cost and evaluates such investments at each reporting period for evidence of impairment, or

observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Equity securities without a readily determinable fair value and their carrying values (in thousands) as of June 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:69.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Zenas Preferred Stock</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">43,780 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64,210 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The Company currently holds an equity interest in Zenas BioPharma, Inc. (Zenas), a private biotechnology company. The Company's equity interests include preferred stock in Zenas which were received as upfront payments and a milestone payment for licensing certain clinical and preclinical assets from the Company. The Company elected the measurement alternative to carry the Zenas equity at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. During the six months ended June 30, 2024, we recorded $20.4 million of impairment charge as a result of Zenas closing a Series C financing transaction on May 3, 2024.</div> <div style="margin-top:12pt;text-indent:36pt">The Company's marketable debt securities held as of June 30, 2024 and December 31, 2023 are summarized below:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money Market Funds </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(279)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,657 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,945 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(374)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342,577 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">566,499 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(653)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">565,858 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">

Reported as</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,624 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Marketable securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">554,234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total investments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">565,858 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money Market Funds </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,520 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,382 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,723 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">413,553 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,037 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(76)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414,514 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">667,455 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,379 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">668,757 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reported as</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"

style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(132)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,478 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(242)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">365,198 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(349)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">91,373 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(304)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">12 months or greater</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
losses</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate Securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,073 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government Securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66,546 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(76)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">74,619 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(77)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 119044000 217000 11895000 62000 246154000 132000 79478000 242000 365198000 349000 91373000 304000 8073000 1000 0 0 66546000 76000 0 0 74619000 77000 0 0 -12000000.0 -9700000 300000 -2600000 Equity securities with a readily determinable fair value, which are categorized as Level 1 in the fair value hierarchy under ASC 820, and their fair values (in thousands) as of June 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-

color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Astria Common Stock</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,311 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,360 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">INmune Common Stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,630 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,231 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Viridian Common Stock</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,330 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,619 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,271 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">42,210 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2311000 5360000 16630000 21231000 9330000 15619000 28271000 42210000 443909 443909 253958 -1300000 400000 -3500000 -3900000 1885533 1885533 -5500000 -4600000 4900000 5200000 717144 -3200000 -6300000 -1200000 -3900000 Below is a reconciliation of net gain (loss) recorded on equity securities during the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net gain (loss) recorded on equity securities </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(12,027)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9,702)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,610)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Net gain (loss) recorded on sale of equity securities </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,012)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">827 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized gain (loss) recorded on equity securities held at the reporting date </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10,015)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10,529)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,610)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -12027000 288000 -9702000 -2610000 -2012000 0 827000 0 -10015000 288000 -10529000 -2610000 Equity securities without a readily determinable fair value and their carrying values (in thousands) as of June 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:69.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-

height:120%">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Zenas Preferred Stock</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">43,780 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64,210 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 43780000 64210000 20400000 Stock Based Compensation In June 2023, our Board of Directors (the Board) and stockholders approved the 2023 Equity Incentive Plan (the 2023 Plan), which became effective as of June 14, 2023. The Board and the requisite stockholders previously approved the 2013 Equity Incentive Plan (the 2013 Plan). We suspended the 2013 Plan, and no additional award may be granted under the 2013 Plan. The 2023 Plan reserve consists of 3,000,000 shares and the remaining available shares from the 2013 Plan as of the effective date of the 2023 Plan. In addition, any shares of common stock covered by awards granted under the 2013 Plan that terminate on or after June 14, 2023 by expiration, forfeiture, cancellation, or other means without the issuance of such shares will be added to the 2023 Plan reserve. The 2023 Plan does not include a provision for an automatic increase in shares, also known as an evergreen provision. As of June 30, 2024, the total number of shares of common stock available for issuance under the 2023 Plan is 18,721,104, which includes shares of common stock that were available for issuance under the prior Plans as of the effective date of the 2023 Plan. As of June 30, 2024, a total of 2,380,651 options have been granted under the 2023 Plan. In November 2013, the Board and our stockholders approved the ESPP, which became effective as of December 5, 2013. As of June 30, 2024, the total number of shares of common stock available for issuance under the ESPP is 987,344. Unless otherwise determined by the Board, beginning on January 1, 2014, and continuing until January 1, 2023, the total number of shares of common stock available for issuance under the ESPP automatically increased annually on January 1 by the lesser of (i) 1% of the total number of issued and outstanding shares of common stock as of December 31 of the immediately preceding year, or (ii) 621,814 shares of common stock. The automatic increase has expired, and the number of shares of common stock available for issuance under the ESPP was not increased on January 1, 2024. As of June 30, 2024, we have issued a total of 787,474 shares of common stock under the ESPP. During the six months ended June 30, 2024, the Company awarded 959,071 RSUs to certain employees. The standard vesting of these awards is generally in three equal annual installments and is contingent on an employee's continued service to the Company. The fair value of these awards is determined based on the intrinsic value of the stock on the date of grant and will be recognized as stock-based compensation expense over the requisite service period. As of June 30, 2024, a total of 1,045,738 RSUs have been granted under the 2023 Plan. The Company extended vesting periods and expiration dates of equity awards for employees who retired in April 2024. There is a $3.1 million incremental expense as a result of the extension of the expiration dates, and there is a $1.2 million expense as a result of the extension of the vesting periods.</div><div style="margin-top:12pt;text-indent:36pt">Total employee, director and non-employee stock-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023 are as follows (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,469 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,471 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,168 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,092 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,443 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,415 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,190 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,563 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,611 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">26,162 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td

style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,945 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,842 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,818 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,825 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">417 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">663 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,034 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,380 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,376 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,674 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,190 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,563 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,611 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">26,162 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table summarizes option activity under our stock plans and related information: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of
Shares Subject
to Outstanding
Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Exercise
Price
(Per
Share)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Remaining
Contractual
Term
(in years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value
(in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">11,142,986</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.60 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.03</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,977 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2,167,253</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">22.43 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options forfeited</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485,918)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">32.84 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options exercised</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(162,895)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.83 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">12,661,426</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">28.48 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.18</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5,813 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Exercisable</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">8,295,121</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">29.38 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4.76</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> We calculate the intrinsic value as the difference between the exercise price of the options and the closing price of common stock of $18.93 per share as of June 30, 2024. The weighted-average fair value of options granted during the six-month periods ended June 30, 2024 and 2023 were $22.43 and $30.65 per share, respectively. There were 1,941,412 options granted during the six-month period ended June 30, 2023. We estimated the fair value of each equity award, including stock options and shares issued under our ESPP, using the Black-Scholes option-pricing model based on the date of grant of such stock option or ESPP share issuance date, with the following weighted average assumptions for the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.4</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.5</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.4</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.1</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.42 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.69 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.18 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.17 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">ESPP</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">ESPP </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 - 2.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 - 2.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 - 2.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 -2.0 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 43.0% - 44.6% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 38.2% - 55.7% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 43.0% - 44.6% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 38.2% - 55.7% </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.71% - 5.40% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.13% - 5.39% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.71% - 5.40% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.13% - 5.39% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> As of June 30, 2024, the unamortized compensation expense related to unvested stock options was $56.9 million. The remaining unamortized compensation expense will be recognized over the next 2.7 years. As of June 30, 2024, the unamortized compensation expense under our ESPP was $1.3 million. The remaining unamortized expense will be recognized over the next 1.4 years.</div><div style="margin-top:12pt;text-indent:36pt">The following table summarizes the RSU activity for the six-month period ended June 30, 2024:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted
Stock
Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted -
Average Grant
Date Fair Value
(Per unit)</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested RSUs at December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,490,040</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">30.66 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">959,071</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.58 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(550,972)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.72 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(119,483)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.80 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested RSUs at June 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">1,778,656</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">26.02 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of June 30, 2024, the unamortized compensation expense related to unvested RSUs was $37.0 million. The remaining unamortized expense will be recognized over the next 2.1 years.</div> 3000000 18721104 2380651 987344 0.01 621814 787474 959071 3 1045738 3100000 1200000 <div style="margin-top:12pt;text-indent:36pt">Total employee, director and non-employee stock-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023 are as follows (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,469 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,471 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,168 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,747 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,092 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,443 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,415 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,190 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,563 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,611 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">26,162 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,945 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,842 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,818 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,825 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">211 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">417 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">663 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,034 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,380 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,376 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,674 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,190 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,563 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,611 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">26,162 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 8469000 4471000 13168000 8747000 8721000 9092000 15443000 17415000 17190000 13563000 28611000 26162000 10945000 6842000 17818000 13825000 211000 341000 417000 663000 6034000 6380000 10376000 11674000 17190000 13563000 28611000 26162000 The following table summarizes option activity under our stock plans and related information: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of
Shares Subject
to Outstanding
Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Exercise
Price
(Per
Share)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Remaining
Contractual
Term
(in years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value
(in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">11,142,986</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.60 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.03</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,977 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2,167,253</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">22.43 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options forfeited</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(485,918)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">32.84 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options exercised</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(162,895)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.83 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">12,661,426</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">28.48 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.18</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5,813 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Exercisable</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">8,295,121</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">

$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">29.38 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4.76</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 11142986 29.60 P6Y10D 9977000 2167253 22.43 485918 32.84 162895 11.83 12661426 28.48 P6Y2M4D 5813000 8295121 29.38 P4Y9M3D 5745000 18.93 22.43 30.65 1941412 We estimated the fair value of each equity award, including stock options and shares issued under our ESPP, using the Black-Scholes option-pricing model based on the date of grant of such stock option or ESPP share issuance date, with the following weighted average assumptions for the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.4</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.5</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.4</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.1</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.42 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.69 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.18 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.17 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> P6Y4M24D P6Y6M P6Y4M24D P6Y1M6D 0.504 0.512 0.501 0.505 0.0442 0.0369 0.0418 0.0417 0 0 0 0 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">ESPP</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">ESPP </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 - 2.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 -

2.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 - 2.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.5 -2.0 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 43.0% - 44.6% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 38.2% - 55.7% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 43.0% - 44.6% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 38.2% - 55.7% </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.71% - 5.40% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.13% - 5.39% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.71% - 5.40% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.13% - 5.39% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> P0Y6M P2Y P0Y6M P2Y P0Y6M P2Y P0Y6M P2Y 0.430 0.446 0.382 0.557 0.430 0.446 0.382 0.557 0.0471 0.0540 0.0013 0.0539 0.0471 0.0540 0.0013 0.0539 0 0 0 0 56900000 P2Y8M12D 1300000 P1Y4M24D The following table summarizes the RSU activity for the six-month period ended June 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted
Stock
Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average Grant
Date Fair Value
(Per unit)</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested RSUs at December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,490,040</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">30.66 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">959,071</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.58 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(550,972)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.72 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(119,483)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.80 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested RSUs at June 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,778,656</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">26.02 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1490040 30.66 959071 22.58 550972 31.72 119483 29.80 1778656 26.02 37000000 P2Y1M6D Leases The Company leases office and laboratory space in Monrovia, California under a lease that expires in December 2025 with an option to renew for an additional five years at then market rates. The Company has assessed that it is unlikely to exercise the option to extend the lease term. In June 2021, the Company entered into an Agreement of Lease (Lease Agreement) for laboratory and office space in Pasadena, California, which will expire in July 2035. The Lease Agreement provides for two separate phases of lease and occupancy. The first phase commenced on August 1, 2022 and provides the Company with an improvement allowance up to $17.0 million. The second phase of the lease agreement will commence no later than September 30, 2026 and includes an additional improvement allowance up to $3.3 million. In August 2022, the Company entered into an amendment, which the Company received an additional $5.0 million in tenant improvement allowance in exchange for an increase in the rental rate of the phase 1 space. The Company received delivery of the second phase premises on December 1, 2022. The Company placed the new facility into service in February 2023. In January 2024, the Company entered into an amendment, in which the Company will be paid for $0.7 million of tenant improvement allowance from the second phase for HVAC costs in the first phase. In August 2023, the Company entered into a Sublease Agreement for office space in San Diego, California. The term of the Sublease Agreement begins in September 2023 and ends in December 2027. In connection with the Sublease Agreement, the Company provided a $0.4 million Letter of Credit to the landlord. The Letter of Credit will decline over the term of the lease. The Company also entered into a Cash Collateral Agreement for $0.4 million, which is classified as restricted cash in the Consolidated Balance Sheets.</div><div style="margin-top:12pt;text-indent:36pt">The Company's lease agreements do not contain any residual value guarantees or restrictive covenants.</div><div style="margin-top:12pt;text-indent:36pt">The following table reconciles the undiscounted cash flows for the operating leases at June 30, 2024 to the operating lease liabilities recorded on the balance sheet (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Years ending December 31,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">For the remainder of 2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,792 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">8,022 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,238 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,560 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,076 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2029</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,331 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,104 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total undiscounted lease payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105,123 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Tenant allowance</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,252)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Imputed interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33,453)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Present value of lease payments</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">68,418 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities - short-term</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,262 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities - long-term</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,156 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">68,418 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">The following table summarizes lease costs and cash payments for the three and six months ended June 30, 2024 and 2023 (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,881 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,020 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,762 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,200 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">453 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total lease costs</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,191 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,239 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,902 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,653 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">807 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,877 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of June 30, 2024, the weighted-average remaining lease term for operating leases is 10.7 years, and the weighted-average discount rate for operating leases is 7.0%. As of June 30, 2023, the weighted-average remaining lease term for operating leases was 11.7 years, and the weighted-average discount rate for operating leases was 8.9%. P5Y 2 17000000.0 3300000 5000000.0 700000 400000 400000 The following table reconciles the undiscounted cash flows for the operating leases at June 30, 2024 to the operating lease liabilities recorded on the balance sheet (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Years ending December 31,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">For the remainder of 2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,792 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,022 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,238 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,560 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,076 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2029</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,331 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,104 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total undiscounted lease payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105,123 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Tenant allowance</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,252)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Imputed interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33,453)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Present value of lease payments</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">68,418 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities - short-term</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,262 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities - long-term</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,156 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">68,418 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2792000 8022000 9238000 9560000 9076000 9331000 57104000 105123000 3252000 33453000 68418000 1262000 67156000 68418000 The following table summarizes lease costs and cash payments for the three and six months ended June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt

solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,881 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,020 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,762 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,200 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">453 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total lease costs</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,191 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,239 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,902 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,653 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">807 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,877 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1881000 2020000 3762000 4200000 310000 219000 1140000 453000 2191000 2239000 4902000 4653000 807000 721000 1877000 1445000 P10Y8M12D 0.070 P11Y8M12D 0.089 Commitments and Contingencies From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred. The Company is obligated to make future payments to third parties pursuant to certain license agreements, including sublicense fees, royalties, and payments that become due and payable on the achievement of certain development and commercialization milestones. As the amount and timing of sublicense fees and the achievement and timing of these milestones are not probable and estimable, such commitments have not been included on the Company's balance sheets for the periods ended June 30, 2024 and December 31, 2023. The Company has also entered into agreements with third-party vendors that will require us to make future payments upon the delivery of goods and services in future periods. Collaboration and Licensing Agreements The following is a summary description of the material collaboration arrangements in the three and six months ended June 30, 2024 and 2023. Alexion Pharmaceuticals, Inc. In January 2013, the Company entered into an Option and License Agreement (the Alexion Agreement) with Alexion Pharmaceuticals, Inc. (Alexion). Under the terms of the Alexion Agreement, the Company granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use the Company's Xtend technology to evaluate and advance compounds. Alexion exercised its rights to one target program, ALXN1210, which is now marketed as Ultomiris®. The Company is entitled to receive royalties based on a percentage of net sales of Ultomiris sold by Alexion, its affiliates or its sublicensees, which percentage is in the low single digits. Alexion's royalty obligations continue on a product-by-product and country-by-country basis until the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country. On November 3, 2023, the Company entered into the Ultomiris Royalty Sale Agreement with OMERS, in which OMERS acquired the rights to certain royalties associated with the existing license relating to Ultomiris in exchange for cash consideration. For the six months ended June 30, 2024, Company earned and recognized $16.3 million in non-cash royalty revenue under the Ultomiris Royalty Sale Agreement. The Company recognized $6.9 million and $16.3 million of non-cash royalty revenue during the three and six months ended June 30, 2024, respectively, and $11.2 million and $21.6 million of royalty revenue under this arrangement for the three and six months ended June 30, 2023, respectively. As of June 30, 2024, there is no receivable and no deferred revenue related to this agreement. Genentech, Inc., and F. Hoffmann-La Roche Ltd In February 2019, the Company entered into a collaboration and license agreement (the Genentech Agreement) with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively, Genentech) for the development and commercialization of novel IL-15 collaboration products (Collaboration Products), including efbalropendekin alfa (also named XmAb306 and RG6323), the Company's IL-15/IL15Rα-Fc candidate. Under the terms of the Genentech Agreement, Genentech received an exclusive worldwide license to XmAb306, and we shared in 45% of development and commercialization costs of Collaboration Products, and we were eligible to share in 45% of net profits and losses from the sale of approved products. However, in the fourth quarter of 2023, we agreed with Genentech to convert our current development cost and profit-sharing arrangement into a royalty and

milestone payment-based arrangement. Pursuant to the terms of the amended agreement with Genentech, effective June 1, 2024, Genentech assumed sole responsibility over all clinical, regulatory and commercial activities. We are eligible to receive up to $600.0 million in milestones, including $115.0 million in development milestones, $185.0 million in regulatory milestones and $300.0 million in sales-based milestones and tiered royalties ranging from low double-digit to mid-teens percentages. The Company did not recognize revenue related to the Genentech Agreement for the three and six months ended June 30, 2024 or 2023. As of June 30, 2024, there is a $7.6 million payable related to cost-sharing development activities during the first half of 2024 for development studies being conducted under the Genentech Agreement. There is no deferred revenue as of June 30, 2024, as obligations to perform research activities have expired. Janssen Biotech, Inc., a Johnson & Johnson company J&J Agreement In November 2020, the Company entered into a Collaboration and License Agreement (the J&J Agreement) with Janssen Biotech, Inc., a Johnson & Johnson company, pursuant to which the Company and J&J conducted research and development activities to discover novel CD28 bispecific antibodies for the treatment of prostate cancer. Xencor together with J&J conducted joint research activities to discover XmAb bispecific antibodies against CD28 and against an undisclosed prostate tumor-target with J&J maintaining exclusive worldwide rights to develop and commercialize licensed products identified from the research activities. Under the J&J Agreement, the Company conducted research activities and applied its bispecific Fc technology to antibodies targeting prostate cancer provided by J&J. Upon completion of the research activities J&J had a candidate selection option to advance an identified candidate for development and commercialization. In November 2021, the Company completed its performance obligations under the research activities and delivered CD28 bispecific antibodies to J&J. In December 2021, J&J selected a bispecific CD28 candidate for further development. J&J will assume full responsibility for development and commercialization of the CD28 bispecific antibody candidate. The Company did not recognize revenue for the three and six months ended June 30, 2024 and 2023 under the J&J Agreement. As of June 30, 2024, there is no deferred revenue related to this Agreement. Second J&J Agreement On October 1, 2021, the Company entered into a second Collaboration and License Agreement (the Second J&J Agreement) with J&J pursuant to which the Company granted J&J an exclusive worldwide license to develop, manufacture, and commercialize plamotamab, the Company's CD20 x CD3 development candidate, and pursuant to which Xencor and J&J conducted research and development activities to discover novel CD28 bispecific antibodies. The parties conducted joint research activities for a two-year period to discover XmAb bispecific antibodies against CD28 and undisclosed B cell tumor-targets with J&J receiving exclusive worldwide rights, subject to certain Xencor opt-in rights, to develop, manufacture and commercialize pharmaceutical products that contain one or more of such discovered antibodies (CD28 Licensed Antibodies). The Agreement became effective on November 5, 2021. The Company collaborated with J&J on clinical development of plamotamab with J&J and shared development costs with J&J paying 80% and the Company paying 20% of certain development costs. In June 2024, the Company was notified that J&J will terminate its rights to plamotamab. The Company is generally responsible for conducting research activities under the Second J&J Agreement, and J&J is generally responsible for all development, manufacturing, and commercialization activities for CD28 Licensed Antibodies that are advanced. Revenue from the research activities was recognized over a period of time through the end of the research term that services were rendered as we determined that the input method was the appropriate approach to recognize income for such services. There is a receivable of $5.2 million as of June 30, 2024, related to cost-sharing activities for development of plamotamab under the Second J&J Agreement. No revenue was recognized for the three and six months ended June 30, 2024, and the Company recognized $22.2 million and $27.5 million of revenue for the three and six months ended June 30, 2023, respectively. There is no deferred revenue as of June 30, 2024 related to the Second J&J Agreement as obligations to perform research activities have expired. MorphoSys AG/Incyte Corporation In June 2010, the Company entered into a Collaboration and License Agreement with MorphoSys AG (MorphoSys), which was subsequently amended. Under the agreement, we granted MorphoSys an exclusive worldwide license to the Company's patents and know-how to research, develop and commercialize the XmAb5574 product candidate (subsequently renamed MOR208 and tafasitamab) with the right to sublicense under certain conditions. In February 2024, Incyte Corporation acquired exclusive global development and commercialization rights to tafasitamab. If certain developmental, regulatory and sales milestones are achieved, the Company is eligible to receive future milestone payments and royalties. On November 3, 2023, the Company entered into the Monjuvi Royalty Sale Agreement with OMERS, pursuant to which OMERS acquired the rights to certain royalties earned after July 1, 2023 associated with the existing license relating to Monjuvi. The Company recognized $1.6 million and $4.4 million of non-cash royalty revenue during the three and six months ended June 30, 2024, respectively. The Company recognized $2.0 million and $3.9 million of royalty revenue during the three and six months ended June 30, 2023, respectively. As of June 30, 2024, there is a receivable of $2.1 million related to estimated royalties due under the arrangement. As of June 30, 2024, there is no deferred revenue related to this agreement. Shanghai Mabgeek Biotech Co., Ltd. On December 22, 2023, the Company entered into a Technology License Agreement with Shanghai Mabgeek Biotech Co., Ltd. (Mabgeek), and the Company and Mabgeek entered into Amendment No. 1 on June 21, 2024 (collectively, Mabgeek Agreement). Under the Mabgeek Agreement, the Company received an upfront payment of $1.5 million and up to $11.9 million of milestones. In addition, the Company is eligible to receive royalties on the net sales of approved products in the low single digits. The Company evaluated the Mabgeek Agreement and determined that the single performance obligation was access to a non-exclusive license to certain patents of the Company which were transferred to Mabgeek in June 2024. The Company recognized $1.5 million of license revenue related to the agreement for the three and six months ended June 30, 2024. There is no deferred revenue as of June 30, 2024 related to this agreement. Vega Therapeutics, Inc. In October 2021, the Company entered into a Technology License Agreement (the Vega Agreement) with Vega Therapeutics, Inc. (Vega), in which the Company provided Vega a non-exclusive license to its Xtend Fc technology. In March 2024, Vega notified the Company that it initiated a Phase 1 study, and the Company recorded milestone revenue of $0.5 million. The Company recognized $0.5 million of revenue for the six months ended June 30, 2024. No revenue was recognized for the three months ended June 30, 2024 or the three and six months ended June 30, 2023. Vir Biotechnology, Inc. In 2019, the Company entered into a Patent License Agreement (the Vir Agreement) with Vir Biotechnology, Inc. (Vir) pursuant to which the Company provided a non-exclusive license to its Xtend technology for up to two targets. In March 2020, the Company entered into a second Patent License Agreement (the Second Vir Agreement) with Vir pursuant to which the Company provided a non-exclusive license to its Xtend technology to extend the half-life of novel antibodies Vir developed as potential treatments for patients with COVID-19, including sotrovimab. Under the terms of the Second Vir Agreement, Vir is responsible for all research, development, regulatory and commercial activities for the antibodies, and the Company is eligible to receive royalties on the net sales of approved products in the mid-single digit percentage range. Vir and its marketing partner, GSK, began recording sales for sotrovimab beginning in June 2021. The Company recognized $0.1 million of revenue for the six months ended June 30, 2024, and the Company recognized $0.1 million and $1.5 million of royalty revenue for the three and six months ended June 30, 2023, respectively. As of June 30, 2024, there is no receivable related to estimated royalty due under this agreement, and there is no deferred revenue related to this agreement. Zenas BioPharma, Inc. In November 2020, the Company entered into a License Agreement (the Zenas Agreement) with Zenas, pursuant to which the Company received an equity interest in Zenas in exchange for the exclusive, worldwide rights to develop and commercialize drug candidates from the Company. The equity in Zenas is recorded at the fair value as of the date of the Zenas Agreement and is reviewed each reporting period for impairment or other evidence of change in value. In November 2021, the Company entered into a second License Agreement (Second Zenas Agreement) with Zenas, pursuant to which the Company received additional equity in Zenas in exchange for the exclusive worldwide rights to develop and commercialize the Company's obexelimab (XmAb5871) drug candidate. Under the license, the Company is eligible to receive development, regulatory and sales milestones in connection with the development of obexelimab and royalties on net sales of approved products. The original equity received for the second license was a warrant to acquire additional shares of Zenas. The warrant was exchanged for additional preferred stock in Zenas in November 2022. The warrant in Zenas was recorded at its fair value as of the date of the Second Zenas Agreement and was reviewed each reporting period for impairment or other evidence of change in value. The preferred shares received in exchange for the warrant were recorded at their fair value at the date of the exchange and is reviewed each reporting period for impairment or other evidence of change in value. In 2023, Zenas initiated a Phase 3 clinical study with obexelimab and also dosed a second patient in the study. The Company received a development milestone in the form of additional preferred stock in Zenas with a fair value of $10.0 million. The Company recognized an impairment charge of $20.4 million in the six months ended June 30, 2024 due to an impairment analysis resulting from the Zenas Series C financing transaction. The Company did not record an impairment charge or change in the value of the Zenas equity in the three and six months ended June 30, 2023. The Company did not recognize any revenue for the three and six months ended June 30, 2024. The Company recognized $10.0 million of milestone revenue for the three and six months ended June 30, 2023, and there is no deferred revenue related to this agreement. Third-Party Licensee In May 2024, the Company entered into a Patent License Agreement (Third-Party Licensee Agreement) with a third-party licensee. The Company completed delivery of the performance obligation under the agreement, and the Company will receive a payment of $7.0 million. The

*Company recognized $7.0 million of license revenue for the three and six months ended June 30, 2024, and there is a receivable of $7.0 million. There is no deferred revenue related to this agreement. Gale Therapeutics Inc. In the fourth quarter of 2023, the Company formed a subsidiary, Gale Therapeutics Inc. (Gale), to develop novel drug candidates with its Fc technologies. In December 2023, the Company entered into a Technology License Agreement (Gale License Agreement) with Gale in which Gale received an exclusive worldwide, royalty-bearing, non-transferable license to preclinical assets in exchange for royalties on future sales and an option for future drug candidates that Gale will develop. Concurrently, the Company entered into a Service Agreement (Gale Services Agreement) to provide research and development services and administrative support for Gale. In exchange for $7.5 million of funding, the Company acquired a majority stake in Gale. Total charges of $4.6 million and $8.0 million under the Gale Services Agreement for the three and six months ended June 30, 2024, respectively, were eliminated in consolidation. In July 2024, the Company entered into a preferred stock purchase agreement to purchase additional shares in Gale for $3.0 million. </div><div style="margin-top:12pt">Revenues earned </div><div style="margin-top:12pt;text-indent:36pt">The revenues recorded for the three and six months ended June 30, 2024 and 2023 were earned principally from the following licensees (in millions):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Alexion</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">16.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">21.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Janssen</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Mabgeek</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">MorphoSys</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vega</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vir</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Viridian</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Zenas</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Third Party Licensee</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">The table below summarizes the disaggregation of revenue recorded for the three and six months ended June 30, 2024 and 2023 (in millions):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research collaboration</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">22.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">22.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>License</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Milestone</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Royalties</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash royalties</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Remaining Performance Obligations and Deferred Revenue The Company does not have any remaining performance obligation as of June 30, 2024. As of June 30, 2023, the Company had deferred revenue of $7.9 million for conducting research activities pursuant to the Second J&J Agreement. All deferred revenue as of June 30, 2023 was classified as current liabilities as the Company's obligations to perform services are due on demand when requested by J&J under the Second J&J Agreement. 1 16300000 6900000 16300000 11200000 21600000 0 0 0.45 0.45 600000000 115000000 185000000 300000000 0 0 0 0 -7600000 0 0 0 0 0 0 P2Y 0.80 0.20 5200000 0 0 22200000 27500000 0 1600000 4400000 2000000.0 3900000 2100000 0 1500000 1500000 0 500000 500000 0 2 100000 100000 1500000 0 0 10000000.0 20400000 0 0 0 0 10000000.0 10000000.0 0 7000000.0 7000000.0 7000000.0 7000000.0 0 0 7500000 4600000 8000000.0 3000000.0 <div style="margin-top:12pt;text-indent:36pt">The revenues recorded for the three and six months ended June 30, 2024 and 2023 were earned principally from the following licensees (in millions):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Alexion</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">16.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Janssen</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Mabgeek </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">MorphoSys</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vega</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vir</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Viridian</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Zenas</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Third Party Licensee</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6900000 11200000 16300000 21600000 0 22200000 0 27500000 1500000 0 1500000 0 1600000 2000000.0 4400000 3900000 0 0 500000 0 0 100000 100000 1500000 0 0 0 0 0 10000000.0 0 10000000.0 7000000.0 0 7000000.0 0 17000000.0 0 45500000 29800000 64500000 <div style="margin-top:12pt;text-indent:36pt">The table below summarizes the disaggregation of revenue recorded for the three and six months ended June 30, 2024 and 2023 (in millions):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research collaboration</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">22.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">22.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> License </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Milestone</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Royalties</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash royalties</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.7 </td><td style="background-

color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">45.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 22200000 0 22500000 8500000 0 8500000 0 0 10000000.0 500000 15000000.0 0 13300000 100000 27000000.0 8500000 0 20700000 0 17000000.0 45500000 29800000 64500000 0 7900000 Income taxes The Company recorded $0.1 million of income tax expense for the three and six months ended June 30, 2024. There is no provision for income tax for the three and six months ended June 30, 2023. As of June 30, 2024, the Company's deferred income tax assets, consisting primarily of net operating loss and tax credit carryforwards, have been fully offset by a valuation allowance. 100000 100000 0 0 Sale of Future Royalties Ultomiris Royalty Sale Agreement The Company evaluated the arrangement and determined that the proceeds from the sale of future royalties should be recorded as deferred income on the balance sheets as none of the criteria for classification as debt were met in accordance with ASC 470 Debt. The Company records the non-cash royalty revenue under the "units-of-revenue" method in the consolidated statements of loss. For the three and six months ended June 30, 2024, the Company recognized $6.9 million and $16.3 million of non-cash royalty revenue, respectively. There is $140.6 million in deferred income as of June 30, 2024. Monjuvi Royalty Sale Agreement The Company evaluated the arrangement and determined that the proceeds from the sale of future royalties should be classified as debt pursuant to ASC 470 Debt. At June 30, 2024, the Company reassessed the estimate of total future royalty payments and updated the estimated effective interest rate to 17.5%. The Company will continue to reassess the estimate of total future royalty payment and prospectively adjust the imputed interest rate and related amortization if the estimate is materially different. For the three and six months ended June 30, 2024, the Company recognized $1.6 million and $4.4 million of non-cash royalty revenue, respectively, and $0.8 million and $1.9 million of non-cash interest expense, respectively.</div><div style="margin-top:12pt;text-indent:36pt">The following table shows the activity within debt for the six months ended June 30, 2024 (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance of debt related to sale of future royalties</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">20,974 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Royalties owed to OMERS</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">834 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Royalties paid to OMERS</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,448)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash interest expense recognized</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,900 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance of debt related to sale of future royalties</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,260 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Debt</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,947 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Debt - long-term</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,313 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total debt</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,260 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6900000 16300000 140600000 0.175 1600000 4400000 800000 1900000 The following table shows the activity within debt for the six months ended June 30, 2024 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance of debt related to sale of future royalties</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">20,974 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Royalties owed to OMERS</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">834 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Royalties paid to OMERS</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,448)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash interest expense recognized</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,900 </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance of debt related to sale of future royalties</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,260 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Debt - short-term</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,947 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Debt - long-term</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,313 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total debt</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,260 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 20974000 834000 4448000 1900000 19260000 6947000 12313000 19260000 false false On June 14, 2024, Bassil Dahiyat, our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 66,192 shares of the Company's common stock until February 13, 2025. June 14, 2024 Bassil Dahiyat Chief Executive Officer true 66192 February 13, 2025 On June 14, 2024, John Desjarlais, our Executive Vice President and Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 81,458 shares of the Company's common stock until February 12, 2025. June 14, 2024 John Desjarlais Executive Vice President and Chief Scientific Officer true 81458 February 12, 2025 On June 28, 2024, Ellen Feigal, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025. June 28, 2024 Ellen Feigal Board of Directors true 5496 June 27, 2025 On June 28, 2024, Kevin Gorman, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,827 shares of the Company's common stock until June 30, 2025. June 28, 2024 Kevin Gorman Board of Directors true 5827 June 30, 2025 On June 28, 2024, Kurt Gustafson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025. June 28, 2024 Kurt Gustafson Board of Directors true 5496 June 27, 2025 On June 28, 2024, Dagmar Rosa-Bjorkeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 5,496 shares of the Company's common stock until June 27, 2025. June 28, 2024 Dagmar Rosa-Bjorkeson Board of Directors true 5496 June 27, 2025 On May 23, 2024, Richard Ranieri, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 15,000 shares of the Company's common stock until May 16, 2025, and it was terminated on June 27, 2024. On June 28, 2024, he adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,496 shares of the Company's common stock until June 27, 2025. May 23, 2024 Richard Ranieri Board of Directors true 15000 May 16, 2025 true June 27, 2024 June 28, 2024 true 20496 June 27, 2025 On June 27, 2024, A Bruce Montgomery, a member of our Board of Directors, terminated a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) entered on August 7, 2023. On June 28, 2024, he adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 26,568 shares of the Company's common stock until June 27, 2025. June 27, 2024 A Bruce Montgomery Board of Directors true June 28, 2024 true 26568 June 27, 2025 "